

FILE 'REGISTRY' ENTERED AT 11:12:46 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
STRUCTURE FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1
DICTIONARY FILE UPDATES: 20 JUN 2007 HIGHEST RN 938114-25-1
New CAS Information Use Policies, enter HELP USAGETERMS for details.
TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006
Please note that search-term pricing does apply when
conducting SmartSELECT searches.
REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:
<http://www.cas.org/support/stngen/stdoc/properties.html>
=>
Uploading C:\Program Files\Stnexp\Queries\10524577.str



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****
Web Page for STN Seminar Schedule - N. America
NEWS 1 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 2 MAR 16 CASREACT coverage extended
NEWS 3 MAR 16 CASREACT coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LWPI reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPIUS removed from database clusters and STN
NEWS 8 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 30 CHEMCAITS enhanced with 1.2 million new records
NEWS 10 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reloaded
NEWS 17 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 18 CA/CAPLUS to be enhanced with pre-1967 CAS Registry Numbers
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01C, CURRENT
MACINTOSH VERSION IS V6.0C(ENG) AND V6.0JC(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:12:37 ON 21 JUN 2007

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY
TOTAL SESSION
0.21 0.21

```

chain nodes :
11 12 14
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-11 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 8-11 9-12
exact bonds :
6-9 8-9
isolated ring systems :
containing 1 :


```

Gl:C,H,X,Cy,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
12:Atom 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Gl C,H,X,Cy,S

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10524577a.str



```

chain nodes :
11 13
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
chain bonds :
8-15 9-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19 19-20
exact/norm bonds :
1-6 4-5 5-6 5-7 7-8 9-11
exact bonds :
6-9 8-9 8-15
normalized bonds :
1-2 2-3 3-4 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :


```

Gl:C,H,X,Cy,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:Atom
13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L2 STRUCTURE UPLOADED

=> d 12
L2 HAS NO ANSWERS
L2 STR



G1 C,H,X,Cy,S

Structure attributes must be viewed using STN Express query preparation.

=> s 11 full
FULL SEARCH INITIATED 11:13:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65646 TO ITERATE

100.0% PROCESSED 65646 ITERATIONS
SEARCH TIME: 00.00.01

L3 2214 SEA SSS FUL L1

=> s 12 full
FULL SEARCH INITIATED 11:13:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 24312 TO ITERATE

100.0% PROCESSED 24312 ITERATIONS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS
SINCE FILE ENTRY TOTAL
344.65 344.86

FILE 'CAPLUS' ENTERED AT 11:14:28 ON 21 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jun 2007 VOL 146 ISS 26
FILE LAST UPDATED: 20 Jun 2007 (20070620/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13 full
L5 88 L3

=> d 1b1b abs hitstr tot

L5 ANSWER 1 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:35679 CAPLUS
DOCUMENT NUMBER: 146:330260

TITLE: FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice

AUTHOR(S): Ohori, Makoto; Takeuchi, Mikio; Maruki, Riyo;

CORPORATE SOURCE: Nakajima, Hidenori; Miyake, Hiroshi

SOURCE: Lead Discovery Research Labs, Astellas Pharma Inc., Tsukuba, 305-8585, Japan
Naunyn-Schmiedeberg's Archives of Pharmacology (2007), 374(4), 311-316

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: Springer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Extracellular signal-regulated kinase (ERK), a serine/threonine protein kinase of the mitogen-activated protein kinase superfamily, is activated by various stimuli in inflammatory cells. We recently described FR180204 (5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine), a novel selective ERK inhibitor. In this paper, we investigated the effect of FR180204 on collagen-induced arthritis (CIA) in DBA/1 mice, an animal model of rheumatoid arthritis (RA) mediated by type II collagen (CII)-reactive T cells and anti-CII antibodies. Preventive administration of FR180204 (100 mg/kg, i.p., b.i.d.) significantly ameliorated the CIA arthritis and body weight loss occurring in the CIA mice. Furthermore, FR180204-treated mice showed a significant decrease in plasma anti-CII antibody levels (62%). FR180204 also attenuated delayed-type hypersensitivity in CII-immunized DBA/1 mice, an inflammatory response elicited by CII-reactive T cells, in a dose-dependent manner (52 and 62% inhibition at 32 and 100 mg/kg, resp.). Moreover, FR180204 inhibited in vitro CII-induced proliferation of lymph node cells prepared from CII-immunized mice, in which CII-specific T cells are known to undergo specific proliferation. In conclusion, our results suggest that ERK regulates both the cell-mediated and humoral immune responses in the development of CIA. ERK inhibitors may be useful as therapeutic reagents for the treatment of RA.


IT 865362-74-9, FR 180204

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice)

RN 865362-74-9 CAPLUS

CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2-OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:952415 CAPLUS
DOCUMENT NUMBER: 145:342443
TITLE: Compositions comprising NEP inhibitors, endogenous endothelin inhibitors and diuretics for treatment of cardiovascular disease

INVENTOR(S): Fischer, Ivan

PATENT ASSIGNEE(S): Straub, Matthias; Witte, Klaus; Ziegler, Dieter;

SOURCE: Solvay Pharmaceuticals GmbH, Germany

U.S. Pat. Appl. Publ., 15pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
US 2006205625 A1 20060914 US 2006-356088 20060217
PRIORITY APPL. INFO.: US 2005-63996P P 20050218
OTHER SOURCE(S): MARPAT 145:342443
AB A novel combination therapy for cardiovascular diseases or conditions, including administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. For example, capsule was formulated containing daglutril calcium 250 mg and hydrochlorothiazide 50 mg.
IT 131185-37-0, FK-838 171050-45-6, FR-166124
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) and diuretics for treatment of cardiovascular disease
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:947629 CAPLUS
DOCUMENT NUMBER: 145:278270
TITLE: Pharmaceutical compositions comprising inhibitors of neutral endopeptidase and inhibitors of the endogenous endothelin and diuretics for the treatment of cardiovascular diseases

INVENTOR(S): Fischer, Ivan

PATENT ASSIGNEE(S): Solvay Pharmaceuticals GmbH, Germany

SOURCE: PCT Int. Appl., 39pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2006087371 A1 20060824 WO 2006-EP60057 20060217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BM, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPL. INFO.: MARPAT 145:278270 EP 2005-101235 A 20050218
OTHER SOURCE(S):
AB A novel combination therapy is described for cardiovascular diseases or conditions, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system and at least one diuretic, preferably a thiazide diuretic or an adenosine A1 antagonist. For example, capsules contained daglutril calcium, and hydrochlorothiazide, corn starch, lactose and Et acetate.
IT 131185-37-0, FR 838 171050-45-6, FR 166124
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) and inhibitors of the endogenous endothelin and diuretics for the treatment of cardiovascular diseases
RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:634999 CAPLUS

DOCUMENT NUMBER: 145:103711

TITLE: Preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm

INVENTOR(S): Uehling, David Edward; Stevens, Kirk Lawrence;

Dickerson, Scott Howard; Waterson, Alex Gregory;
Harris, Philip Anthony; Sammond, Douglas McCord;

Hubbard, Robert Dale; Emerson, Holly Kathleen; Wilson,

Joseph W.

PATENT ASSIGNEE(S): Smithkline Beecham Corp.

SOURCE: PCT Int. Appl. 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2

CODEN: E
E-4-554

DOCUMENT TYPE: Patent

LANGUAGE: FAMILIAR ACC. WHEN COMPLETED:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:


[illegible]

PRIORITY APPL. INFO.:

RESEARCH DESIGN

OTHER SOURCE(S) :

IG



Title compds. I [R1' = (R1); a = 0-3; each R1 = independently alk(en)/yn/yl, (un)substituted hetero/aryl, etc.; A = hetero/aryl, heterocycyl; Y1 = CO, NHCO, CS, NHCS; R2' = (R2)b; each b = independently 0-2; each R2 = independently halo, alk(en)/CN, NO2, etc.; R3' = (R3)d; d = 0-2; each R3 = independently halo, alk(en)/yn/yl, aryloxy, arylaminocarbonyl, etc.; R4' = (R4); e = 0-1; each R4 = independently alk(en)/me, B = hetero/aryl; Z' = (Z)g; g = 0-4; 2 = 1; each Alk = alk(en)/me-(Y2)n-(Alk)p-(R5)q; m, n, p = independently 0-1; each Alk = independently alk(en)/ylene; Y2 = O, CO, SO, NH, etc.; R5 = independently CN, NO2, halo, aryloxy, NH2 and derivs., etc.; and their pharmaceutically acceptable salts, and solvates) were prepared as ErbB kinase inhibitors for treating cancer. Thus, cyclization of 2-(methylthio)-4-[(3-nitrophenyl)ethyl]pyrimidine (preparation given) with 1-aminopyridinium iodide, oxidation, reaction of sulfoxide with 1,4-benzodioxan-6-amine, reduction


reduction of the nitro intermediate gave pyrazolopyridine, and reaction of the amine with *ph* isocyanate gave pyrimidine II. Selected I showed inhibitory activity vs. EGFR or ErbB-2 protein tyrosine kinases with a IC_{50} \geq 7. Selected I showed antiproliferative activity of less than 100 nM in at least one of Bn474, HNS and Colo205 tumor cell lines. I are useful in the treatment of diseases associated with inappropriate ErbB family kinase activity.

IT 895636-33-6P, 2,6-Difluoro-N-[3-[2-[3-[1-


RU: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU ('therapeutic use'); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate; preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)

REG. NO.	NAME	CLASS	DATE	STATUS
895636-33-6	CAPLUS			
	Benzamide, 2, 6-difluoro-N-[3-(3-[3-(1-(methylsulfonyl)ethyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1, 5-a]pyridin-2-yl]phenyl]- (9CI)	(CA INDEX)		




IT 895636-34-7P 895636-35-8P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (drug candidate); Preparation of 2-pyrimidinyl pyrazolopyridines as ErbB
 kinase inhibitors for treating neoplasms
 RN 895636-34-7 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[1-(methylsulfonyl)ethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, (+)-(9CI) (CA
 INDEX NAME)
 Rotation (+).




PAGE 1-A

PAGE 2-A




RN 895636-35-8 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[1-(methylsulfonyl)ethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-, (-)-(9CI) (CA
 INDEX NAME)
 Rotation (-).

PAGE 1-A




PAGE 2-A




yl]phenyl]benzamide 895635-95-7P, N-[3-[3-[2-[(3-chloro-4-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-68-7P, N-[3-[3-[2-chloro-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl-1H-pyrrole-2-carboxamide 895636-76-7P 895637-12-4P, 2,6-difluoro-N-[3-[3-[2-[(3-hydroxy-4-(methyloxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-83-9P, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)-2-pyrimidinamine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasms)


RN 895634-90-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895634-92-1 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-94-3 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 895634-96-5 CAPLUS
 CN Benzamide, 2-chloro-N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-68-4 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-95-7 CAPLUS
 CN Benzamide, N-[3-[3-[2-[(3-chloro-4-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN	895636-68-7	CAPLUS
CN	1H-Pyrrole-2-carboxamide, N-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)	




RN	CAPIUS	CA INDEX NAME
895636-76-7	Benzamide, 2,6-difluoro-N-[3-[7-(trifluoromethyl)-3-(2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-	(9CI)



RN	895637-12-4	CAPLUS
CN	Benzamide, 2,6-difluoro-N-[3-[3-(2-[(3-hydroxy-4-methoxyphenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)	




RN	895637-83-9	CAPLUS
CN	2-Pyrimidinamine, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)-(9CI) (CA INDEX NAME)	




895634-81-8P, 1-[3-(2-[2,3-(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-phenylurea
895634-89-6P, 1-(2-Chlorophenyl)-3-[3-(2-[2,3-(2-[2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]urea 895634-97-6P, N-[3-(3-[2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]thio benzamide 895634-98-7P, 2-Chloro-N-[3-(3-[2-(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]thio benzamide 895634-99-8P, N-[3-(3-[2-(2,3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]-3-methoxythio benzamide 895635-00-4P, 1-Methyl-1H-pyrrole-2-carboxylic acid N-[3-(3-dihydrobenzo[1,4]dioxin-6-yl)amino]pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]amide 895635-01-5P, 2-Chloro-5-fluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]benzamide 895635-06-0P, 2-Fluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]benzamide 895635-07-1P, 2-Fluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]-6-fluoromethylbenzamide 895635-08-2P, 2,3-Difluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]benzamide 895635-09-3P, 4-Fluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]benzamide 895635-10-6P, N-[3-(3-[2-(3-Fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]-3-trifluoromethylbenzamide 895635-11-7P, 3-Fluoro-N-[3-(3-[2-(3-Fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]benzamide 895635-12-8P, N-[3-(3-[2-(3-Fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl)phenyl]-3-methylbenzamide 895635-13-9P, 2,4-Difluoro-N-[3-(3-[2-(3-methylbenzamide 895635-13-9P, 2,4-Difluoro-N-[3-(3-[2-(3-

fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-14-0P, 2-Chloro-4-fluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-15-1P, 2-Chloro-3,6-difluoro-N-[3-(3-[2-(3-fluorophenylamino)pyrimidin-4-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-16-2P, 895635-17-3P, N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide 895635-18-4P, N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-quinolinecarboxamide 895635-19-5P, N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-thiophenecarboxamide 895635-20-8P, N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl-1H-1,2,3-benzotriazole-5-carboxamide 895635-21-9P, 2,6-Difluoro-N-[3-(3-[2-(4-morpholinyl)phenyl]benzamide 895635-22-1P, 895635-26-4P, 2,6-Difluoro-N-[3-(3-[2-(3-methoxyphenyl)phenyl]benzamide 895635-27-5P, 2,6-Difluoro-N-[3-(3-[2-(3-fluoro-4-(methoxyloxy)phenyl]amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-28-6P, N-[3-(3-[2-(3-cyanophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-N-[3-(3-[2-(1H-1,2,3-Benzotriazol-5-yl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-30-0P, N-[3-(3-[2-(4-Aminophenyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-31-1P, 2,6-Difluoro-N-[3-(3-[2-(3-(trifluoromethyl)phenyl]amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-32-2P, 2,6-Difluoro-N-[3-(3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-33-3P, 2,6-Difluoro-N-[3-(3-[2-(3-oxazol-5-yl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-34-4P, N-[3-(3-[2-(3-(Acetylaminophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2,6-difluorobenzamide 895635-35-5P, 2-Chloro-6-fluoro-N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-37-7P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3,5-dimethylisoxazole-4-carboxamide 895635-38-8P, 2,5-Difluoro-N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-39-9P, 2,5-Difluoro-N-[3-(3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl)-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-41-3P, N-[3-(3-[2-(4-(dimethylamino)propyl)amino]-3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-43-5P, 2,6-Difluoro-N-[3-(3-[2-(3-fluoro-4-(piperazinyl)propyl)amino]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-45-7P, 2,5-Difluoro-N-[3-(3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-48-0P, 2,5-Difluoro-N-[3-(3-[2-(3-oxazol-5-yl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-49-1P, 2,5-Difluoro-N-[3-(3-[2-(4-morpholinyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-50-4P, 2,5-Difluoro-N-[3-(3-[2-(3-fluoro-4-(methoxyloxy)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-51-5P, N-[3-(3-[2-(3-(Acetylaminophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2,5-difluorobenzamide 895635-52-6P, N-[3-(3-[2-(3-Cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2,5-difluorobenzamide 895635-53-7P, 2,5-Difluoro-N-[3-(3-[2-(3-(2-oxo-1-pyridinyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide


895635-54-8P, 2,5-Difluoro-N-[3-(3-[2-(4-oxo-1-pyridinyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-55-9P, N-[3-(3-[2-(4-(Ethylsulfonyl)methyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-56-0P, N-[3-(3-[2-(3-(Aminosulfonyl)-4-methylphenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2,5-difluoro-N-[3-(3-[2-(4-methylsulfonyl)methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-58-2P, 2,6-Difluoro-N-[3-(3-[2-(3-(2-(4-morpholinyl)ethyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-59-3P, 2,6-Difluoro-N-[3-(3-[2-(3-(3-(4-morpholinyl)propyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-62-8P, 2,6-Difluoro-N-[3-(3-[2-(4-(2-morpholinyl)ethyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-63-9P, 2,6-Difluoro-N-[3-(3-[2-(3-(4-methyl-1-piperazinyl)methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-64-0P, 2,6-Difluoro-N-[3-(3-[2-(3-(2-hydroxyethyl)sulfonyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-65-1P, 2,6-Difluoro-N-[3-(3-[2-(3-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-66-2P, 2,6-Difluoro-N-[3-(3-[2-(3-(2-(4-morpholinyl)ethyl)oxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-67-3P, N-[3-(3-[2-(3-(2-(Dimethylamino)ethyl)oxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-72-0P, N-[3-(3-[2-(2-Methyl-1,2,3,4-tetrahydro-7-isoquinolyl)phenyl]benzamide 895635-73-1P, 2,6-Difluoro-N-[3-(3-[2-(1,2,3,4-tetrahydro-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-75-3P, 2,6-Difluoro-N-[3-(3-[2-(6-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-76-4P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-77-5P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]isoxazole-5-carboxamide 895635-78-6P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-((trifluoromethyl)oxy)benzamide 895635-79-7P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2-(methoxyloxy)benzamide 895635-80-0P, 2-Chloro-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-3-methylbenzamide 895635-81-1P, 3-Fluoro-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2-methylbenzamide 895635-82-2P, 2,6-Difluoro-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-3-methylbenzamide 895635-83-3P, 2-Chloro-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-4-pyridinecarboxamide 895635-84-4P, 6-Chloro-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-3-pyridinecarboxamide 895635-85-5P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-4-pyridinecarboxamide 895635-86-6P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-3-methyl-2-thiophenecarboxamide 895635-87-7P, 3-Chloro-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2-thiophenecarboxamide 895635-88-8P, 3-Bromo-N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-2-thiophenecarboxamide 895635-89-9P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-3-thiophenecarboxamide 895635-90-2P, N-[3-(3-[2-(3-Fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-1-methyl-1H-pyrrole-2-carboxamide 895635-91-3P,




RN 895634-89-6 CAPLUS
CN Urea, N-(2-chlorophenyl)-N'-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-97-6 CAPLUS
CN Benzenecarbothioamide, N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-98-7 CAPLUS
CN Benzenecarbothioamide, 2-chloro-N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895634-99-8 CAPLUS
CN Benzenecarbothioamide, N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 895635-00-4 CAPLUS
CN 1H-Pyrrole-2-carbothioamide, N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895635-01-5 CAPLUS
CN Benzamide, 2-chloro-5-fluoro-N-[3-{2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-06-0 CAPLUS
CN Benzamide, 2-fluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-07-1 CAPLUS
CN Benzamide, 2-fluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-6-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 895635-08-2 CAPLUS
CN Benzamide, 2,3-difluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-09-3 CAPLUS
CN Benzamide, 4-fluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-10-6 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 895635-11-7 CAPLUS
CN Benzamide, 3-fluoro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-12-8 CAPLUS
CN Benzamide, N-[3-[(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 895635-13-9 CAPLUS
CN Benzamide, 2,4-difluoro-N-[3-[(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-14-0 CAPLUS
CN Benzamide, 2-chloro-4-fluoro-N-[3-[(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-15-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[3-[(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-16-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[3-[(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-17-3 CAPLUS
CN 1H-Pyrazole-5-Carboxamide, N-[3-[(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 895635-18-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(3-(2-((3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 895635-19-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-(3-(2-((3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 895635-20-8 CAPLUS
CN 1H-Benzotriazole-5-carboxamide, N-[3-(3-(2-((3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2,3-dihydro-1-methyl- (9CI) (CA INDEX NAME)




RN 895635-21-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-(3-(2-((3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 895635-23-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-(3-(2-((3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 895635-26-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3-{2-[(3-methoxyphenyl)amino]-4-pyrimidin-2-yl}phenyl)]- (9CI) (CA INDEX NAME)




RN 895635-27-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3-{2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidin-2-yl}phenyl)]- (9CI) (CA INDEX NAME)




RN 895635-28-6 CAPLUS
CN Benzamide, N-[(3-{2-[(3-cyanophenyl)amino]-4-pyrimidin-2-yl}phenyl)]- (9CI) (CA INDEX NAME)



RN 895635-29-7 CAPLUS
CN Benzamide, N-[(3-{2-[(1H-benzotriazol-5-ylamino)-4-pyrimidin-2-yl}phenyl)]- (9CI) (CA INDEX NAME)




RN 895635-30-0 CAPLUS
CN Benzamide, N-[(3-{2-[(4-(aminosulfonyl)phenyl)amino]-4-pyrimidin-2-yl}phenyl)]- (9CI) (CA INDEX NAME)




RN 895635-31-1 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-(trifluoromethyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-32-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-33-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(5-oxazolyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-34-4 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-[(acetyl)amino]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895635-35-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[3-[2-[(3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-37-7 CAPLUS
CN 4-isoxazolecarboxamide, N-[3-[2-[(3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 895635-38-8 CAPLUS


CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-39-9 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-6-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-41-3 CAPLUS
CN Benzamide, N-[3-[3-[2-[[4-[[3-(dimethylamino)propyl]amino]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-43-5 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-45-7 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-48-0 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[3-(5-oxazolyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-49-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[3-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-50-4 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-51-5 CAPLUS
CN Benzamide, N-[3-[2-[(3-(acetyl amino)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-52-6 CAPLUS

CN Benzamide, N-[3-[2-[(3-cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-53-7 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[(3-(2-oxo-1-pyrrolidinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-54-8 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[(3-(2-oxo-1-pyrrolidinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 895635-55-9 CAPLUS
CN Benzamide, N-[3-[2-[[4-[(ethylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-56-0 CAPLUS
CN Benzamide, N-[3-[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 895635-57-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-58-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[2-[[3-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-59-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[2-[[3-(4-morpholinyl)propyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-62-8 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[4-[(2-(4-morpholinyl)ethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


o]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-63-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-64-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(2-hydroxyethyl)sulfonyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-65-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-66-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-67-3 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-[(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-72-0 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-73-1 CAPIUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-75-3 CAPIUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[(6-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-76-4 CAPIUS
CN 3-Pyridinecarboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-77-5 CAPIUS
CN 5-Isoxazolecarboxamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]- (9CI) (CA INDEX NAME)




RN 895635-78-6 CAPIUS
CN Benzamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 895635-79-7 CAPIUS
CN Benzamide, N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl}phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN	895635-80-0	CAPLUS	
CN	Benzamide, 2-chloro-N-[3-[3-[2-((3-fluorophenyl)amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl-		(CA INDEX NAME)




RN	895635-81-1	CAPLUS
CN	Benzamide, 3-fluoro-N-[3-[2-(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2-methyl-	(CA INDEX NAME)




RN	895635-82-2	CAPLUS	(CA INDEX NAME)
CN	Benzamide, 2,6-difluoro-N-[3-{3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl-		




RN	895635-83-3	CAPLUS
CN	4-Pyridinecarboxamide, 2-chloro-N-(3-[3-(2-[(3-fluorophenyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl)-(9CI)	(CA INDEX NAME)




895635-84-4	CAPLUS
3-Pyridinecarboxamide, 6-chloro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI)	(CA INDEX NAME)




RN	895635-85-5	CAPLUS
CN	4-Pyridinecarboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI)	(CA INDEX NAME)




RN 895635-86-6 CAPLUS
CN 2-Thiophenecarboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 895635-87-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895635-88-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-bromo-N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-89-9 CAPLUS
CN 3-Thiophenecarboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-90-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


pyrimidinylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895635-91-3 CAPLUS
CN Benzamide, 5-fluoro-N-[3-{2-[(3-fluorophenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-92-4 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[3-{2-[(3-fluorophenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895635-93-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{2-[(3-isoxazolylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 895635-96-8 CAPLUS
CN Benzamide, N-[3-{2-[(3-chloro-4-methoxyphenyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-97-9 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-cyano-4-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-98-0 CAPLUS
CN Benzamide, N-[3-[3-[2-[(4-chloro-3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-99-1 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-cyano-4-(1H-pyrazol-1-yl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895636-00-7 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-01-8 CAPLUS
CN Benzamide, N-[3-[3-[2-[(4-chlorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-02-9 CAPLUS
CN Benzamide, N-[3-[3-[2-[(4'-cyano[1,1'-biphenyl]-4-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)


RN 895636-05-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(4-(phenylamino)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-06-3 CAPLUS
CN Benzamide, N-[3-[3-[2-[(2,3-dimethyl-6-quinoxaliny)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-07-4 CAPLUS
CN Benzamide, N-[3-[3-[2-[(4-benzoylphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-03-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(4-(4-pyridinylmethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-04-1 CAPLUS
CN Benzamide, N-[3-[3-[2-[(4-cyano-3-methylphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




pyrimidinylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-11-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-(phenylacetamido)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-12-1 CAPLUS
CN Benzamide, N-[3-[3-[2-[[4-((cyclopropylamino)carbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-10-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-((1H-pyrazol-3-yl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-08-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[3-fluoro-4-((4-morpholinyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-09-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-((4-morpholinyl)carbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-13-2 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-14-3 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-[2-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-15-4 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895636-16-5 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-17-6 CAPLUS
 CN Benzamide, N-[3-[3-[2-[[4-[(dimethylamino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-18-7 CAPIUS

CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-19-8 CAPIUS

CN Benzamide, N-[3-[2-[[3-[[[(dimethylamino)acetyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-20-1 CAPIUS

CN Benzamide, 2,6-difluoro-N-[3-[2-[[4-methoxy-3-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-21-2 CAPIUS

CN Benzamide, N-[3-[2-[[4-[[3-(dimethylamino)propyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-22-3 CAPIUS

CN Benzamide, N-[3-[2-[[4-[[[(dimethylamino)acetyl]amino]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-23-4 CAPIUS


CN Benzamide, N-[3-[3-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895636-24-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-25-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(4-[(methylsulfonyl)methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-29-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 895636-26-7 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-(aminosulfonyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-27-8 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3-[2-(aminosulfonyl)ethyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-30-3 CAPLUS
CN Benzamide, N-[3-[(2-methoxy-4-
pyrimidin-2-yl)phenyl]amino]-4-
pyrimidin-2-yl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA
INDEX NAME)




RN 895636-31-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(2-methoxy-4-
[(methoxycarbonyl)methyl]phenyl)amino]-4-pyrimidin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-36-9 CAPLUS
CN Benzamide, N-[3-[(2-[[3-chloro-4-(2-methoxyethoxy)phenyl]amino]-4-
pyrimidin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA
INDEX NAME)




RN 895636-37-0 CAPLUS
CN Benzamide, N-[3-[(2-[[3-chloro-4-(3-(dimethylamino)propoxy)phenyl]amino]-4-
pyrimidin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA
INDEX NAME)




RN 895636-38-1 CAPLUS
CN Benzamide, N-[3-[(2-[[3-chloro-4-(2-(4-morpholinyl)ethoxy)phenyl]amino]-4-
pyrimidin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA
INDEX NAME)




RN 895636-39-2 CAPLUS
CN Benzamide, N-[3-[3-[2-[[[3-chloro-4-(2-(dimethylamino)ethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-41-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[[3-fluoro-4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-42-7 CAPLUS
CN Benzamide, N-[3-[3-[2-[[[4-amino-2-fluorophenoxy]propyl]methoxy]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895636-43-8 CAPLUS
CN Benzamide, N-[3-[3-[2-[[[4-(3-(diethylamino)propoxy]-3-fluorophenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-45-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[[[3-fluoro-4-(2-(2-oxo-1-pyrrolidinyl)ethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-47-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[[[3-fluoro-4-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-58-5 CAPLUS
CN Benzamide, 4-chloro-N-[3-{3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-59-6 CAPLUS
CN Benzamide, 3-amino-N-[3-{3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-60-9 CAPLUS
CN Benzamide, 4-amino-N-[3-{3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-61-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-methyl-N-[3-{2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-62-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[[3-fluoro-4-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-64-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{3-[2-[[3-fluoro-4-(1-pyrazolidinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-65-4 CAPLUS
CN 1H-Pyrazole-2-carboxamide, 1-methyl-N-[3-{3-[2-(phenylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-69-8 CAPLUS
CN 1H-pyrrole-2-carboxamide, N-[3-[3-[2-[(3-cyanophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 895636-82-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-(phenylamino)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-83-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895636-84-7 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-85-8 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-methyl-3-[2-[(3-trifluoromethyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-87-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-88-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(3-fluoro-4-methoxyphenyl)amino]-4-pyrimidinyl]-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-89-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(7-methoxy-3-[(2-[(3-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-91-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[2-methoxy-5-[3-[(2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-99-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[2-fluoro-5-[3-[(2-[(1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-06-6 CAPLUS
CN 1-Propanesulfonic acid, 3-[2-chloro-4-[(4-[2-[(3-[(2,6-difluorobenzoyl)amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl)]-2-pyrimidinyl)aminophenoxy]- (9CI) (CA INDEX NAME)




RN 895637-07-7 CAPLUS
 CN Butanoic acid, 4-[[2-chloro-4-[[4-[[2-[[3-[[2,6-difluorobenzoyl]amino]phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 895637-08-8 CAPLUS
 CN Benzamide, N-[3-[[3-[[2-[[3-chloro-4-[[2-[[methylsulfonyl]amino]ethoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-09-9 CAPLUS
 CN Benzamide, N-[3-[[3-[[2-[[3-chloro-4-[[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895637-11-3 CAPLUS
 CN Formic acid, compd. with N-[3-[[3-[[2-[[3-[[3-(dimethylamino)propoxy]-4-

methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide (9CI) (CA INDEX NAME)


CM 1
 CRN 895637-10-2
 CMF C36 H33 F2 N7 O3




CM 2
 CRN 64-18-6
 CMF C H2 O2




RN 895637-13-5 CAPLUS
 CN Benzamide, N-[3-[[3-[[2-[[3-[[2-[[3-(dimethylamino)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-14-6 CAPLUS
 CN Benzamide, N-[3-[[3-[[2-[[3-[[2-[[3-(dimethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-20-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-21-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(4-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-22-6 CAPLUS
CN Benzamide, N-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895637-25-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(6-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-26-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(6-fluoro-3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-27-1 CAPLUS

CN Benzamide, N-[3-[3-[2-[(7-amino-5,6,7,8-tetrahydro-2-naphthalenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-30-6 CAPLUS
CN Benzamide, N-[3-[7-(dimethylamino)-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1
CRN 895637-29-3
CMF C32 H24 F3 N7 O




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 895637-33-9 CAPLUS
CN Benzamide, N-[3-[3-[2-[(2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895637-36-2 CAPLUS
CN Benzamide, N-[3-[3-[2-[(2-amino-2,3-dihydro-1H-inden-5-yl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-38-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-[2-[(3-(4-methyl-5-oxazolyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 895637-41-9 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isouquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)


CM 1
 CRN 895637-46-4
 CMF C35 H28 F3 N7 O




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 895637-50-0 CAPLUS
 CN Benzamide, N-[5-[3-[2-([3-([2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluoro-(9CI) (CA INDEX NAME)




RN 895637-53-3 CAPLUS



RN 895637-42-0 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[2-([1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 895637-43-1 CAPLUS
 CN Benzamide, N-[3-[2-([3-(aminomethyl)phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-(9CI) (CA INDEX NAME)




RN 895637-47-5 CAPLUS
 CN Benzamide, N-[5-[3-[2-([2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,6-difluoro-mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CN Benzamide, 2,6-difluoro-N-[3-[2-[[3-[(2,6-difluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-(9CI) (CA INDEX NAME)



RN 895637-56-6 CAPLUS
CN Benzamide, N-[3-[2-[[3-[(2,6-difluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-(9CI) (CA INDEX NAME)




RN 895637-58-8 CAPLUS
CN Benzamide, N-[3-[2-[[3-[(2,6-difluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-(9CI) (CA INDEX NAME)




RN 895637-62-4 CAPLUS

CN Benzamide, N-[3-[2-[[3-[(2,6-difluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-(9CI) (CA INDEX NAME)


CM 1
CRN 895637-61-3
CMF C35 H30 Cl F2 N7 O2



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 895637-65-7 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[[3-[(2,6-difluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]amino]-(9CI) (CA INDEX NAME)




RN 895637-70-4 CAPLUS


CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-[2-[(2-(methylsulfonyl)ethyl]amino)methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-72-6 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-75-9 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-[(3-[2-[(dimethylamino)ethoxy]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl]- (9CI) (CA INDEX NAME)




RN 895637-76-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-[2-[(3-fluorophenyl]amino)-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-84-0 CAPLUS
CN Benzamide, N-[5-[3-[2-[(3-[2-[(3-[2-[(dimethylamino)methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-85-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-[(3-[2-[(3-fluorophenyl]amino)-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-90-8 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-(dimethylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-92-0 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-(methyl-2-propenylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-93-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-[2-[(3-[2-(methyl-2-propenylamino)ethoxy]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895637-95-3 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-(dimethylamino)ethoxy}phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-96-4 CAPLUS
CN Benzamide, N-[3-[2-[(3-[2-(dimethylamino)ethoxy}phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-98-6 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[2-[(3-[2-(methyl-5-benzothiazolyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)


pyrimidinylpyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)





RN 895638-09-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isouinoliny]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 895638-10-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(3-fluoro-4-[(1-methyl)-2-pyrrolidiny]methoxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)



RN 895637-99-7 CAPLUS
CN Benzamide, N-[3-[3-[2-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-7-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895638-00-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 895638-01-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-[5-fluoro-2-[(3-fluorophenyl]amino]-4-

RN 895638-11-6 CAPUS

CN Benzamide, 2,6-difluoro-N-[3-[3-[2-[2-[(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-
alpyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




IT

895634-85-2P, 3-[2-(Methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895634-86-3P, 3-[2-(Methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895634-87-4P, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 895634-88-8P, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-pyrimidinamine 895635-03-7P, 895635-04-8P, 2,2,2-trifluoro-N-[3-[3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895635-05-9P, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl](3-fluorophenyl)amine 895635-25-3P, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895635-46-8P, N-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,5-difluorobenzamide 895635-69-3P, N-[3-(3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-71-9P, N-[3-[3-[2-[(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895635-74-2P 895636-50-7P 895636-51-8P, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-(1-pyrrolidinyl)ethyl]oxy]phenyl]-2-pyrimidinamine 895636-70-1P, N-[3-[5-(hydroxymethyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895636-71-2P, 5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895636-72-3P, 3-[2-(Methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)-5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-3-[2-(methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)pyrazolo[1,5-a]pyridine 895636-74-5P, 5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]methyl]-2-(3-nitrophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 895636-75-6P, 895636-76-6P, 3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-5-yl]methanol 895636-80-3P, N-[3-[3-(2-methylsulfonyl)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-81-4P, N-[3-[3-(2-methylsulfonyl)-4-pyrimidinyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-86-9P, N-[3-[3-(2-chloropyrimidin-4-yl)-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895636-90-5P, N-[3-[3-(2-chloropyrimidin-4-yl)-7-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide


895636-95-0P, 2,2,2-trifluoro-N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-(methylthio)phenyl]acetamide 895636-96-1P, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-(methylthio)phenyl]-2,6-difluorobenzamide 895636-97-2P, 2,6-difluoro-N-[2-(methylthio)-5-[3-[2-[(2-trifluoroacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-03-3P 895637-04-4P, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorobenzamide 895637-05-5P, 2,6-difluoro-N-[2-fluoro-5-[3-[2-[(2-trifluoroacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-16-8P 895637-18-0P, 3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]aniline 895637-19-1P, N-[3-[3-(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895637-23-7P, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluorobenzamide 895637-28-2P, 2,6-difluoro-N-[3-[3-[2-[(7-(trifluoroacetyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-31-7P, 2-(3-bromophenyl)-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-7-amine 895637-37-3P, 2,6-difluoro-N-[3-[3-[2-[(2-trifluoroacetyl)amino]-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-45-3P, 2,6-difluoro-N-[3-[3-[2-[(3-[(trifluoroacetyl)amino]methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-48-6P, 2,2,2-trifluoro-N-[5-[3-[2-[(2-dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]acetamide 895637-52-2P, 4-[2-(3-amino-4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-[(2-dimethylamino)ethyl]oxy]phenyl]-2-pyrimidinamine 895637-55-5P, 2,6-difluoro-N-[3-[3-[2-[(3-[(methyl trifluoroacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-57-7P, 2,5-difluoro-N-[3-[3-[2-[(3-[(trifluoroacetyl)amino]methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-69-1P, 2,5-difluoro-N-[3-[3-[2-[(3-[(2-methylsulfonyl)ethyl]amino]methyl]phenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]benzamide 895637-71-5P, 2,6-difluoro-N-[3-[3-[2-[(3-[(2-methylsulfonyl)ethyl]amino]methyl]phenyl]amino]methyl]phenyl]benzamide 895637-73-7P, 2,2,2-trifluoro-N-[3-[3-[2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895637-74-8P, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-2-methyl-1,2,3,4-tetrahydro-7-isoquinolinamine 895637-89-5P, 4-[2-(3-bromophenyl)-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-[3-fluorophenyl]-2-pyrimidinamine 895637-94-2P, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-[(methyl(2-propen-1-yl)amino)ethyl]oxy]phenyl]-2-pyrimidinamine 895637-97-5P, 2,2,2-trifluoro-N-[3-[3-[2-[(3-[3-chloropropyl]oxy]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide 895638-03-6P, 2-(3-bromophenyl)-3-[2-chloro-5-fluoro-4-[2-(3-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)-2-pyrimidinamine 895638-05-8P, N-[4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-2-pyrimidinyl]-2-methyl-1,2,3,4-tetrahydro-7-isoquinolinamine

895638-07-0P, 2,2,2-Trifluoro-N-[3-[3-(2-Chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide
 895638-08-1P, 2,2,2-Trifluoro-N-[3-[3-(5-fluoro-2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]acetamide
 RL: RCI (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(Intermediate; preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors for treating neoplasm)
 RN 895634-85-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 895634-86-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylsulfinyl)-4-pyrimidinyl]-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 895634-87-4 CAPLUS
 CN 2-Pyrimidinamine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[2-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 895634-88-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,3-


dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)




RN 895635-03-7 CAPLUS
 CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895635-04-8 CAPLUS
 CN Acetamide, N-[3-[3-(3-(3-(3-fluorophenyl)amino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-05-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 895635-25-3 CAPLUS
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-46-8 CAPLUS
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895635-69-5 CAPLUS
CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-71-9 CAPLUS
CN Benzamide, N-[3-[3-(2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895635-74-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[3-(2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-50-7 CAPLUS
CN Acetamide, N-[3-[3-(2-[[3-(2-chloroethoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895636-51-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(2-(1-pyrrolidinylethoxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 895636-70-1 CAPLUS
CN Benzamide, N-[3-[5-(hydroxymethyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-71-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)]- (9CI) (CA INDEX NAME)




RN 895636-72-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[2-(methylthio)-4-pyrimidinyl]-2-(3-nitrophenyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 895636-73-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-3-[2-(methylsulfonyl)-4-pyrimidinyl]-2-(3-nitrophenyl)]- (9CI) (CA INDEX NAME)




RN 895636-74-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-2-(3-nitrophenyl)-3-(4-pyrimidinyl)]- (9CI) (CA INDEX NAME)




RN 895636-75-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanol, 2-(3-aminophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 895636-80-3 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[3-(2-(methylthio)-4-pyrimidinyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-81-4 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[3-[3-(2-(methylsulfinyl)-4-pyrimidinyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895636-86-9 CAPLUS
 CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-7-methylpyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-90-5 CAPLUS
 CN Benzamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-7-methoxypyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-95-0 CAPLUS
 CN Acetamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895636-96-1 CAPLUS
 CN Benzamide, N-[5-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-methoxyphenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895636-97-2 CAPLUS
 CN Benzamide, 2,6-difluoro-N-[2-methoxy-5-[3-[2-[[1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isquinolyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-03-3 CAPIUS
CN Acetamide, N-[5-{3-[(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl}-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895637-04-4 CAPIUS
CN Benzamide, N-[5-{3-[(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl}-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-05-5 CAPIUS
CN Benzamide, 2,6-difluoro-N-[2-fluoro-5-{3-[(1,2,3,4-tetrahydro-2-(trifluoroacetyl)-7-isoquinolinyl]amino}-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl- (9CI) (CA INDEX NAME)




RN 895637-16-8 CAPIUS
CN Acetamide, N-[3-{3-[(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl}-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895637-18-0 CAPIUS
CN Benzenamine, 3-[3-[(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-19-1 CAPIUS
CN Benzamide, N-[3-{3-[(2-chloro-4-pyrimidinyl)-4-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl}-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-23-7 CAPLUS
CN Benzamide, N-[3-[(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-28-2 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(2-[[5,6,7,8-tetrahydro-7-(trifluoroacetyl)amino]-2-naphthalenyl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-31-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-3-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 895637-37-3 CAPLUS
CN Benzamide, N-[3-[(2-[(2,3-dihydro-2-[(trifluoroacetyl)amino]-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 895637-45-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-[(2-[(3-[(trifluoroacetyl)amino]methyl]phenyl)amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-48-6 CAPLUS
CN Acetamide, N-[5-[3-[(2-[(2-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]amino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]-2-fluorophenyl]-2,2,2-trifluoroethyl]- (9CI) (CA INDEX NAME)





RN 895637-55-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[3-{2-[[3-[[methyl(trifluoroacetyl)amino]meth-
yl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA
INDEX NAME)




RN 895637-57-7 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-{2-[[3-[[[trifluoroacetyl]amino]methyl]phe-
nyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA
INDEX NAME)




RN 895637-69-1 CAPLUS
CN Benzamide, 2,5-difluoro-N-[3-{2-[[3-[[[2-(methylsulfonyl)ethyl](trifluo-
roacetyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-
yl]phenyl]- (9CI) (CA INDEX NAME)







RN 895637-71-5 CAPLUS
CN Benzamide, 2,6-difluoro-N-[(3-{[3-{[2-(methylsulfonyl)ethyl] (trifluoroacetyl)amino]methyl}phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-73-7 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-[3-[2-{[1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-74-8 CAPLUS
CN 7-Isoquinolinamine, N-[4-[2-{(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-1,2,3,4-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 895637-89-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 895637-94-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[2-(methyl-2-propenylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 895637-97-5 CAPLUS
CN Acetamide, N-[3-[3-[2-{[3-(3-chloropropoxy)phenyl]amino]-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 895638-03-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-bromophenyl)-3-(2-chloro-5-fluoro-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 895638-04-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]-5-fluoro-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 895638-05-8 CAPLUS
CN 7-Isoquinolinamine, N-[4-(2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)-5-fluoro-2-pyrimidinyl]-1,2,3,4-tetrahydro-2-methyl-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoroacetamide (9CI) (CA INDEX NAME)



RN 895638-07-0 CAPLUS
CN Acetamide, N-[3-(2-chloro-5-fluoro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 895638-08-1 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-(3-[3-(5-fluoro-2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino]-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl)- (9CI) (CA INDEX NAME)




IT 895635-36-6, 4-[2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-1-(3-fluorophenyl)-2-pyrimidinamine 895635-40-2 895635-70-8
[3-(3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]amine
895636-53-0, N-[4-(2-(3-Aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl]phenylamine 895636-63-2, 3-[3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-N-(2,6-difluorophenyl)benzamide
895637-24-8, 3-[3-(2-Chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-


a)pyridin-2-yl]aniline 895637-63-5, N-[3-(3-(2-Chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]-2,6-difluoro-3-methylbenzamide

RL: RCT (Reactant); RACT (Reactant or reagent)
for preparing of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors


RN 895635-36-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-1-(3-fluorophenyl)-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 895635-40-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 895635-70-8 CAPLUS
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 895636-53-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 895636-63-2 CAPLUS
CN Benzenamide, 3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 895637-24-8 CAPLUS
CN Benzenamine, 3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 895637-63-5 CAPLUS
CN Benzenamide, N-[3-[3-(2-chloro-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,6-difluoro-3-methyl- (9CI) (CA INDEX NAME)



IT 895637-17-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 2-pyrimidinyl pyrazolopyridines as ErbB kinase inhibitors
 for treating neoplasms)
 RN 895637-17-9 CAPLUS
 CN Acetamide, N-[3-[3-(2-chloro-4-pyrimidinyl)-6-fluoropyrazolo[1,5-a]pyridin-2-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:496072 CAPLUS
 DOCUMENT NUMBER: 145:8184
 TITLE: Process for preparing pyrazolopyridine compounds
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006055245	A2	20060526	WO 2005-US39571	20051101
WO 2006055245	A3	20060817		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GM, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPL. INFO.: MARPAT 145:8184				
OTHER SOURCE(S): US 2004-628820P P 20041117				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The present invention provides a process for preparing pyrazolopyridine compounds. I [R1 = (hetero)aryl; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, cycloalkyl, etc.; p = 0-3; R6 = halo, alkyl, cycloalkyl, etc.] comprising the steps of

(a) reacting II with a hindered amide base to produce an anion and reacting the anion with 9-methoxy-9-borabicyclo[3.3.1]nonane; (b) adding a compound R1X (wherein X = halo or triflate) in the presence of a palladium catalyst to prepare a compound of formula I wherein R2 = SMe; (c) optionally converting I into its pharmaceutically acceptable salt or solvate; and (d) optionally converting I or a pharmaceutically acceptable salt or solvate into a different compound I. Thus, treating 2-(4-fluorophenyl)-3-(2-(methylthio)pyrimidin-4-yl)pyrazolo[1,5-a]pyridine (2-step synthesis given) with lithium diisopropylamide in THF followed by addition of 9-methoxy-9-borabicyclo[3.3.1]nonane, and after 1 h K3PO4, DMF, 4-iodotoluene and PdCl2(dppf):CH2Cl2 afforded 67% III.


IT 401816-34-OP 888021-52-1P 888021-53-2P
 888021-54-3P 888021-55-4P 888021-69-OP
 888021-71-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (process for preparing pyrazolopyridine compds.)


RN 401816-34-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 888021-52-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(4-methoxyphenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 888021-53-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(3-methoxyphenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 888021-54-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 888021-55-4 CAPLUS
CN Ethanone, 1-{4-[2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-7-yl]phenyl}- (9CI) (CA INDEX NAME)




RN 888021-69-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-58-7 CAPLUS
CN Benzenamine, 4-[2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




IT 888021-56-5P 888021-57-6P 888021-58-7P
888021-59-8P 888021-60-1P 888021-61-2P
888021-62-3P 888021-63-4P 888021-64-5P
888021-65-6P 888021-66-7P 888021-67-8P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing pyrazolopyridine compds.)
RN 888021-56-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(4-fluorophenyl)-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-57-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(3-methoxyphenyl)-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-59-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 888021-60-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-(cyclopropylmethoxy)phenyl)-7-(4-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-61-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-(cyclopropylmethoxy)phenyl)-7-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 888021-62-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-(cyclopropylmethoxy)phenyl)-7-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 888021-63-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-(cyclopropylmethoxy)phenyl)-7-(3-methylphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 888021-64-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




L5 ANSWER 7 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:386432 CAPLUS
 DOCUMENT NUMBER: 144:425692
 TITLE: Methods using TGF- β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries
 INVENTOR(S): Ling, Leona E.; Fu, Kai; Gill, Alan; Gotwals, Philip J.
 PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
 SOURCE: PCT Int. Appl., 228 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044509	A2	20060427	WO 2005-US36770	20051013
WO 2006044509	A3	20060817		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005295734	A1	20060427	AU 2005-295734	20051013
PRIORITY APPL. INFO.:			US 2004-619116P	P 20041015
			WO 2005-US36770	W 20051013


OTHER SOURCE(S): MARPAT 144:425692
 AB The invention discloses the use of TGF- β type I receptor inhibitors and Alk4 inhibitors and implantable devices including these compounds in treating, preventing, or reducing intimal thickening, vascular remodeling, restenosis (e.g., coronary, peripheral, carotid restenosis), vascular diseases, (e.g., organ transplant-related, cardiac, lung and renal), and hypertension (e.g., primary and secondary hypertension, systolic hypertension, pulmonary hypertension, and hypertension-induced vascular remodeling resulting in target organ damage).

IT RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TGF- β type I receptor inhibitors and Alk4 inhibitors for treating vascular injuries)


RN 672932-46-6 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 672932-50-2 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 672932-51-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:342780 CAPLUS
 DOCUMENT NUMBER: 144:390930
 TITLE: Preparation of pyridazinone derivatives as inhibitors of the production and transduction of cytokines

INVENTOR(S): Yamazaki, Hitoshi; Kasahara, Chiyoashi; Shigenaga, Shinji; Higuchi, Koichi; Mizuhara, Hidekazu; Yasuda, Minoru; Yokomoto, Masaharu; Misumi, Keiji; Kinoshita, Tomohiko; Katayama, Kimiko
 PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan; Wakunaga Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 124 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006038734	A1	20060413	WO 2005-JP18901	20051007
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ,			

LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZB, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MM, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, LS, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: AU 2004-905844 A 20041008
OTHER SOURCE(S): MARPAT 144:390930

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and II [R1 = (un)substituted lower alkyl, aryl; R2 = (un)substituted aryl or thienyl; R3 = H, lower alkyl; A = O, S; R4 = H, (un)substituted amino, piperazin-1-yl, etc.; R5 = H, lower alkyl, hydroxy(lower)alkyl; R6 = H, (un)substituted amino, N-lower alkoxy(carbonyl)piperazinyl; or R5R6 = -Y-CH-CH-CH-, -Z-(CH2)3-, Y = CH, N; Z = CH2, NH; with provisos; and their salts] were prepared as inhibitors of the production and transduction of cytokines. Thus, reacting 6-[2-amino-4-(4-fluorophenyl)-1,3-thiazol-5-yl]-3(2H)-pyridazinone (preparation given) with 1-oxaspiro[2.5]octane in dioxane in the presence of NaOH gave pyridazinone III. Pyridazinone III inhibited TNF- α production in THP-1 cells at 100 nM. I and II are useful for treating cytokines mediated diseases, such as pain, rheumatoid arthritis, inflammation, psoriasis, etc.

IT 882975-01-1P, 2-[(1-hydroxycyclohexyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug candidate; preparation of pyridazinones as inhibitors of the production and transduction of cytokines)


RN 882975-01-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-hydroxycyclohexyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 882974-78-9P, 2-(2,6-dichlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone 882975-12-4P, 2-(2-chlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone 882975-13-5P, 2-(2-methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of pyridazinones as inhibitors of the production and transduction of cytokines)

RN 882974-78-9 CAPLUS


CN 3(2H)-Pyridazinone, 2-(2,6-dichlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 882975-12-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-chlorophenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 882975-13-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methylphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 131185-06-3, 6-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone
RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of pyridazinones as inhibitors of the production and transduction of cytokines)

RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 9 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN


2006:19715 CAPLUS
 144:163524
 Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines
 with potent activity against herpesviruses
 Allen, Scott H.; Johns, Brian A.; Gudmundsson,
 Kristjan S.; Freeman, George A.; Boyd, F. Leslie;
 Sexton, Connie H.; Selleseth, Dean W.; Creech, Katrina
 L.; Moniri, Kelly R.
 Department of Medicinal Chemistry, GlaxoSmithKline
 Research and Development, Research Triangle Park, NC,
 27709, USA
 Bioorganic & Medicinal Chemistry (2006), 14(4),
 944-954
 CODEN: BMCEP; ISSN: 0968-0896
 Elsevier B.V.
 Journal
 English

CASREACT 144:163524
 AB A novel series of potent C-6 substituted pyrazolo[1,5-a]pyridine
 inhibitors of herpes simplex viruses has been identified. A synthetic
 methodol. was developed involving functionalization of a C-6
 trifluoromethyl pyrazolo[1,5-a]pyridine to allow facile access to a
 diverse set of analogs from common late stage intermediates. The
 expansion of the SAR of this series at the 6 position allows for
 modifications to developability parameters such as clog P, while
 maintaining potency comparable to acyclovir.
 468062-75-1P 473712-17-3P 474304-08-0P
 874668-24-3P

IT 468062-75-1P 473712-17-3P 474304-08-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 Preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 468062-75-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-
 2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473712-17-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-
 pyrimidinyl]-2-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 474304-08-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-
 (cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX
 NAME)




RN 874668-24-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-
 (4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 468062-82-0P 468062-84-2P 468063-30-1P
 473711-98-7P 473711-99-8P 474303-58-7P
 474303-60-1P 474303-61-2P 474303-62-3P
 474303-63-4P 474303-64-5P 474303-65-6P
 474303-66-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 468062-82-0 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-84-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-methanamine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468063-30-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 473711-98-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-6-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473711-99-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474303-58-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 474303-60-1 CAPLUS
 CN Pyrrolidine, 1-[(7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 474303-61-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 474303-62-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-hydroxy- (9CI)
(CA INDEX NAME)




RN 474303-63-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-(4-morpholinylethyl)- (9CI)
(CA INDEX NAME)




RN 474303-64-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(3-(1H-imidazol-1-yl)propyl)- (9CI)
(CA INDEX NAME)




RN 474303-65-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-hydroxy-1-(hydroxymethyl)ethyl)- (9CI)
(CA INDEX NAME)




RN 474303-66-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
(CA INDEX NAME)




IT 437611-97-7, GW 3733
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 437611-97-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-81-9P
 468062-83-1P 468063-25-4P 468063-27-6P
 468063-28-7P 468063-29-8P 473712-18-4P
 474304-03-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (pyrazolo[1,5-a]pyridines with potent activity against herpes viruses)
 RN 468062-79-5 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-81-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 468062-83-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[6-(bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-27-6 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-; ethyl ester (9CI) (CA INDEX NAME)




RN 468063-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)



RN 473712-18-4 CAPLUS
CN Carbamic acid, [3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 474304-05-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 88 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2005:1241434 CAPLUS
DOCUMENT NUMBER: 144:63899
TITLE: Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative
AUTHOR(S): Kinoshita, Takayoshi; Warizaya, Masaichi; Ohori, Makoto; Sato, Kentaro; Neya, Masahiro; Fujii, Takashi
CORPORATE SOURCE: Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd, Tsukuba, Ibaraki, 300-2698, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(1), 55-58
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

alpyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 871568-26-2 CAPLUS
CN 1H-Pyrazolo[3,4-c]pyridazin-1-ethanol, 3-amino-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 11 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1162315 CAPLUS
DOCUMENT NUMBER: 144:345937

TITLE: Synthesis and evaluation of [¹¹C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain

AUTHOR(S): Matsuya, Takahiro; Takamatsu, Hiroyuki; Murakami, Yoshihiro; Noda, Akihiro; Ichise, Rikuya; Awaga, Yuji; Nishimura, Shintaro

CORPORATE SOURCE: Basic Research Division, The Medical and Pharmacological Research Center Foundation, Ishikawa, 925-0613, Japan


SOURCE: Nuclear Medicine and Biology (2005), 32(8), 837-844
CODEN: NMBIEO; ISSN: 0969-8051

PUBLISHER: Elsevier Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This report describes the synthesis of [¹¹C]2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone ([¹¹C]FR194921), a highly selective, nonxanthine-type adenosine A1 receptor antagonist, used in brain imaging in rats and conscious monkeys as a potential novel PET tracer. [¹¹C]FR194921 was successfully synthesized in 19 min after [¹¹C]CH₃I formation. The radiochem. yield was 38±3%; and radioactivity was 4.1±0.4 GBq, calculated from end of synthesis; radiochem. purity was higher than 99%; and the specific radioactivity was 25.0±8.1 GBq/μmol-1 (n=5). In a rat experiment, the distribution of [¹¹C]FR194921 was higher in the hippocampus, striatum and cerebellum regions. This accumulation was significantly decreased by approx. 50% by pretreatment with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), an adenosine A1 receptor antagonist, which indicated specific binding of the radioligand to adenosine A1 receptors. In conscious monkey PET expts., [¹¹C]FR194921 accumulated in several regions of the brain, especially in the occipital cortex.




I

AB A series of pyrazolopyridazine compds. were briefly investigated as ERK2 inhibitors. The crystal structure of ERK2 complexed with the allyl derivative (I) was determined. The compound induces structural change including movement of

the glycine-rich loop and peptide flip between Met108-Glu109. As a result, the newly formed subsite can recognize small hydrophobic substituents but not hydrophilic ones.


IT 871568-25-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative)

RN 871568-25-1 CAPLUS
CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(2-propenyl)- (9CI) (CA INDEX NAME)



IT 865362-74-9 871568-24-0 871568-26-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative)

RN 865362-74-9 CAPLUS
CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (CA INDEX NAME)




RN 871568-24-0 CAPLUS
CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 1-methyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

thalamus and striatum. These results suggest that [11C]FR194921 can be used as an agent for imaging adenosine A1 receptors in vivo by positron emission tomog. (PET).

IT 881030-50-8P

RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (synthesis and evaluation of [11C]FR194921 as nonxanthine-type PET tracer for adenosine A1 receptors in brain)


RN 881030-50-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-(methyl-11C)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 202646-90-0, Desmethyl-FR194921

RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis and evaluation of [11C]FR194921 as nonxanthine-type PET tracer for adenosine A1 receptors in brain)

RN 202646-90-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1024651 CAPLUS
DOCUMENT NUMBER: 143:460071

TITLE: Pyrazolo[1,5-a]pyridines as p38 Kinase Inhibitors
AUTHOR(S): Stevens, Kirk L.; Jung, David K.; Alberti, Michael J.; Badiang, Jennifer G.; Peckham, Gregory E.; Veal, Jim M.; Cheung, Mui; Harris, Philip A.; Chamberlain, Stanley D.; Feel, Michael R.

CORPORATE SOURCE: Research and Development, Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA

SOURCE: Organic Letters (2005), 7(21), 4753-4756

CODEN: ORLEF7; ISSN: 1523-7060


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:460071

GI



I


AB A convergent synthesis of substituted pyrazolo[1,5-a]pyridines, e.g., I, has been achieved either via a regioselective [3 + 2]-cycloaddn. of N-aminopyridines with alkynes or by thermal cyclization of disubstituted azirines. Subsequent palladium-catalyzed introduction of pyridines or de novo synthesis of pyrimidines afforded inhibitors of p38 kinase.

IT 401816-10-2P 401816-13-5P 401816-14-6P
401816-32-8P 401816-41-9P 401816-44-2P
401816-51-1P 401816-54-4P 401816-57-7P
401816-61-3P 401816-62-4P 401816-67-9P
401816-68-0P 401816-79-3P 401816-80-6P
401816-89-5P 468062-94-4P 468062-95-5P
468062-99-9P 468063-20-9P 468063-23-2P
468063-44-7P 869334-80-5P 869334-81-6P
869334-82-7P 869334-83-8P 869334-84-9P
869334-85-0P 869334-86-1P 869334-87-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (regioselective preparation, p38 kinase inhibitory activity, and structure-activity relationship of pyrazolopyridines using a [3 + 2]-cycloaddn. or thermal cyclization as the key reaction)


RN 401816-10-2 CAPLUS

CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-14-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-41-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-44-2 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-51-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-54-4 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-61-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 401816-62-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-67-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-(4-methyl-1-piperazinyl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-68-0 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 401816-79-3 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-80-6 CAPLUS
CN 1,3-Propanediamine, N,N-dimethyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-89-5 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 468063-23-2 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-(2-(cyclopropylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 869334-80-5 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[4-fluoro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-94-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)-
(9CI) (CA INDEX NAME)



RN 468062-95-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-99-9 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-20-9 CAPLUS


CN 2-Pyrimidinamine, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 869334-85-0 CAPLUS
CN 1-Propanol, 3-[[4-[6-(trifluoromethyl)-2-[3-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 869334-86-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N,N-dimethyl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 869334-87-2 CAPLUS
CN 1-Propanol, 3-[[4-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 869334-81-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 869334-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 869334-83-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 869334-84-9 CAPLUS




IT 401815-97-2P 401816-29-3P 401816-55-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (regioselective preparation, p38 kinase inhibitory activity, and
 structure-activity relationship of pyrazolopyridines using a [3 +
 2]-cycloaddn. or thermal cyclization as the key reaction)
 RN 401815-97-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-
 (9CI) (CA INDEX NAME)



RN 401816-29-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(2-fluoro-4-
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-55-5 CAPLUS
 CN 2-Pyrimidinamine, 4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
 a]pyridin-3-yl}-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (9CI) (CA INDEX
 NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

15 ANSWER 13 OF 88 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:993256 CAPLUS
 DOCUMENT NUMBER: 143:318600
 TITLE: Identification of a selective ERK inhibitor and
 structural determination of the inhibitor-ERK2 complex
 AUTHOR(S): Otori, Makoto; Kinoshita, Takayoshi; Okubo, Mitsuru;
 Sato, Kentaro; Yamazaki, Akiko; Arakawa, Hiroyuki;
 Nishimura, Shintaro; Inamura, Noriaki; Nakajima,
 Hidenori; Neya, Masahiro; Miyake, Hiroshi; Fujii,
 Takashi
 CORPORATE SOURCE: Lead Discovery Research Laboratories, Astellas Pharma
 Inc., Tsukuba, Ibaraki, 300-8585, Japan
 SOURCE: Biochemical and Biophysical Research Communications
 (2005), 336(1), 357-363
 CODEN: BRC9; ISSN: 0006-291X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Selective inhibition of extracellular signal-regulated kinase (ERK)
 represents a potential approach for the treatment of cancer and other
 diseases; however, no selective inhibitors are currently available. Here,
 the authors describe an ERK-selective inhibitor, FR180204, and determine the
 structural basis of its selectivity. FR180204 inhibited the kinase
 activity of ERK1 and ERK2, with Ki values 0.31 and 0.14 μM, resp.
 Lineweaver-Burk anal. of the binding interaction revealed that FR180204
 acted as competitive inhibitor of ATP. In mink lung epithelial Mv1Lu
 cells, FR180204 inhibited TGFβ-induced luciferase-expression. X-ray
 crystal structure anal. of the human ERK2/FR180204 complex revealed that
 Q105, D106, I156, and C166, which form the ATP-binding pocket on ERK, play
 important roles in the drug/protein interaction. These results suggest
 that FR180204 is an ERK-selective and cell-permeable inhibitor, and could
 be useful for elucidating the roles of ERK as well as for drug
 development.
 IT 865362-74-9, FR 180204
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)
 (identification of a selective ERK inhibitor and structural determination of
 inhibitor-ERK2 complex)
 RN 865362-74-9 CAPLUS
 CN 1H-Pyrazolo[3,4-c]pyridazin-3-amine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)- (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


I5 ANSWER 14 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:777994 CAPLUS
 DOCUMENT NUMBER: 143:367266
 TITLE: Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses
 AUTHOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.; Wang, Zhicheng; Turner, Elizabeth M.; Allen, Scott H.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie J.; Selleseth, Dean W.; Moniri, Kelly R.; Creech, Katrina L.
 CORPORATE SOURCE: GlaxoSmithKline Research and Development, Department of Medicinal Chemistry, Research Triangle Park, NC, 27709-3398, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(18), 5346-5361
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:367266
 AB Herpesviruses are a significant source of human disease; amongst these herpes simplex virus 1 (HSV-1) and HSV-2 are very prevalent and cause recurrent infections. A pyrazolo[1,5-a]pyridine scaffold that showed promising activity against HSV-1 and HSV-2 in Vero cell antiviral assays was recently reported. Here, the synthesis and anti-herpetic activity of several 3-pyrimidinyl-2-(phenyl)pyrazolo[1,5-a]pyridine derivs. with differing 2-Ph substitution patterns is described. Approaches to rapidly access a number of analogs with different 2-Ph substitution patterns are outlined. Several of the compds. described have comparable activity to acyclovir against HSV-1 and HSV-2.
 IT 437611-97-7
 RL: PAC (Pharmacological activity); BIOL (Biological study) (preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of antiviral activity of N-cyclopentyl[(cyclopentylamino)pyrimidinyl](fluorophenyl)pyrazolo[1,3-a]pyridinamine)
 RN 437611-97-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 437611-98-8P 460078-20-0P 460078-26-6P
 460078-37-9P 460078-45-9P 460078-46-0P
 460078-55-1P 460078-60-8P 460078-71-1P
 460078-74-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)
 RN 437611-98-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-20-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-26-6 CAPLUS
 CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-37-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-aminophenyl)-N-cyclopentyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-aminophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(2-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-60-8 CAPLUS
CN Benzonitrile, 3-[7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-46-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-71-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-74-4 CAPLUS
CN Phenol, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




IT 437611-99-9P 437612-02-7P 437612-76-5P
460078-29-9P 460078-30-2P 460078-31-3P
460078-33-5P 460078-34-6P 460078-35-7P
460078-36-8P 460078-38-0P 460078-44-8P
460078-50-6P 460078-56-2P 460078-57-3P
460078-59-5P 460078-61-9P 460078-62-0P
460078-66-4P 460078-75-5P 460078-76-6P
460078-77-7P 460079-24-7P 866393-63-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation of (pyrimidinyl)phenyl)pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)
RN 437611-99-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-76-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-29-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-30-2 CAPLUS
CN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460078-31-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-33-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-34-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-(cyclobutylmethoxy)phenyl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-35-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-36-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl]-4-yl-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-38-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-(cyclohexylamino)phenyl)- (9CI) (CA INDEX NAME)




RN 460078-44-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-(dimethylamino)phenyl)- (9CI) (CA INDEX NAME)




RN 460078-50-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[1,1'-biphenyl]-3-yl-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-56-2 CAPLUS
CN Acetamide, N-[3-(7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-57-3 CAPLUS
CN Methanesulfonamide, N-[3-(7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-59-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 460078-61-9 CAPLUS
CN Benzamide, 3-[7-(cyclopentylamino)-3-(2-(cyclopentylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-62-0 CAPLUS
CN Benzoic acid, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl] - (9CI) (CA INDEX NAME)




RN 460078-66-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl) - (9CI) (CA INDEX NAME)




RN 460078-75-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(cyclopropylmethoxy)phenyl] - (9CI) (CA INDEX NAME)




RN 460078-76-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl) - (9CI) (CA INDEX NAME)




RN 460078-77-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl] - (9CI) (CA INDEX NAME)




RN 460079-24-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 866393-63-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(4-(1-methylpropoxy)phenyl)]- (9CI) (CA INDEX NAME)




IT 460078-70-0P 460079-65-6P 866393-64-8P
866393-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyrimidinyl)(phenyl)pyrazolo[1,5-a]pyridine derivs. and study of their activity against herpesvirus)
RN 460078-70-0 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-65-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 866393-64-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[(4-[(diphenylmethyl)amino]phenyl)]- (9CI) (CA INDEX NAME)



RN 866393-65-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-[(diphenylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT.

15 ANSWER 15 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:202833 CAPLUS
DOCUMENT NUMBER: 142:430228
TITLE: Pyrazolopyridine antihyperlipemics: SAR of C2' and C7 amine substituents
AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Turner,

Elizabeth M.; Allen, Scott H.; Samano, Vicente A.; Ray, John A.; Freeman, George A.; Boyd, F. Leslie; Sexton, Connie J.; Selleseth, Dean W.; Creech, Katrina L.; Moniri, Kelly R.

GlaxoSmithKline Research and Development, Department of Medicinal Chemistry, Research Triangle Park, NC, 27709-3398, USA

Bioorganic & Medicinal Chemistry (2005), 13(7), 2397-2411

CODEN: BMCEP; ISSN: 0968-0896 Elsevier Ltd.

Journal English

CASREACT 142:430228

CORPORATE SOURCE:

SOURCE:


PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GI




AB A series of potent pyrimidinylpyrazolo[1,5-a]pyridine inhibitors, e.g., I, of herpes simplex virus 1 replication have been identified. Several complementary synthetic methods were developed to allow facile access to a diverse set of analogs from common late stage intermediates. Detailed examination of the amine substituents at the C2' position of the pyrimidine and C7 position of the core pyrazolopyridine is described. The antiviral data suggested that non-polar amines were preferred for optimal activity. Admnl., the 2' position has been shown to require an NH group to retain activity levels similar to that of the gold standard acyclovir.

IT 437384-04-8P 437384-12-8P 437384-13-9P
437611-97-7P 437611-99-9P 437612-00-5P
437612-01-6P 437612-02-7P 437612-07-2P
437612-08-3P 437612-09-4P 437612-17-4P
437612-19-6P 437612-27-6P 437612-28-7P
437612-29-8P 437612-30-1P 437612-31-2P
437612-32-3P 437612-34-5P 437612-36-7P
437612-39-0P 437612-40-3P 437612-41-4P
437612-43-6P 437612-44-7P 437612-45-8P
437612-50-5P 850999-17-6P 850999-18-7P
850999-30-3P 850999-31-4P 850999-44-9P
850999-51-8P 850999-52-9P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, antitherapeutic activity, and structure-activity relationship of (aminopyrimidinyl)aminopyrazolopyridines)


RN 437384-04-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437384-12-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-((4-methoxyphenyl)amino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 437384-13-9 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-((4-fluorophenyl)amino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437611-97-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


RN 437612-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-07-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-08-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-09-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-[(4-fluorophenyl)-3-[2-[(4-morpholinyl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437611-99-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-01-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)







RN 437612-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-19-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-27-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-28-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 437612-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-31-2 CAPLUS


CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 437612-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-34-5 CAPLUS
CN 1-Propanol, 3-[[4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 437612-36-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 437612-39-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-40-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-41-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[2-(4-morpholinyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


RN 437612-43-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 437612-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 437612-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 437612-50-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 850999-17-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-1-pyrrolidinyl- (9CI) (CA INDEX NAME)




RN 850999-18-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 850999-30-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N,2-bis(4-fluorophenyl)-3-[2-(4-fluorophenyl)amino]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 850999-31-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N,2-bis(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 850999-44-9 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)]-7-(1-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 850999-51-8 CAPLUS
CN 1-Piperazineethanol, 4-[[4-(7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 850999-52-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[[4-(2-methoxyethyl)-1-piperazinyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 401816-34-0P 401816-35-1P 437612-22-1P
437612-33-4P 437613-05-3P 437613-07-3P
437613-08-6P 468062-98-8P 850999-40-3P
850999-41-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, antihypertensive activity, and structure-activity relationship of (aminopyrimidinyl)aminopyrazolopyridines)


RN 401816-34-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-22-1 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437612-33-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437613-07-5 CAPLUS
CN 2(1H)-Pyrimidinethione, 4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 437613-08-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468062-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 850999-40-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 850999-41-6 CAPLUS
CN 2-Pyrimidinamine, 4-(7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1068075 CAPLUS
DOCUMENT NUMBER: 142:168975
TITLE: "Lead Hopping". Validation of Topomer Similarity as a Superior Predictor of Similar Biological Activities
AUTHOR(S): Cramer, Richard D.; Jilek, Robert J.; Guesseger, Stefan; Clark, Stephanie J.; Wendt, Bernd; Clark, Robert D.
CORPORATE SOURCE: Tripos Discovery Research, Cornwall, EX23 8LY, UK
SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6777-6791
CODEN: JMCWAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Two extensive studies quantifying the ability of topomer shape similarity to forecast a variety of biol. similarities are described. In a prospective trial of "lead hopping", using topomer similarity for virtual screening and queries from the patent literature, biol. assays of 308 selected compds. (representing 0.03% of those available, per assay type) yielded 11 successful "lead hops" in the 13 assays attempted. The hit rate averaged over all assays was 39% ("activity" defined as inhibition 22% at 10 μ M), significantly greater than an unexpectedly high neg. control hit rate of 13%. The average "Tanimoto 2D fingerprint similarity" between query and "lead hop" structures (0.36) was little more than the Tanimoto similarity between random drug-like structures. Topomer shape and Tanimoto 2D fingerprint similarities were also compared retrospectively, in their tendencies to concentrate together potential and actual drugs reported to belong to the same "activity class", for twenty

classes. Among the most similar 3% of structures (corresponding to "20.85 Tanimoto" for these structures), an average of 62% of the topomer similar selection possessed a near neighbor belonging to the same activity class, roughly a one-third superiority over the "Tanimoto ≥ 0.85 " selection containing 48% actives in avoiding false positives. Conversely, the least similar 75% of structures contained 0.3% actives for topomer similarity vs. 1.0% actives for Tanimoto 2D fingerprint similarity, a 3-fold superiority for topomers in avoiding false negatives.

IT 202646-80-8
RL: PAC (Pharmacological activity); BIOL (Biological study) (validation of topomer similarity as a superior predictor of similar biol. activities of "Lead hopping")
RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:798011 CAPLUS
DOCUMENT NUMBER: 142:148488
TITLE: Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors
AUTHOR(S): Mamoto, Takuwa; Tada, Miho; Mihara, Takuma; Ueyama, Noriko; Matsuoka, Hideaki; Harada, Katsuya; Yamaji, Takayuki; Shirakawa, Kiyoharu; Kuroda, Satoru; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya; Mutoh, Seitaro
CORPORATE SOURCE: Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
SOURCE: Journal of Pharmacological Sciences (Tokyo, Japan) (2004), 96(1), 42-52
CODEN: JESTGJ; ISSN: 1347-8613
PUBLISHER: Japanese Pharmacological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Adenosine A1 receptors in the brain are believed to play an important role in brain functioning. We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone), and characterized the pharmacol. activity in the present study. FR194921 showed potent and selective affinity for the adenosine A1 receptor without affinity for A2A and A3 receptors and did not show any species differences in binding affinity profile among human, rat, and mouse. Pharmacokinetic study in rats revealed that FR194921 was orally active and highly brain penetrable. Oral administration of FR194921 dose-dependently ameliorated the hypolocomotion induced by the A1 receptor agonist N6-cyclopentyladenosine in rats, indicating this compound exerts A1-antagonistic action in vivo. In the passive avoidance test, scopolamine (1 mg/kg)-induced memory deficits were significantly ameliorated by FR194921 (0.32, 1 mg/kg). In two animal models of anxiety, the social interaction test and elevated plus maze, FR194921 showed specific anxiolytic activity without significantly influencing general behavior. In contrast, FR194921 did not show


antidepressant activity even at a dose of 32 mg/kg in the rat forced swimming test. These results indicate that the novel, potent, and selective adenosine A₁ receptor antagonist FR194921 exerts both cognitive-enhancing and anxiolytic activity, suggesting the therapeutic potential of this compound for dementia and anxiety disorders.

IT 202646-80-8, FR 194921

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmacol. characterization of FR194921)

RN 202646-80-8 CAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) [CA INDEX NAME]



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:343857 CAPLUS
 DOCUMENT NUMBER: 141:405831

TITLE: Effects of the adenosine A₁ receptor inhibitor FK 838 on proximal tubular fluid output in rats

AUTHOR(S): Bak, Martin; Thomsen Klaus

CORPORATE SOURCE: Institute for Basic Psychiatric Research, Department of Biological Psychiatry, Aarhus University Hospital, Risskov, DK-8240, Den.

SOURCE: Nephrology, Dialysis, Transplantation (2004), 19(5), 1077-1082

CODEN: NDTREA; ISSN: 0931-0509

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background. Adenosine A₁ receptor blockade has been suggested as a treatment in conditions with sodium and fluid retention because it increases urinary Na⁺ excretion and increases proximal tubular fluid output. In the present study, we examine the time course for the renal responses to adenosine A₁ receptor blockade in order to investigate whether the effects may be prolonged and not just temporary. Methods. The acute effects of the adenosine A₁ receptor inhibitor FK 838 on segmental tubular Na⁺ handling were examined by a renal clearance technique in conscious chronically instrumented rats. Lithium clearance (Cl_{Li}) was used as a clearance marker of proximal tubular fluid output. Results. Acute adenosine A₁ receptor inhibition did not affect the glomerular filtration rate (GFR) significantly. In contrast, the inhibition led to significant increases in Cl_{Li} (from 290±28 to 431±28 μl/min/100 g), fractional Li⁺ excretion (FELi) (from 33±2 to 47±3%) and fractional Na⁺ excretion (FENA) (from 0.44±0.07 to 2.03±0.42%). Sodium excretion, expressed as a fraction of proximal tubular fluid output (CNa/Cl_{Li}), rose from 1.3±0.2 to 4.2±0.4%, suggesting that the natriuretic effect was supported by inhibition of distal nephron Na⁺ reabsorption. All values returned to baseline values during the clearance study and thereby indicated that neither proximal tubular fluid output nor urinary sodium excretion remained elevated for a prolonged time. Conclusion. It is concluded that in conscious unstressed rats, acute adenosine A₁ receptor inhibition by FK 838 led to a significant natriuresis that was caused by inhibition of proximal tubular Na⁺


reabsorption, possibly with a contribution from inhibition of distal nephron Na⁺ reabsorption. The increased proximal tubular fluid output and the increased urinary Na⁺ excretion returned to baseline values during the clearance study, indicating that none of these effects of adenosine A₁ blockade were long lasting.

IT 131185-37-0, FK 838

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (diuretic FK 838 increased Cl_{Li}, FELi, CNa/Cl_{Li} and FENA without causing any significant change in GFR in conscious rat showing that natriuretic effect was due to combined effect on proximal tubules and distal nephron)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) [CA INDEX NAME]



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:333716 CAPLUS
 DOCUMENT NUMBER: 140:357367

TITLE: Preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection

INVENTOR(S): Gudmundsson, Kristjan S.; Johns, Brian A.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033454	A1	20040422	WO 2003-030334	20030924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2003275266	A1	20040504	AU 2003-275266	20030924
EP 1546148	A1	20050629	EP 2003-759540	20030924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504728	T	20060209	JP 2004-543022	20030924
US 2005282842	A1	20051222	US 2005-530101	20050401
US 7153863	B2	20061226		
US 2007112014	A1	20070517	US 2006-554615	20061031
PRIORITY APPLN. INFO.:			US 2002-415939P	P 20021003

OTHER SOURCE(S): WO 2003-US30334 W 20030924
US 2005-530101 A3 20050401
MARPAT 140:357367



AB The title compds. [I: p = 0-4; R1 = halo, alkyl, cycloalkyl, etc.; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; R5 = H, halo, alkyl, etc.] were prepared. Thus, coupling 2-fluoro-4-iodopyridine with pentene followed by reacting 3-(2-fluoro-4-(pent-1-ynyl)pyridine with 1-aminopyridinium iodide afforded 3-(2-fluoropyridin-4-yl)-2-propylpyrazolo[1,5-a]pyridine which showed IC50 of >40 µM against HSV-1. The pharmaceutical compns. comprising the compound I are claimed.


IT 681262-20-4P, 2-Cyclopropyl-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 681262-21-5P, N-Cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681262-22-6P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-cyclopropylpyrazolo[1,5-a]pyridin-7-amine

RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection)


RN 681262-20-4 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-cyclopropyl-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681262-21-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 681262-22-6 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-cyclopropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

I5 ANSWER 20 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267334 CAPLUS

DOCUMENT NUMBER: 140:303661

TITLE: Preparation of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases

INVENTOR(S): Beight, Douglas Wade; Bonjoukian, Rosanne; Liao, Junkai; McMillen, William Thomas; Parkhurst, Brandon Lee; Sawyer, Jason Scott; Yingling, Jonathan Michael; York, Jeremy Schulenburg

PATENT ASSIGNED(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 98 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026871	A1	20040401	WO 2003-US26297	20030916
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2003268156	A1	20040408	AU 2003-268156	20030916
EP 1543001	A1	20050622	EP 2003-749105	20030916
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005222197	A1	20051006	US 2005-524577	20050215
PRIORITY APPL. INFO.:			US 2002-411560P	P 20020917
			WO 2003-US26297	W 20030916
OTHER SOURCE(S):			MARPAT 140:303661	
GI				




AB Novel pyrazolopyridines (shown as I; variables defined below; e.g. II) are disclosed and their use as pharmaceutical agents, in particular their use as TGF- β signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF β . Inhibitory activities (IC50 in μ M) for >100 examples of I against TGF- β type I receptor kinase, TGF- β type II receptor kinase, p38 α /SRPK2 α , and TGF- β dependent luciferase production was at least 10, 20, 20, and 20, resp.; several specific values in each case are reported, e.g. 0.102 μ M for 4-[2-(5-butylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline in the TGF- β type I receptor kinase test. Although the methods of preparation are not claimed, approx. 130 I and approx. 90 intermediate example preps. and/or characterization data are included. For example, II was prepared (62 %) by coupling 3-bromo-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine with p-fluorophenylboronic acid. The pyridine reactant was prepared by action of N-bromosuccinimide on 2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid, which was prepared by base hydrolysis of 2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid diester, which was prepared by cyclization of 1-aminopyridinium iodide with (6-methylpyridin-2-yl)propynoic acid Et ester, which was prepared by reaction of Et chloroformate and BuLi with 2-ethyl-6-methylpyridine, which was prepared from 2-bromo-6-methylpyridine and trimethylsilylacetylene. For I: R1 is (un)substituted pyridine, furyl or thiophenyl; R2 is (un)substituted quinoline, Ph, naphthalene, pyridine, quinazoline, cinnoline, indole, imidazo[1,2-a]pyridin-2-yl, benzofuran, dihydrobenzofuran, dihydrobenzo[1,4]dioxane, benzodioxolane, benzochiophene, 2-aminobenzimidazole, imidazo[1,2-a]pyridine. R7 is H, benzyl, aryl, C1-C4 alkyls, halogens, -CO2(C1-C4 alkyl), -CONR6R6, -Cl-C4 alc., -SO2(C1-C4 alkyl), or -COR8, wherein R6 is (C1-C4 alkyl)R9, R8 is (C1-C4 alkyl) or (C2-C4 alkenyl), and R9 is NR3R4; wherein R3 and R4 = (C1-C4 alkyl); addnl. details are given in the claims.

IT 676343-50-3p, 7-Methoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-52-5p, 7-Methoxy-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-74-1p, 2-Fluoro-5-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzaldehyde 676343-84-3p, 4-[2-(6-Chloropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-03-9p, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 676344-04-0p, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-4-carboxylic acid ethyl ester 676344-14-2p, 7-Bromo-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-19-7p, 2-(6-Chloropyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-23-3p, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-bromoquinoline 676344-24-4p, 2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid ethyl ester 676344-25-5p, 2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid ethyl ester 676344-29-9p, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methyl ester 676344-40-4p, 3-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl]acrylic acid


methyl ester 676344-54-0p, [3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-6-yl]methanol
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrazolopyridines as TGF- β signal transduction inhibitors useful against cancer and other diseases)
 RN 676343-50-3 CAPLUS
 CN Quinoline, 7-methoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-52-5 CAPLUS
 CN Quinoline, 7-methoxy-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
 (CA INDEX NAME)




RN 676343-74-1 CAPLUS
 CN Benzaldehyde, 2-fluoro-5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-84-3 CAPLUS
 CN Quinoline, 4-[2-(6-chloro-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
 (CA INDEX NAME)




RN 676344-03-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (9CI). (CA INDEX NAME)




RN 676344-04-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-, ethyl ester (9CI). (CA INDEX NAME)




RN 676344-14-2 CAPLUS
CN Quinoline, 7-bromo-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI). (CA INDEX NAME)




RN 676344-19-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-chloro-2-pyridinyl)-3-(4-fluorophenyl)- (9CI). (CA INDEX NAME)




RN 676344-23-3 CAPLUS
CN Quinoline, 7-bromo-4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI). (CA INDEX NAME)




RN 676344-24-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 2-(2-pyridinyl)-3-(4-quinolinyl)-, ethyl ester (9CI). (CA INDEX NAME)




RN 676344-25-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(2-pyridinyl)-3-(4-quinolinyl)-, ethyl ester (9CI). (CA INDEX NAME)




RN 676344-29-9 CAPLUS
CN 7-Quinolincarboxylic acid, 4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI). (CA INDEX NAME)



RN 676344-40-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 676344-54-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




IT 676343-55-8P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-58-1P, Dimethyl[4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]amine 676343-59-2P, 3-(4-Methoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-60-3P, 3-[4-(Methanesulfonyl)phenyl]-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-61-6P, 2-(6-Methylpyridin-2-yl)-3-phenylpyrazolo[1,5-a]pyridine 676343-62-7P, 2-(6-Methylpyridin-2-yl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyridine 676343-63-8P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)-6-phenylpyrazolo[1,5-a]pyridine 676343-64-9P, 3-(4-Fluorophenyl)-6-methanesulfonyl-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-65-0P, 2-(6-Methylpyridin-2-yl)-3-(4-trifluoromethylphenyl)pyrazolo[1,5-a]pyridine 676343-66-1P, 3-(6-Methoxypyridin-3-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-67-2P, 3-(Benzodioxol-5-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-68-3P, 3-(3,5-Difluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-69-4P, 2-(6-Methylpyridin-2-yl)-3-(p-tolyl)pyrazolo[1,5-a]pyridine 676343-70-7P, 3-(1H-Indol-5-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-71-8P, 3-[2-(6-Methylpyridin-2-

yl)pyrazolo[1,5-a]pyridin-3-yl]benzamide 676343-72-9P, 3-(3,4-Dimethoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-73-0P, N,N-Dimethyl-3-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzamide 676343-75-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenylamine 676343-76-3P, N-[4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]acetamide 676343-77-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenol 676343-78-5P, 3-(2,3-Dihydro-benzol[1,4]dioxin-6-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-79-6P, 3-(3-Methoxyphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-80-9P, 3-(3-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-81-0P, 2-(6-Ethylpyridin-2-yl)-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine 676343-82-1P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]phenol 676343-83-2P, N-[2-Fluoro-5-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzyl]-N,N-dimethylethane-1,2-diamine 676343-85-4P, 3-(4-Fluorophenyl)-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-86-5P, 7-Ethoxy-4-[4-phenyl]-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-87-6P, 7-Ethoxy-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-88-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-89-8P, 7-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-90-1P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-91-2P, 6,7-Dimethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-92-3P, 7-Chloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-93-4P, 6-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-94-5P, 3-(4-Fluoronaphthalen-1-yl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676343-95-6P, 4-[2-(Furan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-96-7P, 4-[2-(Thiophen-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-97-8P, 6,7-Difluoro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-98-9P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-99-0P, 4-[2-(6-Ethylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-100-6P, 6,7-Dichloro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-01-7P, 7-Ethoxy-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-02-8P, 2-(6-Ethylpyridin-2-yl)-3-(4-Fluoronaphthalen-1-yl)pyrazolo[1,5-a]pyridine 676344-05-1P, 3-(4-Fluorophenyl)-4-iodo-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-06-2P, 3-(4-Fluorophenyl)-2-(6-propylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-07-3P, 2-(6-Ethylpyridin-2-yl)-3-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine 676344-08-4P, 3-(Pyridin-4-yl)-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-09-5P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-10-8P, 4-[2-(6-Fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-11-9P, 4-[2-(3-Butylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-12-0P, 8-Fluoro-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-13-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-6-trifluoromethylquinoline 676344-15-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-trifluoromethylquinoline 676344-16-4P, 3-(3-Chloro-4-fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-17-5P, 2-(6-Methylpyridin-2-yl)-3-(2,4,5-trifluorophenyl)pyrazolo[1,5-a]pyridine 676344-18-6P, 3-(4-Fluoro-3-trifluoromethylphenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-20-0P, 4-[2-(5-Bromopyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-21-1P, 4-[5-Benzyl-2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-22-2P, 4-[5-Benzyl-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-bromoquinoline 676344-26-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-

carboxylic acid methyl ester 676344-27-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-6-carboxylic acid methyl ester 676344-30-2P, 3-(4-Fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid (2-dimethylaminoethyl)amide 676344-31-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-6-carboxylic acid (2-dimethylaminoethyl)amide 676344-32-4P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (2-dimethylaminoethyl)amide 676344-33-5P, 5-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]benzofuran-2-carboxylic acid (2-dimethylaminoethyl)amide 676344-34-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-(4-methylpiperazin-1-yl)propyl)amide 676344-35-7P, 4-[2-(6-Methoxypyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-36-8P, 4-[2-(6-Ethoxypyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-37-9P, 3-(4-Fluorophenyl)-2-(6-methoxypyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-38-0P, 2-(6-Ethoxypyridin-2-yl)-3-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 676344-39-1P, 7-Benzyl-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-41-5P, 3-(4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)acrylic acid 676344-42-6P, 4-[2-(6-Ethylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-43-7P, 4-[2-(6-Phenylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-44-8P, 4-[2-(6-Morpholin-4-yl)pyridin-2-yl]pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-45-9P, 3-(4-Fluorophenyl)-2-(6-methylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-46-0P, 3-(4-Methylsulfonylphenyl)-2-(6-methylsulfonylpyridin-2-yl)pyrazolo[1,5-a]pyridine 676344-47-1P, Dimethyl[2-[[4-(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)sulfonyl]ethyl]amine 676344-48-2P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid dimethylamide 676344-49-3P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-6-carboxylic acid dimethylamide 676344-50-6P, 4-[2-(6-Vinylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-51-7P, 16-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]imidazo[1,2-a]pyridin-2-yl]amine 676344-52-8P, 16-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-1H-benzimidazol-2-yl]amine 676344-55-1P, 6-[(Allyloxymethyl)-3-(4-fluorophenyl)-2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(pyrrolidin-1-yl)propyl]amide 676344-57-3P, 3-[4-(2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinolin-7-yl]propionamide 676344-58-4P, 3-[4-(2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinolin-7-yl]propylpropionamide 676344-59-5P, N-(2-Dimethylaminoethyl)-3-[4-(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)quinolin-7-yl]propionamide 676344-60-8P, 2-(Pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]pyridine-5-carboxylic acid (3-dimethylaminopropyl)amide 676344-61-9P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (2-hydroxyethyl)amide 676344-62-0P, Carboxylic hydrazide 676344-63-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-hydroxypropyl)amide 676344-64-2P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid methylamide 676344-65-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-ethoxypropyl)amide 676344-66-4P, Carboxylic acid [3-(morpholin-4-yl)propyl]amide 676344-67-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [3-(imidazol-1-yl)propyl]amide 676344-68-6P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid (3-dimethylaminopropyl)amide 676344-69-7P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-


carboxylic acid [2-(2-methoxyphenyl)ethyl]amide 676344-70-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid [2-(morpholin-4-yl)ethyl]amide 676344-71-1P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline-7-carboxylic acid amide 676344-72-2P, Dimethyl[3-[[4-(2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)pyrazolo[1,5-a]pyridin-7-yl]oxy]propyl]amine 676344-73-3P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(morpholin-4-yl)ethoxy]quinoline 676344-74-4P, Disopropyl[2-[[4-(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]ethyl]amine 676344-75-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]ethoxyquinoline 676344-76-6P, Dimethyl[1-methyl-2-[[4-(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)ethoxy]ethyl]amine 676344-77-7P, Methyl[3-[[4-(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)pyrazolo[1,5-a]pyridin-7-yl]oxy]ethyl]amine 676344-78-8P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(piperidin-1-yl)ethoxy]quinoline 676344-79-9P, Diethyl[2-[[4-(2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]ethyl]amine 676344-80-2P, Dimethyl[3-[[4-(2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]propyl]amine 676344-81-3P, 7-[2-(Morpholin-4-yl)ethoxy]-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-82-4P, Disopropyl[2-[[4-(2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]ethyl]amine 676344-83-5P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-[[4-(2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]propyl]-1,3-dihydrobenzimidazol-2-one 676344-85-7P, 3-[4-(2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)propionic acid methyl ester 676344-86-8P, Diethyl[3-[[4-(2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]propyl]amine 676344-87-9P, Methyl[3-[[4-(2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]propyl]amine 676344-88-0P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(Piperidin-1-yl)propoxy]-1-propoxy]quinoline 676344-89-1P, 7-[3-(Piperidin-1-yl)propoxy]-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-90-4P, Diethyl[2-[[4-(2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]ethyl]amine 676344-91-5P, Dimethyl[2-[[4-(2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-yl)oxy]ethyl]amine




RN 676343-58-1 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

(drug candidate; preparation of pyrazolopyridines as TGF- β signal transduction inhibitors useful against cancer and other diseases)
RN 676343-55-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)


(Therapeutic use): BIOL (Biological study); PREP (Preparation); USES (Uses)




RN 676343-59-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-methoxyphenyl)-2-(6-methyl-2-pyridinyl)-phenyl- (9CI) (CA INDEX NAME)




RN 676343-60-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676343-61-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-phenyl- (9CI) (CA INDEX NAME)




RN 676343-62-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(4-pyridinyl)-phenyl- (9CI) (CA INDEX NAME)




RN 676343-63-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 676343-64-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676343-65-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676343-66-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridinyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-67-2 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(1,3-benzodioxol-5-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-68-3 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(3,5-difluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-69-4 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-methylphenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-70-7 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(1H-indol-5-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-71-8 CAPIUS
CN Benamide, 3-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (CA INDEX NAME) (9CI)




RN 676343-72-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-(3,4-dimethoxyphenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-73-0 CAPIUS
CN Benamide, N,N-dimethyl-3-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-75-2 CAPIUS
CN Benzenamine, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-76-3 CAPIUS
CN Acetamide, N-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 676343-77-4 CAPLUS
CN Phenol, 4-([2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-78-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-79-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methoxyphenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-80-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-81-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 676343-82-1 CAPLUS
CN Phenol, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-83-2 CAPLUS
CN 1,2-Ethanediamine, N'-([2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)methyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 676343-85-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676343-86-5 CAPLUS
CN Quinoline, 7-ethoxy-4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-87-6 CAPLUS
CN Quinoline, 7-ethoxy-4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-88-7 CAPLUS
CN Quinoline, 4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-89-8 CAPLUS
CN Quinoline, 7-ethoxy-4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-90-1 CAPLUS
CN Quinoline, 4-phenyl-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-91-2 CAPLUS
CN Quinoline, 6,7-dimethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-92-3 CAPLUS
CN Quinoline, 7-chloro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-93-4 CAPLUS
CN Quinoline, 6-ethoxy-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 676343-94-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluoro-1-naphthalenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 676343-95-6 CAPLUS
CN Quinoline, 4-[2-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-96-7 CAPLUS
CN Quinoline, 4-[2-(2-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-97-8 CAPLUS


CN Quinoline, 6,7-difluoro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-98-9 CAPLUS
CN Quinoline, 6,7-dichloro-4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-99-0 CAPLUS
CN Quinoline, 4-[2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 676344-00-6 CAPLUS
CN Quinoline, 6,7-dichloro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-01-7 CAPLUS
CN Quinoline, 7-ethoxy-4-([2-(6-ethyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-naphthalen-1-yl)- (CA INDEX NAME)




RN 676344-02-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-fluoro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 676344-05-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-4-iodo-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-06-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-propyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-07-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethyl-2-pyridinyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676344-08-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-pyridinyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-09-5 CAPLUS
CN Quinoline, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-10-8 CAPLUS
CN Quinoline, 4-[2-(6-fluoro-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 676344-11-9 CAPLUS
CN Quinoline, 4-[2-(5-butyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 676344-12-0 CAPLUS
CN Quinoline, 8-fluoro-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-13-1 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 676344-15-3 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676344-16-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-chloro-4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-17-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-(2,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)


(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-26-6 CAPLUS
CN 7-Quinolincarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676344-27-7 CAPLUS
CN 6-Quinolincarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676344-30-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-31-3 CAPLUS




RN 676344-18-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-fluoro-3-(trifluoromethyl)phenyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 676344-20-0 CAPLUS
CN Quinolone, 4-[2-(5-bromo-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-21-1 CAPLUS
CN Quinolone, 4-[5-(phenylmethyl)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-22-2 CAPLUS
CN Quinolone, 7-bromo-4-[2-(6-methyl-2-pyridinyl)-5-


CN 6-Quinolinescarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-32-4 CAPLUS
CN 7-Quinolinescarboxamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-33-5 CAPLUS
CN 2-Benzofurancarboxamide, N-[2-(dimethylamino)ethyl]-5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-34-6 CAPLUS
CN 7-Quinolinescarboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-35-7 CAPLUS
CN Quinolinescarboxamide, 4-[2-(6-methoxy-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-36-8 CAPLUS
CN Quinolinescarboxamide, 4-[2-(6-ethoxy-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-37-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676344-38-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(6-ethoxy-2-pyridinyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676344-39-1 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 676344-41-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]- (9CI) (CA INDEX NAME)




RN 676344-42-6 CAPLUS
CN Quinoline, 4-[2-[6-(ethylthio)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-43-7 CAPLUS
CN Quinoline, 4-[2-[6-(phenylthio)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676344-44-8 CAPLUS
CN Quinoline, 4-[2-[6-(4-morpholinyl)-2-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-[6-(methylthio)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 676344-46-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylthio)phenyl]-2-[6-(methylthio)-2-pyridinyl]- (9CI) (CA INDEX NAME)


(CA INDEX NAME)




RN 676344-47-1 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[[4-(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl)thio]- (9CI) (CA INDEX NAME)




Me₂N-CH₂-CH₂-S
RN 676344-48-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N,N-dimethyl-2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA INDEX NAME)




Me₂N-C(=O)-
RN 676344-49-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N,N-dimethyl-2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA INDEX NAME)




Me₂N-C(=O)-
RN 676344-50-6 CAPLUS
CN Quinoline, 4-[2-(6-ethenyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)




RN 676344-51-7 CAPLUS
CN Imidazo[1,2-a]pyridin-2-amine, 6-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-52-8 CAPLUS
CN 1H-Benzimidazol-2-amine, 5-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-(6-methyl-2-pyridinyl)-6-[(2-propenyloxy)methyl]- (9CI) (CA INDEX NAME)




H₂C=CH-CH₂-O-CH₂-
RN 676344-56-2 CAPLUS
CN 7-Quinolincaboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 676344-57-3 CAPLUS
CN 7-Quinolonepropanamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-58-4 CAPLUS
CN 7-Quinolonepropanamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-pyridinyl)pyrazolo[1,5-a]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 676344-59-5 CAPLUS
CN 7-Quinolonepropanamide, N-[2-(dimethylamino)ethyl]-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-60-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[3-(dimethylamino)propyl]-2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA INDEX NAME)




RN 676344-61-9 CAPLUS
CN 7-Quinolonecarboxamide, N-(2-hydroxyethyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-62-0 CAPLUS
CN 7-Quinolonecarboxylic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrazide (9CI) (CA INDEX NAME)




RN 676344-63-1 CAPLUS
CN 7-Quinolonecarboxamide, N-(3-hydroxypropyl)-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-64-2 CAPLUS
CN 7-Quinolincarboxamide, N-methyl-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-65-3 CAPLUS
CN 7-Quinolincarboxamide, N-(3-ethoxypropyl)-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-66-4 CAPLUS
CN 7-Quinolincarboxamide, 4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 676344-67-5 CAPLUS
CN 7-Quinolincarboxamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-68-6 CAPLUS
CN 7-Quinolincarboxamide, N-[3-(dimethylamino)propyl]-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-69-7 CAPLUS
CN 7-Quinolincarboxamide, N-[2-(2-methoxyphenyl)ethyl]-4-[(2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 676344-70-0 CAPLUS
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 676344-71-1 CAPLUS
CN 7-Quinolincarboxamide, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676344-72-2 CAPLUS
CN 1-Propanamine, N,N-dimethyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




Me₂N-(CH₂)₃-O
RN 676344-73-3 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 676344-74-4 CAPLUS
CN 2-Propanamine, N-(1-methylethyl)-N-[2-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



(1-Pr)₂N-CH₂-CH₂-O
RN 676344-75-5 CAPLUS
CN Quinoline, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[2-(1H-pyrol-1-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 676344-76-6 CAPLUS
CN 2-Propanamine, N,N-dimethyl-1-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 676344-77-7 CAPLUS
CN 1-Propanamine, N-methyl-3-[[4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-

Cc1ccc2c(c1)c3ccccc3n2-c4ccc5ccccc5n4

RN 676344-78-8 CAPLUS

Cc1ccc2nc3c(cc12)c1cccnc13OCCN4CCCCC4

RN 676344-79-9 CAPLUS

Cc1ccc2c(c1)c3ccccc3n2

RN	676344-80-2	CAPLUS
----	-------------	--------

676344-81-3 CAPLUS

C1=CC=C2C(=C1)N=CN=C2C3=CC=CC=C3C4=CC=CC=C5C(=C4)N=CN=C5C6=CC=CC=C6OCCN7CCOCC7

RN 676344-82-4 CAPLUS

c1ccc(cc1)-c2cc3ccccc3n2


RN 676344-83-5 CAPLUS

Cc1ccc2c(c1)c3ccccc3n2-c4ccc5c(c4)Oc6ccccc6N7CCOCC7


676344-84-6 CAPLUS

Cc1ccc2nc3ccccc3nc21Oc4ccc5c(c4)nc6ccccc6n5C(=O)N(CCCN7C(=O)c8ccccc87)C9=CC=CC=C9


RN 676344-85-7 CAPLUS
CN 7-Quinolonepropanoic acid, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676344-86-8 CAPLUS
CN 1-Propanamine, N,N-diethyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-87-9 CAPLUS
CN 1-Propanamine, N-ethyl-N-methyl-3-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-88-0 CAPLUS
CN Quinolone, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)




RN 676344-89-1 CAPLUS
CN Quinolone, 7-[3-(1-piperidinyl)propoxy]-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676344-90-4 CAPLUS
CN Ethanamine, N,N-diethyl-2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




RN 676344-91-5 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[[4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-7-quinolinyl]oxy]- (9CI) (CA INDEX NAME)




IT 676344-28-8, 6-Bromo-4-[2-(6-methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as TGF-β signal transduction inhibitors useful against cancer and other diseases)

RN 676344-28-8 CAPLUS
CN Quinoline, 6-bromo-4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




IT 676343-49-0P, 4-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-ol 676343-51-4P, 4-[2-(Pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinolin-7-ol 676343-53-6P, 7-(3-Chloropropoxy)-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676343-54-7P, 7-(2-Chloroethoxy)-4-[2-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]quinoline 676344-53-9P, [6-[2-(6-Methylpyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]-1-(propan-2-ylsulfonyl)-1H-benzimidazol-2-yl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as TGF- β signal transduction inhibitors useful against cancer and other diseases)


RN 676343-49-0 CAPLUS
CN 7-Quinolol, 4-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 676343-51-4 CAPLUS
CN 7-Quinolol, 4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 676343-53-6 CAPLUS
CN Quinoline, 7-(3-chloropropoxy)-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676343-54-7 CAPLUS
CN Quinoline, 7-(2-chloroethoxy)-4-[2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 676344-53-9 CAPLUS
CN 1H-Benzimidazol-2-amine, 1-[[1-(6-methylethyl)sulfonyl]-6-[2-(6-methyl-2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L5 ANSWER 21 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:220201 CAPLUS
DOCUMENT NUMBER: 140:270867
TITLE: Preparation of pyrazolopyridines as antagonists of Alk 5 and/or Alk 4

INVENTOR(S): Lee, Wen-Cherng; Carter, Mary Beth; Sun, Lihong; Lyne, Paul; Chuang, Claudio; Zheng, Zhongli; Singh, Juvinder; Boriack-Sjodin, Paula
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE


RN 437612-03-8 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-22-1 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 437612-48-1 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl- (9CI) (CA INDEX NAME)



RN 437612-94-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:827761 CAPLUS
DOCUMENT NUMBER: 140:59556
TITLE: novel class of antihyperpetics
Pyrazolo[1,5-a]pyridines: synthetic approaches to a novel class of antihyperpetics
AUTHOR(S): Johns, Brian A.; Gudmundsson, Kristjan S.; Turner, Elizabeth M.; Allen, Scott H.; Jung, David K.; Sexton, Connie J.; Boyd, F. Leslie; Reel, Michael R.
CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Virology, GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709-3398, USA
SOURCE: Tetrahedron (2003), 59(45), 9001-9011
CODEN: TETRAH; ISSN: 0040-4020
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
L5 CASREACT 140:59556

AB Synthesis of a novel class of 7-amino-3-pyrimidinylpyrazolo[1,5-a]pyridine antihyperpetic comps. is described. The synthetic methodol. is designed to allow for rapid analog synthesis around the C-3 and C-7 positions of the pyrazolo[1,5-a]pyridine. 7-Chloropyrazolo[1,5-a]pyridine, produced through an azirine rearrangement, served as a key building block. Two complementary methodologies for construction of the C-3 pyrimidine are described. These methods include the development of a novel cyclization utilizing alkynyl ketones or enones to give highly substituted pyrimidines. The outlined strategies facilitated late stage manipulation of either the C-3 or C-7 positions providing flexibility for rapid analog synthesis. Comps. thus prepared included N-[3-(2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-1,2-ethanediamine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine, N-[3-(2-(cyclopentylamino)-6-methyl-4-pyrimidinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]glycine Me ester, etc. Only the preparation of these comps. was reported; pharmacol. data were not given.
437612-03-8P, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl-2-pyrimidinamine 437612-22-1P, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl-2-pyrimidinamine 437612-48-1P, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]-2-pyrimidinamine 437612-94-7P, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]-2-pyrimidinamine 437612-97-0P, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl-2-pyrimidinamine
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolo[1,5-a]pyridine derivs.)


IT

pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-04-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-(cyclopentylamino)-6-methyl-4-pyrimidinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-10-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-11-8 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 437612-97-0 CAPLUS

CN 2-Pyrimidinamine, 4-(7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




IT


437611-97-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-04-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-10-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl-2-pyrimidinamine 437612-11-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl-2-pyrimidinamine 437612-12-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-[[[tetrahydro-2H-pyran-2-yl]oxymethyl]-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-15-2P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-2-pyrimidinamine hydrochloride 437612-16-3P, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-1,2-ethanediamine 437612-19-6P, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-20-9P, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]glycine methyl ester 437612-49-2P, N-Cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine 437612-78-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine RL: SN (Synthetic preparation); PREP (Preparation) (preparation of pyrazolo[1,5-a]pyridine derivs.)

RN 437611-97-7 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-




RN 437612-12-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-15-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 437612-16-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 437612-19-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-20-9 CAPLUS
CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)


NAME)



RN 437612-49-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-([2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl))- (9CI) (CA INDEX NAME)



RN 437612-78-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-([2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl))- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


I5 ANSWER 23 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:740795 CAPLUS
DOCUMENT NUMBER: 139:301697
TITLE: An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistant rats

AUTHOR(S): Schnackenberg, Christine G.; Merz, Emily; Brooks, David P.
CORPORATE SOURCE: Department of Renal Biology, UW-2521, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, 19406, USA
SOURCE: British Journal of Pharmacology (2003), 139(8), 1383-1388
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 1 Loop and thiazide diuretics are common therapeutic agents for the treatment of sodium retention and edema. However, resistance to diuretics and decreases in renal function can develop during diuretic therapy. Adenosine causes renal vasoconstriction, sodium resorption, and participates in the tubuloglomerular feedback mechanism for the regulation of glomerular filtration rate. 2 We tested the hypothesis that the selective adenosine A1 receptor antagonist FK838 is orally active and causes diuresis and natriuresis, but maintains glomerular filtration rate in normal rats or in rats with furosemide resistance. 3 In normal male Sprague-Dawley rats, FK838 dose-dependently increased urine flow and sodium and chloride excretion while sparing potassium. In combination with furosemide, FK838 enhanced the diuretic and natriuretic actions of furosemide to the same extent as hydrochlorothiazide and did not increase the potassium loss in normal rats. In furosemide-resistant rats, FK838 increased urine flow and electrolyte excretion to a greater extent than hydrochlorothiazide. In addition, hydrochlorothiazide significantly decreased glomerular filtration rate, whereas FK838 maintained glomerular filtration rate in furosemide-resistant rats. 4 This study shows that the adenosine A1 receptor antagonist FK838 is orally active and causes potent diuresis and natriuresis and maintains glomerular filtration rate in normal or furosemide-resistant rats. Adenosine A1 receptor antagonists may be novel therapeutics for the treatment of edema in normal or otherwise diuretic-resistant patients.

IT 131185-37-0, FK838
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
 (orally active adenosine A1 receptor antagonist, FK838, increases renal
 excretion and maintains glomerular filtration rate in
 furosemide-resistant rats)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-(9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:652131 CAPLUS
 DOCUMENT NUMBER: 139:214237

TITLE: Preparation of nitrate prodrugs able to release nitric
 oxide in a controlled and selective way and their use
 for prevention and treatment of inflammatory, ischemic
 and proliferative diseases
 Scaramuzzino, Giovanni

INVENTOR(S): Italy
 PATENT ASSIGNEE(S): Eur. Pat. Appl., 313 pp.
 SOURCE: CODEN: EPXIXM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1336602	A1	20030820	EP 2002-425075	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLM. INFO.: EP 2002-425075 20020213				




AB New pharmaceutical compds. of general formula F-(X)q (I) (q = 1-5,
 preferably 1; F is chosen among drugs such as 8-tocopherol,
 clidanac, diethylhomopermine, glucosamine, thymocartin, vofopitant, etc.;
 X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt,
 nitrite ester, ONO, thioinitrite, SNO, etc.; T = OR1-M, OR1R1-M,
 SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc.; R1 = saturated or unsatd., linear or

branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd.,
 optionally heterosubstituted or branched cycloalkylene, having 3 to 7
 carbon atoms or an optionally heterosubstituted arylene having 3 to 7
 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon
 atom alkyl, saturated or unsatd., optionally heterosubstituted or branched 3-7
 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 =
 OH, SH, F, Cl, Br, OFO3R2, CO2H, etc.; bond between F and Y = carboxylic
 ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.;
 V = Z-M2, O2-M2, NR2R1-M; ZM2 = COCH2CH(M2)CH2N-ME3, COCH2CH2COM2, COCH(NHR2)CH2M2,
 etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2,
 etc.] were prepared. For example, 8-tocopherol reacted with
 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of
 general formula I are nitrate prodrugs which can release nitric oxide in
 vivo in a controlled and selective way and without hypotensive side
 effects and for this reason they are useful for the preparation of medicines
 for prevention and treatment of inflammatory, ischemic, degenerative and
 proliferative diseases of musculoskeletal, tegumental, respiratory,
 gastrointestinal, genito-urinary and central nervous systems.

IT 586347-52-6P
 RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of nitrate prodrugs for treating or preventing inflammatory,
 ischemic, degenerative, and proliferative diseases)

RN 586347-52-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-,
 mononitrate (9CI) (CA INDEX NAME)

CM: 1
 CRN 340321-70-2
 CMF C20 H17 N3 O3 S



CM 2
 CRN 7697-37-2
 CMF H N O3



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 25 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:472515 CAPLUS
 DOCUMENT NUMBER: 139:53015
 TITLE: Preparation of pyrazolopyridine derivatives as

antiherpes agents
 Gudmundsson, Kristjan; Johns, Brian A.
 Smithkline Beecham Corporation, USA
 PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 Patent
 English
 1

INVENTOR(S):
 PATENT ASSIGNEE(S):
 SOURCE:
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT:
 PATENT INFORMATION:


against HSV-1 of 1.5 µM.
 544675-24-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of Pyrazolopyridine derivs. as antihherpes agents)
 544675-24-3 CAPLUS
 RN 2-Pyrimidinamine, 4,4'-pyrazolo[1,5-a]pyridine-2,3-diylbis[N-cyclopentyl-
 (9CI) (CA INDEX NAME)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050120	A1	20030619	WO 2002-US37052	20021120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KR, KP, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UM, VC, VE, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, MW, SD, SL, SZ, TZ, UG, ZM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
AU 2002357740	A1	20030623	AU 2002-357740	20021120
EP 1453830	A1	20040908	EP 2002-792278	20021120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005316916	T	20050609	JP 2003-551144	20021120
US 2004248903	A1	20041209	US 2004-496358	20040520
US 7199120	B2	20070403	US 2001-339585P	P 20011211
PRIORITY APPLN. INFO.:			WO 2002-US37052	W 20021120
OTHER SOURCE(S):			MARPAT 139:53015	
GI				




AB Pyrazolopyridines I (R = (un)substituted aryl, heteroaryl; R1 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted OH, CO2H, CONH2, C(=O)NH2, SH, S(O)H, SO2H, NH2, acyl, CN, NO2, N3; p = 0-4; R2 = halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, (un)substituted OH, SH, S(O)H, SO2H, NH2; R3, R4 = H, halo, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, (un)substituted OH, CO2H, CONH2, CSNH2, SH, S(O)H, SO2H, NH2, acyl] were prepared Thus, 7-chloro-2-(4-pyridinyl)pyrazolo[1,5-a]pyridine was obtained from 6-chloro-2-picolone and Et isonicotinate in 3 steps and was acetylated, treated with cyclopentylamine, and cyclized with N-cyclopentylguanidine to give the pyrazolopyridine II which had IC50


IT 544675-20-9P 544675-22-1P 544675-28-7P
 544675-31-2P 544675-32-3P 544675-33-4P
 544675-34-5P 544675-35-6P 544675-36-7P
 544675-40-3P 544675-41-4P 544675-42-5P
 544675-43-6P 544675-44-7P 544675-45-8P
 544675-46-9P 544675-47-0P 544675-48-1P
 544675-49-2P 544675-50-5P 544675-51-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridine derivs. as antihherpes agents)
 RN 544675-20-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 544675-22-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 544675-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2,3-bis(2-(cyclopentylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-31-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2,3-bis(2-(butylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-32-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-2,3-bis(2-(cyclopropylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-33-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(4-morpholinyl)-2,3-bis(2-(4-morpholinyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-34-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-methylpropyl)-2,3-bis(2-(2-methylpropylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(phenylmethyl)-2,3-bis(2-(phenylmethylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN * 544675-36-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-(1-methylethyl)-2,3-bis[2-(1-methylethylamino)-4-pyrimidinyl]-(9CI) (CA INDEX NAME)




RRN	CN	NAME
544675-40-3	CAPLUS	Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-[2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)




544675-41-4 CAPLUS
Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-[2-(cyclopentylamino)-4-pyridinyl]-3-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)





NRN	CN	NAME	CA INDEX
544675-42-5	CAPUS	Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-[2-[(1-methylethyl)amino]-4-pyridinyl]- (9CI)	(CA INDEX NAME)




544675-43-6 CAPLUS
Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[2-{{1-methylethyl}amino}-4-pyridinyl]- (9CI) (CA INDEX NAME)




NRN	544675-44-7	CAPLUS
CN	Pyrazolo[1,5-a]pyridin-7-amine, pyridinyl-2-(2-furanyl)- (9CI)	N-cyclopentyl-3-[2-(cyclopentylamino)-4- (CA INDEX NAME)





RN 544675-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 544675-46-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-methyl-2-furanyl)- (9CI) (CA INDEX NAME)




RN 544675-48-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)







RN 544675-49-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 544675-50-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(5-bromo-2-furanyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-51-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



IT 544675-66-3P 544675-67-4P 544675-68-5P
544675-70-9P 544675-71-0P 544675-72-1P
544675-73-2P 544675-74-3P 544675-75-4P
544675-76-5P 544675-77-6P 544675-83-4P
544675-90-3P 544675-91-4P 544675-95-8P
544675-99-2P 544676-06-4P 544676-07-5P
544676-08-6P
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of pyrazolopyridine derivs. as antiherpes agents)
RN 544675-66-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2,3-bis[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-67-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2,3-bis[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-68-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2,3-bis[2-(methylsulfinyl)-4-


Pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-70-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 2-(2-fluoro-4-pyridinyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-71-0 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544675-72-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(2-(1-methylethyl)amino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544675-73-2 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 544675-74-3 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 544675-75-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-(1-methylethyl)amino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 544675-76-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544675-77-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-[(1-methylethyl)amino]-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 544675-83-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-(2-fluoro-4-pyridinyl)-2-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 544675-90-3 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methyl-2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 544675-91-4 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methyl-2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)






RN 544675-95-8 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 544675-99-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(5-bromo-2-furanyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 544676-06-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-fluoro-4-pyridinyl)-2-(2-methyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 544676-07-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methyl-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 544676-08-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(2-methyl-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




IT 544675-26-5P 544675-37-8P 544675-38-9P
RL: RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)


(Preparation of pyrazolopyridine derivs. as antihelminthics agents)
RN 544675-26-5 CAPLUS
CN 2-Pyrimidinamine, 4,4'-(7-chloropyrazolo[1,5-a]pyridine-2,3-diyl)bis[N-cyclopentyl]- (9CI) (CA INDEX NAME)




RN 544675-37-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluoro-4-pyridinyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 544675-38-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 544675-21-0P 544675-30-1P 544675-39-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridine derivs. as antiherpes agents)
RN 544675-21-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-cyclopentyl-3-[2-(methylethylamino)-4-pyrimidinyl]-2-(2-pyridinyl))- (9CI) (CA INDEX NAME)



RN 544675-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-(2-methoxyethyl)-2,3-bis[2-(2-methoxyethyl)amino]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 544675-39-0 CAPLUS
CN 2-Pyrimidinamine, N-(1-methylethyl)-4-[2-(2-(1-methylethylamino)-4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:434561 CAPLUS
DOCUMENT NUMBER: 139:22210
TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists
INVENTOR(S): Tanaka, Akira; Minagawa, Masatoshi; Akahane, Atsushi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCI Int. Appl., 63 pp.
CODEN: PIXXDZ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045950	A1	20030605	WO 2002-JP12381	20021127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, SN, TD, TG				
AU 2002347633	A1	20030610	AU 2002-347633	20021127
PRIORITY APPLN. INFO.:			AU 2001-9163	A 20011129
			WO 2002-JP12381	W 20021127
OTHER SOURCE(S):			MARPAT 139:22210	
GI.				



AB Pyrazolopyridine compds. of formula I (R1 = H, alkyl, cycloalkyl; R2 = H, (substituted) OH, acyl, (substituted) amino; R3 = H, halo) are prepared. The pyrazolopyridine compds. and salts thereof are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like. Thus, II was prepared and showed adenosine antagonist activity and anticatalepsy activity.

IT 537047-93-1P 537047-96-4P 537047-97-5P

537047-98-6P 537048-06-9P 537048-11-6P

537048-15-0P 537048-16-1P 537048-17-2P

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); RACT (Reactant or reagent); USES (Uses)

(Preparation of pyrazolopyridine derivs. as adenosine antagonists)

CN 537047-93-1 CAPLUS

CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-


methylethyl)- (9CI) (CA INDEX NAME)



RN 537047-96-4 CAPLUS

CN 2(1H)-Pyridinone, 5-(5-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-

methylethyl)- (9CI) (CA INDEX NAME)




RN 537047-97-5 CAPLUS

CN Acetic acid, [[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-

phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX


NAME)



RN 537047-98-6 CAPLUS

CN Acetic acid, [[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-

phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 537048-06-9 CAPLUS

CN Carbamic acid, [2-[[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-

phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]-, 1,1-dimethylethyl ester


(9CI) (CA INDEX NAME)



RN 537048-11-6 CAPLUS

CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[5-[(5-nitro-2-pyridinyl)oxy]-2-

phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 537048-15-0 CAPLUS


CN Methanesulfonic acid, trifluoro-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-

pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX


NAME)



RN 537048-16-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 537048-17-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




IT 537047-87-3P 537047-88-4P 537047-89-5P
537047-90-8P 537047-91-9P 537047-92-0P
537047-94-2P 537047-95-3P 537047-99-7P
537048-00-3P 537048-01-4P 537048-02-5P
537048-03-6P 537048-04-7P 537048-05-8P
537048-07-0P 537048-08-1P 537048-09-2P
537048-10-5P 537048-12-7P 537048-13-8P
537048-14-9P 537048-18-3P 537048-19-4P
537048-20-7P 537048-21-8P 537048-22-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridine deriva. as adenosine antagonists)


RN 537047-87-3 CAPLUS
CN 2(1H)-Pyridinone, 1-methyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-88-4 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-89-5 CAPLUS
CN 2(1H)-Pyridinone, 1-ethyl-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-90-8 CAPLUS
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-propyl- (9CI) (CA INDEX NAME)




RN 537047-91-9 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537047-92-0 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-methyl- (9CI) (CA INDEX NAME)




RN	537047-94-2	CAPLUS
CN	2 (1H)-Pyridinone, 1-ethyl-5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI)	(CA INDEX NAME)




RN	537047-95-3	CAPLUS
CN	2(1H)-Pyridinone, 5-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-propyl- (9CI)	(CA INDEX NAME)




537047-99-7 CAPIUS
Acetamide, 2-[[[3,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




NRN	537048-00-3	CAPLUS
CN	Acetamide, 2-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy)-N-methyl-	(9CI) (CA INDEX NAME)




RN	537048-01-4	CAPLUS
CN	Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-ethyl-	(9CI) (CA INDEX NAME)




537048-02-5	CAPLUS
2(1H)-Pyridinone, 5-[5-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5- a]pyridin-3-yl]-1-(1-methyl)ethyl)- (9CI) (CA INDEX NAME)	




URN	537048-03-6	CAPLUS
CN	2(1H)-Pyridinone, 1-(1-methylethyl)-5-[5-(2-(4-morpholinyl)ethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




NRN	537048-04-7	CAPLUS
CN	2(1H)-Pyridinone, 1-(1-methylethyl)-5-[2-phenyl-5-(2-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




RN 537048-05-8 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-methoxyethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-07-0 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-aminoethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-08-1 CAPLUS
CN Carbamic acid, {2-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]ethyl}methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-09-2 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(2-(methoxylamino)ethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-10-5 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[(2-phenyl-5-[(tetrahydro-2H-pyran-2-yl)methoxy]pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 537048-12-7 CAPLUS
CN 2(1H)-Pyridinone, 5-[(5-(5-amino-2-pyridinyl)oxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 537048-13-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-14-9 CAPLUS
CN 2(1H)-Pyridinone, 1-(1-methylethyl)-5-[(2-phenyl-5-(4-piperidinyl)oxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 537048-18-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl]-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 537048-19-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-N-methyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 537048-20-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-N-ethyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 537048-21-8 CAPLUS
CN Carbamic acid, [3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridinyl)-2-phenylpyrazolo[1,5-a]pyridine-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 537048-22-9 CAPLUS
CN 2(1H)-Pyridinone, 5-(5-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 131185-46-1P 537048-24-1P 537048-25-2P
537048-26-3P 537048-27-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridine derivs. as adenosine antagonists)
RN 131185-46-1 CAPLUS
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 537048-24-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[6-(methylsulfonyl)-3-pyridinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 537048-25-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 537048-26-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 537048-27-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-3-(6-methoxy-3-pyridinyl)-2-phenyl-
(9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:251382 CAPLUS
DOCUMENT NUMBER: 139:223688
TITLE: Allosteric interactions and QSAR: on the role of
ligand hydrophobicity
AUTHOR(S): Hansch, Corwin; Garg, Rajni; Kurup, Alka; Mekapati,
Suresh Babu
CORPORATE SOURCE: Department of Chemistry, Pomona College, Claremont,
CA, 91711, USA
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(9),
2075-2084
CODEN: BMCEP; ISSN: 0968-0896


PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A study of a very large database of QSAR (9100) has uncovered a few
unusual examples where as one increases the hydrophobicity of the members
of a set of congeners, activity decreases until at a certain point,
activity begins to increase. Obviously a change in mechanism is involved.
The only way we have found to rationalize this unusual event is by a
change in the structure of the receptor. We have found this to occur with
Hb, a substance first used to define allosteric reactions.

IT 131185-37-0 171050-45-6 171050-95-6
171050-96-7 171050-97-8 171051-01-7
171051-02-8 171051-08-4 171051-34-6
171051-47-1 171051-52-8
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
study)
(AZA adenosine receptor antagonist activity; parabolic relationship
between ligand hydrophobicity and activity in QSAR studies in relation
to allosteric interactions)


RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinylcyclohexanecarboxylic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171050-95-6 CAPLUS
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-96-7 CAPLUS
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-97-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-
pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-01-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-08-4 CAPLUS
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 171051-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(2-hydroxyethyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171051-52-8 CAPLUS
CN 1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 28 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN.
ACCESSION NUMBER: 2003:221686 CAPLUS
DOCUMENT NUMBER: 138:238180
TITLE: Preparation of pyrazolopyridines for treatment of herpes infections
INVENTOR(S): Johns, Brian A.; Gudmundsson, Kristjan
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022845	A1	20030320	WO 2002-US27251	20020827
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH,			

4-(*n*-cyclopentyl)-3-[2-(*n*-cyclopentylamino)-4-pyridinyl]-2-(4-fluorophenyl)pyrazolo[1,5-*a*]pyridine-5-amine was prepared in 7 steps starting from 4-chloro-2-picoline and Et 4-fluorobenzoate and involving the following intermediates: 2-(4-chloro-2-pyridinyl)-1-[4-(fluorophenyl)ethanone, 2-(4-chloro-2-pyridinyl)-1-(4-fluorophenyl)ethanone, 5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-*a*]pyridine, 1-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-*a*]pyridin-3-yl]-2-buten-1-one, and 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-*a*]pyridin-3-yl]-*N*-cyclopentyl-2-pyrimidinamine. For i: R1 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -OR, -OR', -OR10A, -OR10H, -C(O)Ar, -C(O)Het, -COR9, -C(O)NR78, -C(O)NR7A, -C(O)NR10A, -C(S)NR911, -C(S)NH(NH)NR78, -C(S)NH(NH)NR7A, -S(O)NR9, -S(O)NR7, -S(O)NR78, -S(O)2NR7A, -R10Cycloalkyl, -R10A, -R10Het, -R10OR, -R10OC(O)R9, -R10OC(O)Ar, -R10OC(O)Het, -R10OS(O)NR9, -R10C(O)R9, -R10OCOR9, -R10C(O)NR911, -R10C(S)NR911, -R10C(NH)NR911, -R10SO2NR911, -R10SO2NH(NH)NR911, -R10NR78, -R10NR7A, -R10NH(COR9), -R10NH(COR9), -R10NH(CNH)NR911, cyano, azido and nitro; Ar is aryl. R2 = halo, alkyl, alkenyl, cycloalkyl, cycloalkenyl, Ar, Het, -OR', -OR, -OR10Het, -OR10NR78 and -S(O)NR9, -NR78, -NHHet, -NR10A, -NR10H, -OR10Het, -OR10NR78 and -S(O)NR9.

C1CCNCC1c2nc3c(ncn3C4=CC=CC=C4)cc5c2ncc(NC6CCCC6)c5

NR	473712-02-6	CAPLUS
Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)		

II


473711-94-3P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-(pyrimidinyl)-2-(4-fluorophenyl)pyrazolo[1,5-*a*]pyridin-5-amine 473712-02-6P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-*a*]pyridin-5-amine 501953-11-3P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl-1-(3-*n*-butyl-4-fluorophenyl)pyrazolo[1,5-*a*]pyridin-5-amine 501953-14-6P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(methylsulfonyl)pyrazolo[1,5-*a*]pyridin-5-amine (methylsulfonyl)pyrazolo[1,5-*a*]pyridin-5-amine (preparation); RCT (Reactant); SPN (synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); RCT (Reactant or reagent); USES (Uses) (drug candidate; preparation of pyrazolopyridines for treatment of herpes infections)

IRN	CAPIUS	INSTRUCTIONS)
473711-94-3	CAPIUS	
Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)	CA INDEX NAME)	

(Uses)
(drug candidate; preparation of pyrazolopyridines for treatment of herpes infections)


RN 501953-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 501953-13-5 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-ethoxy-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 501953-15-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 501953-16-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(methoxy)- (9CI) (CA INDEX NAME)




RN 501953-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethoxy)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 501953-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethoxy)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 501953-12-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-5-amine
501953-13-5P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-ethoxy-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-amine
501953-15-7P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(2-methoxyethoxy)pyrazolo[1,5-a]pyridin-5-amine
501953-16-8P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyethoxy)pyrazolo[1,5-a]pyridin-5-amine
501953-17-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(ethoxysulfonyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-amine
501953-18-0P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(isopropylsulfonyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-5-amine
501953-19-1P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(phenylsulfonyl)pyrazolo[1,5-a]pyridin-5-amine
501953-20-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-(isopropylsulfonyl)pyrazolo[1,5-a]pyridin-5-amine
RL: PAC (Pharmacological activity); SEN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


RN 501953-20-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-[(1-methylethyl)thio]- (9CI) (CA INDEX NAME)




IT 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-87-5P, 4-[5-Chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines for treatment of herpes infections)
RN 468062-85-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
I5 ANSWER 29 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:221519 CAPLUS
DOCUMENT NUMBER: 138:231748




RN 501953-17-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-[(1-methylethyl)thio]- (9CI) (CA INDEX NAME)



RN 501953-18-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-[(1-methylethyl)thio]- (9CI) (CA INDEX NAME)



RN 501953-19-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-7-(phenylthio)- (9CI) (CA INDEX NAME)



TITLE:

Methods using adenosine A1 receptor antagonists for treating pulmonary disease

INVENTOR(S):

Smiths, Glenn J.; Spina, Francis G.

PATENT ASSIGNEE(S):

Biogen, Inc.; USA; Musc Foundation for Research Development

SOURCE:

PCT Int. Appl., 81 pp.

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200302284	A1	20030320	WO 2002-US28580	20020906
W:	AE, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SV, TC, TD, TH, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, BT, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2459533	A1	20030320	CA 2002-2459533	20020906
AU 20030324	A1	20030324	AU 2002-341618	20020906
EP 1429775	A1	20030324	EP 2002-715769	20020906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012329	A	20040921	BR 2002-12329	20020906
HU 200401805	A2	20041228	HU 2004-1805	20020906
HU 200401805	A3	20070502		
CN 1564688	A	20050112	CN 2002-819526	20020906
JP 200501915	T	20050120	JP 2003-526413	20020906
NZ 532083	A	20051028	NZ 2002-532083	20020906
IN 2004K00276	A	20050331	IN 2004-KN276	20040301
ZA 2004001765	A	20050405	ZA 2004-1765	20040303
NO 2004000982	A	20040603	NO 2004-982	20040305
US 2004259889	A1	20041223	US 2004-488573	20040817
PRIORITY APPL. INFO.:			US 2001-317908P	P 20010906
			WO 2002-US28580	W 20020906

OTHER SOURCE(S):

MARPAT 138:231748

AB Methods useful for reducing pulmonary vasoconstriction or improving pulmonary hemodynamics in a patient are disclosed. More particularly, the invention discloses administering adenosine A1 receptor antagonists to reduce pulmonary vasoconstriction and improve pulmonary hemodynamics.

IT

131185-37-0 141060-57-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A1 receptor antagonists for treating pulmonary disease)

RN 131185-37-0 CAPLUS


CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

(CH₂)₃-CO₂H



RN 141060-57-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-(1H-tetrazol-5-yl)ethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:177128 CAPLUS

DOCUMENT NUMBER:

139:276830

TITLE:

Manufacturing process development of new adenosine antagonist FR120838

AUTHOR(S):

Hashimoto, Norio

CORPORATE SOURCE:

Lab. for Synthetic Technology, Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE:

Purosese Kenisutori no Shintenkai (2003), 228-237.

Shi Emu Shi Shuppan: Tokyo, Japan.

CODEN: 69DQZM; ISBN: 4-88231-384-7

Conference; General Review

DOCUMENT TYPE:

Japanese

LANGUAGE:

Japanese

AB

A review on development of synthetic process for a new adenosine antagonist FR 120838 (FK 838).

IT

131185-37-0P, FK838


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(development of synthetic process for a new adenosine antagonist FR 120838 (FK 838))

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

(CH₂)₃-CO₂H



L5 ANSWER 31 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:42271 CAPLUS

DOCUMENT NUMBER:

138:106706

TITLE:

Preparation of pyridazinones as adenosine receptor antagonists

INVENTOR(S):

Tsutsumi, Hideo; Akahane, Atsushi

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT:


1

PATENT INFORMATION:


PATENT NO. _____ KIND DATE APPLICATION NO. DATE
 WO 2003004494 AI 20030116 WO 2002-JP6671 20020702
 W: JP, US
 RW: AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU,
 NL, PT, SE, SK
 PRIORITY APPLN. INFO.: AU 2001-6064 A 20010702
 OTHER SOURCE(S): MARPAT 138:106706
 GI




AB Title compds. [I; R1-R4 = H, suitable substituent; R1R2, R2R3 = (substituted) (heteroatom-interrupted) (CH2)n; n = 1-12; W = CH:CHCH:CH, CH:NCH:CH2, etc.], were prepared Thus, 6-[2-(1-hydroxycyclopentyl)pyrazolo[1,5-a]pyridin-3-yl]-2-isopropyl-3(2H)-pyridazinone was refluxed 14 h with Nafion NR50 in HOAc 6-[2-(1-cyclopenten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-isopropyl-3(2H)-pyridazinone. This showed adenosine A1 receptor binding activity with Ki = 0.19 nM.
 IT 487062-21-5P 487062-24-8P 487062-27-1P
 487062-28-2P 487062-29-3P 487062-30-6P
 487062-31-7P 487062-32-8P 487062-33-9P
 487062-34-0P 487062-35-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of pyridazinones as adenosine receptor antagonists)
 RN 487062-21-5 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-24-8 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclopenten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-27-1 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclobuten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-28-2 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cyclohepten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-29-3 CAPIUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-cycloocten-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 487062-30-6 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(6-methyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-31-7 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-32-8 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(4,4-dimethyl-1-cyclohexen-1-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-33-9 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(2,5-dihydro-2-methyl-3-furyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-34-0 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487062-35-1 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,6-dihydro-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 487062-98-6P 487063-04-7P 487063-29-6P
 487063-30-9P 487063-31-0P 487063-32-1P
 487063-33-2P 487063-34-3P 487063-35-4P
 487063-36-5P 487063-37-6P 487063-38-7P
 487063-39-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Preparation of pyridazinones as adenosine receptor antagonists)
 RN 487062-98-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-04-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclopentyl)pyrazolo[1,5-a]pyridin-3-
 yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-29-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclobutyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 487063-30-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycycloheptyl)pyrazolo[1,5-a]pyridin-3-
 yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-31-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxycyclooctyl)pyrazolo[1,5-a]pyridin-3-yl]-
 2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-32-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[2-[(1R,2S)-1-hydroxy-2-
 methylcyclohexyl]pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 487063-33-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-((1R,2R)-1-hydroxy-2-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 487063-34-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(cis-1-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 487063-35-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(trans-1-hydroxy-4-methylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 487063-36-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(1-hydroxy-4,4-dimethylcyclohexyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 487063-37-6 CAPLUS
CN Pentitol, 1,4-anhydro-2,5-dideoxy-3-C-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)



RN 487063-38-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(tetrahydro-4-hydroxy-2H-pyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 487063-39-8 CAPLUS
 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(tetrahydro-4-hydroxy-2H-thiopyran-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

15 ANSWER 32 OF 88 CAPJUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:906238 CAPJUS
DOCUMENT NUMBER: 138:4598
Preparation of substituted 5,6-dihydro-4H-pyrrrolo[1,2-


INVENTOR(S): Jason Scott; Beight, Douglas Wade; Ciapetti, Sawyer; DeBello, Todd; Coffey, Alexander; Glenn; Goodson, Theodore Jr.; Harrell, David Kent; Li, Hong-yu; Liao, Junkai; Mcmillen, William Thomas; Miller, Shawn Christopher; Morth, Nicolas Anthony; Vingling, Jonathan Michael; Smith, Edward C. R. Eli Lilly and Company, USA; et al.
PATENT ASSIGNEE(S): PCT Int. Appl., 305 pp.

CODEN: FRAADZ
 PATENT
 DOCUMENT TYPE:
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094833	A1	20021128	WO 2002-US11884	20020513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MA, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, RW, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SY, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW				

[illegible]

OTHER SOURCE(S) : MARPAT 138:4598
GI




Title compds. I [R1 = Ph, pyridine, pyridine-N-oxide, quinoline, naphthyridine, etc.; R2 = quinoline, quinoline-N-oxide, naphthalene, pyridine, pyridine-N-oxide, quinoxaline, etc.; p = 1-8; R3 = H, alkyl, alkyldioxy, hydroxy, dialkylamino, etc.; X = C, O, S] were prepared. For instance, 1-[(2-(6-Bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene)amino]pyrrolidin-2-one (preparation given) was treated with NaH in DMF at 80-85° for 18 h to afford II in 54% yield. Selected compds. of the invention had IC50 < 20.00 μ M for the TGF- β type I receptor.


receptor.
476477-76-6p, 2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-
IT

alipiperidum)-O-
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


476477-76-6 CAPLUS
 INDEX NAME) 2-(2-pyridinyl)-3-(4-quinolinyl)- (9CI) (CA
 2-²pyrazoles as TGF- β signal transduction inhibitors
 (preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrrolo[1,2-²
 (preparation); ROCI (reactant or reagent); US25 1058)



IT 476476-22-9P, 7-Benzyloxy-2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidine 476477-77-7P, 7-Acetoxy-2-(pyridin-2-yl)-3-(quinolin-4-yl)pyrazolo[1,5-a]piperidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of (hetero)aromatic substituted 5,6-dihydro-4H-pyrazolo[1,2-b]pyrazoles as TGF- β signal transduction inhibitors)
 RN 476476-22-9 CAPLUS
 CN Quinoline, 4-[7-(phenylmethoxy)-2-(2-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 476477-77-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-ol, 2-(2-pyridinyl)-3-(4-quinolinyl)-, acetate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L5 ANSWER 33 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:849629 CAPLUS
 DOCUMENT NUMBER: 137:337887
 TITLE: Pyrazolopyridines as virucides for herpes virus infections
 INVENTOR(S): Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 150 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088124	A2	20021107	WO 2002-US10687	20020405
WO 2002088124	A3	20030508		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, MG, MU, MY, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002305143	A1	20021111	AU 2002-305143	20020405
EP 1385847	A2	20040204	EP 2002-733945	20020405
EP 1385847	B1	20050601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004527560	T	20040909	JP 2002-585423	20020405
AT 296826	T	20050615	AT 2002-733945	20020405
ES 2242028	T3	20051101	ES 2002-2733945	20020405
US 2004142941	A1	20040722	US 2003-473751	20031001
US 6962914	B2	20051108		
US 2005192303	B1	20050901	US 2005-95212	20050331
US 7030134	B2	20060418		
US 2005192295	B1	20050901	US 2005-95361	20050331
PRIORITY APPL. INFO.:			US 2001-286948P	P 20010427
			WO 2002-US10687	W 20020405
			US 2003-473751	A3 20031001
OTHER SOURCE(S):		MARPAT 137:337887		
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazolopyridines I [Y = N, CH; R = (un)substituted Ph; R1 = halo, aryl, heterocyclic, amino; R2 = halo, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted OH, SH, S(O)H, SO2H, NH2; R3, R4 = H, halo, alkyl, alkenyl, cycloalkyl, aryl, heterocyclic, (un)substituted OH, CO2H, SO2NH2, NH2, alkyl, acyl; R5 = halo, alkenyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclic, (un)substituted alkyl, OH, CO2H, CONH2, CSNH2, c(-NH)NH2, SH, SO2H, SO2NH2, NH2, acyl, CN, NO2, N3; p = 1-3] were prepared for use in treating herpes virus infections. Thus, the pyrazolopyridine II was prepared from 4-FC6H4COMe, 2-chloro-5-trifluoromethylpyridine, 1-pyrrolidinedicarboximidamide, and cyclopentylamine in 9 steps. II had IC50 against HSV-1 of 5.3 μ M.
 IT 474303-58-7P 474303-59-8P 474303-67-8P
 474303-72-5P 474303-85-0P 474303-86-1P
 474303-88-3P 474303-90-7P 474303-91-8P
 474303-92-9P 474303-93-0P 474303-94-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RCT (Reactant or reagent); USES (Uses)
 (Preparation of pyrazolopyridines as virucides for herpes virus infections)
 RN 474303-58-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-

(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI)
(CA INDEX NAME)




RN 474303-59-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 474303-67-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[5,7-dichloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 474303-72-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[5,7-dichloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 474303-85-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474303-86-1 CAPLUS
CN Phenol, 4-[5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 474303-88-3 CAPLUS
CN Phenol, 4-[5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(cyclopentylamino)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 474303-90-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5,7-dichloro-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 474303-91-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 474303-92-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 474303-93-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474303-94-1 CAPLUS
CN Phenol, 4-[5-chloro-7-(cyclopentylamino)-3-[2-(cyclopropylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




IT 474303-56-5P 474303-57-6P 474303-60-1P
474303-61-2P 474303-62-3P 474303-63-4P
474303-64-5P 474303-65-6P 474303-66-7P
474303-68-9P 474303-69-0P 474303-70-3P
474303-71-4P 474303-73-6P 474303-74-7P
474303-75-8P 474303-76-9P 474303-77-0P
474303-78-1P 474303-79-2P 474303-80-5P
474303-81-6P 474303-82-7P 474303-83-8P
474303-84-9P 474303-87-2P 474303-89-4P
474303-95-2P 474303-96-3P 474303-97-4P
474303-98-5P 474303-99-6P 474304-00-2P
474304-01-3P 474304-08-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


[Preparation of pyrazolopyridines as virucides for herpes virus infections]
RN 474303-56-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 474303-57-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 474303-60-1 CAPLUS
CN Pyrrolidine, 1-[[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 474303-61-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 474303-62-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-hydroxy- (9CI) (CA INDEX NAME)




RN 474303-63-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-(4-morpholinylethyl)- (9CI) (CA INDEX NAME)




RN 474303-64-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 474303-65-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 474303-66-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-68-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-69-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5,7-diamine, N'-dicyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-70-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474303-71-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5,7-diamine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N'-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 474303-73-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 474303-74-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474303-75-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474303-76-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 474303-77-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-78-1 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 474303-79-2 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)-7-(1-piperidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 474303-80-5 CAPLUS
CN 2-Pyrimidinamine, 4-[(5-chloro-2-(4-fluorophenyl))-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 474303-81-6 CAPLUS
CN Guanidine, N-[5-chloro-3-[(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]]-N'-cyclopentyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 474303-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopropyl-3-[(2-(cyclopropylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)




RN 474303-83-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[(5,7-dichloro-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 474303-84-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-2-(3-chlorophenyl)-N-cyclopentyl-3-[(2-(cyclopentylamino)-4-pyrimidinyl)]- (9CI) (CA INDEX NAME)




RN 474303-87-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-3-[(2-(cyclopentylamino)-4-pyrimidinyl)-N-cyclopropyl-2-(4-(cyclopropylmethoxy)phenyl)]- (9CI) (CA INDEX NAME)




RN 474303-89-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-{4-(cyclopropylmethoxy)phenyl}- (9CI) (CA INDEX NAME)



RN 474303-95-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-{4-(cyclopropylmethoxy)phenyl}- (9CI) (CA INDEX NAME)




RN 474303-96-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 7-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-97-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 4,6-dibromo-N-cyclopentyl-3-[2-


(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 474303-98-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 4,6-dibromo-3-[5-bromo-2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474303-99-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 6-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474304-00-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-


pyrimidinyl]-2-(4-fluorophenyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 474304-01-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 474304-08-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-85-3P
468062-87-5P 468063-27-6P 473711-94-3P
474304-02-4P 474304-03-5P 474304-04-6P
474304-05-7P 474304-07-9P
RL: RCT (Reactant); SEN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as virucides for herpes virus infections)
RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468062-85-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-27-6 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 473711-94-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 474304-02-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




RN 474304-03-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




RN 474304-04-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 474304-05-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




RN 474304-07-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-chloro-2-(4-methoxyphenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(triethoxymethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 34 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:814131 CAPLUS
 DOCUMENT NUMBER: 137:325427
 TITLE: Preparation of antiviral 3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridines
 INVENTOR(S): Cheung, Mui; Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083672	A1	20021024	WO 2002-08793	20020321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SW, T2, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF			
AU 2002254326	A1	20021028	AU 2002-254326	20020321
EP 1377575	A1	20040107	EP 2002-723554	20020321
EP 1377575	B1	20060705		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004529926	T	20040530	JP 2002-581427	20020321
AT 332301	T	20060715	AT 2002-723554	20020321
US 2004167335	A1	20040826	US 2003-473491	20030925
US 7141569	B2	20061128		
US 2006235043	A1	20061019	US 2006-422357	20060606
PRIORITY APPLN. INFO.:			US 2001-282749P	P 20010410
			WO 2002-US8793	W 20020321
			US 2003-473491	A3 20030925
OTHER SOURCE(S):			MARKPAT 137:325427	
GI				




AB The title compds. [I; R1 = H; R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, cycloalkyl, etc.; p = 1-3; R6 = halo, alkyl, cycloalkyl, etc.], useful in treatment of herpes viral infections, were prepared E.g., a 7-step synthesis of I [R1 = H; R2 = cyclopentylamino; Y = N; R3, R4 = H; q = 1; R5 = 4-F; p = 1; R6 = 5-(cyclopentylamino)], starting from 4-chloro-2-picolone and Et 4-fluorobenzoate, which showed IC50 of 0.5 μM against HSV-1, was given.
 IT 468062-85-3P 468062-87-5P 473711-94-3P
 473711-95-4P 473711-97-6P 473712-02-6P
 473712-09-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 [Preparation of antiviral pyrazolopyridines for treating herpes viral infections]
 RN 468062-85-3 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 473711-94-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473711-95-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473711-97-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 473712-02-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 473712-09-3 CAPLUS
CN Phenol, 4-[5-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




IT 473711-96-5P 473711-98-7P 473711-99-8P
473712-00-4P 473712-01-5P 473712-03-7P
473712-04-8P 473712-05-9P 473712-06-0P
473712-07-1P 473712-08-2P 473712-10-6P
473712-11-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of antiviral pyrazolopyridines for treating herpes viral infections)

RN 473711-96-5 CAPLUS
CN Methanesulfonamide, N-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 473711-98-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-6-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-
(4-methoxyphenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 473712-04-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-bromo-N-cyclopentyl-3-[2-
(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX
NAME)




RN 473712-05-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-chloro-N-cyclopentyl-3-[2-
(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX
NAME)




RN 473712-06-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-bromo-N-cyclopentyl-3-[2-
(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX
NAME)




RN 473711-99-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-
(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 473712-00-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-
(4-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 473712-01-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-
(4-fluorophenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 473712-03-7 CAPLUS




RN 473712-07-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, 4-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 473712-08-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-butyl-3-[2-(butylamino)-4-pyridinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 473712-10-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 473712-11-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 468062-79-5P 468062-80-8P 468062-81-9P
473712-17-3P 473712-18-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antiviral pyrazolopyridines for treating herpes viral infections)
RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468062-81-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 473712-17-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 473712-18-4 CAPLUS
CN Carbanic acid, [3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 35 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:77725 CAPLUS
DOCUMENT NUMBER: 137:288973
TITLE: Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections
INVENTOR(S): Boyd, F. Leslie; Gudmundsson, Kristjan; Johns, Brian A.
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078701	A1	20021010	WO 2002-US8621	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GU, GW, ML, MR, NE, NG, SN, TD, TG				
AU 2002254310	A1	20021015	AU 2002-254310	20020320
EP 1372642	A1	20040102	EP 2002-723538	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525150	T	20040819	JP 2002-576967	20020320
US 2005107400	A1	20050519	US 2003-473197	20030924
PRIORITY APPL. INFO.:			US 2001-280047P	P 20010330
			US 2001-307189P	P 20010723
			WO 2002-US8621	W 20020320
OTHER SOURCE(S):				
GI				




I


AB The present invention provides methods using I (e.g. 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine) for the treatment or prophylaxis of viral infections such as herpes viral infections. IC50 values are reported for about 70 of the claimed compounds against HSV-1 (e.g. 0.2 µM for N-cyclopropyl-4-[6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine). In I, Z is CH or N; a is 1 or 2; b is 1, 2 or 3; c is 1, 2 or 3; each R1 is independently selected from -(X)d-(CH2)e-R5 wherein d is 0 or 1; e is 0 to 6; X is selected from O, NR6 and S(O)f where f is 0, 1 or 2. R5 is selected from H, halo, Cl-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, cyano, nitro, trihalomethyl, NR7R8, C6H4(CH2)NR7R8, C(O)R7, C(O)NR7R8, C(O)R7, C(O)NR7R8, CO2R7, CO2R7, SO2R7, SO2NR7R8, C(NR7)NR7R8, N(R7)C(NR7)NR7R8, NHC(O)R7 and N(C1-3alkyl)C(O)R7. Each R2 is independently selected from H, cyano, halo, trihalomethyl, OCl-6alkyl, Cl-6alkyl, C2-6alkenyl, C2-6alkynyl, S(O)GCl-6alkyl where g is 0, 1 or 2, NCl-6alkyl (Cl-6alkyl), wherein d is 0 or 1; e is 0 to 6; Y is O or S(O)f where f is 0, 1 or 2. R3 is selected from H, halo, Cl-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, cyano, nitro, trihalomethyl, phthalimido, C6H4NR7R8, C6H4(CH2)NR7R8, C(O)R7, C(O)NR7R8, OC(O)R7, OC(O)NR7R8, CO2R7, CO2NR7R8 and C(NR7)NR7R8. R6 is selected from H, Cl-6alkyl, C2-6alkenyl, heteroaryl, cycloalkyl, and heterocyclyl. R7 and R8 are each independently selected from H, Cl-8alkyl, C2-6alkenyl, SO2Cl-6alkyl, (CH2)m-cycloalkyl, (CH2)m-aryl, (CH2)m-heterocyclyl and (CH2)m-heteroaryl, wherein m is 0, 1 or 2, or R7 and R8 together with the N atom to which they are bound, form a heterocyclyl group. Addnl. conditions for I are stated in the claims. Although neither the methods of preparation nor the compounds are claimed, approx. 100 example preps. are included.

IT 401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 437612-52-7P, 7-Chloro-2-(4-fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 468062-75-1P, [3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-6-yl]methanol 468062-85-3P, 4-[5-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-95-5P, 2-(4-Fluorophenyl)-7-methylthio-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-97-7P, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-00-5P, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-02-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-04-9P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-13-0P,


2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(ethylsulfinyl)pyrazolo[1,5-a]pyridine 468063-14-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridine 468063-15-2P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 468063-21-0P, 468063-25-4P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylate 468063-29-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylic acid 468063-49-2P, N-Cyclopentyl-4-[2-(2,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); NACT (Reactant or reagent); USES (Uses) (intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
 RN 401815-63-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridyl)- (9CI) (CA INDEX NAME)




RN 401816-32-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-34-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468062-75-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468062-85-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-95-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-97-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-04-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-13-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(ethylsulfinyl)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-14-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-(ethylthio)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-15-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468063-21-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 468063-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 468063-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 468063-49-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




IT 401815-97-2P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-15-7P, 3-(2,6-Difluoro-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-18-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-24-8P, 6-Bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-55-3P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methoxybenzyloxy)propyl]-2-pyrimidinamine 437612-75-4P, 4-[7-Chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 437613-05-3P, N-Butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-79-5P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-

6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-80-8P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-81-9P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468062-83-1P, 4-[6-(Bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-98-8P, 7-Chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 468063-27-6P, 4-[7-Chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-28-7P, Ethyl 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate
RU: RCI (Reactant); SFN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 401815-97-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-15-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-18-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)


RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-81-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 401816-24-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-55-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (9CI) (CA INDEX NAME)




RN 437612-75-4 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)







RN 468062-83-1 CAPLUS
CN 2-Pyrimidinamine, 4-[6-(bromomethyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468062-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 468063-27-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468063-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



IT 468063-31-2P, N-Butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 468063-31-2 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



IT

401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-(1H-imidazol-5-yl)ethyl)-2-pyridinamine 401816-00-0P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-01-1P, 3-[[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 401816-03-3P, N'-[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]-1,3-propanediamine 401816-04-4P, 3-(2-Butoxypropyl)-4-yl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyridinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyridinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyridinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyridinamine 401816-12-4P, 2-[[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyridinamine 401816-17-9P, N-Benzyl-6-fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyridinamine 401816-22-6P, 3-[[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-37-3P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-40-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyridinamine 401816-41-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-44-2P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethoxy)-2-pyridinamine 401816-48-6P, N-Butyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-49-7P, N-Benzyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-50-0P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-53-3P, 4-[2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethoxy)-2-pyridinamine 401816-54-4P, 3-[[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 401816-57-7P, N-Cyclopropyl-4-[6-cyano-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-62-4P, 3-[[5-Bromo-4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 401816-66-0P, N'-[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)]pyrimidin-2-yl]-N-(3-(4-methylpiperazin-1-yl)propyl)amine 401816-71-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-5-yl)ethyl]-2-pyridinamine 401816-72-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-73-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)-2-pyridinamine


401816-74-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)-2-pyridinamine 401816-79-3P, N-[4-(2-(4-Fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl)]pyrimidin-2-yl]-N3,N3-dimethylpropane-1,3-diamine 437612-79-8P, N-Cyclopentyl-6-[2-(4-Fluorophenyl)-7-(methoxythio)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468062-82-0P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 468062-84-2P, N-Cyclopentyl-4-[6-(cyclopentylamino)methyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-86-4P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-5-(1-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-87-5P, 4-[5-Chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-94-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468062-96-6P, 2-(4-Fluorophenyl)-7-methylsulfinyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468062-99-9P, N-Butyl-4-[7-(2-Fluoroethoxy)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-01-6P, N-Benzyl-4-[7-(2-Fluoroethoxy)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-03-8P, N-Butyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-05-0P, N-Benzyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-06-1P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-07-2P, N-Cyclopentyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-08-3P, N-Cyclohexyl-4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-09-4P, 3-[[4-(2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)amino]-1-propanol 468063-10-7P, 2-(4-Fluorophenyl)-3-(2-methoxy-4-pyridinyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, (2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, 2-(4-Fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyridinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-20-9P, 2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-23-2P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)-2-pyrimidinamine 468063-24-3P, 4-pyridin-3-yl]-2-pyrimidinamine 468063-24-3P, N-[4-(5-Chloro-7-(ethylsulfonyl)-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]-N-cyclopentylamine 468063-30-1P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-32-3P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-33-4P, N-Butyl-4-[2-(4-Fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-34-5P, N-Cyclopropyl-4-[7-ethyl-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-35-6P, N,N-Dimethyl 2-(4-Fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-pyrazolo[1,5-a]pyridinecarboxamide 468063-36-7P, 1-[3-[[4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]propyl]-2-pyrrolidinone 468063-37-8P, 6-Fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-methyl-2-pyrimidinamine 468063-38-9P, 4-[4-Fluoro-2-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl-2-pyrimidinamine 468063-39-0P, N-Allyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-40-3P, 5-[6-Chloro-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 468063-41-4P, 3-[[5-Bromo-4-(2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]amino]-1-propanol 468063-42-5P, Methyl 3-[2-[[3-(acetyloxypropyl)amino]-4-pyridinyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468063-43-6P, 3-[2-(Cyclopropylamino)-4-pyrimidinyl]-2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylic acid 468063-44-7P, 3-[2-(Cyclopropylamino)-4-pyrimidinyl]-2-(4-Fluorophenyl)-N,N-

dimethylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-45-8P,
N-Cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxamide 468063-46-9P,
N-Cyclopentyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-2-pyrimidinamine 468063-48-1P 468063-50-5P,
5-Bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentylpyrimidin-2-amine 468063-51-6P, N-Cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468063-52-7P, N-Cyclopropyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-53-8P, N-Cyclopropyl-4-[2-(4-methoxyphenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-54-9P, Ethyl 3-[2-(cyclopropylamino)pyrimidin-4-yl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-6-carboxylate 468063-55-0P, 3-[2-(cyclopropylamino)pyrimidin-4-yl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-6-carboxamide 468063-56-1P, 4-[5-Chloro-2-(4-cyclopropylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 468063-57-2P, 4-[7-Butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-58-3P, 4-[5-Chloro-2-(3-chlorophenyl)-7-(methanesulfonyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-59-4P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-60-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(isopropylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl] pyrimidin-2-amine (isopropylthio) (Pharmacological activity): SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)


RN 401815-99-4 CAPIUS

CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 401816-00-0 CAPIUS

CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-01-1 CAPIUS

CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-03-3 CAPIUS

CN 1,3-Propanediamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-04-4 CAPIUS

CN Pyrazolo[1,5-a]pyridine, 3-(2-butoxy-4-pyridinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-05-5 CAPIUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl- (9CI) (CA INDEX NAME)




RN 401816-06-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 401816-07-7 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl- (9CI) (CA INDEX NAME)




RN 401816-08-8 CAPLUS
CN 3-Pyridinemethanamine, N-[4-(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-09-9 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (9CI) (CA INDEX NAME)



RN 401816-12-4 CAPLUS
CN Ethanol, 2-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenylmethyl- (9CI) (CA INDEX NAME)




RN 401816-14-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


CN 1,3-Propanediamine, N-[4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)





RN 401816-37-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-40-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-41-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 401816-19-1 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-22-6 CAPLUS
CN 1-Propanol, 3-[[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-25-9 CAPLUS


CN 2-Pyrimidinamine, N-Cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-53-3 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 401816-54-4 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-44-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 401816-48-6 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-49-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-50-0 CAPLUS


RN 401816-72-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-73-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-74-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-79-3 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-62-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-68-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401816-71-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 468062-86-4 CAPIUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-87-5 CAPIUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468062-94-4 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-96-6 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylsulfinyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437612-79-8 CAPIUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-92-0 CAPIUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-94-2 CAPIUS
CN Pyrazolo[1,5-a]pyridine-6-methanamine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)







RN 468062-99-9 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[(7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-01-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-03-8 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-05-0 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 468063-06-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-07-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 468063-08-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclohexyl-4-[(2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)


RN 468063-12-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-20-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468063-23-2 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-24-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-09-4 CAPLUS
CN 1-Propanol, 3-[(4-{2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 468063-10-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-11-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-phenoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-34-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-36-7 CAPLUS
CN 2-Pyrrolidinone, 1-[3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 468063-37-8 CAPLUS
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 468063-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 468063-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-33-4 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)







RN 468063-38-9 CAPLUS
CN 2-Pyridinamine, 4-[(4-fluoro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-39-0 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 468063-40-3 CAPLUS
CN 2-Pyridinamine, 5-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 468063-41-4 CAPLUS
CN 1-Propanol, 3-[[5-bromo-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]]-2-pyridinylamino]- (9CI) (CA INDEX NAME)




RN 468063-42-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-[[3-(acetyloxy)propylamino]-4-pyridinyl]-2-(4-fluorophenyl)]-, methyl ester (9CI) (CA INDEX NAME)




RN 468063-43-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468063-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 468063-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 468063-46-9 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 468063-48-1 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-50-5 CAPLUS
CN 2-Pyrimidinamine, 5-bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-51-6 CAPLUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-52-7 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-53-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-methoxyphenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-54-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-55-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 468063-59-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)morpholinyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-57-2 CAPLUS
CN 2-Pyrimidinamine, 4-[7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-58-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)





468063-60-7 CAPLUS
2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-[(1-methylethyl)thio]-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)



1 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

LL5 ANSWER 36 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:77724 CAPLUS
DOCUMENT NUMBER: 137:294953

DOCUMENT NUMBER: 157123455
TITLE: Preparation and use of pyrazolopyridines for treatment

INVENTOR(S):
or prophylaxis of herpes viral infections
Alberti, Michael John; Chamberlain, Stanley D.;

Chuang, Mu; Gudmundsson, Kristjan; Harris, Philip
Anthony; Johns, Brian A.; Jung, David Kendall; Peel,

PATENT ASSIGNEE(S):
Michael Robert; Stanford, Jennifer Badiang
Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE:	English
ENTRY ACC:	2
ENTRY CONT:	2

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT INFORMATION:

[illegible]

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----

WO 2002078700	A1	20021010	WO 2002-US8524	20020320
---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	TC	TM	TW	XT	DE	CH
BW:	IS	MM	MZ	SD	SI	SZ
CH, CM, KE	IS	MM	MZ	SD	SI	SZ



RW: GH, GM, RE, LS, MW, MZ, SZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, MC, NL, PT, SE, TR

CI, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BE, BJ, CE, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG

[illegible]


AU 2002305067	Al	20021015	AU 2002-305067	20020320
EP 1372643	Al	20040102	EP 2002-733866	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525149	T	20040819	JP 2002-576966	20020320
US 2005059677	Al	20050317	US 2003-473196	20030924
US 7034030	B2	20060425		
US 2006059319	Al	20060316		
US 7109209	B2	20060919	US 2005-245972	20051007
PRIORITY APPLN. INFO.:				
			US 2001-280047P	P 20010330
			US 2001-307189P	P 20010723
			US 2001-307786P	P 20010725
			US 2001-315090P	P 20010827
			WO 2002-US8524	W 20020320
			US 2003-473196	A3 20030924

OTHER SOURCE(S): MARPAT 137:294953




The present invention provides I (variables defined below; e.g. 4-[7'-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (Example 41)), methods for their preparation and their use for the treatment or prophylaxis of viral infections such as herpes viral infections. IC50 values are reported for about 20 of the claimed compounds against HSV-1, e.g. 0.28 µM for Example 41. In I, R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10A, -R10B, -R10C, -R10D, -OR7, -OAr, -OHet, -OR10A, -OR10Het, -R10OR9, -R10NR7R8, -R10NR7AY, -R10C(O)R9, -C(O)R9, -C(O)Ar, -C(O)Het, -R10C(O)R9, -R10C(O)Alk, -R10C(O)R10, -CO2R9, -C(O)NR9R11, -R10C(S)NR9R11, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7AY, -R10SO2NHCO9, -C(NH)NR7R8, -C(NH)NR7AY, -R10SO2R9, -R10NSO2R9, -R10NSO2R9, -R10NSO2R9, -S(O)nR9, -S(O)nAy, -S(O)nHet, cyano, azido and nitro. Each R7 and R8 are the same or different and are independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -R10Cycoalkyl, -OR9, -R10OR9, -R10NR9R11, -R10C(O)R9, -C(O)Ar, -CO2R9, -R10CO2R9, -C(O)NR9R11, -R10C(O)NR9R11, -C(S)NR9R11, -R10C(S)NR9R11, -R10CN(H)NR9R11, -R10NSO2R9, -SO2R10, -R10SO2R10, -R10NHCO9 and -R10SO2NHCO9. Each R9 and R11 are the same or different and are independently selected from H, alkyl, cycloalkyl, -R10Cycoalkyl, -R10OH, -R10(OR10)w where w is 1-10, and

CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)




RN 468063-15-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-(9CI) (CA INDEX NAME)




IT 437612-75-4P, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyrimidinamine 437613-05-3P, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-79-5P, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-80-8P, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468062-85-3P, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468062-98-8P, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-17-4P, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine hydrochloride 468063-27-6P, 4-[7-chloro-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-28-7P, Ethyl 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-6-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 437612-75-4 CAPLUS
CN 2-pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-(9CI) (CA INDEX NAME)

-R10NR10R10. Each R10 is the same or different and is independently alkyl, cycloalkyl, alkenyl, cycloalkenyl and alkynyl; Ar is an aryl; Het is a 5- or 6-membered heterocyclic or heteroaryl group; n is 0-2. R2 is H, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -NR7R8, Ar, -NHR10Ar, -OR7, -OAr, -S(O)nR9, -S(O)nAr, -R10NR7R8, -R10NR7Ar, Het, -NHR10Het, -NHR10Het, -OHet and -OR10Het. Y is N or CH; R3 and R4 are the same or different and are each independently H, halo, alkyl, cycloalkyl, alkenyl, aryl, -OR7, -OAr, -R10OR7, -R10ORAr, -NR7R8, -NR7Ar, -R10NR7R8, -R10NR7Ar, -C(O)R7, -C(O)Ar, -CO2R7, -CO2Ar, -SO2NHR9, Het, -NHR10Het and -NHR10Het; q is 0-5. Each R5 is the same or different and is independently halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ar, -NHR10Ar, -NR7Ar, Het, -NHR10Het, -NHR10Het, -OR7, -OAr, -OHet, -R10OR9, -NR7R8, -R10NR7R8, -R10NR7Ar, -C(O)R9, -C(O)Ar, -C(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ar, -C(O)NHR10Het, -R10C(O)NR9R11, -C(S)N R9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ar, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ar, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -S(O)nR9, cyano, azido and nitro; or two adjacent R5 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or aryl. P is 0-3; and each R6 is the same or different and is independently halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -R10cycloalkyl, Ar, Het, -R10Ar, -R10Het, -OR7, -OAr, -OHet, -R10OR9, -OR10Ar, -OR10Het, -R10NR7R8, -R10NR7Ar, -R10C(O)R9, -C(O)R9, -C(O)Ar, -C(O)Het, -CO2R9, -R10CO2R9, -C(O)NR7R8, -C(O)NR7Ar, -C(O)NHR10Het, -R10C(O)NR9R11, -C(S)NR9R11, -R10C(S)NR9R11, -R10NHC(NH)NR9R11, -C(NH)NR7R8, -C(NH)NR7Ar, -R10C(NH)NR9R11, -S(O)2NR7R8, -S(O)2NR7Ar, -R10SO2NHCOR9, -R10SO2NR9R11, -R10SO2R9, -S(O)nR9, cyano, azido and nitro; or two adjacent R6 groups together with the atoms to which they are bonded form a C5-6 cycloalkyl or a 5- or 6-membered heterocyclic group containing 1 or 2 heteroatoms; wherein when Y is CH, R3 is not -NR7Ar; . . . approx. 45 Example preps. are included. Several methods of preparation are claimed, e.g. reaction of II (R1a = H, halo, etc. as specified in the claims) with H2NC(NH)R2 to give I (R1a in place of R1 and other variables are subsets of those defined for I above) and when R1a = H, halo, converting this compound to a subset of I. For example, to a solution of 1-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-butyne-1-one (2.0 mmol) in DMF was added cyclopentylamine hydrochloride (4.1 mmol) followed by anhydrous K carbonate (4.1 mmol). The resulting mixture was heated at 80° for 12 h; upon cooling to room temperature, H2O was added, the mixture was extracted with EtOAc, the EtOAc phase was washed with brine, dried (Mg sulfate), filtered and concentrated in vacuo; the resulting residue was purified by flash chromatog. (1:1 EtOAc-hexane) to give, after recrystn. from MeCN, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (74%) as a white solid. To a solution of 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine (0.37 mmol) in anhydrous THF (5 ml) at -78° was added BuLi (1.1 mmol of 1.6M solution in hexane); the resulting solution was stirred for 10 min at -78°, followed by addition of di-Et disulfide (1.1 mmol). The reaction was stirred at -78° for 20 min and then allowed to warm to room temperature; H2O and EtOAc were added to the reaction mixture; the phases were separated, the aqueous phase washed with EtOAc and the combined organic phase dried (Mg sulfate), filtered and concentrated in vacuo; the resulting solid was purified by flash chromatog. (1:1 EtOAc-hexane) to give, after recrystn. from EtOAc N-[4-[5-chloro-7-(ethylsulfanyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N-cyclopentylamine (52%) as a solid.
IT 401815-63-2P, 2-(4-fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine 468063-15-2P, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 401815-63-2 CAPLUS


CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468062-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 468063-17-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 468063-27-6 CAPLUS
CN 2-Pyrimidinamine, 4-{7-chloro-2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl}-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-79-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-80-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-6-(triethoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468062-85-3 CAPLUS




RN 468063-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-, ethyl ester (9CI)
(CA INDEX NAME)




IT 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 437612-52-7P, 7-Chloro-2-(4-fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-95-5P, 2-(4-Fluorophenyl)-7-methylthio-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-97-7P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-00-5P, 7-(2-Fluoroethoxy)-2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridine 468063-02-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-04-9P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-13-0P, 2-(4-Fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]-7-(ethylsulfinyl)pyrazolo[1,5-a]pyridine 468063-14-1P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(ethylthio)pyrazolo[1,5-a]pyridine 468063-21-0P, 2-(4-Fluorophenyl)-3-[2-(fluoro-4-pyridinyl)-7-methoxy]pyrazolo[1,5-a]pyridine 468063-25-4P, Ethyl 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylate 468063-29-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxylic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)
RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-34-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468062-95-5 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylthio)-3-(4-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-97-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468063-00-5 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 7-(2-fluoroethoxy)-2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468063-02-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylthio)-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-04-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-13-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 7-(ethylsulfinyl)-2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468063-14-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 7-(ethylthio)-2-(4-fluorophenyl)-3-(2-(methylthio)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468063-21-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 468063-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 468063-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 401816-37-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

IT


401816-37-3P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 437612-79-8P, N-Cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 468062-94-4P, 2-(4-Fluorophenyl)-7-methyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-96-6P, 2-(4-Fluorophenyl)-7-methylsulfinyl-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 468062-99-9P, N-Butyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-01-6P, N-Benzyl-4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-03-8P, N-Butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-05-0P, N-Benzyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-06-1P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-07-2P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-08-3P, N-Cyclohexyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-09-4P, 3-[4-[2-(4-Fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinylamino]-1-propanol 468063-10-7P, 2-(4-Fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-11-8P, 2-(4-Fluorophenyl)-3-[2-(phenyloxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-12-9P, 2-(4-Fluorophenyl)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridine 468063-20-9P, 2-(4-Fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 468063-23-2P, N-Butyl-4-[2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-24-3P, N-[4-[5-Chloro-7-(ethylsulfonyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N-cyclopentylamine 468063-30-1P, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridine-6-carboxamide 468063-31-2P, N-Butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-32-3P, N-Butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-33-4P, N-Butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-34-5P, N-Cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 468063-35-6P, N,N-Dimethyl 2-(4-fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-7-pyrazolo[1,5-a]pyridinylcarboxamide 468063-57-2P, 4-[7-Butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-58-3P, 4-[5-Chloro-2-(3-chlorophenyl)-7-(methylsulfonyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 468063-59-4P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine 468063-60-7P, N-Cyclopentyl-4-[2-(4-fluorophenyl)-7-(isopropylthio)-5-morpholinopyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation and use of pyrazolopyridines for treatment or prophylaxis of herpes viral infections)




RN 437612-79-8 CAPLUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-(2-(4-fluorophenyl)-7-(methythio)pyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 468062-94-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methyl-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468062-96-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(methylsulfinyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 468063-05-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 468063-01-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-(2-fluoroethoxy)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 468063-03-8 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)







RN 468063-06-1 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468063-07-2 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-08-3 CAPLUS
 CN 2-Pyrimidinamine, N-cyclohexyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-09-4 CAPLUS


CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 468063-10-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-methoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-11-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-phenoxy-4-pyrimidinyl)-7-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 468063-12-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)-3-[2-(2,2,2-trifluoroethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-(2-(cyclopentylamino)-4-pyrimidinyl)-N-cyclopropyl-2-(4-fluorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 468063-31-2 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-butyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-33-4 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-octylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-30-1 CAPLUS




RN 468063-20-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-methoxy-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 468063-23-2 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)-7-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-24-3 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




CN 2-Pyrimidinamine, 4-[5-chloro-2-(3-chlorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 468063-59-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(methylthio)-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 468063-60-7 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-[(1-methylethyl)thio]-5-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:720128 CAPLUS
DOCUMENT NUMBER: 137:379680
TITLE: Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists
AUTHOR (S): Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga; Ciacci, Andrea; Corelli, Federico; Fossa, Paola;



RN 468063-34-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[7-ethyl-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 468063-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 468063-57-2 CAPLUS
CN 2-Pyrimidinamine, 4-[7-butoxy-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 468063-58-3 CAPLUS

CORPORATE SOURCE: Lucacchini, Antonio; Manetti, Fabrizio; Martini, Claudia; Menozzi, Giulia; Mosti, Luisa; Ranise, Angelo; Schenone, Silvia; Tafi, Andrea; Trincavelli, Maria Letizia
 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Genoa, I-16132, Italy
 Journal of Medicinal Chemistry (2002), 45(22), 4875-4887
 CODEN: JMCWAR; ISSN: 0022-2623
 SOURCE: American Chemical Society
 PUBLISHER: Journal
 DOCUMENT TYPE: English
 LANGUAGE: CASREACT 137:379680
 OTHER SOURCE(S):

AB We present a combined computational study aimed at identifying the three-dimensional structural properties required for different classes of compounds to show antagonistic activity toward the A1 adenosine receptor (AR). Particularly, an approach combining pharmacophore mapping, mol. alignment, and pseudoreceptor generation was applied to derive a hypothesis of the interaction pathway between a set of A1 AR antagonists taken from the literature and a model of the putative A1 receptor. The pharmacophore model consists of seven features and represents an improvement of the N6-C8 model, generally reported as the most probable pharmacophore model for A1 AR agonists and antagonists. It was used to build up a pseudoreceptor model able to rationalize the relationships between structural properties and biol. data of, and external to, the training set. In fact, to further assess its statistical significance and predictive power, the pseudoreceptor was employed to predict the free energy of binding associated with compounds constituting a test set. While part of these mols. was also taken from the literature, the remaining compounds were designed and synthesized by our research group. All of the new compounds were tested for their affinity toward A1, A2a, and A3 AR, showing interesting antagonistic activity and A1 selectivity.

IT 131185-37-0
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (therapeutic use); BIOL (biological study); USES (Uses)
 (synthesis, mol. modeling studies, and pharmacol. activity of selective A1 receptor antagonists)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L5 ANSWER 38 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: "2002:716277 CAPLUS
 DOCUMENT NUMBER: 137:247709
 TITLE: Preparation of 3-(4-pyrimidinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-amine for treating herpes viral infections
 INVENTOR(S): Boyd, F. Leslie; Gudmundsson, Kristjan; Johns, Brian A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 191 pp.
 CODEN: PIXX22

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072581	A2	20020919	WO 2002-US6552	20020305
WO 2002072581	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CE, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248531	A1	20020924	AU 2002-248531	20020305
EP 1366048	A2	20031203	EP 2002-248531	20020305
EP 1366048	B1	20040825	EP 2002-248531	20020305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 274515	T	20040915	AT 2002-248531	20020305
JP 2004529119	T	20040924	JP 2002-248531	20020305
ES 2227451	T3	20050401	ES 2002-248531	20020305
US 2005049260	A1	20050303	US 2003-468729	20030822
US 7153855	B2	20061226		
US 2006293344	A1	20061228	US 2006-468319	20060830
PRIORITY APPL. INFO.:			US 2001-274297P	P 20010308
			WO 2002-US6552	W 20020305
			US 2003-468729	A3 20030822


OTHER SOURCE(S):
 GI MAREPAT 137:247709




AB The title compounds. [I; R1 = halo, NR7R8, aryl, etc. (wherein R7, R8 = H, alkyl, cycloalkyl, etc.); R2 = halo, alkyl, cycloalkyl, etc.; Y = N, CH; R3, R4 = H, halo, alkyl, etc.; q = 0-5; R5 = halo, alkyl, alkenyl, etc.; when q = 1 and R5 is in the para position, R5 is not halo; when Y = CH, R3 is not NR7(aryl)], useful for the prophylaxis or treatment of herpes viral infections, were prepared E.g., a multi-step synthesis of I [R1, R2 = cyclopentylamino; R3, R4 = H; Y = N; R5 = 4-MeO], starting with 6-chloro-2-picolone, which showed IC50 of 0.3 μM against HSV-1, was given.

IT 437611-98-8P 460078-20-OP 460078-24-4P
 460078-25-5P 460078-26-6P 460078-37-9P
 460078-46-0P 460078-47-1P 460078-55-1P
 460078-60-8P 460078-67-5P 460078-70-0P
 460078-71-1P 460078-74-4P 460078-78-8P


460078-80-2P 460078-86-8P 460078-87-9P
 460078-88-0P 460078-89-1P 460079-01-0P
 460079-04-3P 460079-10-1P 460079-11-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 Preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 Preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amines
 for treating herpes viral infections)
 RN 437611-98-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-
 (butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-20-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
 pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-24-4 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-7-(1-
 pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-25-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(4-methoxyphenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-
 a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-26-6 CAPLUS
 CN Phenol, 4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-
 pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-37-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-aminophenyl)-N-butyl-3-[2-
 (butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-46-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-
 (cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-47-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-55-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-aminophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-60-8 CAPLUS
CN Benzonitrile, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-67-5 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5,6-dimethyl- (9CI) (CA INDEX NAME)




RN 460078-70-0 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-71-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-74-4 CAPLUS
CN Phenol, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-78-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[(2-(cyclopropylamino)-4-pyrimidinyl)-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)



RN 460078-80-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[(2-(cyclopentylamino)-4-pyrimidinyl)-N-cyclopropyl-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 460078-86-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[(2-(cyclopropylamino)-4-pyrimidinyl)-2-(4-methoxyphenyl)]- (9CI) (CA INDEX NAME)




RN 460079-01-0 CAPLUS
CN 1,4-Butanediamine, N-[3-[(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]]- (9CI) (CA INDEX NAME)


RN 460078-87-9 CAPLUS
CN Phenol, 4-[3-[(2-(cyclopentylamino)-4-pyrimidinyl)-7-(cyclopropylamino)pyrazolo[1,5-a]pyridin-2-yl]]- (9CI) (CA INDEX NAME)










RN 460078-88-0 CAPLUS
CN Phenol, 4-[7-(cyclopentylamino)-3-[(2-(cyclopropylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]]- (9CI) (CA INDEX NAME)



RN 460078-89-1 CAPLUS
CN Phenol, 4-[7-(cyclopropylamino)-3-[(2-(cyclopropylamino)-4-pyrimidinyl)pyrazolo[1,5-a]pyridin-2-yl]]- (9CI) (CA INDEX NAME)






RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


[preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo(1,5-a)pyridin-7-amines for treating herpes viral infections]

RN 437613-19-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-[[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-27-7 CAPLUS


CN Phenol, 4-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-28-8 CAPLUS
CN Phenol, 4-[3-(2-amino-4-pyrimidinyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-29-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-30-2 CAPLUS
CN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 460078-31-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-butoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-32-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(2-methylpropoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-33-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-34-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[(4-(cyclobutylmethoxy)phenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]]- (9CI) (CA INDEX NAME)




RN 460078-35-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-36-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[(1,1'-biphenyl)-4-yl-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]]- (9CI) (CA INDEX NAME)




RN 460078-38-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[(4-(cyclohexylamino)phenyl)]- (9CI) (CA INDEX NAME)




RN 460078-39-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[(4-(1-methylethylphenyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 460078-40-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[(4-(phenylamino)phenyl)]- (9CI) (CA INDEX NAME)




RN 460078-41-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-N-phenyl-2-[4-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-42-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[4-(bis(cyclopropylmethyl)amino)phenyl]-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-43-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-[(cyclopropylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-44-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(2-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-48-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-2-(3-bromophenyl)-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-49-3 CAPLUS
CN 2-Pyrimidinamine, 4-[[2-(3-bromophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-50-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-[[1,1'-biphenyl]-3-yl]-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-51-7 CAPLUS
CN 2-Pyrimidinamine, 4-[[2-(1,1'-biphenyl)-3-yl]-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-52-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-53-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-54-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-56-2 CAPLUS
CN Acetamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-57-3 CAPLUS
CN Methanesulfonamide, N-[3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-58-4 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-aminophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460078-59-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 460078-61-9 CAPLUS
CN Benzamide, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-62-0 CAPLUS
CN Benzoic acid, 3-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 460078-63-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-methoxyphenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-64-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-amino-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-65-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-[(phenylmethyl)amino]phenyl)- (9CI) (CA INDEX NAME)




RN 460078-66-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-68-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5,6-dimethyl-4-pyrimidinyl]-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-69-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)-2-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 460078-72-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 460078-73-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 460078-75-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-76-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 460078-77-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-79-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 460078-81-3 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-methoxyphenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)-N-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)



RN 460078-90-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-91-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-92-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(cyclopropylmethoxy)phenyl]- (9CI) (CA INDEX NAME)


RN 460078-82-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-83-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-methoxyphenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460078-84-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460078-85-7 CAPLUS




RN 460078-93-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-[4-(2-propenyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-94-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-[[[(4-methoxyphenyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 460078-95-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 460078-96-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-97-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



RN 460078-98-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460078-99-3 CAPLUS
CN Glycine, N-[3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]]-, methyl ester (9CI) (CA INDEX NAME)




RN 460079-00-9 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[4-[[7-(butylamino)-3-[[2-(butylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460079-02-1 CAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[4-[[3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 460079-03-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 460079-05-4 CAPLUS
CN Guanidine, [4-[[3-[[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 460079-06-5 CAPLUS
CN Methanesulfonylpyrazolo[1,5-a]pyridin-7-yl]amino]butyl]- (9CI) (CA INDEX NAME)




460079-07-6	CAPLUS
Benzesulfonamide, N-[[[4-[[3-[(2-cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazol-5-yl]amino]butyl]amino]carbonyl]-4-methyl-, (9CI)	(CA INDEX NAME)




PAGE 1-A




460079-08-7 CAP4US
Butanoic acid, 4-[[4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxycarbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]amino]-4-oxo- (CA INDEX NAME) (9CI)




460079-09-8 CAPLUS
Phosphoramidic acid, [4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl]-, diethyl ester (9CI) (CA INDEX NAME)




460079-14-5 CAPLUS
1-Butanol, 4-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazol[5,4-b]pyridin-7-yl]amino], dihydrogen phosphate (ester), diammonium salt (9CI) (CA INDEX NAME)


$$\bullet 2 \text{ NH}_3$$


NRN	460079-17-8	CAPLUS	Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-azidophenyl)-N-cyclopentyl-3-(2-(cyclopentylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)
-----	-------------	--------	---




RN	460079-19-0	CAPLUS	(CA INDEX NAME)
CN	Pyrrolidine, 1-[[[3-(2-cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]acetyl)-	(9CI)	




460079-21-4 CAPLUS
Methanesulfonamide, N-[2-[[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




NRN	460079-22-5	CAPLUS
CN	1,2-Ethanediamine, N-[3-(2-(cyclopentylamino)-4-pyrimidinyl)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)	




NRN	460079-23-6	CAPLUS
CN	2-Pyrimidinamine, N-cyclopentyl-4-[2-(3-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




NRN	460079-24-7	CAPLUS
CN	Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-{2-(cyclopentylamino)-4-pyrimidinyl}-2-[3-(trifluoromethyl)phenyl]- (9CI)	(CA INDEX NAME)




REF	REG NO	DATE	CLASS	NAME	CA INDEX NAME
460079-25-8	CAPLUS			Pyrzolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopropyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI)	(CA INDEX NAME)




RN 460079-26-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 460079-27-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 460079-28-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 460079-29-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-30-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 460079-31-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 460079-32-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



IT 460079-83-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine
for treating herpes viral infections)


RN 460079-83-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chloro-3-
((diphenylmethyle)amino)phenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 460079-35-0P 460079-50-9P 460079-51-0P
460079-65-6P 460079-73-6P 460079-74-7P
460079-80-5P 460079-81-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 3-(4-pyrimidinyl)-2-phenyl-pyrazolo[1,5-a]pyridin-7-amine
for treating herpes viral infections)


RN 460079-35-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-
[4-((diphenylmethyle)amino)phenyl]- (9CI) (CA INDEX NAME)




RN 460079-50-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyrimidinyl]-2-[3-((diphenylmethyle)amino)phenyl]- (9CI) (CA INDEX
NAME)




RN 460079-51-0 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-[3-((diphenylmethyle)amino)phenyl]-
7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 460079-65-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-
yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-73-6 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-
yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 460079-74-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 460079-80-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



RN 460079-81-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-bromophenyl)-7-chloropyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)



L5 ANSWER 39 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:466008 CAPLUS
DOCUMENT NUMBER: 137:33325
TITLE: Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyrimidine derivs. as antiviral agents
INVENTOR(S): Boyd, F. Leslie; Chamberlain, Stanley D.; Cheung, Mui; Gudmundsson, Kristjan; Harris, Philip Anthony; Johns, Brian A.; Jung, David Kendall; Peel, Michael Robert; Stanford, Jennifer Badiang; Sexton, Connie Jo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048148	A2	20020620	WO 2001-US44231	20011126
WO 2002048148	A3	20030501		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 200239348	A	20020624	AU 2002-39348	20011126
EP 1377573	A2	20040107	EP 2001-987099	20011126
EP 1377573	B1	20050727		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004515550	T	20040527	JP 2002-549679	20011126
AT 300541	T	20050815	AT 2001-987099	20011126
ES 2243579	T3	20051201	ES 2001-1987099	20011126
US 2005049259	A1	20050303	US 2003-433881	20030605
US 7163940	B2	20070116		
PRIORITY APPLN. INFO.:				
			US 2000-255763P	P 20001215
			US 2001-274284P	P 20010308
			WO 2001-US44231	W 20011126
OTHER SOURCE(S):			MARPAT 137:33325	
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R1 = cyclopentylamino, CH3(CH2)3NH, Cl, NHNH2, H2NCH2CH2NH, NH2, 4-methylpiperidinyl, 4-CH3OC6H4NH, Br, CH3OCH2CH2NH, HO2CCH2NH, cyclopropylamino, (CH3)2N, 4-morpholinyl; R2 = NH2, cyclopentylamino, CH3(CH2)3NH, CH3S-O, HO(CH2)3NH, CH2:CHCH2NH, 4-morpholinyl, cyclopropylamino, pyrrolidinyl, (CH3)2N, 3-(4-morpholinyl)propylamino, CH3(HOOCCH2)2N, R3 = H, CH3, (CH3)2NCH2, [tetrahydro-2H-pyran-2-yl]oxy)methyl, HOCH2, C6H5, COOH, 4-pyridinyl; R4 = H, CH3; R5 = F, Br, Cl; X = N, CH], salts, and pharmaceutical compds. containing the same are prepared as antiviral agents. Title compds. I are tested for HSV-1 inhibition and the results demonstrate that title compds. I are useful for the treatment and prophylaxis of herpes viral infections. Thus, the title compound II was prepared from 6-chloro-2-picoline, Et 4-fluorobenzoate, and cyclopentylamine via cyclization.


IT 437612-03-8P 437612-12-9P 437612-13-0P
437612-20-9P 437612-22-1P 437612-23-2P
437612-33-4P 437612-46-9P 437612-48-1P
437612-50-5P 437612-52-7P 437612-57-2P
437612-60-7P 437612-70-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RCT (Reactant or reagent); USES (Uses)
(Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)


RN 437612-03-8 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-12-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[[[tetrahydro-2H-pyran-2-yl]oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-13-0 CAPLUS
CN 4-Pyrimidinmethanol, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




RN 437612-20-9 CAPLUS
CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 437612-22-1 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437612-23-2 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




RN 437612-33-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437612-46-9 CAPLUS
CN 4-Pyrimidinemethanamine, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-48-1 CAPLUS
CN 2-Pyrimidinamine, 4-(7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl-5-methyl- (9CI) (CA INDEX NAME)




RN 437612-50-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-(butylamino)-4-pyrimidinyl)-2-(4-fluorophenyl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 437612-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-57-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-bromo-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 437612-60-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3,7-bis(2-fluoro-4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 437612-70-9 CAPLUS
CN 4-Pyrimidinecarboxamide, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




IT 437611-97-7P 437611-98-8P 437611-99-9P
437612-00-5P 437612-01-6P 437612-02-7P
437612-04-9P 437612-05-0P 437612-06-1P
437612-07-2P 437612-08-3P 437612-09-4P
437612-10-7P 437612-11-8P 437612-14-1P
437612-15-2P 437612-16-3P 437612-17-4P
437612-18-5P 437612-19-6P 437612-21-0P
437612-24-3P 437612-25-4P 437612-26-5P
437612-27-6P 437612-28-7P 437612-29-8P
437612-30-1P 437612-31-2P 437612-32-3P
437612-34-5P 437612-35-6P 437612-36-7P
437612-37-8P 437612-38-9P 437612-39-0P


437612-40-3P 437612-41-4P 437612-42-5P
437612-43-6P 437612-44-7P 437612-45-8P
437612-47-0P 437612-49-2P 437612-51-6P
437612-53-8P 437612-54-9P 437612-55-0P
437612-56-1P 437612-58-3P 437612-59-4P
437612-61-8P 437612-62-9P 437612-63-0P
437612-64-1P 437612-65-2P 437612-66-3P
437612-67-4P 437612-68-5P 437612-69-6P
437612-71-0P 437612-72-1P 437612-73-2P
437612-74-3P 437612-75-4P 437612-76-5P
437612-77-6P 437612-78-7P 437612-79-8P
437612-80-1P 437613-20-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)
RN 437611-97-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-{2-(cyclopentylamino)-4-pyrimidinyl}-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437611-98-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437611-99-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-00-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-01-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-02-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-04-9 CAPLUS




RN 437612-05-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(1-pyrrolidinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-06-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-07-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-08-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-(2-amino-4-pyrimidinyl)-N-cyclopentyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-09-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[[3-(4-morpholinyl)propylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-10-7 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-11-8 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 437612-14-1 CAPLUS
CN Glycine, N-[4-{7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl}-2-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 437612-15-2 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 437612-16-3 CAPLUS
CN 1,2-Ethanediamine, N-[3-{2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl}]- (9CI) (CA INDEX NAME)




RN 437612-17-4 CAPLUS
CN 4-Pyrimidinmethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-18-5 CAPLUS
CN 4-Pyrimidinethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-19-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-21-0 CAPLUS
CN Glycine, N-[3-{2-(cyclopentylamino)-6-methyl-4-pyrimidinyl}-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 437612-24-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 4-[2-(4-fluorophenyl)-2-(cyclopentylamino)-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 437612-26-5 CAPLUS
CN 2-(1H)-Pyridinone, 4-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrazone (9CI) (CA INDEX NAME)




RN 437612-27-6 CAPLUS
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-28-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-7-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 437612-29-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-N-cyclopropyl-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-30-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 437612-31-2 CAPLUS


CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-32-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(4-morpholinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-34-5 CAPLUS
CN 1-Propanol, 3-[[4-(7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 437612-35-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(2-propenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-39-0 CAPLUS




RN 437612-36-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-37-8 CAPLUS
CN 1-Piperazineethanol, 4-[4-(7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-38-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-(4-methoxyethyl)-1-piperazinyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-40-3 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(3-(1H-imidazol-1-yl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-41-4 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-(4-morpholinylethyl)amino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-42-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-[(2-(4-morpholinylethoxy)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-43-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-(4-morpholinylethyl)- (9CI) (CA INDEX NAME)




RN 437612-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 437612-45-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 437612-47-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-
 ((dimethylamino)methyl)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA
 INDEX NAME)




RN 437612-49-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5-
 methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-51-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-
 fluorophenyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 437612-53-8 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-fluorophenyl)-N-[2-(1-methyl-2-
 pyrrolidinylethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-54-9 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-fluorophenyl)-N-methyl-3-(4-
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-55-0 CAPLUS
 CN Pyrazolo[1,5-a]pyridin-7-amine, N,N-diethyl-2-(4-fluorophenyl)-3-(4-
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-56-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-iodo-3-(4-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 437612-58-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-amine, N-butyl-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-59-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-7-(1H-imidazol-1-yl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 437612-61-8 CAPLUS
CN 1,3-Propanediamine, N,N'-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3,7-diyl]di-4,2-pyridinediyl]bis- (9CI) (CA INDEX NAME)




H₂N⁺ (CH₂)₃⁺ NH₂
RN 437612-62-9 CAPLUS
CN 2-Pyridinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl- (9CI) (CA INDEX NAME)




RN 437612-63-0 CAPLUS
CN 2-Pyridinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

N#Cc1ccc(cc1)-c2nc3cc(Cl)ccc3n2-c4ccccc4FCCCCNc1ccc2nc3c(ncn3c2c1-c1ccc(I)cc1)nc(COCCF)nc1OCCNc1nc2c(c3ccccc3n2)c4ccccc4n1C1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=CC=C4N5C=CC=CC=C5N6C=CC=CC=C6N7C=CC=CC=C7N8C=CC=CC=C8N9C=CC=CC=C9N10C=CC=CC=C10N11C=CC=CC=C11N12C=CC=CC=C12N13C=CC=CC=C13N14C=CC=CC=C14N15C=CC=CC=C15N16C=CC=CC=C16N17C=CC=CC=C17N18C=CC=CC=C18N19C=CC=CC=C19N20C=CC=CC=C20N21C=CC=CC=C21N22C=CC=CC=C22N23C=CC=CC=C23N24C=CC=CC=C24N25C=CC=CC=C25N26C=CC=CC=C26N27C=CC=CC=C27N28C=CC=CC=C28N29C=CC=CC=C29N30C=CC=CC=C30N31C=CC=CC=C31N32C=CC=CC=C32N33C=CC=CC=C33N34C=CC=CC=C34N35C=CC=CC=C35N36C=CC=CC=C36N37C=CC=CC=C37N38C=CC=CC=C38N39C=CC=CC=C39N40C=CC=CC=C40N41C=CC=CC=C41N42C=CC=CC=C42N43C=CC=CC=C43N44C=CC=CC=C44N45C=CC=CC=C45N46C=CC=CC=C46N47C=CC=CC=C47N48C=CC=CC=C48N49C=CC=CC=C49N50C=CC=CC=C50N51C=CC=CC=C51N52C=CC=CC=C52N53C=CC=CC=C53N54C=CC=CC=C54N55C=CC=CC=C55N56C=CC=CC=C56N57C=CC=CC=C57N58C=CC=CC=C58N59C=CC=CC=C59N60C=CC=CC=C60N61C=CC=CC=C61N62C=CC=CC=C62N63C=CC=CC=C63N64C=CC=CC=C64N65C=CC=CC=C65N66C=CC=CC=C66N67C=CC=CC=C67N68C=CC=CC=C68N69C=CC=CC=C69N70C=CC=CC=C70N71C=CC=CC=C71N72C=CC=CC=C72N73C=CC=CC=C73N74C=CC=CC=C74N75C=CC=CC=C75N76C=CC=CC=C76N77C=CC=CC=C77N78C=CC=CC=C78N79C=CC=CC=C79N80C=CC=CC=C80N81C=CC=CC=C81N82C=CC=CC=C82N83C=CC=CC=C83N84C=CC=CC=C84N85C=CC=CC=C85N86C=CC=CC=C86N87C=CC=CC=C87N88C=CC=CC=C88N89C=CC=CC=C89N90C=CC=CC=C90N91C=CC=CC=C91N92C=CC=CC=C92N93C=CC=CC=C93N94C=CC=CC=C94N95C=CC=CC=C95N96C=CC=CC=C96N97C=CC=CC=C97N98C=CC=CC=C98N99C=CC=CC=C99N100C=CC=CC=C100N101C=CC=CC=C101N102C=CC=CC=C102N103C=CC=CC=C103N104C=CC=CC=C104N105C=CC=CC=C105N106C=CC=CC=C106N107C=CC=CC=C107N108C=CC=CC=C108N109C=CC=CC=C109N110C=CC=CC=C110N111C=CC=CC=C111N112C=CC=CC=C112N113C=CC=CC=C113N114C=CC=CC=C114N115C=CC=CC=C115N116C=CC=CC=C116N117C=CC=CC=C117N118C=CC=CC=C118N119C=CC=CC=C119N120C=CC=CC=C120N121C=CC=CC=C121N122C=CC=CC=C122N123C=CC=CC=C123N124C=CC=CC=C124N125C=CC=CC=C125N126C=CC=CC=C126N127C=CC=CC=C127N128C=CC=CC=C128N129C=CC=CC=C129N130C=CC=CC=C130N131C=CC=CC=C131N132C=CC=CC=C132N133C=CC=CC=C133N134C=CC=CC=C134N135C=CC=CC=C135N136C=CC=CC=C136N137C=CC=CC=C137N138C=CC=CC=C138N139C=CC=CC=C139N140C=CC=CC=C140N141C=CC=CC=C141N142C=CC=CC=C142N143C=CC=CC=C143N144C=CC=CC=C144N145C=CC=CC=C145N146C=CC=CC=C146N147C=CC=CC=C147N148C=CC=CC=C148N149C=CC=CC=C149N150C=CC=CC=C150N151C=CC=CC=C151N152C=CC=CC=C152N153C=CC=CC=C153N154C=CC=CC=C154N155C=CC=CC=C155N156C=CC=CC=C156N157C=CC=CC=C157N158C=CC=CC=C158N159C=CC=CC=C159N160C=CC=CC=C160N161C=CC=CC=C161N162C=CC=CC=C162N163C=CC=CC=C163N164C=CC=CC=C164N165C=CC=CC=C165N166C=CC=CC=C166N167C=CC=CC=C167N168C=CC=CC=C168N169C=CC=CC=C169N170C=CC=CC=C170N171C=CC=CC=C171N172C=CC=CC=C172N173C=CC=CC=C173N174C=CC=CC=C174N175C=CC=CC=C175N176C=CC=CC=C176N177C=CC=CC=C177N178C=CC=CC=C178N179C=CC=CC=C179N180C=CC=CC=C180N181C=CC=CC=C181N182C=CC=CC=C182N183C=CC=CC=C183N184C=CC=CC=C184N185C=CC=CC=C185N186C=CC=CC=C186N187C=CC=CC=C187N188C=CC=CC=C188N189C=CC=CC=C189N190C=CC=CC=C190N191C=CC=CC=C191N192C=CC=CC=C192N193C=CC=CC=C193N194C=CC=CC=C194N195C=CC=CC=C195N196C=CC=CC=C196N197C=CC=CC=C197N198C=CC=CC=C198N199C=CC=CC=C199N200C=CC=CC=C200N201C=CC=CC=C201N202C=CC=CC=C202N203C=CC=CC=C203N204C=CC=CC=C204N205C=CC=CC=C205N206C=CC=CC=C206N207C=CC=CC=C207N208C=CC=CC=C208N209C=CC=CC=C209N210C=CC=CC=C210N211C=CC=CC=C211N212C=CC=CC=C212N213C=CC=CC=C213N214C=CC=CC=C214N215C=CC=CC=C215N216C=CC=CC=C216N217C=CC=CC=C217N218C=CC=CC=C218N219C=CC=CC=C219N220C=CC=CC=C220N221C=CC=CC=C221N222C=CC=CC=C222N223C=CC=CC=C223N224C=CC=CC=C224N225C=CC=CC=C225N226C=CC=CC=C226N227C=CC=CC=C227N228C=CC=CC=C228N229C=CC=CC=C229N230C=CC=CC=C230N231C=CC=CC=C231N232C=CC=CC=C232N233C=CC=CC=C233N234C=CC=CC=C234N235C=CC=CC=C235N236C=CC=CC=C236N237C=CC=CC=C237N238C=CC=CC=C238N239C=CC=CC=C239N240C=CC=CC=C240N241C=CC=CC=C241N242C=CC=CC=C242N243C=CC=CC=C243N244C=CC=CC=C244N245C=CC=CC=C245N246C=CC=CC=C246N247C=CC=CC=C247N248C=CC=CC=C248N249C=CC=CC=C249N250C=CC=CC=C250N251C=CC=CC=C251N252C=CC=CC=C252N253C=CC=CC=C253N254C=CC=CC=C254N255C=CC=CC=C255N256C=CC=CC=C256N257C=CC=CC=C257N258C=CC=CC=C258N259C=CC=CC=C259N260C=CC=CC=C260N261C=CC=CC=C261N262C=CC=CC=C262N263C=CC=CC=C263N264C=CC=CC=C264N265C=CC=CC=C265N266C=CC=CC=C266N267C=CC=CC=C267N268C=CC=CC=C268N269C=CC=CC=C269N270C=CC=CC=C270N271C=CC=CC=C271N272C=CC=CC=C272N273C=CC=CC=C273N274C=CC=CC=C274N275C=CC=CC=C275N276C=CC=CC=C276N277C=CC=CC=C277N278C=CC=CC=C278N279C=CC=CC=C279N280C=CC=CC=C280N281C=CC=CC=C281N282C=CC=CC=C282N283C=CC=CC=C283N284C=CC=CC=C284N285C=CC=CC=C285N286C=CC=CC=C286N287C=CC=CC=C287N288C=CC=CC=C288N289C=CC=CC=C289N290C=CC=CC=C290N291C=CC=CC=C291N292C=CC=CC=C292N293C=CC=CC=C293N294C=CC=CC=C294N295C=CC=CC=C295N296C=CC=CC=C296N297C=CC=CC=C297N298C=CC=CC=C298N299C=CC=CC=C299N300C=CC=CC=C300N301C=CC=CC=C301N302C=CC=CC=C302N303C=CC=CC=C303N304C=CC=CC=C304N305C=CC=CC=C305N306C=CC=CC=C306N307C=CC=CC=C307N308C=CC=CC=C308N309C=CC=CC=C309N310C=CC=CC=C310N311C=CC=CC=C311N312C=CC=CC=C312N313C=CC=CC=C313N314C=CC=CC=C314N315C=CC=CC=C315N316C=CC=CC=C316N317C=CC=CC=C317N318C=CC=CC=C318N319C=CC=CC=C319N320C=CC=CC=C320N321C=CC=CC=C321N322C=CC=CC=C322N323C=CC=CC=C323N324C=CC=CC=C324N325C=CC=CC=C325N326C=CC=CC=C326N327C=CC=CC=C327N328C=CC=CC=C328N329C=CC=CC=C329N330C=CC=CC=C330N331C=CC=CC=C331N332C=CC=CC=C33Cc1nc(NC2CCCC2)c3ccccc3c1-c1ccc(F)cc1-c2nc3ccccc3c2NClc1ccc2c(c1)c(c3ccncc32)c4ccccc4F


RN	437612-71-0	CAPLUS
CN	4-pyrimidinecarboxamide, N-cyclopentyl-2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-	(CA INDEX NAME)
		(9CI)




RN 437612-72-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-3-(2-cyclopropyl-4-pyrimidinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-73-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-chloro-2-(4-fluorophenyl)-3-[2-(1-methylethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-74-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-7-(2-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-75-4 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 437612-76-5 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-77-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(dimethylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-78-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-79-8 CAPLUS
CN 4-Pyrimidinamine, N-cyclopentyl-6-[2-(4-fluorophenyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 437612-80-1 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[6-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437613-20-2 CAPLUS
CN 4-Pyrimidinmethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


IT 401815-63-2P 437612-94-7P 437612-97-0P
437613-02-0P 437613-05-3P 437613-07-5P
437613-08-6P 437613-09-7P 437613-12-2P
437613-19-9P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)


RN 401815-63-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437612-94-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[[tetrahydro-2H-pyran-2-yl]oxymethyl]- (9CI) (CA INDEX NAME)




RN 437612-97-0 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 437613-02-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 437613-05-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437613-07-5 CAPLUS
CN 2(1H)-Pyrimidinethione, 4-[7-(butylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437613-08-6 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-(2-methylthio)-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 437613-09-7 CAPLUS
CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-(iodomethyl)- (9CI) (CA INDEX NAME)



RN 437613-12-2 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-
alpyridin-3-yl]-2-(cyclopentylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 437613-19-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-
[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 40 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:466007 CAPLUS
DOCUMENT NUMBER: 137:33316
TITLE: Preparation of pyrazolopyridinamine derivatives as
antiviral agents
INVENTOR(S): Chamberlain, Stanley D.; Gudmundsson, Kristjan; Johns,
Brian A.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Repl., 109 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048147	A2	20020620	WO 2001-US44210	20011126
WO 2002048147	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NC, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, ST, SV, SZ, TD, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			


KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, IU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, IQ, GW, ML, MR, NE, SN, TD, TG
AU 200239344 A 20020624 AU 2002-39344 20011126
EP 1341788 A2 20030910 EP 2001-987095 20011126
EP 1341788 B1 20050810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004518651 T 20040624 JP 2002-549678 20011126
AT 301653 T 20050815 AT 2001-987095 20011126
ES 2245380 T3 20060101 ES 2001-1987095 20011126
US 2004072853 A1 20040415 US 2003-433884 20030605
US 6919352 B2 20050719
US 2005182080 A1 20050818 20050317
US 7087618 B2 20060808
US 2005171133 A1 20050804 20050318
US 7160897 B2 20070109
PRIORITY APPL. INFO.:
OTHER SOURCE(S): MARPAT 137:33316
G1




AB Title compds. [I; R = F, OCH3; R1 = 3-N3, 3-NH2, 3-CH2OH, 3-NO2, H, 3-COC6H5, 4-F, 4-OCH3, 3,4,5-(OCH3)3; R2 = 7-cyclopentylamino, H, SCH2CH3; R3 = Cl, cyclopentylamino, H] are prepared from condensation of picolines and alkyl benzoates followed by cyclization and addition reaction. Title compds. 1, pharmaceutically acceptable salt, solvate, or physiolo. functional derivative are useful in the prophylaxis or treatment of conditions or diseases associated with herpes viral infections in an animal.
IT 437384-04-8P 437384-11-7P 437384-12-8P
437384-13-9P 437384-14-0P 437384-23-1P
437384-32-2P 437384-33-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
[preparation of pyrazolopyridinamine derivs. as antiviral agents]
RN 437384-04-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-(2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 437384-11-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-
(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-12-8 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-
methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-13-9 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-
fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-14-0 CAPLUS
CN Methanone, [3-[[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-
a]pyridin-3-yl]-2-pyrimidinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 437384-23-1 CAPLUS
CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-
yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 437384-32-2 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-[(3-
nitrophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-33-3 CAPLUS
CN Benzenemethanol, 3-((4-((7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl)amino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-phenyl-1H-pyrazole-4-carboxamide (CA INDEX NAME) (9CI)




IT 437384-29-7P 437384-30-OP 437384-31-1P
437384-36-6P 437384-37-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridinamine derivs. as antiviral agents)
RN 437384-29-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-30-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-31-1 CAPLUS
CN 2-Pyrimidinamine, 4-[[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl]- (9CI) (CA INDEX NAME)



RN 437384-36-6 CAPLUS
CN 1,3-Benzenediamine, N-[[4-[[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)





RN 437384-37-7 CAPLUS
CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-((3-azidophenyl)amino)-4-pyrimidinyl]-N-cyclopentyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:171898 CAPLUS
 DOCUMENT NUMBER: 136:232298
 TITLE: Pyrazolopyridine compounds and pharmaceutical use thereof as adenosine receptor antagonists
 INVENTOR(S): Akahane, Acsushi; Tanaka, Akira; Minagawa, Masatoshi; Itani, Hirokichi; Ohtake, Hiroaki
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018382	A1	20020307	WO 2001-JP7322	20010827
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001080188	A5	20020313	AU 2001-80188	20010827
EP 1313733	A1	20030528	EP 2001-958521	20010827
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004507542	T	20040311	JP 2002-523897	20010827
US 2004110763	A1	20040610	US 2003-34894	20030226
PRIORITY APPLN: INFO:			AU 2000-9698	A 20000828
			WO 2001-JP7322	W 20010827
OTHER SOURCE(S):				
GI				




AB Pyrazolopyridines I are disclosed [wherein: R1 = H, (un)substituted lower alkyl or cycloalkyl which may be interrupted by an O or N; R2 = H, halo, or lower alkoxy; R3 = independent substituent(s); and n = 1 to 4; or a salt thereof]. The compds. are adenosine antagonists, and are thus useful for the prevention and/or treatment of a wide variety of medical conditions, e.g., depression, dementia (e.g., Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. In particular, treatment of Parkinson's disease and/or associated symptoms is specifically claimed. Over 330 example compds. are described. For instance, cyclization of 1-amino-4-methoxyphenylidinium iodide with 3-(benzenesulfonyl)-6-(phenylethynyl)pyridazine, gave 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine. This compound was hydrolyzed at the phenylsulfinyl group, and the resultant pyridazinone was N-alkylated with NaH/DMF and iso-PrI to give title compound II. In radioligand binding assays, II had Ki values of 0.15 nM for human A1 receptors and 1.38 nM for human A2A receptors. In an anticonvulsant test in mice, 6 tested example compds. I at 3.2 mg/kg orally completely suppressed the cataleptic effects of haloperidol at 0.32 mg/kg i.p.


IT 403490-01-7P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-03-9P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-05-1P, 5-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-24-4P, 2-[2-[[3-(1-Isopropyl-6-oxo-1,6-dihydro-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]ethyl]-1H-indole-1,3(2H)-dione 403490-59-5P, Tert-Butyl 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-3-piperidinecarboxylate 403490-61-9P, 5-(4-Piperidinyl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-77-7P, Ethyl [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetate 403490-79-9P, [[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetic acid 403490-87-9P, 5-[2-Oxo-2-(1-piperazinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403491-38-3P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 5-yl trifluoromethanesulfonate 403491-41-8P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-

yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylate 403491-43-OP.
 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxylic acid 403492-02-4P, 3-(4-Hydroxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-07-9P, tert-Butyl 4-(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)-1-piperazinecarboxylate 403492-13-7P, 5-(1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-89-7P, tert-Butyl [3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbamate 403492-91-1P, 5-Amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-06-1P, 5-(4-Bromobutanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-91-4P, 4-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Drug candidate; Preparation of pyrazolopyridines as adenosine receptor antagonists)


RN 403490-01-7 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-03-9 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-05-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(5-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-24-4 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 403490-59-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403490-61-9 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-piperidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 403490-77-7 CAPLUS
CN Acetic acid, 1-(((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy)-, ethyl ester (9CI) (CA INDEX NAME)



RN 403490-79-9 CAPLUS
CN Acetic acid, 1-(((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403490-87-9 CAPLUS
CN Piperazine, 1-(((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy)acetyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 403491-38-3 CAPLUS
CN Methanesulfonic acid, trifluoro-, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)




RN 403491-41-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 403491-43-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 403492-02-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(4-hydroxy-1-piperidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-07-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403492-13-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-89-7 CAPLUS
CN Carboxylic acid, [3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403492-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403493-06-1 CAPLUS
CN Butanamide, 4-bromo-N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)



RN 403493-91-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 403490-07-3P, 5-[2-(Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-10-8P, 5-[2-(4-Morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

403490-13-1P, 5-[(4-Methoxyphenyl)lauryl]oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-15-3P, 5-Benzoyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-16-4P, 5-Phenethyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-18-6P, 5-Isopropoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-20-0P, 5-[3-(2R)-2-(Methoxymethyl)-4-morpholinyl]propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-22-2P, 5-[2-Pyridinylmethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-26-6P, 5-[2-Aminoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-28-8P, 5-[3-Dimethylaminopropoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-30-2P, 5-[2-(1-Piperidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-32-4P, 5-[2-(1-Pyrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-34-6P, 5-[2-(3R,5S)-3,5-Dimethyl-4-morpholinyl]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-36-8P, 5-[4-Pyridinylmethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-38-0P, 5-[3-Pyridinylmethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-40-4P, 5-Propoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-42-6P, 5-Isopentyloxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-47-1P, 5-[2-Cyclohexylethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-49-3P, 5-[2-(2R,6S)-2,6-Dimethyl-4-morpholinyl]ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-51-7P, 5-[2-(Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-53-9P, 5-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-55-1P, 5-[2-Oxopropoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-57-3P, 5-[2-(2-Oxo-1-pyrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-63-1P, 5-[2-Pyridinyloxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-65-3P, Benzyl [(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetate 403490-67-5P
403490-69-7P, 2-Phenylpyrazolo[1,5-a]pyridine 403490-69-7P, 2-phenylpyrazolo[1,5-a]pyridine
403490-71-1P, 2-phenylpyrazolo[1,5-a]pyridine 403490-71-1P, 2-phenylpyrazolo[1,5-a]pyridine
403490-73-3P, N-[3-[(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]phenyl]acetamide 403490-75-5P, 5-Phenoxo-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403490-77-7P, tert-Butyl 4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]piperazine-1-carboxylate 403490-79-1P, 2-phenylpyrazolo[1,5-a]pyridine
403490-81-3P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethylacetamide
403490-83-3P, N-Dimethyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide
403490-85-7P, tert-Butyl 4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]piperazine-1-carboxylate 403490-89-1P, 2-phenylpyrazolo[1,5-a]pyridine
403490-91-5P, N-Isobutyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-phenylacetamide 403490-93-7P, 2-phenylpyrazolo[1,5-a]pyridine 403490-93-7P, 2-phenylpyrazolo[1,5-a]pyridine

5-(Tetrahydropyran-4-yl)oxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-95-9P, 5-[(5-Methoxy-2-pyridinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-97-1P, 5-[(5-Nitro-2-pyridinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403490-99-3P, Methyl [(3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetate 403491-01-0P, 5-[2-(4-Methyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-03-2P, 5-[2-(4-Morpholinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-05-4P, N,N-Bis[2-ethoxyethyl]-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-07-6P, 5-[2-(4-Benzyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-09-8P, 5-[2-(4-Acetyl-1-piperazinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-11-2P, N,N-Dimethyl-4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-1-piperazinecarboxamide 403491-13-4P, N,N-Dimethyl-4-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1-piperidinecarboxamide 403491-15-6P, 5-[(1-Acetyl-4-piperidinyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-17-8P, N-[2-(Dimethylamino)ethyl]-2-[[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-19-0P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(3-methoxybenzyl)acetamide 403491-21-4P, 2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-[2-(2-pyridinyl)ethyl]acetamide 403491-23-6P, N-Cyclopropyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-25-8P, N-Cyclopentyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-27-0P, N-Cyclohexyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-29-2P, N-(4-Hydroxycyclohexyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-31-6P, N-Butyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-33-8P, N-(2-Methoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-36-1P, N-(2-Ethoxyethyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetamide 403491-45-2P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carbonitrile 403491-47-4P, N,N-Dimethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-49-6P, 5-(1-Pyrolidinyl)carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-51-0P, 5-[(4-Methyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-53-2P, N-(2-Hydroxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-55-4P, N-[2-(Dimethylamino)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-58-7P, N-(2-Ethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-60-1P, N-Methyl-N-[2-(pyridin-2-yl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-62-3P, 5-[(4-Acetyl-1-piperazinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-64-5P, 5-[(cis-2,6-Dimethyl-4-

morpholinyl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-66-7P, N-Benzyl-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-68-9P, N-(tert-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-70-3P, 5-[[4-phenyl-1-piperidinyl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-72-5P, N-Diethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-74-7P, N-(2-Isopropoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-76-9P, N-(3-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-78-1P, N-Methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-80-5P, 5-(1-Piperidinylcarbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-82-7P, N-[2-(1-Pyrrolidinylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-84-9P, N-(5-Methyl-1,3-thiazol-2-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-86-1P, N-(2-Phenoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-88-3P, N-Bis(2-methoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-90-7P, N-(1-Methyl-1-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-92-9P, N-Isopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403491-93-0P, 5-(4-Methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-96-3P, 5-(4-Morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403491-98-5P, 5-(4-Phenyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-00-2P, 5-(cis-2,6-Dimethyl-4-morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-04-6P, 5-[[4-(2-Pyridinyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-09-1P, 5-(4-Benzyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-11-5P, 5-(4-Methoxy-1-piperidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-15-9P, Methyl 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-1-piperazinecarboxylate 403492-17-1P, 4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl-1-piperazinecarboxamide 403492-19-3P, 5-[[4-(Methylsulfonfyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-21-7P, 5-[[4-(Phenylsulfonfyl)-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-23-9P, 5-(4-Benzoyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-25-1P, 5-(4-Acetyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-27-3P, 5-[[4-(Dimethylamino)acetyl]-1-piperazinyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-29-3P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-31-9P, 5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-33-1P, 5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-35-3P, 5-Methoxy-3-(3-oxo-2-(tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-37-5P, 5-Methoxy-3-(3-oxo-2-(3R)-tetrahydrofuran-3-yl)-2,3-

dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-39-7P, 5-Methoxy-3-(3-oxo-2-((3S)-tetrahydrofuran-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-41-1P, 5-Methoxy-3-(3-oxo-2-(1-methoxy-2-propyl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-43-3P, 5-Methoxy-3-(3-oxo-2-(1-methylpiperidin-4-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-45-5P, 5-Methoxy-3-(3-oxo-2-(1-methylpiperidin-3-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-47-7P, 5-Methoxy-3-(3-oxo-2-(tetrahydropyran-4-yl)-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-49-9P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-51-3P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-53-5P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-55-7P, 5-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-57-9P, 5-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-59-1P, 5-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-61-5P, 5-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-63-7P, 5-Methoxy-3-(3-oxo-2-propyl-2,3-dihydropyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403492-65-9P, 7-Amino-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-67-1P, 7-Amino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-69-3P, 4-Bromo-5-methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-71-7P, 5-(3-Hydroxy-3-methyl-1-butynyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-73-9P, 5-[[1-Hydroxycyclohexyl]ethynyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-75-1P, 5-Phenylethynyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-77-3P, N-Cyclopropyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-79-5P, N-Cycloheptyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-81-9P, 5-[[Hexahydro-1H-azepin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-83-1P, 5-[[4-(2-Pyridinyl)-1-piperazinyl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-85-3P, N-(n-Butyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-87-5P, N-(2-Pyridinylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403492-93-3P, 5-Acetylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-95-5P, 5-Benzoylamino-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-97-7P, 5-(2-Methylpropanoylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403492-99-9P, 5-(Methylsulfonylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-04-9P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbamate 403493-08-3P, 5-(2-Oxo-1-pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-10-7P, 5-[[Bis(methoxymethylamino)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-12-9P, 5-[[1-Methyl-4-piperidinyl]oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-


6-yl)-2-phenylpyrazolo[1,5-a]pyridine hydrochloride 403493-14-1P
1,1-Dibenzyl-4-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine]oxy]piperidinium bromide
403493-16-3P, 5-[(4-Methoxybenzyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-18-3P, 5-[(4-Trifluoromethyl)-2-pyridinyl]oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-20-3P, 5-Nicotinamide-6-oxyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-22-3P, 5-(12-Oxo-2-(1-piperidinyl)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-24-3P, N-(tert-Butyl)-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-yl]oxy]acetamide
403493-26-3P, N-Cyclohexyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-yl]oxy]acetamide
403493-28-7P, 3-(2,3-Dihydropyridazin-6-yl)-6-methoxy-2-phenylpyrazolo[1,5-a]pyridine 403493-30-1P, 6-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-32-3P, 6-Hydroxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-34-5P, 6-(12-(N,N-Dimethylamino)ethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-36-7P, 6-(12-(2R,6S)-2,6-Dimethyl-4-morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-38-9P, 6-(2-Pyridinylmethoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-40-3P
2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetic acid 403493-42-5P, Ethyl
2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetate 403493-44-7P, N,N-Dimethyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-46-9P, 6-(2-(1-Pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl)oxy]acetamide 403493-48-1P, 6-(2-(1-Pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl)oxy]acetamide 403493-50-5P, 6-(2-(1-Pyridinyl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl)oxy]acetamide 403493-52-7P, N-Cyclopentyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-54-9P, N-Isopropyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-56-1P, N-Isobutyl-2-[[3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetamide 403493-58-3P, 6-(Trifluoromethanesulfonyl)oxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-60-7P, 6-(2R,6S)-2,6-Dimethyl-4-morpholinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-62-3P, 6-(4-Methyl-1-piperazinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-64-1P, Methyl 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxylate 403493-66-3P, 3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxylic acid 403493-68-5P, N,N-Dimethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxamide 403493-70-9P, 6-[(4-Methyl-1-piperazinyl)carboxyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-72-1P, 6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]carboxyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-74-3P, N-Isobutyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-6-carboxamide 403493-76-5P, 7-Acetylamine-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
403493-78-7P, 7-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine

phenylpyrazolo[1,5-a]pyridine 403493-80-1P, 7-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-82-3P, 7-Methoxy-3-(3-oxo-2-methyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-84-5P, 7-Methoxy-3-(3-oxo-2-ethyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-85-6P, 7-Methoxy-3-(3-oxo-2-n-propyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-87-8P, 4-Methoxy-3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-89-0P, 4-Methoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-91-2P, 4-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-93-6P, 4-Ethoxy-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-95-8P, 4-(n-Propoxy)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-97-0P, 4-(2-Dimethylamino)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403493-99-2P, 4-(2-Morpholinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-01-9P, 5-[[1,4-Diazabicyclo[4.3.0]non-4-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-03-1P, 5-[[Morpholin-4-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-05-3P, N-Allyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-07-5P, (R)-N-(1-Phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-09-7P, N-(4-Methoxyphenethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-11-1P, N-(2-(Hydroxymethyl)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-15-5P, N-(3-Methoxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-17-1P, N-(1-Phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-19-9P, N-(2-Methoxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-21-3P, 5-[[4-Hydroxypiperidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-23-5P, N-(2-Methoxyethyl)-N-methyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-25-7P, N-(4-Hydroxybutyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-27-9P, N-(2-(2-Pyridinyl)ethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-29-1P, N-(2-(4-Chlorophenyl)ethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-31-5P, N-(5-Methylisoxazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-33-7P, N-(6-Methoxy-3-pyridinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-35-9P 403494-37-1P, N-[4-(Difluoromethoxy)phenyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-39-3P, (S)-5-[[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-41-7P, N-(4-Phenoxypheyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-43-9P, N-Cyclooctyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-45-1P, N-(1-Naphthylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-47-3P, N-(5-Hydroxy-1-naphthyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-49-5P, 5-[[4-(Methanesulfonylamino)piperidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine


alpyridine 403494-51-9P, 5-[(3-Hydroxypiperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-53-1P, N-(2-Oxohomopiperidin-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Drug candidate; preparation of pyrazolopyridines as adenosine receptor antagonists)


RN 403490-07-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-10-8 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[2-(1-methylethyl)-6-[5-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-13-1 CAPLUS
 CN Benzenesulfonic acid, 4-methoxy-, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl ester (9CI) (CA INDEX NAME)




RN 403490-15-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(phenylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 403490-16-4 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-phenylethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-18-6 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[2-(1-methylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-20-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-[5-[3-[(2R)-2-(methoxymethyl)-4-morpholinyl]propoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403490-22-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-


pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-26-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-aminoethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-28-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[3-(dimethylamino)propoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403490-30-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-(1-piperidinyl)ethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-(1-pyrrolidinyl)ethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-34-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-(1-methylethyl)-4-morpholinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 403490-36-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-38-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(3-pyridinylmethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403490-40-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-5-propoxypyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-42-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(3-methylbutoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-cyclohexylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-49-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(2-[(2R,6S)-2,6-dimethyl-4-morpholinylethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)



RN 403490-51-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[2-(diethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-53-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-ethoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-55-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-oxopropoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


CN 3(2H)-Pyridazinone, 6-[5-(2-cyclopentylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403490-69-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[2-(1-aziridinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403490-71-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-73-3 CAPLUS
CN Acetamide, N-[3-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 403490-67-5 CAPLUS


RN 403490-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-[2-(2-oxo-1-pyrrolidinylethoxy)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-63-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(2-pyridinyloxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-65-3 CAPLUS
CN Acetic acid, [[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)







RN 403490-75-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-((1-methylethyl)-6-(5-phenoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403490-81-3 CAPLUS
CN Acetamide, 2-([3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403490-83-5 CAPLUS
CN Acetamide, 2-([3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 403490-85-7 CAPLUS
CN 1-piperazinecarboxylic acid, 4-([3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]acetyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403490-89-1 CAPLUS
CN Acetamide, 2-([3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-N-phenyl- (9CI) (CA INDEX NAME)




RN 403490-91-5 CAPLUS
CN Acetamide, 2-([3-([1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)oxy]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 403490-93-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-([2-phenyl-5-[(tetrahydro-2H-pyran-4-yl)oxy]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403490-95-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 403490-97-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-1-(1-methylethyl)]- (9CI) (CA INDEX NAME)




RN 403490-99-3 CAPLUS
CN Acetic acid, [[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 403491-01-0 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403491-03-2 CAPLUS
CN Morpholine, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403491-05-4 CAPLUS
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-bis(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 403491-07-6 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403491-09-8 CAPLUS
CN Piperazine, 1-acetyl-4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403491-11-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403491-13-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403491-15-6 CAPLUS
CN Piperidine, 1-acetyl-4-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-17-8 CAPLUS
CN Acetamide, 2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-(dimethylamino)ethyl)- (9CI) (CA INDEX NAME)




RN 403491-19-0 CAPLUS
CN Acetamide, 2-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403491-21-4 CAPLUS
 CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-[2-(2-pyridinylethyl)]- (9CI) (CA INDEX NAME)




RN 403491-23-6 CAPLUS
 CN Acetamide, N-cyclopropyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-25-8 CAPLUS
 CN Acetamide, N-cyclopentyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-27-0 CAPLUS
 CN Acetamide, N-cyclohexyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-29-2 CAPLUS
 CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)



RN 403491-31-6 CAPLUS
 CN Acetamide, N-butyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403491-33-8 CAPLUS
 CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 403491-36-1 CAPLUS

Acetamide, 2-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 403491-45-2 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carbonitrile, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- [9CI] (CA INDEX NAME)




RN 403491-47-4 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




NRN 403491-49-6 CAPLUS

40391-49-6 CARLOS
Pyridoline, 1-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl]- (9CI) (CA INDEX NAME)




403491-51-0 CAPLUS

RN	403491-51-0	CAPLUS
CN	Piperazine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-methyl-	(9CI) (CA INDEX NAME)



RN 403491-53-2 CAPLUS


Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)



URN 403491-55-4 CAPLUS


Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(dimethylamino)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)

RN 403491-62-3 CAPLUS
CN Piperazine, 1-acetyl-4-[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403491-64-5 CAPLUS
CN Morpholine, 4-[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 403491-66-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 403491-68-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1,1-dimethylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-56-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403491-58-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-ethoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-60-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 403491-78-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 403491-80-5 CAPLUS
CN Piperidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403491-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)




RN 403491-76-9 CAPLUS


RN 403491-70-3 CAPLUS
CN Piperidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 403491-72-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-diethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-74-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(1-methylethoxyethyl)]-2-phenyl- (9CI) (CA INDEX NAME)







RN 403491-84-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(5-methyl-2-thiazolyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-86-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-phenoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-88-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-bis(2-methoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-90-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-methyl-1-phenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403491-92-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-methylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403491-93-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(4-methyl-1-piperazinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403491-96-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(4-morpholinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


RN 403492-09-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-(phenylmethyl)-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-11-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(4-methoxy-1-piperidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-15-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 403492-17-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403491-98-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-phenyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-00-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403492-04-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(4-(2-pyridinyl)-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-19-3 CAPLUS
CN Piperazine, 1-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-(methylsulfonyl)]- (9CI) (CA INDEX NAME)



RN 403492-21-7 CAPLUS
CN Piperazine, 1-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-(phenylsulfonyl)]- (9CI) (CA INDEX NAME)




RN 403492-23-9 CAPLUS
CN Piperazine, 1-benzoyl-4-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]]- (9CI) (CA INDEX NAME)




RN 403492-25-1 CAPLUS
CN Piperazine, 1-acetyl-4-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]]- (9CI) (CA INDEX NAME)


RN 403492-27-3 CAPLUS
CN Piperazine, 1-[3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-4-[(dimethylamino)acetyl]]- (9CI) (CA INDEX NAME)




RN 403492-29-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-31-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethyl-6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 403492-33-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 403492-35-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)




RN 403492-37-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-((3R)-tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403492-39-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-((3S)-tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403492-41-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methoxy-1-methylethyl)-6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-43-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 403492-45-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methyl-3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 403492-47-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 403492-49-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403492-51-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-53-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-55-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-57-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-59-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 403492-61-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethyl-6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-63-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-fluorophenyl)-5-methoxypyrazolo[1,5-a]pyridin-3-yl]-2-propyl- (9CI) (CA INDEX NAME)




RN 403492-65-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[7-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-67-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[7-amino-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-69-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-bromo-5-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403492-71-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-(3-hydroxy-3-methyl-1-butynyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-73-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[(1-hydroxycyclohexyl)ethynyl]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-75-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-(phenylethynyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403492-77-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclopropyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403492-79-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cycloheptyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403492-81-9 CAPLUS
CN 1H-Azepine, 1-[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]hexahydro- (9CI) (CA INDEX NAME)




RN 403492-83-1 CAPLUS
CN Piperazine, 1-[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 403492-85-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-butyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403492-87-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN	403492-93-3	CAPLUS
CN	Acetamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-	(9CI) (CA INDEX NAME)

RN 403492-93-3 CAPLUS




RN	403492-95-5	CAPLUS
CN	Benzamide, N-[3-{1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)	

RN 403492-95-5 CAPLUS




RN	403492-97-7	CAPUS
CN	Propanamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-2-methyl-	(9CI) (CA INDEX NAME)

RN 403492-97-7 CAPLUS




RN	403492-99-9	CAPLUS
CN	Methanesulfonamide, N-[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)	

RN 403492-99-9 CAPLUS




<p> RN 403493-04-9 CAPLUS CN Carbamic acid, [3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME) </p>	<p> RN 403493-04-9 CAPLUS CN Carbamic acid, [3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME) </p>
--	--

RN 403493-04-9 CAPLUS




RN	403493-08-3	CAPLUS
CN	3 (2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-oxo-1-pyrrolidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)

RN 403493-08-3 CAPLUS



RN	403493-10-7	CAPLUS
CN	3(2H)-Pyridazinone, 6-[5-[bis(methoxymethyl)amino]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)	


RN 403493-10-7 CAPLUS



RN	403493-12-9	CAPLUS
CN	3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-[(1-methyl-4-piperidinyl)oxy]-2-	


RN 403493-12-9 CAPLUS

phenylpyrazolo[1,5-a]pyridin-3-yl]-, Hydrochloride (9CI) (CA INDEX NAME)




• x HCl

RN 403493-14-1 CAPLUS
CN Piperidinum, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-1,1-bis(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




• Br⁻


RN 403493-16-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[5-[[4-methoxyphenyl]methoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-18-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-[2-phenyl]-5-[[4-(trifluoromethyl)-2-pyridinyl]oxy]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403493-20-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)



RN 403493-22-1 CAPLUS
CN Piperidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)




RN 403493-24-3 CAPLUS
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]oxy]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 403493-26-5 CAPLUS


CN Acetamide, N-cycloheptyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo(1,5-a)pyridin-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(1,6-dihydro-3-pyridazinyl)-6-methoxy-2-phenyl- (9CI) (CA INDEX NAME)



RN 403493-30-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(6-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-32-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(6-hydroxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-34-5 CAPLUS

CN 3(2H)-Pyridazinone, 6-[6-(2-(dimethylamino)ethoxy)-2-phenylpyrazolo(1,5-a)pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-36-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[6-(2-[(2R,6S)-2,6-dimethyl-4-morpholinylethoxy]-2-phenylpyrazolo(1,5-a)pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 403493-38-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-6-(2-pyridinylmethoxy)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403493-40-3 CAPLUS
CN Acetic acid, [[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo(1,5-a)pyridin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-42-5 CAPLUS

CN Acetic acid, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403493-44-7 CAPLUS

CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 403493-46-9 CAPLUS

CN Pyrrolidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)



RN 403493-48-1 CAPLUS


CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 403493-50-5 CAPLUS


CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 403493-52-7 CAPLUS

CN Acetamide, N-cyclopentyl-2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]- (9CI) (CA INDEX NAME)




RN 403493-54-9 CAPLUS


CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 403493-56-1 CAPLUS
CN Acetamide, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-6-yl]oxy]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 403493-58-3 CAPLUS
CN Methanesulfonic acid, trifluoro-, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-6-yl ester (9CI) (CA INDEX NAME)




RN 403493-60-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403493-62-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methylethyl)-6-[[6-(4-methyl-1-piperazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 403493-64-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 403493-66-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403493-68-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N,N-dimethyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403493-70-9 CAPIUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 403493-72-1 CAPIUS
CN Morpholine, 4-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]carbonyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403493-74-3 CAPIUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methylpropyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403493-76-5 CAPIUS
CN Acetamide, N-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 403493-78-7 CAPIUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-80-1 CAPIUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-82-3 CAPIUS
CN 3(2H)-Pyridazinone, 6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 403493-84-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethyl-6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)





RN 403493-85-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-propyl-6-(7-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2- (9CI) (CA INDEX NAME)




RN 403493-87-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-89-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-93-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(4-ethoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-95-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-(2-phenyl-4-propoxypyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 403493-97-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-[2-(dimethylamino)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 403493-99-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[4-[2-(4-morpholinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 403494-01-9 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)octahydro-1H-benz[e][1,2-b:4,5-b']diazepine-10-yl)ethyl 2-methyl-2-oxopropylcarbamate (CA INDEX NAME) (9CI)



RN 403494-03-1 CAPLUS
CN Morpholine, 4-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide (CA INDEX NAME) (9CI)




RN 403494-05-3 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)octahydro-1H-benz[e][1,2-b:4,5-b']diazepine-10-yl)ethyl 2-methyl-2-oxopropylcarbamate (CA INDEX NAME) (9CI)




RN 403494-07-5 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)octahydro-1H-benz[e][1,2-b:4,5-b']diazepine-10-yl)ethyl 2-methyl-2-oxopropylcarbamate (CA INDEX NAME) (9CI)

Absolute stereochemistry.




RN 403494-09-7 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)octahydro-1H-benz[e][1,2-b:4,5-b']diazepine-10-yl)ethyl 2-methyl-2-oxopropylcarbamate (CA INDEX NAME) (9CI)




RN 403494-11-1 CAPLUS
CN Pyrrolo[1,2-a]pyrazine, 2-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)octahydro-1H-benz[e][1,2-b:4,5-b']diazepine-10-yl)ethyl 2-methyl-2-oxopropylcarbamate (CA INDEX NAME) (9CI)

CN 4-Piperidinol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403494-23-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyethyl)-N-methyl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-25-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxybutyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 403494-15-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-methoxypropyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-17-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 403494-19-9 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-21-3 CAPLUS




RN 403494-29-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-(4-chlorophenyl)ethyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-31-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(5-methyl-3-isoxazolyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-33-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(6-methoxy-3-pyridinyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403494-35-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-chloro-4-methylphenyl)-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-37-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(difluoromethoxy)phenyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-39-3 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[(3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403494-41-7 CAPLUS

403454-41-1 CAPLOS
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-phenoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-43-9 CAPLUS

RN	403494-43-9	CAPLUS
CN	Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclooctyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)	




RN 403494-45-1 CAPLUS

NAME	CA INDEX
403494-43-1 CAPLUS	
CN	
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1-naphthalenylmethyl)-2-phenyl-	(9CI)




RN 403494-47-3 CAPLUS

RN	403494-47-3	CAPLOS
CN	Pyrzolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(5-hydroxy-1-naphthalenyl)-2-phenyl-	(9CI) (CA INDEX NAME)




RN 403494-49-5 CAPLUS


403494-49-5	CAPLUS
4-Piperidinamine, 1-((3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl)carbonyl)-N-(methanesulfonyl)- (9CI)	(CA INDEX NAME)



RN 403494-51-9 CAPLUS


RN	403494-51-9	CAPLUS
CN	3-Piperidinol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-	(9CI) (CA INDEX NAME)





RN 403494-53-1 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(hexahydro-2-oxo-1H-azepin-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



IT


403494-55-3P, N-(5-Phenyl-1H-pyrazol-3-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-57-5P, (S)-5-[(2-Methoxymethyl)pyrrolidin-1-yl]carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-59-7P, N-(2,3-Dihydroxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-61-1P, N-(2-Hydroxy-3-chlorophenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-63-3P, (R)-5-[(2-Methoxymethyl)pyrrolidin-1-yl]carbonyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-66-6P, N-(2-Furylmethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-68-8P, N-(2-Morpholinoethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-70-2P, N-(1S,2S)-2-Hydroxy-1-(hydroxymethyl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-72-4P, N-(4-Methylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-77-9P, N-Isobutyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-79-1P, N-Cyclohexyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-81-5P, N-(2,3-Diethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-83-7P, (S)-5-[(3-(Methylaminocarbonyl)-1,2,3,4-tetrahydroisoquinolin-2-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-85-9P, 5-[(2,3-Dihydro-1H-indol-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403494-86-0P, N-Hexyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide

carboxamide 403494-88-2P, N-(3-Phenylpropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-90-6P, N-(3,4-Dimethoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-92-8P, N-(1-(2-Hydroxyethyl)-4-(ethoxycarbonyl)-1H-pyrazol-5-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-94-0P, N-(2-Hydroxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-95-1P, N-(2-Hydroxy-2-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-97-3P, N-(1-(1-Naphthyl)ethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403494-99-5P, N-(4-(Acetylamino)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-00-1P, 5-[(4-(2-Hydroxyethyl)piperidin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-01-2P, N-(2-Methoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-03-4P, N-(3-(Dimethylamino)propyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-05-6P, N-(2-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-07-8P, N-(1H-Indol-5-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-09-0P, N-Methyl-N-phenethyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-11-4P, (S)-N-(1-(Hydroxymethyl)-2-methylpropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-13-6P, N-(3-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-15-8P, (R)-N-(1-(1-Naphthyl)ethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-17-0P, 5-[(4-((4-Fluorophenyl)carbonyl)amino)piperidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-19-2P, N-(3-Ethoxypropyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-20-5P, N-(4-Methoxybenzyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-21-6P, N-(3-Hydroxyphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-23-8P, N-(1H-Indazol-6-yl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-25-0P, N-(4-(Diethylamino)phenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-27-2P, 5-[(4-(4-(Ethoxycarbonyl)phenyl)piperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-29-4P, 5-[(4-((4-Ethoxycarbonyl)piperazin-1-yl)carbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-30-7P, N-Cyclopentyl-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-31-8P, N-(2,3-Dimethoxyethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-32-9P, N-(4-Hydroxyphenethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-33-0P, N-(3-Acetylphenyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-34-1P, 5-[(4-Phenylpiperazin-1-yl)carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403495-35-2P, N-(3-(Methylthio)propyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide 403495-36-3P, (S)-N-(2-Hydroxy-1-phenylethyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide




RN 403494-57-5 CAPLUS
CN Pyrrolidine, 1-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl)pyrazolo[1,5-a]pyridin-5-yl)carbonyl)-2-(methoxymethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403494-59-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,3-dihydroxypropyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-61-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(5-chloro-2-hydroxyphenyl)-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-63-3 CAPLUS
CN Pyrrolidine, 1-((3-((1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl)pyrazolo[1,5-a]pyridin-5-yl)carbonyl)-2-(methoxymethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 403494-66-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-furanylmethyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403494-68-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-(4-morpholinyl)ethyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403494-70-2 CAPLUS


403494-70-2 CAPLUS
Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]-2-phenyl- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403494-72-4 CAPLUS

NRN	403494-72-4	CAPLUS
CNCN	Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)	




403494-77-9 CAPLUS

URN	403494-77-9	CAPLUS
CN	Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methylpropyl)-2-phenyl- (9CI)	(CA INDEX NAME)




NRN 403494-79-1 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclohexyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



403494-81-5 CAPLUS


NRN	NAME	403494-81-5	CAPLUS
129	Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(2,2-diethoxyethyl)-3-[1,6-dihydro-1-[1-methylethyl]-6-oxo-3-pyridazinyl]-2-phenyl-	9CI	[CA INDEX NAME]




403494-83-7 CAPLUS

403494-83-7 CAPLUS
3-Isosquinoxalinocarboxamide, 2-[[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-
pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-1,2,3,4-
tetrahydro-N-methyl-, (3S)- (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403494-85-9 CAPLUS
CN 1H-Indole, 1-([3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 403494-86-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-hexyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-88-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 403494-90-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3,4-dimethoxyphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-92-8 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonylamino]-1-(2-hydroxyethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403494-94-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxypropyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-95-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxy-2-phenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-97-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[1-(1-naphthalenyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403494-99-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(acetamino)phenyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-00-1 CAPLUS
CN 4-Piperidineethanol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 403495-01-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-methoxyethyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-03-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[3-(dimethylamino)propyl]-2-phenyl- (9CI) (CA INDEX NAME)


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403495-13-6 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3-methoxyphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-15-8 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1R)-1-(1-naphthalenyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 403495-17-0 CAPLUS

CN Benzamide, N-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-piperidinyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 403495-05-6 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(2-methoxyphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-07-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1R)-1-(1-naphthalenyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-09-0 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-11-4 CAPLUS




RN 403495-19-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(3-ethoxypropyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-20-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-[(4-methoxyphenyl)methyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-21-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-(3-hydroxyphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-23-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-N-1H-indazol-6-yl-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-25-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[4-(diethylamino)phenyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-27-2 CAPLUS
CN Benzoic acid, 4-[(3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl)carbonyl]-1-piperazinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403495-29-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 403495-30-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-cyclopentyl-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-31-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-32-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-33-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-acetylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-34-1 CAPLUS
CN Piperazine, 1-([3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 403495-35-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(3-methylthio)propyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-36-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-37-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-38-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-fluorophenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-39-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-methylbutyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-40-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(phenylmethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-41-0 CAPLUS


CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(3-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-42-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-43-2 CAPLUS
CN 1H-Indole, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3-dihydro-6-nitro- (9CI) (CA INDEX NAME)




RN 403495-44-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-pentyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-45-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[(2-chlorophenyl)methyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-46-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-(1-methylethyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-47-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(phenylmethyl)-N-(6,7,8,9-tetrahydro-1-hydroxy-5H-benzocyclohepten-6-yl)- (9CI) (CA INDEX NAME)




RN 403495-48-7 CAPLUS
CN Piperidine, 4-cyclohexyl-1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-6-oxo-3-pyridazinyl- (9CI) (CA INDEX NAME)




RN 403495-49-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[[4-chlorophenyl)methyl]-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-50-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(diphenylmethyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-51-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-cyanophenyl)-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-52-3 CAPLUS
CN 1H-Pyrido[3,4-b]indole, 2-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3,4,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 403495-53-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 403495-54-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2,4-dimethylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-55-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-(2-hydroxyethyl)phenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-56-7 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]pyrazolo[1,5-a]pyridine-5-yl]carbonyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 403495-57-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3,4-dimethylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-58-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-methoxy-2-methylphenyl)-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-59-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxy-3-nitrophenyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403495-60-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(5-chloro-2-nitrophenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-61-4 CAPLUS
CN 1H-Pyrido[3,4-b]indole, 2-[(3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2,3,4,9-tetrahydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 403495-62-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(trans-4-hydroxycyclohexyl)-2-phenyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 403495-63-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(2-[bis(1-methylethyl)amino]ethyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-64-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(1,2-diphenylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-65-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-hydroxy-2-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-66-9 CAPLUS
 CN Carbamic acid, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-67-0 CAPLUS
 CN Piperidine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI) (CA INDEX NAME)




RN 403495-68-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(2-hydroxy-1,1-dimethylethyl)-2-phenyl]- (9CI) (CA INDEX NAME)



RN 403495-69-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[2-(diethylamino)ethyl]-3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]- (9CI) (CA INDEX NAME)




RN 403495-70-5 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 403495-71-6 CAPLUS
 CN 1H-1-Benzazepine-1-acetic acid, 3-[[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 403495-72-7 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)




RN 403495-73-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 403495-74-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-75-0 CAPLUS
CN Piperazine, 1-[[3-[[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-4-(diphenylmethoxy)- (9CI) (CA INDEX NAME)



RN 403495-76-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-[(4-methylphenyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-77-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




403495-78-3 ·CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[4-(phenylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 403495-79-4 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-phenoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




NRN 403495-80-7 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(4-bromo-3-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




403495-81-8 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-bromo-4-methylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-82-9 CAPLUS

Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI)
(CA INDEX NAME)




403495-83-0 CAPLUS +


Pyrazolo[1,5-a]pyridine-5-carboxamide, N-{3-chloro-5-(trifluoromethyl)-2-pyridinyl}-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-84-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-(3-benzoylphenyl)-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-85-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-(4-methylphenoxy)phenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-86-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(3-iodophenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-87-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-[[[3-(1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine-5-yl]carbonyl]amino]-4,5-dihydro-, methyl ester (9CI) (CA INDEX NAME)




RN 403495-88-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-N-(4-(4-fluorophenoxy)phenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 403495-89-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, N-[1,6-dihydro-1-(1-methylethyl)-4-hydroxybutyl]-3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Pyrazolo[1,5-a]pyridine, 2-(2-fluorophenyl)-5-methoxy-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 403495-96-5 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 403495-97-6 CAPIUS
CN Pyrazolo[1,5-a]pyridine-7-carboxylic acid, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 403495-98-7 CAPIUS
CN Carbamic acid, [3-(6-methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 403496-05-9 CAPIUS
CN Urea, N,N'-bis[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]- (9CI) (CA INDEX NAME)



IT 403495-90-9P, 3-(3-Phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine 403495-95-4P, 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(2-fluorophenyl)pyrazolo[1,5-a]pyridine 403495-96-3P, 5-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 403495-97-6P, 3-(6-Methoxy-3-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine-7-carboxylic acid 403495-98-7P, tert-Butyl [3-(3-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridin-7-yl]carbamate 403495-99-8P, 7-Amino-3-(3-methoxy-6-pyridazinyl)-2-phenylpyrazolo[1,5-a]pyridine 403496-03-7P, 7-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine 403496-04-8P, 4-Methoxy-3-(3-phenylsulfonylpyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazolopyridines as adenosine receptor antagonists)

RN 403495-90-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 5-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 403495-95-4 CAPIUS

Cc1ccnnc1-c2c3ccccc3nn2-c4ccccc4

IL5 ANSWER 42 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:157771 CAPLUS

INVENTOR(S): Alberti, Michael John; Baldwin, Ian Robert; Cheung, Wui; Cockerill, Stuart; Flack, Stephen; Harris, Philip Anthony; Jung, David Kendall; Peckham, Gregory; Peel, Michael Robert; Stanford, Jennifer Badiang; Stevens, Kirk; Veal, James Marvin
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
PCT Int. Appl., 173 pp.
SOURCE:

CODEN: 1	DOCUMENT TYPE:
Patent	LANGUAGE:
English	FAMILY ACC. NUM. COUNT:
1	PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016359	A1	20020228	WO 2001-GB3783	20010822
W: AE, AG, AL, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MG, MK, MM, MW, MZ, NO, NZ, OL, PA, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, ZA, ZW				
RW: GH, GN, KE, LS, MW, MI, SD, SL, SZ, TG, UG, ZW, AT, BE, CH, CY, DE, DK, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GM, GO, GW, ML, ME, NE, SN, TN, TD, TG				
CA 2420024	A1	20020228	CA 2001-823108	20010822
AU 200182318	A	20020304	AU 2001-823108	20010822
EP 1311507	A1	20030521	EP 2001-960928	20010822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013448	A	20030617	BR 2001-13448	20010822
JP 2004050736	T	20040304	JP 2002-521460	20010822
HU 2004000757	A2	20040728	HU 2004-757	20010822
LT 318914	T	20060315	AT 2001-960928	20010822
AT 1798747	T	20060705	CN 2001-817742	20010822
ES 2259331	T3	20060101	ES 2001-1960928	20010822
IN 2003KN00168	A	20050311	IN 2003-KN168	20030211

COc1ccnnc1-c2cc3nc(C(=O)NCCOC)nc3cc2c4ccccc4

Pyrazolo[1,5-a]pyridin-7-amine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)

Cc1cc2nc3c(ncn3c2c1)Nc4ccccc4

NRN	403496-03-7	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 7-methoxy-2-phenyl-3-[6-(phenylsulfonyl)]-3-pyridazinyl]- (9CI)	(CA INDEX NAME)


Cc1cc2nc3c(ncn3C4=CC=CC=C4)c5ccc(cc52)S(=O)(=O)C6=CC=CC=C6

403496-04-8	CAPLUS
Pyrasolo[1,5-a]pyridine, 4-methoxy-2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI)	(CA INDEX NAME)

COc1ccc2c(c1)c3ccnnc3c2c4ccc(cc4)S(=O)(=O)c5ccccc5

T 131185-62-1, 3-(6-Methoxy-3-pyridazinyl)-2-phenylpyrazolo(1,5-


ZA 2003001318 A 20040622 2A 2003-1318 20030218
 NO 2003000779 A 20030407 NO 2003-779 20030219
 US 2004053942 A1 20040318 US 2003-362146 20030707
 US 7166597 B2 20070123 GB 2000-20556 A 20000822
 PRIORITY APPLN. INFO.: GB 2000-20576 A 20000822
 WO 2001-GB3783 W. 20010822
 OTHER SOURCE(S): MARPAT 136:200184
 GI




AB Title compds. I (wherein Z = CH or N; m = 1-2; n = 1-3; p = 1-3; R1 = independently Xd(CH2)R5; d = 0-1; e = 0-6; X = O, NR6, or SOO-2; R3 = H, halo, OH, CN, NO2, trihalomethyl, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, (hetero)aryl, phthalimido, aminophenyl, aminobenzyl, acyl(oxy), carbamoyl(oxy), carboxylate, sulfamoyl, carboximidamido, etc.; R4 = independently Yd(CH2)R3; R5 = H, halo, OH, CN, NO2, trihalomethyl, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl, (hetero)aryl, amino, aminophenyl, aminobenzyl, acyl(oxy), carbamoyl(oxy), carboximidamido, acylamino, sulfamoyl, etc.; R6 = H, (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or their salts, solvates, or physiol. functional derivs. thereof) were prepared as p38 and JNK3 protein kinase inhibitors. For example, cycloaddn. of Me 3-(4-fluorophenyl)propiolate (2-step preparation given) and 1-aminopyridinium iodide in AcCN in the presence of 1,8-diazabicycloundec-7-ene gave Me 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate (70t), which was hydrolyzed to the acid (100t). Reaction with sodium bicarbonate, followed by N-bromosuccinimide, in DMF afforded the bromo derivative (80t). Reductive addition of 4-(tributylstannyl)pyridine using Pd(PPh3)4 in toluene gave II (80t). The latter inhibited p38 kinase and tumor necrosis factor (TNF) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 values of < 0.5 μM. I are useful for the treatment of inflammatory and autoimmune diseases, cancer, and a variety of other conditions related to regulation of p38 kinase and/or JNK kinase.

IT 401816-55-5P, 4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methoxybenzyloxy)propyl]-2-pyrimidinamine
 401816-63-3P, Methyl 4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfide
 401816-84-0P, Methyl 4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfone
 401816-87-3P, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl methyl sulfide
 401816-88-4P, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl methyl sulfone
 401816-91-9P, Methyl 4-[6-(trifluoromethyl)-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfide
 401816-92-0P, Methyl 4-[6-(trifluoromethyl)-2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl sulfone
 RL: RCT (Reactant); SEN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)
 (intermediate; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)
 401816-55-5 CAPLUS
 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-[(4-methoxyphenyl)methoxy]propyl]- (9CI) (CA INDEX NAME)




401816-63-5 CAPLUS
 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




401816-64-6 CAPLUS
 Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




401816-70-4 CAPLUS
 Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 2-(4-fluorophenyl)-3-[2-[(3-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 401816-83-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-([2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)phenyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 401816-84-0 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 3-([2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)phenyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 401816-87-3 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)phenyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 401816-88-4 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)phenyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 401816-91-9 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)phenyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 401816-92-0 CAPIUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)phenyl)-2-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


RN 401815-73-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanol, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 401815-85-8 CAPLUS
CN Benzoic acid, 3-(aminosulfonyl)-4-chloro-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-90-5 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[[2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl


RN 401815-97-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-
(9CI) (CA INDEX NAME)




IT 401815-65-4P, 2-(4-Fluorophenyl)-6-methyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-73-4P, 2-(4-Fluorophenyl)-5-hydroxymethyl-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-85-8P, [2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl 3-(aminosulfonyl)-4-chlorobenzoate 401815-90-5P, 2-[[2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]-1H-isoindole-1,3(2H)-dione hydrochloride 401815-97-2P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-15-7P, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-18-0P, 2-(4-Fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-24-8P, 6-Bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-26-0P, 6-Cyano-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-29-3P, 6-Cyano-2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)pyrazolo[1,5-a]pyridine 401816-34-0P, 2-(4-Fluorophenyl)-3-(2-[methylthio]pyrimidin-4-yl)pyrazolo[1,5-a]pyridine 401816-35-1P, 2-(4-Fluorophenyl)-3-(2-[methylsulfinyl]pyrimidin-4-yl)pyrazolo[1,5-a]pyridine 401816-50-0P, N-Cyclopropyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-65-7P, 2-(4-Fluorophenyl)-3-(2-[methylthio]-4-pyrimidinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-66-8P, 2-(4-Fluorophenyl)-3-(2-[methylsulfonyl]-4-pyrimidinyl)-6-trifluoromethylpyrazolo[1,5-a]pyridine 401816-68-0P, N-[3-(4-Methylpiperazin-2-yl)propyl]-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (protein kinase inhibitor; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)

RN 401815-65-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-6-methyl-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)







RN 401816-15-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2,6-difluoro-4-pyridinyl)-2-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 401816-18-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-fluoro-4-pyridinyl)-6-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401816-24-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(2-fluoro-4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-35-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylsulfinyl)-4-
pyrimidinyl)- (9CI) (CA INDEX NAME)


RN 401816-26-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401816-29-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-(2-fluoro-4-
pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-34-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(methylthio)-4-
pyrimidinyl)- (9CI) (CA INDEX NAME)




RN	401816-50-0	CAPLUS
CN	2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)	(CA INDEX NAME)




RN	401816-65-7	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)	



RN	401816-66-8	CAPLUS
CN	Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)	



RN	401816-68-0	CAPLUS
CN	2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5- a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)	



401815-63-2P, 2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-
a]pyridine 401815-66-7P, 2-(4-Fluorophenyl)-6-methyl-3-(4-
pyridyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-69-8P,
2-(4-Fluorophenyl)-5-methyl-3-(4-pyridyl)pyrazolo[1,5-a]pyridine
hydrochloride 401815-70-1P, 2-(4-Fluorophenyl)-4-methyl-3-(4-
pyridyl)pyrazolo[1,5-a]pyridine hydrochloride 401815-72-3P,
2-(4-Fluorophenyl)-5-methoxy-3-(4-pyridyl)pyrazolo[1,5-a]pyridine
401815-74-5P, 2-(4-Fluorophenyl)-4-hydroxymethyl-3-(4-
pyridyl)pyrazolo[1,5-a]pyridine 401815-76-7P,
6-Fluoro-2-(4-fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridine
hydrochloride 401815-77-8P, 4-Fluoro-2-(4-fluorophenyl)-3-(4-
pyridyl)pyrazolo[1,5-a]pyridine 401815-78-9P,
2-(2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl
2-methylbenzoate 401815-79-0P, [2-(4-Fluorophenyl)-3-(4-
pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl isonicotinate
401815-80-3P, [2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-
a]pyridin-5-yl)methyl nicotinate 401815-81-4P,
[2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl
3-bromo-2-thiophenecarboxylate 401815-82-5P,
[2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl
6-aminocotinate 401815-83-6P, [2-(4-Fluorophenyl)-3-(4-
pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl 5-(methylsulfonyl)-2-
thiophenecarboxylate 401815-84-7P, [2-(4-Fluorophenyl)-3-(4-
pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl 2-aminocotinate
401815-86-9P, [2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-
a]pyridin-5-yl)methyl 3-methyl-2-thiophenecarboxylate 401815-87-0P
2, [2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl
2-methoxybenzoate 401815-88-1P, [2-(4-Fluorophenyl)-3-(4-
pyridyl)pyrazolo[1,5-a]pyridin-5-yl)methyl 2,3-dichlorobenzoate
401815-89-2P, 2-[2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-
a]pyridin-5-yl)methyl]-1H-isindole-1,3(2H)-dione 401815-91-6P,
[2-(4-Fluorophenyl)-3-(4-pyridyl)pyrazolo[1,5-a]pyridin-5-yl]methanamine

401815-92-7P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401815-94-9P, 5-(n-Butoxy)-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-96-1P, 5-(Benzoyloxy)-2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine 401815-99-4P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-(1H-imidazol-5-yl)ethyl)-2-pyridinamine 401816-00-0P, N-Butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-01-1P, 3-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine]-1-propanol 401816-02-2P, N-(4-Chlorophenyl)-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-03-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,3-propanediamine 401816-04-4P, 3-(2-Butoxy-4-pyridinyl)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine 401816-05-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl-2-pyridinamine 401816-06-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-methoxybenzyl)-2-pyridinamine 401816-07-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl-2-pyridinamine 401816-08-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyridinamine 401816-09-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-2-pyridinamine 401816-10-2P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-2-pyridinamine 401816-11-3P, N1-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl-1,4-butanediamine 401816-12-4P, 2-[4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine]-1-ethanol 401816-13-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-14-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-Benzyl-6-fluoro-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-19-1P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-isopropyl-2-pyridinamine 401816-20-4P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-22-6P, 3-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine]-1-propanol 401816-25-9P, N-(3-Aminopropyl)-4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinamine 401816-28-2P, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridine-6-carboxamide 401816-31-7P, 6-Cyano-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl-2-pyridinamine 401816-32-8P, 2-(4-Fluorophenyl)-3-(4-pyrimidinyl)pyrazolo[1,5-a]pyridine 401816-36-2P, 2-(4-Fluorophenyl)-3-[2-(methylsulfonyl)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 401816-37-3P, N-Butyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-38-4P, N-Cyclopropyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-39-5P, N-Benzyl-4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-40-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyrimidinamine 401816-41-9P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-44-2P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-48-6P, N-Butyl-4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-49-7P, N-Benzyl-4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-51-1P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-propyl)-2-pyrimidinamine 401816-53-3P, 4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyrimidinamine 401816-54-4P, 3-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine]-1-propanol 401816-57-7P, N-Cyclopropyl-4-[6-cyano-2-(4-


fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 401816-61-3P, 2-(4-Fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide 401816-62-4P, 2-(4-Fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide 401816-67-9P, 2-(4-Fluorophenyl)-3-[2-[(3-(4-methylpiperazinopropyl)amino)-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide 401816-71-5P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-(1H-imidazol-5-yl)ethyl)-2-pyrimidinamine 401816-72-6P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(3-pyridinylmethyl)-2-pyrimidinamine 401816-73-7P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2-pyridinylmethyl)-2-pyrimidinamine 401816-74-8P, 4-[2-(4-Fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(4-pyridinylmethyl)-2-pyrimidinamine 401816-76-0P, 2-(4-Fluorophenyl)-3-[2-phenoxypyrimidin-4-yl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401816-77-1P, 3-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]oxy]-N,N-dimethylaniline 401816-78-2P, 3-[2-(2,5-Dimethylphenoxypyrimidin-4-yl)-2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridine 401816-79-3P, N-[3-(Dimethylamino)propyl]-N-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-80-6P, N-[3-(Dimethylamino)propyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-85-1P, N-[4-[2-(3-Chloro-4-yl)-N-[3-(dimethylamino)propyl]amine 401816-89-5P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[3-(dimethylamino)propyl]amine 401816-93-1P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(dimethylamino)ethyl]amine 401816-95-3P, N-[4-(Diethylamino)butyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-96-4P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diethylamino)butyl]amine 401816-97-5P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[4-(diethylamino)butyl]amine 401816-98-6P, N-[2-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401816-99-7P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diethylamino)ethyl]amine 401817-00-3P, N-[2-(diethylamino)ethyl]-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-01-4P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(dipropylamino)ethyl]amine 401817-02-5P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(dipropylamino)ethyl]amine 401817-03-6P, N-[4-[2-(3-Chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diethylamino)ethyl]amine 401817-04-7P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(diethylamino)ethyl]amine 401817-05-8P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(pyrrolidin-1-ylethyl)amine 401817-06-9P, N-(2-Pyrrolidin-1-ylethyl)-N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-07-0P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-08-1P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-09-2P, N-[4-[2-(3-Pyrrolidin-1-ylethyl)amine 401817-09-2P, N-[4-[2-(3-Chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[4-(pyrrolidin-1-ylbutyl)amine 401817-10-5P, N-[4-[2-(4-Fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-

yl]pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-11-6P,
N-(2-piperidin-1-ylethyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine
401817-12-7P, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-13-8P, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-piperidin-1-ylethyl)amine 401817-14-9P, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-15-0P, N-(3-piperidin-1-ylpropyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-16-1P,
N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine
401817-18-3P, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-piperidin-1-ylpropyl)amine 401817-19-4P, N-(2-azepan-1-ylethyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-20-7P,
N-(2-azepan-1-ylethyl)-N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine
401817-21-8P, N-(2-azepan-1-ylethyl)-N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine
401817-22-9P, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-morpholin-4-ylethyl)amine 401817-23-0P, N-(2-morpholin-4-ylethyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-24-1P,
N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(2-morpholin-4-ylethyl)amine
401817-25-2P, N-(3-morpholin-4-ylpropyl)-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine 401817-26-3P, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-morpholin-4-ylpropyl)amine 401817-27-4P, N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-(3-morpholin-4-ylpropyl)amine 401817-28-5P,
N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[3-(4-methylpiperazin-1-yl)propyl]amine
401817-29-6P, N-[4-{2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(4-methylpiperazin-1-yl)ethyl]amine 401817-31-0P,
N-[2-(4-propylpiperazin-1-yl)ethyl]-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]amine
401817-32-1P, N-[4-{2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(4-propylpiperazin-1-yl)ethyl]amine 401817-33-2P,
N-[4-{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]pyrimidin-2-yl]-N-[2-(4-propylpiperazin-1-yl)ethyl]amine
RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)


RN 401815-63-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 401815-68-7 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-6-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 401815-69-8 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 401815-70-1 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-4-methyl-3-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 401815-72-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-methoxy-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 401815-74-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-methanol, 2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401815-76-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 401815-77-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 4-fluoro-2-(4-fluorophenyl)-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 401815-78-9 CAPLUS
CN Benzoic acid, 2-methyl-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]
pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-79-0 CAPLUS
CN 4-Pyridinecarboxylic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]
pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-80-3 CAPLUS
CN 3-Pyridinecarboxylic acid, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-
a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-81-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-bromo-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-82-5 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-amino-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-83-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-(methylsulfonyl)-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-84-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-amino-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-86-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 3-methyl-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-87-0 CAPLUS
CN Benzoic acid, 2-methoxy-, [2-(4-fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-
a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-88-1 CAPLUS
CN Benzoic acid, 2,3-dichloro-, [2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl ester (9CI) (CA INDEX NAME)




RN 401815-89-2 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(4-fluorophenyl)-3-(4-
pyridinyl)pyrazolo[1,5-a]pyridin-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN	401815-91-6	CAPLUS
CN	Pyrazolo[1,5-a]pyridine-5-methanamine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-(9CI)	(CA INDEX NAME)




401815-92-7	CAPLUS
Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyridinyl)-6-(trifluoromethyl)- (9CI)	(CA INDEX NAME)




<p> RN 401815-94-9 CAPLUS CN Pyrazolo[1,5-a]pyridine, 5-butoxy-2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME) </p>	<p> 1 </p>
---	------------




401815-96-1 CAPLUS
Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-5-(phenylmethoxy)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN	401815-99-4	CAPLUS
CN	2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)	




401816-00-0	CAPLUS
2-Pyridinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo(1,5-a)pyridin-3-yl]-	(9CI) (CA INDEX NAME)




NRN	401816-01-1	CAPLUS
CN	1-Propanol, 3-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]-	(9CI) (CA INDEX NAME)




RN 401816-02-2 CAPLUS
CN 2-Pyridinamine, N-[(4-chlorophenyl)methyl]-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-03-3 CAPLUS
CN 1,3-Propanediamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 401816-04-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-butoxy-4-pyridinyl)-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-05-5 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-hexyl- (9CI) (CA INDEX NAME)




RN 401816-09-9 CAPLUS


RN 401816-06-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 401816-07-7 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-pentyl- (9CI) (CA INDEX NAME)




RN 401816-08-8 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-propyl-
(9CI) (CA INDEX NAME)




RN 401816-10-2 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 401816-11-3 CAPLUS
CN 1,4-Butanediamine, N-{4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl}- (9CI) (CA INDEX NAME)




RN 401816-12-4 CAPLUS
CN Ethanol, 2-[[4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-13-5 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 401816-14-6 CAPLUS
CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-17-9 CAPLUS
CN 2-Pyridinamine, 6-fluoro-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N,N-phenylmethyl- (9CI) (CA INDEX NAME)




RN 401816-19-1 CAPLUS


CN 2-Pyridinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-20-4 CAPLUS
CN 2-Pyridinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-22-6 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-25-9 CAPLUS
CN 1,3-Propanediamine, N-[4-[6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 401816-28-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 401816-31-7 CAPLUS
CN 2-Pyridinecarbonitrile, 6-(cyclopropylamino)-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-32-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 401816-36-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylsulfonyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-37-3 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-38-4 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-39-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 401816-40-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-41-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-44-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-48-6 CAPLUS
CN 2-Pyrimidinamine, N-butyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-49-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 401816-51-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401816-52-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 401816-53-3 CAPLUS


CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 401816-54-4 CAPLUS
CN 1-Propanol, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-61-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 401816-62-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-hydroxypropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-67-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 2-(4-fluorophenyl)-3-[2-[(3-(4-methyl-1-piperazinyl)propyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401816-71-5 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(2-(1H-imidazol-4-yl)ethyl)]- (9CI) (CA INDEX NAME)




RN 401816-72-6 CAPLUS



RN 401816-73-7 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(2-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 401816-74-8 CAPLUS
CN 2-Pyrimidinamine, 4-[(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)-N-(4-pyridinylmethyl)]- (9CI) (CA INDEX NAME)




RN 401816-76-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-(2-(2-phenoxy-4-pyrimidinyl)-6-(trifluoromethyl))- (9CI) (CA INDEX NAME)


RN 401816-80-6 CAPLUS
CN 1,3-Propanediamine, N,N-dimethyl-N'-[4-(6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 401816-85-1 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-89-5 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-93-1 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-77-1 CAPLUS
CN Benzenamine, 3-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 401816-78-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[2-(2,5-dimethylphenoxy)-4-pyrimidinyl]-2-(4-fluorophenyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 401816-79-3 CAPLUS
CN 1,3-Propanediamine, N'-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)







RN	CN	401816-95-3	CAPLUS
		1, 4-Butanediamine, N, N-diethyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1, 5-a]pyridin-3-yl]-2-pyrimidinyl]-	(9CI)
		(CA INDEX NAME)	




401816-96-4 CAPIUS
1, 4-Butanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1, 5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl-
(9CI) (CA INDEX NAME)




401816-97-5 CAPLUS
1,4-Butanediamine, N'-{4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl}-N,N-diethyl-
(9CI) (CA INDEX NAME)




401816-98-6 CAPIUS
1,2-Ethanediamine, N,N-diethyl-N'-(4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)-(CA INDEX NAME) (9CI)




RRN	CA INDEX NAME
401816-99-7	CAPLUS
1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-diethyl-	(9CI) (CA INDEX NAME)




401817-00-3 CAPUS¹
1,2-Ethanediamine, N,N-dipropyl-N'-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 401817-01-4 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 401817-02-5 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 401817-03-6 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 401817-04-7 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 401817-05-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 401817-06-9 CAPLUS
CN 2-Pyrimidinamine, N-[2-(1-pyrrolidinyl)ethyl]-4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


RN 401817-10-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-11-6 CAPLUS
CN 2-Pyrimidinamine, N-[2-(1-piperidinylethyl)-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 401817-12-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-13-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-07-0 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-08-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-pyrrolidinylethyl)]- (9CI) (CA INDEX NAME)




RN 401817-09-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 401817-18-3 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401817-19-4 CAPLUS
CN 1H-Azepine-1-ethanamine, hexahydro-N-[4-{6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-20-7 CAPLUS
CN 1H-Azepine-1-ethanamine, N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]hexahydro- (9CI) (CA INDEX NAME)




RN 401817-21-8 CAPLUS
CN 1H-Azepine-1-ethanamine, N-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]hexahydro- (9CI) (CA INDEX NAME)




RN 401817-14-9 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401817-15-0 CAPLUS
CN 2-Pyrimidinamine, N-[3-(1-piperidinyl)propyl]-4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401817-16-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)







RN 401817-23-9 CAPLUS
CN 4-Morpholineethanamine, N-[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-23-0 CAPLUS
CN 4-Morpholineethanamine, N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-24-1 CAPLUS
CN 4-Morpholineethanamine, N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-25-2 CAPLUS
CN 4-Morpholinepropanamine, N-[4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-26-3 CAPLUS
CN 4-Morpholinepropanamine, N-[4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-27-4 CAPLUS
CN 4-Morpholinepropanamine, N-[4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 401817-28-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 401817-29-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 401817-31-0 CAPLUS
CN 2-Pyrimidinamine, N-[2-(4-propyl-1-piperazinyl)ethyl]-4-[6-(trifluoromethyl)-2-(4-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401817-32-1 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-propyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 401817-33-2 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(4-propyl-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 401815-95-0, 2-(4-Fluorophenyl)-3-(4-pyridinyl)pyrazolo[1,5-a]pyridin-5-ol
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)
RN 401815-95-0 CAPLUS
CN Pyrazolo[1,5-a]pyridin-5-ol, 2-(4-fluorophenyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:915602 CAPLUS
 DOCUMENT NUMBER: 136:303408
 TITLE: New developments in A1 and A2 adenosine receptor antagonists
 AUTHOR(S): Kiec-Kononowicz, K.; Drabczynska, A.; Pekala, E.; Michalak, B.; Miller, C.E.; Schumacher, B.; Karolak-Wojciechowska, J.; Dudek, H.; Rockitt, S.; Warchow, R.
 CORPORATE SOURCE: IUPAC Commission, Medical College, Department of Chemical Technology of Drugs, Jagiellonian University, Krakow, PL 30-688, Pol.
 SOURCE: Pure and Applied Chemistry (2001), 73(9), 1411-1420
 CODEN: PACHAS; ISSN: 0033-4545
 PUBLISHER: International Union of Pure and Applied Chemistry
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review with refs. The aim of this article is to briefly present progress in the development of the potent adenosine receptor (AR) antagonists with high selectivity for either A1, A2A or A2B ARs. The structural requirements for each AR subtype were discussed as well as their potential therapeutic use. In the search for new AR antagonists, a series of imidazo-, pyrimido-, and diazepino-purindione derivs. as well as oxazolo-, oxazino-, and oxazepino-purindiones were designed, synthesized, and preliminarily evaluated in pharmacol. studies. Oxygen-containing tricyclic derivs. were shown to be moderately potent AR antagonists exhibiting selectivity either for A1 or A2A ARs. Tricyclic purindiones with nitrogen in the third ring were generally more A2A AR selective. The compds. tested in vivo according to the Antiepileptic Drug Development Program of the National Institutes of Health (USA) were generally active as anticonvulsants in chemical induced seizures.


IT 131185-37-0P, Fk 838
 RI: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses)
 (new developments in A1 and A2 adenosine receptor antagonists)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:916663 CAPLUS
 DOCUMENT NUMBER: 135:357918
 TITLE: Process for the preparation of pyrazolo[1,5-a]pyridines
 INVENTOR(S): Fitzgerald, Russ N.; Jung, David Kendall; Eaddy, John F.
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083479	A2	20011108	WO 2001-US13801	20010427
WO 2001083479	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001059242	A5	20011112	AU 2001-59242	20010427
EP 1276742	A2	20030122	EP 2001-932738	20010427
EP 1276742	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531906	T	20031028	JP 2001-580907	20010427
AT 268771	T	20040615	AT 2001-932738	20010427
ES 222372	T3	20050201	ES 2001-1932738	20010427
US 2003212275	A1	20031113	US 2002-258679	20021025
US 6756498	B2	20040629	US 2000-200400P	20000428
			WO 2001-US13801	20010427
PRIORITY APPLN. INFO.:			CASREACT 135:357918; MARPAT 135:357918	
OTHER SOURCE(S):				
GI				




II

AB The title compds. (I; R0, R1 = H, halo, alkyl, etc.; R2 = H, alkyl, alkyl substituted by one or more fluorine atoms, etc.; R3 = H, Ph substituted by SO2(alkyl) or SO2NH2) were prepared by rearrangement of an azirine II or a protected derivative thereof, in the presence of a catalyst and a solvent. Thus, treating a solution of 1-(3-fluorophenyl)-2-(5-trifluoromethyl)-2-

pyridyl)ethanone oxime (preparation given) and Et3N in CH2Cl2 with TFAA followed by rearrangement of the resulting azirine II [R0 = 3-F; R1, R3 = H; R2 = 5-CF3] in the presence of FeCl2 in DME afforded I [R0 = 3-F; R1, R3 = H; R2 = 6-CF3].


IT 267235-56-3P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

RN 267235-56-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
alpyridin-3-yl]- (9CI) (CA INDEX NAME)




L5 ANSWER 45 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:584502 CAPLUS
DOCUMENT NUMBER: 135:352333
TITLE: Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability

AUTHOR(S): Kuroda, Satoru; Takamura, Fujiko; Tenda, Yoshiyuki; Itani, Hiromichi; Tomishima, Yasuyo; Akahane, Atsushi; Sakane, Kazuo
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka 532-8514, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(8), 988-998
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:352333
GI




AB A novel series of 3-(2-substituted-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines were synthesized and evaluated for their in vitro adenosine A1 and A2A receptor binding activities, and in vitro metabolism by rat liver in order to search for orally active compounds. Most of the test compounds were potent adenosine A1 receptor antagonists with high A1 selectivity and the A1 affinity and A1 selectivity of carbonyl derivatives was particularly high. In particular, I was an extremely potent and selective adenosine A1 antagonist with high A1 selectivity (Ki=0.026 nM, A2A/A1=5400). In terms of metabolic stability, 2-oxopropyl, 2-hydroxypropyl, N-methylacetamide, 2-(piperidin-1-yl)ethyl and 1-methylpiperidin-4-yl (FR194921) derivatives were the most stable compounds of this series of analogs. Further in vivo evaluation indicated that several of the compounds, including FR194921 were detected in both plasma and brain after oral administration in rats. In particular, FR194921 displayed good plasma and brain concentrations. As a result, we could show that FR194921 is a good candidate for an orally active adenosine A1 receptor antagonist with high blood-brain barrier permeability and good bioavailability (Ki=6.6 nM, A2A/A1=820, BA=60.64.9% (32 mg/kg)).
IT 141060-39-1P 202646-80-8P, FR 194921
202646-91-1P 202646-92-2P 202646-94-4P
202646-96-6P 202646-98-8P 202646-99-9P
210879-61-1P 210879-63-3P 210879-64-4P
210879-67-7P 210879-68-8P 210879-69-9P
210879-71-3P 210880-05-0P 210880-07-2P
210880-09-4P 210880-11-8P 210880-20-9P
210880-21-0P 210880-23-2P 210880-25-4P
210880-27-6P 210880-28-7P 210880-29-8P
210880-31-2P 222722-65-8P 222722-71-6P
222722-94-3P 222722-96-5P 372492-23-4P
RL: BPR (Biological process); BSU (Biological study; unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)
RN 141060-39-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-(1-piperidinyl)ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-92-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-94-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-96-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-(1-methylethyl)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-98-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-(phenylmethyl)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-99-9 CAPLUS
CN Piperidine, 1-acetyl-4-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 210879-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-63-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-64-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 210879-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-68-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-05-0 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-07-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-09-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-11-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-20-9 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-21-0 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1,1-dimethylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-23-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-25-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-27-6 CAPLUS
CN Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 222722-65-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 222722-71-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-94-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-(hexahydro-1H-azepin-1-yl)ethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-96-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-[(2R,6S)-2,6-dimethyl-1-piperidinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl))-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 372492-23-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)


(synthesis of adenosine A1 receptor antagonists with high blood-brain barrier permeability)

RN 131185-06-3


CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 202646-90-0P 210880-36-7P 726182-36-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of adenosine A₁ receptor antagonists with high blood-brain
 barrier permeability)
 RN 202646-90-0 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-
 piperidinyl)- (9CI) (CA INDEX NAME)



RN 210880-36-7 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 (9CI) (CA INDEX NAME)




RN 726182-36-1 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 , ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 46 OF 88 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2001:581708 CAPLUS
 DOCUMENT NUMBER: 135:147440
 TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors as
 gastroprokinetic agents
 INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan
 PATENT ASSIGNEE(S): GlaxoSmithKline, UK
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:
 PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 200105673 A1 20010809 WO 2001-GB423 20010201
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 200130395 A 20010814 AU 2001-30395 20010201
 EP 1259239 A2 20021127 EP 2001-902541 20010201
 EP 1259239 B1 20070328
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003521516 T 20030713 JP 2001-556472 20010201
 AT 357918 T 20070415 AT 2001-902541 20010201
 US 2003022897 A1 20030130 US 2002-182080 20020725
 US 6759413 B2 20040706
 US 2004192694 A1 20040930 US 2004-786423 20040225
 US 2000-2336 GB 2000-2336 A 20000201
 US 2001-GB423 W 20010201
 US 2002-182080 A1 20020725
 AB The invention provides a COX-2 inhibitor or a pharmaceutically acceptable
 derivative thereof for use in the treatment of a disorder ameliorated by a
 gastroprokinetic agent.
 IT 267235-56-3 267235-56-3d, derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (cyclooxygenase-2 inhibitors as gastroprokinetic agents)
 RN 267235-56-3 CAPLUS
 CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-
 a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 267235-56-3 CAPLUS
CN Benzenesulfonamide, 4-([2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 47 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:581693 CAPLUS
DOCUMENT NUMBER: 135:147439
TITLE: Use of cyclooxygenase-2 (COX-2) inhibitors for constipation
INVENTOR(S): Mangel, Allen Wayne; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXAD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056555	A2	20010809	WO 2001-GB416	20010201
WO 2001056555	A3	20020808		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CN, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1251839 A2 20021030 EP 2001-948935 20010201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, JP 2003521511 T 20030715 JP 2001-556247 20010201
US 2003013717 A1 20030116 US 2002-182169 20020725
PRIORITY APPL. INFO.: GB 2000-2312 A 20000201
WO 2001-GB416 W 20010201
AB The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of constipation.
IT 267235-56-3 267235-56-3D, derivs. (cyclooxygenase-2 inhibitors for treatment of constipation)
RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
CN Benzenesulfonamide, 4-([2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-56-3 CAPLUS
CN Benzenesulfonamide, 4-([2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 48 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:517649 CAPLUS
DOCUMENT NUMBER: 135:107325
TITLE: Preparation of pyrazolopyridines as adenosine antagonists and their use for treatment of various

INVENTOR(S): Akabane, Atsushi; Kuroda, Satoshi; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001192384	A	20010717	JP 2000-378350	20001213
PRIORITY APPLN. INFO.:			AU 1999-4622	A 19991213
OTHER SOURCE(S):			MARPAT 135:107325	




AB Pyrazolopyridines I [R = lower alkenyl- or aryl-substituted lower alkyl (linked by O), Ar1; R1 = substituted oxadiazolyl, thiazolyl, oxazolyl, imidazolyl; A = lower alkylene] or their salts are prepared by N-substitution of I (R = H), cyclocondensation of I (R = AC(NH2); NOH; A = same as above) with R2COX2 (R2 = lower alkyl; X2 = leaving group), etc. Thus, 2.88 g I (R = H) was treated with NaH and allyl bromide at room temperature for 2 h in DMF to give 2.04 g I (R = allyl), which inhibited binding of [3H]DPCPX to A1 receptor, and [3H]CGS21680 to A2a receptor with Ki values of 0.04 and 2.69 nM, resp.

IT 141060-46-0P 350227-04-2P 350227-07-5P
 350227-09-7P 350227-11-1P 350227-13-3P
 350227-15-5P 350227-17-7P 350227-19-9P
 350227-21-3P 350227-22-4P 350227-24-6P
 350227-26-8P 350227-28-0P 350227-30-4P
 350227-32-6P 350227-34-8P 350227-36-0P
 350227-38-2P 350227-40-6P 350227-42-8P
 350227-44-0P 350227-46-2P 350227-48-4P
 350227-50-8P 350227-52-0P 350227-54-2P
 350227-56-4P 350227-58-6P 350227-59-7P
 350227-61-1P 350227-63-3P 350227-65-5P
 350227-67-7P 350227-69-9P 350227-71-3P
 350227-73-5P 350227-88-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES: (Uses)
 (preparation of pyrazolopyridines as adenosine antagonists for treatment of various diseases)
 141060-46-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 350227-04-2 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 350227-07-5 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(3-(phenylmethoxy)propyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-09-7 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-11-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[(4-methyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-13-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(5-acetyl-4-methyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-15-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-phenyl-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-17-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(4-(3,4,5-trimethoxyphenyl)-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-19-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 350227-21-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4,5-dimethyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-22-4 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-24-6 CAPLUS
CN Piperidine, 1-[(2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]-4-thiazolyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 350227-26-8 CAPLUS
CN 4-Thiazolecarboxamide, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)methyl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 350227-28-0 CAPLUS
CN 4-Thiazolecarboxamide, N,N-dimethyl-2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 350227-30-4 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-(dimethylamino)ethyl]-2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 350227-32-6 CAPLUS
CN 4-Thiazolecarboxamide, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 350227-34-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[4-(hydroxymethyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-36-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[4-(4-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-38-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[4-(2-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-40-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[4-(3-methoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-42-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[4-(2,5-dimethoxyphenyl)-2-thiazolyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-44-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-((2-phenylpyrazolo[1,5-a]pyridin-3-yl)methyl)-2-((3-phenylpyrazolo[1,5-a]pyridin-3-yl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-46-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-(4-nitrophenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-48-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-ethyl-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-50-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-methylphenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-52-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-(4-chlorophenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-54-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4-(2,4-dimethoxyphenyl)-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-56-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-((4,5-diphenyl-2-thiazolyl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-58-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-((4-(trifluoromethyl)-2-thiazolyl)methyl)- (9CI) (CA INDEX NAME)




RN 350227-59-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-methyl-5-phenyl-2-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[(5-propyl-1,2,4-oxadiazol-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 350227-63-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(5-ethyl-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-65-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4,5-dimethyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4,5-diphenyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-2-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-73-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(4-phenyl-1H-imidazol-1-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-88-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-5-phenyl-1H-imidazol-2-yl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-06-3 141060-69-7 202647-16-3
 210880-36-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Preparation of pyrazolopyridines as adenosine antagonists for treatment of
 various diseases)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA
 INDEX NAME)




RN 141060-69-7 CAPLUS
 CN 1(6H)-Pyridazineacetonitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)- (9CI) (CA INDEX NAME)




RN 202647-16-3 CAPLUS
 CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)- (9CI) (CA INDEX NAME)




RN 210880-36-7 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 (9CI) (CA INDEX NAME)




IT 350227-76-8P 350227-79-1P 350227-81-5P
 350227-84-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (Preparation of pyrazolopyridines as adenosine antagonists for treatment of
 various diseases)
 RN 350227-76-8 CAPLUS
 CN 1(6H)-Pyridazineethanimidamide, N-hydroxy-6-oxo-3-(2-phenylpyrazolo[1,5-
 a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 350227-79-1 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 , 1-methyl-2-oxopropyl ester (9CI) (CA INDEX NAME)



RN 350227-81-5 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 , 1,2-diphenylethyl ester (9CI) (CA INDEX NAME)




RN 350227-84-8 CAPLUS
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
, 2-oxo-2-phenylethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 49 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:371567 CAPLUS
DOCUMENT NUMBER: 135:5612
TITLE: Preparation of new pyrazolo terpyridines as remedies
for inflammation, autoimmune diseases
INVENTOR(S): Yanamoto, Hirofumi; Takahashi, Fumie; Kato, Takeshi;
Nakamura, Katsuya; Manabe, Koji
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001139575	A	20010522	JP 1999-323692	19991115
PRIORITY APPL. INFO.:			JP 1999-323692	19991115
OTHER SOURCE(S):			MARPAT 135:5612	

GI




I




II


AB The pyrazolo terpyridine or that salt which is cyclooxygenase - 2 (COX-II)
inhibitors, those production methods, the medicine composition, and the person
or
the animal which contain those inflammation condition, u painfully,
prevention of the autoimmune disease and / or the method of treating is
offered. Below-mentioned general formula (I) { in the formula, the R1 and
the R2, the resp. hydrogen, the hydrogen, the low-grade alkyl group and
the halogen et cetera, mean, R3 such as low-grade alkyl group and the
cyclo (low grade) alkyl group resp. } So the chemical compound which is
displayed or that salt.
IT 340321-35-9P 340321-41-7P 340321-70-2P
RU: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (preparation); USES (Uses)
(preparation of new pyrazolo terpyridines as remedies for inflammation
autoimmune diseases)
RN 340321-35-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 340321-41-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 340321-70-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




IT 340322-61-4 340322-64-7 340322-66-9
340322-74-9 340322-75-0 340322-76-1
340322-80-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of new pyrazolo terpyridines as remedies for inflammation
autoimmune diseases)


RN 340322-61-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-(4-methylphenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340322-64-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[4-(methylthio)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340322-66-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 340322-74-9 CAPLUS
CN 1H-Pyrrole, 2,5-dimethyl-1-[[4-[2-(4-(methylamino)phenyl)pyrazolo[1,5-
a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)






RN 340322-75-0 CAPLUS
CN 1H-Pyrrole, 2,5-dimethyl-1-[[4-[2-(4-(phenylmethoxy)phenyl)pyrazolo[1,5-
a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 340322-76-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-bromophenyl)-3-[4-(methylsulfonyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 340322-80-7 CAPLUS
CN 1H-Pyrrrole, 1-[[[4-methylphenyl]ethynyl]sulfonyl]-3-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]]- (9CI) (CA INDEX NAME)




IT 291743-98-1P 340323-05-9P 340323-06-0P
340323-08-2P 340323-09-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of new pyrazolo terpyridines as remedies for inflammation autoimmune diseases)
RN 291743-98-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 340323-05-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-chlorophenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 340323-06-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylthio)phenyl]-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 340323-08-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclohexyl-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 340323-09-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-methoxyphenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




IT 267235-61-0P 267235-62-1P 267235-87-0P
291743-97-0P 340321-37-1P 340321-38-2P
340321-39-3P 340321-40-6P 340321-42-8P
340321-43-9P 340321-44-0P 340321-45-1P

340321-46-2P 340321-47-3P 340321-49-5P
 340321-50-8P 340321-51-9P 340321-52-0P
 340321-53-1P 340321-55-3P 340321-56-4P
 340321-57-5P 340321-58-6P 340321-59-7P
 340321-60-0P 340321-61-1P 340321-62-2P
 340321-63-3P 340321-64-4P 340321-65-5P
 340321-66-6P 340321-67-7P 340321-68-8P
 340321-69-9P 340321-71-3P 340321-72-4P
 340321-73-5P 340321-74-6P 340321-75-7P
 340321-76-8P 340321-77-9P 340321-78-0P
 340321-79-1P 340321-80-4P 340321-81-5P
 340321-82-6P 340321-83-7P 340321-84-8P
 340321-85-9P 340321-86-0P 340321-87-1P
 340321-88-2P 340321-89-3P 340321-90-6P
 340321-91-7P 340321-92-8P 340321-93-9P
 340321-94-0P 340321-95-1P 340321-96-2P
 340321-97-3P 340321-98-4P 340321-99-5P
 340322-00-1P 340322-01-2P 340322-02-3P
 340322-03-4P 340322-04-5P 340322-05-6P
 340322-06-7P 340322-07-8P 340322-08-9P
 340322-09-0P 340322-10-3P 340322-11-4P
 340322-12-5P 340322-13-6P 340322-14-7P
 340322-15-8P 340322-16-9P 340322-17-0P
 340322-18-1P 340322-19-2P 340322-20-5P
 340322-21-6P 340322-22-7P 340322-24-9P
 340322-25-0P 340322-26-1P 340322-27-2P
 340322-28-3P 340322-30-7P 340322-31-8P
 340322-32-9P 340322-33-0P 340322-34-1P
 340322-35-2P 340322-38-5P 340322-39-6P
 340322-40-9P 340322-41-0P 340322-42-1P
 340322-43-2P 340322-44-3P 340322-45-4P
 340322-46-5P 340322-47-6P 340322-48-7P
 340322-49-8P 340322-50-1P 340322-51-2P
 340322-52-3P 340322-53-4P 340322-54-5P
 RN 267235-61-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-62-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 267235-87-0 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 6-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 291743-97-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 340321-37-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-cyclohexyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-38-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-39-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(3-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RL: SPN (Synthetic preparation); THU (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of new pyrazolo terpyridines as remedies for inflammation autoimmune diseases)


RN 340321-44-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-45-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 340321-46-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 340321-47-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(5-methyl-2-pyridinyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-49-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-methylphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-40-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-42-8 CAPLUS
CN Benzonitrile, 4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-43-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)







RN 340321-50-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(1-methylethyl)phenyl]-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-51-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 340321-52-0 CAPLUS
CN Benzenesulfonamide, 4-[2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340321-53-1 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340321-55-3 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-56-4 CAPLUS
CN Benzenesulfonamide, 4-(3-phenylpyrazolo[1,5-a]pyridin-2-yl)- (9CI) (CA INDEX NAME)




RN 340321-57-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 340321-58-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-59-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-3-(4-(methanesulfonyl)phenyl)-
(9CI) (CA INDEX NAME)




RN 340321-60-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-methyl-3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-61-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-(4-(methanesulfonyl)phenyl)-2-
phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 340321-62-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-methanol, 3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-63-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 4-methyl-3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-64-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-(4-(methanesulfonyl)phenyl)-2-
phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 340321-65-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-7-methanol, 3-(4-(methanesulfonyl)phenyl)-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-66-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-chlorophenyl)-3-(4-(methanesulfonyl)phenyl)-
(9CI) (CA INDEX NAME)




RN 340321-67-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 340321-68-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2-methoxyphenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-69-9 CAPLUS
CN Benzenesulfonamide, 4-(2-cyclohexylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 340321-71-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-methoxyphenyl)-2-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-72-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(methylsulfonyl)phenyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 340321-73-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(4-fluorophenyl)-2-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 340321-74-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-75-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-76-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 7-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)




RN 340321-77-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-78-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-79-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-(methoxymethyl)-3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-80-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-81-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-82-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 5-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)



RN 340321-83-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-
phenyl- (9CI) (CA INDEX NAME)




RN 340321-84-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine-4-methanol, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-
(9CI) (CA INDEX NAME)



HO-CH₂

RN 340321-85-9 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 4-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



CH₂F₂


RN 340321-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyridine-7-carbonitrile, 3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-87-1 CAPLUS

CN Ethanone, 1-[4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 340321-88-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 6-bromo-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 340321-89-3 CAPLUS


CN Pyrazolo[1,5-a]pyridin-6-amine, 3-[4-(methylsulfonyl)phenyl]-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



• x HCl

RN 340321-90-6 CAPLUS


CN Pyrazolo[1,5-a]pyridin-6-amine, N-methyl-3-[4-(methylsulfonyl)phenyl]-2-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



• x HCl

RN 340321-91-7 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 7-(fluoromethyl)-3-[4-(methylsulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 340321-92-8 CAPLUS

CN Benzenamine, 4-[3-[4-(methylsulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)


2-yl]- (9CI) (CA INDEX NAME)




RN 340321-93-9 CAPLUS
CN Benzenamine, N,N-dimethyl-4-[3-(4-(methylsulfonyl)phenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-94-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(2,4-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)- (9CI) (CA INDEX NAME)




RN 340321-95-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[4-(methoxymethoxy)phenyl]-3-(4-(methylsulfonyl)phenyl)- (9CI) (CA INDEX NAME)




RN 340321-96-2 CAPLUS
CN Benzenesulfonamide, 4-[3-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-




RN 340321-97-3 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-98-4 CAPLUS
CN Benzenesulfonamide, 4-[3-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340321-99-5 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-methylphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-00-1 CAPLUS
CN Benzenesulfonamide, 4-[3-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-2-yl]-
(9CI) (CA INDEX NAME)




RN 340322-01-2 CAPLUS
CN Benzenesulfonamide, 4-[3-[3-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-02-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 340322-03-4 CAPLUS
CN Benzenesulfonamide, 4-[2-(6-methyl-3-pyridinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-04-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-05-6 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)



RN 340322-06-7 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-07-8 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-08-9 CAPLUS


CN Benzenesulfonamide, 4-[2-[4-(difluoromethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-09-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(trifluoromethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-10-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-chloro-4-methoxyphenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-11-4 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-fluoro-4-methoxyphenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-12-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-chloro-4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-13-6 CAPLUS
CN Benzenesulfonamide, 4-[2-(2,3-dihydro-1H-inden-5-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-14-7 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-15-8 CAPLUS
CN Benzamide, 4-[3-[(4-aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]-
(9CI) (CA INDEX NAME)




RN 340322-16-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-17-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-methylsulfonyl)phenyl]pyrazolo[1,5-a]
pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-18-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-acetylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)





RN 340322-19-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-propoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-20-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-(2-chloroethoxy)phenyl)pyrazolo[1,5-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)






RN 340322-21-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-(2-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
 (CA INDEX NAME)






RN 340322-22-7 CAPLUS
 CN Benzenesulfonamide, 4-[2-(2-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
 (CA INDEX NAME)






RN 340322-24-9 CAPLUS
 CN Benzenesulfonamide, 4-[2-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-25-0 CAPLUS
 CN Benzenesulfonamide, 4-[2-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-26-1 CAPLUS
 CN Benzenesulfonamide, 4-[2-[5-(trimethylsilyl)-3-isoxazolyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-27-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(5-ethoxy-3-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 340322-28-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(3-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-30-7 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-oxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-31-8 CAPLUS
CN Benzenesulfonamide, 4-[2-(5-isoxazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 340322-32-9 CAPLUS
CN Benzenesulfonamide, 4-[2-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-33-0 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-amino-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 340322-34-1 CAPLUS
CN Benzenesulfonamide, 4-[2-(2-chloro-4-thiazolyl)pyrazolo[1,5-a]pyridin-3-
yl]- (9CI) (CA INDEX NAME)




RN 340322-35-2 CAPLUS
CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-
yl]phenyl]- (9CI) (CA INDEX NAME)




RN 340322-38-5 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-[1-methylethenyl]phenyl]pyrazolo[1,5-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)




RN 340322-39-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(dimethylamino)phenyl]pyrazolo[1,5-a]pyridin-3-
yl]- (9CI) (CA INDEX NAME)




RN 340322-40-9 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-aminophenyl)pyrazolo(1,5-a)pyridin-3-yl]-
(9CI) (CA INDEX NAME)



RN 340322-41-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-[methyl(methylsulfonyl)amino]phenyl]pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 340322-42-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[4-(2-propenyloxy)phenyl]pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 340322-46-5 CAPLUS
CN Benzenesulfonamide, 4-[2-(6-chloro-3-pyridinyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)


RN 340322-43-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(1-methyl-1H-pyrrol-3-yl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-44-3 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-cyanophenyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 340322-45-4 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-ethenylphenyl)pyrazolo(1,5-a)pyridin-3-yl]- (9CI) (CA INDEX NAME)









RN 340322-47-6 CAPLUS
CN Benzenesulfonamide, N-[4-[3-[(4-aminosulfonyl)phenyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 340322-48-7 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-thienyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)





RN 340322-49-8 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-ethenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 340322-50-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-azetidiny)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 340322-51-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[(3-furanyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)




RN 340322-52-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[(4-methylamino)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)


DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069464	A1	20001123	WO 2000-JP3015	20000511
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KR, KZ, LC, LG, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CN, CO, CR, CU, EE, EG, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, EP 1177797	A1	EP 2000-925617	20000511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, US 2004152639	A1	US 2003-716865	20031120
			JP 1999-131108	A 19990512
			WO 2000-JP3015	W 20000511
			US 2001-926469	BI 20011108



PRIORITY APPL. INFO.:
 OTHER SOURCE(S): MARPAT 134:533
 GI





RN 340322-53-4 CAPLUS
 CN Benzenesulfonamide, 4-[3-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-2-yl]- (9CI) (CA INDEX NAME)




RN 340322-54-5 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-thiazolyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 50 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:824128 CAPLUS
 DOCUMENT NUMBER: 134:533
 TITLE: Novel use of adenosine ALA2a receptor dual antagonists
 INVENTOR(S): Matsuo, Nobuya; Moriguchi, Akira; Tada, Miho; Mihara, Takuma
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: FIXXD2




III



II


AB Preventives and/or remedies for Parkinson's disease and symptoms associating therewith such as anxiety, depression and/or memory disorder which contain as the active ingredient an adenosine ALA2a receptor dual antagonists or salts thereof. Markush's structures of pyrazolopyridine derivs. (I), pyrazolopyrazine derivs. (II), and xanthine derivs. (III) were given.
 IT 202646-79-5
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 RN (novel use of adenosine ALA2a receptor dual antagonists in psychiatry)
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 51 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:628138 CAPLUS
 DOCUMENT NUMBER: 133:222726
 TITLE: Preparations of pyrazolopyridines as selective inhibitors of COX-2
 INVENTOR(S): Campbell, Ian Baxter; Lambeth, Paul Francis; Naylor, Alan; Pegg, Neil Anthony
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032008	A1	20000908	WO 1999-EPI0263	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1157025	A1	20011128	EP 1999-968808	19991222
EP 1157025	B1	20040310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002538157	T	20021112	JP 2000-602234	19991222
AT 261444	T	20040315	AT 1999-968808	19991222
ES 2216631	T3	20041016	ES 1999-968808	19991222
US 6498166	B1	20021224	US 2001-890925	20010830
PRIORITY APPLN. INFO:			GB 1999-4506	A 19990227
			GB 1999-20904	A 19990903
			WO 1999-EPI0263	W 19991222
OTHER SOURCE(S):				
GI				




AB The title compds. [I; R0, R1 = H, halo, alkyl, etc.; R2 = halo, CN, CONR4R5, etc.; R3 = alkyl, NH2; R4, R5 = H, alkyl, (un)substituted Ph; NR4R5 = saturated 4-8 membered ring] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared and formulated. E.g., a multi-step synthesis of I [R0 = 4-F; R1 = H; R2 = 6-CN; R3 = NH2] which showed IC50 of 21 nM against COX-2 vs. IC50 of 20,950 nM against COX-1, was given.
 IT 291743-84-5P 291743-85-6P 291743-86-7P
 291743-87-8P 291743-88-9P 291743-89-OP
 291743-90-3P 291743-91-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridines as selective inhibitors of COX-2)
 RN 291743-84-5 CAPLUS
 CN Benzenesulfonamide, 4-[(6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 291743-85-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 2-(4-fluorophenyl)-3-[(4-methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 291743-86-7 CAPLUS
 CN Benzenesulfonamide, 4-[(6-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 291743-87-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 291743-88-9 CAPLUS
CN Benzenesulfonamide, 4-[6-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-89-0 CAPLUS
CN Benzenesulfonamide, 4-[6-chloro-2-(4-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 291743-90-3 CAPLUS
CN Benzenesulfonamide, 4-[6-chloro-2-(3-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 291743-91-4 CAPLUS
CN Benzenesulfonamide, 4-(6-chloro-2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 291743-97-0P 291743-98-1P 291743-99-2P
RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
291743-97-0 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 291743-98-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

RN 204504-56-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 164 THERE ARE 164 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 53 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:314697 CAPLUS
DOCUMENT NUMBER: 132:321858
TITLE: Preparation of pyrazolopyridines as selective COX-2 inhibitors
INVENTOR(S): Campbell, Ian Baxter; Naylor, Alan
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026216	A1	20000511	WO 1999-EP8186	19991101
W: AE, AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CN, GA, GN, GW, ML, MR, NE, NG, SN, TD, TG				
CA 2349567	A1	20000511	CA 1999-2349567	19991101
BR 9915011	A	20010807	BR 1999-15011	19991101
EP 1127058	A1	20010829	EP 1999-955897	19991101
EP 1127058	B1	20040901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101208	T2	20011022	TR 2001-200101208	19991101
HU 200104204	A2	20020429	HU 2001-4204	19991101
JP 2002528547	T	20020903	JP 2000-579604	19991101
JP 3420751	B2	20030630		
NZ 511349	A	20031031	NZ 1999-511349	19991101
AU 767464	B2	20031113	AU 2000-12667	19991101
AU 767464	T	20040915	AT 1999-955897	19991101
ES 2228127	T3	20050401	ES 1999-955897	19991101
TW 342836	B	20030721	TW 1999-88119040	19991101
IN 2001K000463	A	20050311	IN 2001-KN463	20010124
ZA 2001003344	A	20020724	ZA 2001-3344	20010424
US 7223772	B1	20070529	US 2001-830836	20010501
NO 2001002156	A	20010702	NO 2001-2156	20010502
NO 318884	B1	20050518	GB 1998-24062	A 19981103

PRIORITY APPLN. INFO.:

RN 291743-99-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-bromo-2-(4-fluorophenyl)-3-(4-(methylthiophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 52 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:416645 CAPLUS
DOCUMENT NUMBER: 133:38215
TITLE: Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6077842	A	20000620	US 1998-200376	19981124
PRIORITY APPLN. INFO.:			US 1998-200376	19981124
OTHER SOURCE(S):			MARKPAT 133:38215	
AB A method is provided for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to pyrazolopyridylpyridazinone derivs. Preparation of compds. of the invention is included.				
IT 204504-56-3P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(pyrazolopyridylpyridazinone derivative preparation for inhibition of neoplastic cells)				

GB 1999-20909 A 19990903
 WO 1999-EP8186 W 19991101

OTHER SOURCE(S): MARPAT 132:321858
 GI




I

AB The title compds. [1: R0, R1 = H, halo, alkyl, etc.; R2 = H, alkyl, alkyl substituted by one or more fluorine atoms, etc.; R3 = alkyl, NH2] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared and formulated. E.g., a multi-step synthesis of I [R0 = 3-F; R1 = H; R2 = 6-CF3; R3 = NH2] which showed IC50 of 34 nM against COX-2, was given.


IT 267235-24-5P 267235-56-3P 267235-57-4P
 267235-58-5P 267235-59-6P 267235-60-9P
 267235-61-0P 267235-62-1P 267235-63-2P
 267235-64-3P 267235-65-4P 267235-66-5P
 267235-67-6P 267235-68-7P 267235-69-8P
 267235-70-1P 267235-72-3P 267235-73-4P
 267235-74-5P 267235-75-6P 267235-76-7P
 267235-77-8P 267235-78-9P 267235-79-0P
 267235-80-3P 267235-81-4P 267235-82-5P
 267235-83-6P 267235-84-7P 267235-85-8P
 267235-86-9P 267235-87-0P 267235-88-1P
 267235-89-2P 267235-90-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridines as selective COX-2 inhibitors)


RN 267235-24-5 CAPLUS
 CN Acetamide, N-[[4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-56-3 CAPLUS
 CN Benzenesulfonamide, 4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-57-4 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 267235-58-5 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-59-6 CAPLUS
 CN Benzenesulfonamide, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-60-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-[(4-fluorophenyl)-3-[(4-(methylsulfonyl)phenyl)-6-(trifluoromethyl)-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-61-0 CAPLUS
CN Benzenesulfonamide, 4-[2-phenyl-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-62-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-[(4-(methylsulfonyl)phenyl)-2-phenyl-6-(trifluoromethyl)-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-63-2 CAPLUS
CN Benzenesulfonamide, 4-[2-(4-methylphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 267235-64-3 CAPLUS
CN Acetamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 267235-65-4 CAPLUS
CN Acetamide, N-[[4-[2-(4-ethoxyphenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-66-5 CAPLUS
CN Acetamide, N-[[4-[2-phenyl]-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-67-6 CAPLUS
CN Acetamide, N-[[4-[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)

CN Propanamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 267235-72-3 CAPLUS

CN Benzamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-73-4 CAPLUS

CN Butanoic acid, 4-[[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 267235-74-5 CAPLUS


CN Butanoic acid, 4-[[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-



● Na


RN 267235-68-7 CAPLUS

CN Acetamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 267235-69-8 CAPLUS

CN Propanamide, N-[[4-(2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-70-1 CAPLUS


a[pyridin-3-yl]phenyl]sulfonyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 267235-75-6 CAPIUS
CN Pentanamide, N-[[4-[[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-76-7 CAPIUS
CN Acetamide, 2-(acetyloxy)-N-[[4-[[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-77-8 CAPIUS
CN Acetamide, 2-chloro-N-[[4-[[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 267235-78-9 CAPIUS
CN Acetamide, 2-(diethylamino)-N-[[4-[[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 267235-79-0 CAPIUS
CN Carbamic acid, [[4-[[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 267235-80-3 CAPIUS
CN Carbamic acid, [[4-[[2-(3-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


NAME)




RN 267235-81-4 CAPLUS
CN Benzenesulfonamide, 4-[(6-chloro-2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-82-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-chloro-2-(3-ethoxyphenyl)-3-[(4-(methylsulfonyl)phenyl)]- (9CI) (CA INDEX NAME)




RN 267235-83-6 CAPLUS
CN Benzenesulfonamide, 4-[(6-methyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-84-7 CAPLUS
CN Benzenesulfonamide, 4-[(2-(3-fluorophenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-85-8 CAPLUS
CN Benzenesulfonamide, 4-[(2-(3-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-86-9 CAPLUS
CN Benzenesulfonamide, 4-[(2-(4-ethoxyphenyl)-6-methylpyrazolo[1,5-a]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 267235-87-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 6-methyl-3-[4-(methanesulfonyl)phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 267235-88-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-fluorophenyl)-6-methyl-3-[4-(methanesulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 267235-89-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(3-ethoxyphenyl)-6-methyl-3-[4-(methanesulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 267235-90-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-(4-ethoxyphenyl)-6-methyl-3-[4-(methanesulfonyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 54 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:291038 CAPLUS
DOCUMENT NUMBER: 132:308348
TITLE: Preparation of pyridazinylopyrazolopyridines as

adenosine antagonists
INVENTOR(S): Akihane, Atsushi; Kuroda, Satoru; Itani, Hiromichi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024742	A1	20000504	WO 1999-JP5696	19991014
W: BR, CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2002528453	T	20020903	JP 2000-578312	19991014
PRIORITY APPL. INFO.:			AU 1998-6721	A 19981023
			WO 1999-JP5696	W 19991014

OTHER SOURCE(S):
AB R1212R2 [Z1 = pyrazolo[1,5-a]pyridine-2,3-diyl; Z2 = 3-oxo-2,3-dihydropyridazine-6,2-diyl]; R1 = substituted Ph; R2 = H or alkyl] were prepared. Thus, 2-(MeO)C6H4I was alkylated by HC.tplbond.CSMe3 and the product deprotected to give HC.tplbond.CC6H4(OMe)-2 which was treated with EtMgBr/Ac2O to give MeOC.tplbond.CC6H4(OMe)-2. The latter was

cyclocondensed with 1-aminopyridinium iodide to give I (R1 = C6H4(OMe)-2, R2 = H). Data for biol. activity of I were given.

IT


265660-54-6P 265660-55-7P 265660-56-8P
265660-57-9P 265660-58-0P 265660-59-1P
265660-60-1P 265660-61-5P 265660-62-6P
265660-63-7P 265660-64-8P 265660-65-9P
265660-66-0P 265660-67-1P 265660-68-2P
265660-69-3P 265660-71-7P 265660-72-8P
265660-73-9P 265660-74-0P 265660-75-1P
265660-76-2P 265660-77-3P 265660-78-4P
265660-79-5P 265660-80-8P 265660-81-9P
265660-82-0P 265660-83-1P 265660-84-2P
265660-85-3P 265660-86-4P 265660-87-5P
265660-88-6P 265660-89-7P 265660-90-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridazinylopyrazolopyridines as adenosine antagonists)


RN 265660-54-6 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-55-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-56-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-57-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-58-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-59-1 CAPLUS


CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-60-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-61-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-62-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-methyl- (9CI) (CA INDEX NAME)




RN 265660-63-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-methyl- (9CI) (CA INDEX NAME)




RN 265660-64-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-65-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-66-0 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-67-1 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-68-2 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
2-methyl- (9CI) (CA INDEX NAME)




RN 265660-69-3 CAPIUS
CN 3(2H)-Pyridazinone, 6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-71-7 CAPIUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-
yl]- (9CI) (CA INDEX NAME)




RN 265660-72-8 CAPIUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-(3-methylphenyl)pyrazolo[1,5-
a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-73-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-
(9CI) (CA INDEX NAME)




RN 265660-74-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-
methyl- (9CI) (CA INDEX NAME)




RN 265660-75-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-
methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-76-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-
3-yl]- (9CI) (CA INDEX NAME)




RN 265660-77-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-(3-(trifluoromethyl)phenyl)pyrazolo[1,5-
a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-78-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-ethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-
methyl- (9CI) (CA INDEX NAME)




RN 265660-79-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(1-methylethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(propyloxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-81-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-[2-[3-(phenylmethoxy)phenyl]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-82-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-83-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)





RN 265660-84-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 265660-85-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(5-bromo-2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 265660-88-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(2-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 265660-89-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(3-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 265660-90-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 265660-87-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 2000:125853 CAPLUS
 132:245853

Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines

Kuroda, Satoru; Akahane, Ritsushi; Itani, Hiromichi; Nishimura, Shintaro; Durkin, Kieran; Tenda, Yoshiyuki; Sakane, Kazuo

Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan

Bioorganic & Medicinal Chemistry (2000), 8(1), 55-64
 CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A novel series of 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines was synthesized and evaluated for in vitro adenosine A1 and A2A receptor binding activities. Most of the cyclohexenyl derivs. (7a-e, 8a-s) were found to be potent adenosine A1 receptor antagonists. In a series of analogs of FR166124 (3a), alc. 7c, nitrile 7e and amide derivs. (7d, 8c, 8r) were found to be more potent A1 antagonists with higher A2A/A1 selectivity than FR166124. Amongst them, 8r showed considerable water solubility (33.3 mg/mL), but lower than that of the sodium salt of FR166124 (> 200 mg/mL). Admnl., FR166124 had strong diuretic activity by both p.o. and iv administration in rats (min. ED=0.1 and 0.032 mg/kg, resp.).


IT 171050-45-6, FR166124 171051-35-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(Synthesis and structure-activity of novel 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


RN 171050-45-6 CAPLUS

CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171051-35-7 CAPLUS

CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 171050-95-6P 171051-04-OP 171051-07-3P


171051-08-4P 171051-11-9P 171051-12-OP

171051-14-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (Synthesis and structure-activity of novel 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


RN 171050-95-6 CAPLUS

CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-04-0 CAPLUS


CN Glycine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-07-3 CAPLUS
CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-08-4 CAPLUS
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171051-11-9 CAPLUS
CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-12-0 CAPLUS
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 171051-14-2 CAPLUS

CN β-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 171050-85-4P 171050-87-6P 171050-88-7P
171050-96-7P 171050-97-8P 171050-98-9P
171050-99-0P 171051-01-7P 171051-02-8P
171051-10-8P 171051-13-1P 171051-15-3P
171051-19-7P 171051-22-2P 171051-23-3P
171051-24-4P 171051-47-1P 171051-52-8P
171051-55-1P 262358-35-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Synthesis and structure-activity of novel 3-(2-cyclohexenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


RN 171050-85-4 CAPLUS
CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-87-6 CAPLUS
CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171050-88-7 CAPLUS
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 171050-96-7 CAPLUS
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-97-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171050-98-9 CAPLUS
CN Glycine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171050-99-0 CAPLUS
CN p-Alanine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-01-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-10-8 CAPLUS
CN 1-Cyclohexene-1-acetamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-13-1 CAPLUS
CN 1-Cyclohexene-1-acetamide, N-(2-hydroxyethyl)-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN	171051-15-3	CAPLUS
CN	1-Cyclohexene-1-acetamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI)	(CA INDEX NAME)




RN	171051-19-7	CAPLUS
CN	Thiomorpholine, 4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)	




RN	171051-22-2	CAPLUS
CN	Morpholine, 4-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]- (9CI) (CA INDEX NAME)	




171051-23-3 CAPLUS
 Pyrrolidine, 1-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN	171051-24-4	CAPLUS
CN	Piperidine, 1-([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl)-(9CI) (CA INDEX NAME)	




RN	171051-47-1	CAPLUS
CN	3(2H)-Pyridazinone, 2-(2-(2-hydroxyethyl)-1-cyclohexen-1-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI)	(CA INDEX NAME)




RN	171051-52-8	CAPLUS
CN	1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI)	(CA INDEX NAME)



RN	171051-55-1	CAPLUS
CN	Piperazine, 1-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]- (9CI) (CA INDEX NAME)	



RN 262358-35-0 CAPLUS
CN Piperazine, 1-methyl-4-((2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)-1-cyclohexen-1-yl)acetyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

IT 171051-36-8 171051-40-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(Synthesis and structure-activity of novel 3-(2-cyclohexenyl)-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines as adenosine A1 receptor antagonists in vitro)


RN 171051-36-8 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 171051-40-4 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 56 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:34554 CAPLUS

DOCUMENT NUMBER: 132:83673

TITLE: Combination of loop diuretics with adenosine

Al-receptor antagonists for treatment of hypertension and related diseases

INVENTOR(S): Hropot, Max

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 10 pp.

CODEN: EPXMDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

EP 970696 A1 20000112 EP 1998-108127 19980505

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: EP 1998-108127 19980505

AB The invention relates to a pharmaceutical composition containing combination of a loop diuretic and an adenosine A1 receptor antagonist. This composition is useful for the treatment of and/or prophylaxis of hypertension, renal failure or disorders with increased proximal tubular reabsorption, e.g., congestive heart failure, liver cirrhosis or nephrotic syndrome. KW-3902 (30 g) was dissolved in a mixed solvent of EtOH (350 g) and CH2Cl2 (350 g), and Eudragit L 100 (90 g) was added to the solution. The resulting solution was sprayed on the mixture of furosemide (120 g) and lactose (760 g), and granulated at 60° with a fluidized bed granulator. After drying, the granules were sieved (24 mesh) and mixed uniformly and homogeneously with magnesium stearate in a blender. The resulting granules were filled into hard gelatin capsules. The capsules containing 5 mg KW-3902 and 20 mg of furosemide were obtained. Results of salivary expts. show that KW-3902 at 0.01 and 0.1 mg/kg and furosemide at 10, 20 and 30 mg/kg body weight in male Wistar rats orally caused a significant increase in urine volume, sodium and chloride excretion as compared to the control. The combinations of KW-3902 at 0.1 mg/kg with furosemide at 10 mg/kg exerted significant additive or even synergistic effects with respect to urine volume, sodium and chloride excretion in the collection periods 1-4 h as compared with single compds.

IT


RL: BAC (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Combination of loop diuretics with adenosine A1-receptor antagonists for treatment of hypertension and related diseases)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 57 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 132:49958 CAPLUS
 DOCUMENT NUMBER: 1999:819369
 TITLE: Preparation of pyrazolopyridine derivatives as adenosine antagonists
 INVENTOR(S): Akahane, Atsushi; Nishimura, Shintaro; Kuroda, Satoru; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967239	A1	19991229	WO 1998-JP2794	19980622

W: CA, CN, JP, KR, US
 RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: MARPAT 132:49958
 OTHER SOURCE(S): 19980622



AB The title compounds, I [R = alkanylalkyl, etc.] are prepared. These compounds are adenosine antagonists and useful as recognition augmenters, nootropic drugs, mental stimulants, analgesic agents, cardiac protective drugs, antidepressive drugs, cerebral vasodilators, tranquilizers, remedies for cardiac failure, cardiac tonics, hypotensive drugs, drugs for renal insufficiency, remedies for nephrotoxicity, renal protective agents, renal function improving drugs, diuretic agents, remedies for edema, antioleptic drugs, antialsthatmatics, bronchodilators, remedies for apnea, remedies for gout, remedies for hyperuricemia, remedies for sudden infant death syndrome (SIDS), drugs for improving immunosuppression by adenosine, antidiabetic drugs, antitumor drugs, remedies for pancreatitis, remedies for Meniere syndrome, antianemic agents, remedies for thrombosis, remedies for heart infarction, remedies for embolism, remedies for arteriosclerosis obliterans, remedies for thrombotic phlebitis, remedies for brain

infarction, remedies for transient cerebral ischemia, remedies for angina pectoris, etc. In an in vitro test for adenosine A1 antagonism, 3-[2-(1-methyl-2-oxopropyl)-3-oxo-2,3-dihydropyridazine-6-yl]-2-phenylpyrazolo[1,5-a]pyridine at 3.2 x 10⁻⁷ M showed > 90% inhibition of binding of [3H]-N6-cyclohexyladenosine.


IT

210879-61-1P 210879-62-2P 210879-63-3P
 210879-64-4P 210879-65-5P 210879-66-6P
 210879-67-7P 210879-68-8P 210879-69-9P
 210879-70-2P 210879-71-3P 210879-72-4P
 210879-73-5P 210879-74-6P 210879-75-7P
 210879-76-8P 210879-77-9P 210879-78-0P
 210879-79-1P 210879-80-4P 210879-81-5P
 210879-82-6P 210879-83-7P 210879-84-8P
 210879-85-9P 210879-88-2P 210879-96-2P
 210879-99-5P 210880-03-8P 210880-04-9P
 210880-07-2P 210880-09-4P 210880-11-8P
 210880-13-0P 210880-14-1P 210880-15-2P
 210880-16-3P 210880-18-5P 210880-20-9P
 210880-23-2P 210880-25-4P 210880-27-6P
 210880-28-7P 210880-29-8P 210880-30-1P
 210880-31-2P 210880-33-4P 210880-34-5P
 210880-35-6P 252953-71-2P 252953-72-3P
 252953-73-4P 252953-74-5P 252953-75-6P
 252953-76-7P


RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolopyridine derivs. as adenosine antagonists)

RN 210879-61-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-62-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1-methyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-63-3 CAPLUS


CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-64-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-65-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-acetyl-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-66-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-methyl-2-oxopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-68-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-70-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-72-4 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-73-5 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 210879-74-6 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-75-7 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-76-8 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester, (αZ)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 210879-77-9 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 210879-78-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-79-1 CAPLUS
CN Benzoic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-80-4 CAPLUS
CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210879-81-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-82-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-{1,1'-biphenyl-[3-yl]-4-yl-2-oxoethyl})-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-83-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-(3-pyridinylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-84-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-tricyclo[3.3.1.1^{3,7}]dec-1-ylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-85-9 CAPLUS
CN Glycine, N-(2,2-dimethyl-1,3-dioxo-4-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-88-2 CAPLUS
CN 2-Piperidineacetic acid, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-96-2 CAPLUS
CN 2-Piperidineacetic acid, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210879-99-5 CAPLUS
CN Benzoic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-03-8 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, α,α -dimethyl-, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-04-9 CAPLUS
CN Benzoic acid, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 210880-07-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-09-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-11-8 CAPIUS
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-13-0 CAPIUS
CN 1(6H)-Pyridazinebutanamide, N,N,α-tetramethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-14-1 CAPIUS
CN 1(6H)-Pyridazinepentanamide, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-15-2 CAPIUS
CN 1(6H)-Pyridazinepentanamide, N-methyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-16-3 CAPIUS
CN 1(6H)-Pyridazinepentanamide, N,N-dimethyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-18-5 CAPIUS
CN Piperidine, 1-[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)




RN 210880-20-9 CAPIUS
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-23-2 CAPIUS


RN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-25-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-27-6 CAPLUS
CN Pyrrolidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-


pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-30-1 CAPLUS
CN Piperazine, 1-methyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS
CN Thiomorpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-33-4 CAPLUS
CN 1(6H)-Pyridazinebutanamide, N,N-dimethyl-β, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-34-5 CAPLUS
CN Piperidine, 1-[[1,3-dioxo-4-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)butyl]- (9CI) (CA INDEX NAME)




RN 210880-35-6 CAPLUS
CN 3-Pyrrolidinone, 1-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 252953-71-2 CAPLUS
CN Benzeneacetic acid, α-[[[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}butyl]amino]-, methyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252953-72-3 CAPLUS
CN Glycine, N-[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252953-73-4 CAPLUS

CN Benzeneacetic acid, α-[[[1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}butyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252953-74-5 CAPLUS
CN 1(6H)-Pyridazinebutanenitrile, β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 252953-75-6 CAPLUS
CN 1(6H)-Pyridazinebutanenitrile, β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 252953-76-7 CAPLUS
CN Azetidine, 1-[[1,4-dioxo-5-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl}pentyl]- (9CI) (CA INDEX NAME)




IT 131185-06-3 131185-08-5 210880-36-7.
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Preparation of pyrazolopyridine derivs. as adenosine antagonists)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-08-5 CAPLUS
 CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-36-7 CAPLUS
 CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:652945 CAPLUS
 DOCUMENT NUMBER: 132:49932
 TITLE: Process Improvements in the Production of a Novel Non-Xanthine Adenosine A1 Receptor Antagonist. A

AUTHOR(S):
 CORPORATE SOURCE:
 SOURCE:
 PUBLISHER:
 DOCUMENT TYPE:
 LANGUAGE:
 OTHER SOURCE(S):
 GI

"One-Pot" Horner-Emmons Isomerization Reaction
 Zanka, Atsuhiko; Itoh, Norihumi; Kuroda, Satoru
 Technological Development Laboratories, Fujisawa
 Pharmaceutical Co. Ltd., Osaka, 532-8514, Japan
 Organic Process Research & Development (1999), 3(6),
 394-399
 CODEN: OPRDFK; ISSN: 1083-6160
 American Chemical Society
 Journal
 English
 CASREACT 132:49932




I


AB Pilot plant scale synthesis of 2-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazin-6-one]-1-cyclohexen-1-yl] acetic acid (FRI66124) (I) is described. The process involved efficient isomerization of regioisomers produced in a Horner-Emmons reaction and employed ester exchange and hydrolysis with NaOH in MeOH. Challenges encountered in the final purification stage to afford high quality drug substance in pure crystalline form are also described. Process improvements and optimization of each step permitted elimination of column chromatog., resulting in a straightforward, practical, and cost-effective synthesis of I. These methods were successfully scaled up in a pilot plant to give bulk drug suitable for pharmacol. and toxicol. evaluation.

IT 252765-35-8P 252765-36-9P 252765-37-0P
 RL: BYP (Byproduct); PREP (Preparation)
 (manuf of adenosine A1 receptor antagonist
 phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
 via successive Horner-Emmons reaction, isomerization, and hydrolysis of
 phenylpyrazolopyridinylpyridazine)
 RN 252765-35-8 CAPLUS
 CN Cyclohexanol, 2-[[6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinylloxy]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 252765-36-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(sulfoxy)cyclohexyl]- (9CI) (CA INDEX NAME)



RN 252765-37-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(methylthio)methoxy]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 171050-45-6P
RL: IMF (Industrial manufacture); PREP (Preparation)
(manuf of adenosine A1 receptor antagonist
phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
via successive Horner Emmons reaction, isomerization, and hydrolysis of
phenylpyrazolopyridinylpyridazone)
RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




IT 171050-40-1P 171050-43-4P 171051-34-6P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(manuf of adenosine A1 receptor antagonist
phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
via successive Horner Emmons reaction, isomerization, and hydrolysis of
phenylpyrazolopyridinylpyridazone)
RN 171050-40-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

RN 171050-40-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-43-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1R,2R)-2-hydroxycyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 131185-06-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(manuf of adenosine A1 receptor antagonist
phenylpyrazolopyridinylpyridazinonecyclohexenyl acetic acid (FRI66124)
via successive Horner Emmons reaction, isomerization, and hydrolysis of
phenylpyrazolopyridinylpyridazone)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 171051-36-8P 171051-40-4P
RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(optimization of conditions for double bond isomerization of tert-Bu


RN 171051-36-8 CAPLUS
 CN Pyridazinylcyclohexanonecyclohexylmethylencarboxylate)
 Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-
 pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA
 INDEX NAME)

Double bond geometry as shown.




RN 171051-40-4 CAPLUS
 CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-
 pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA
 INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 59 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:548679 CAPLUS
 DOCUMENT NUMBER: 131:299420
 TITLE: Synthesis of the water-soluble adenosine A1 receptor
 antagonist FR166124 through a novel sequential
 Horner-Emmons / isomerization reaction
 AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi;
 Nishimura, Shintaro; Durkin, Kieran; Kinoshita,
 Takayoshi; Nakanishi, Isao; Sakane, Kazuo
 CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa
 Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan
 SOURCE: Tetrahedron (1999), 55(34), 10351-10364
 CODEN: TETRAE; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:299420
 GI



AB An efficient synthesis of FR166124 I (R = H) was achieved through a novel
 sequential Horner-Emmons - isomerization reaction of cyclohexanone II with
 tert-Bu diethylphosphonoacetate as the key process. E.g., cyclohexene
 oxide was treated with a phenylpyrazolopyridinylpyridazine in a
 toluene/water mixture in the presence of sodium hydroxide and
 triethylbenzylammonium chloride to give a cyclohexanol derivative in 80% yield
 which undergoes Swern oxidation with DMSO, oxalyl chloride, and triethylamine
 in methylene chloride to give II in 88% yield. E.g., II is added to a
 mixture of sodium hydride and tert-Bu diethylphosphonoacetate in toluene at
 4° and allowed to warm to room temperature over 24h to give I (R = Me3C)
 in 80% yield, along with three isomers, formed by incomplete or undesired
 isomerization of the double bond, which were separated by chromatog.; addition


of F3CCO2H to a solution of I (R = Me3C) in methylene chloride provides I (R =
 H) (FR166124) in 75% yield. Extensive studies of the
 olefination/isomerization reaction indicated that temperature, base and
 conformation of the Horner-Emmons products were important factors in the
 isomerization reaction, leading to a proposed mechanism for this unusual
 Horner-Emmons reaction.

IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(Preparation of the adenosine A1 antagonist FR166124 with a novel
 Horner-Emmons olefination/isomerization as the key step)

RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA
 INDEX NAME)




IT 171050-40-1P 171051-34-6P 247110-27-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(Preparation of the adenosine A1 antagonist FR166124 with a novel
 Horner-Emmons olefination/isomerization as the key step)


RN 171050-40-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-
 3-yl)- (9CI) (CA INDEX NAME)

CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-36-8 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2E) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 171051-40-4 CAPLUS
CN Acetic acid, [2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


I5 ANSWER 60 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:504267 CAPLUS
DOCUMENT NUMBER: 131:266565

TITLE: Discovery of FRI66124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist


AUTHOR(S): Kuroda, Satoru; Akahane, Atsushi; Itani, Hiromichi; Nishimura, Shintaro; Durkin, Kieran; Kinoshita, Takayoshi; Tenda, Yoshiyuki; Sakane, Kazuo
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, 532-8514, Japan



RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 247110-27-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 171050-45-6P, FRI66124
RL: SPN (Synthetic preparation); PREP (Preparation)
(Preparation of the adenosine A1 antagonist FRI66124 with a novel Horner-Emmons olefination/isomerization as the key step)


RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




IT 171051-35-7P 171051-36-8P 171051-40-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(the regio- and stereoselectivity, product analyses and energies of isomers formed in a novel Horner-Emmons olefination/isomerization reaction)

RN 171051-35-7 CAPLUS


SOURCE: Bioorganic & Medicinal Chemistry Letters (1999),
9(14), 1979-1984
CODEN: BMCLES; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel 3-(2-cycloalkyl and cycloalkenyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridines were synthesized and evaluated for their adenosine A1 receptor binding activities. In this series, FR166124 was found to be the most potent and selective adenosine A1 receptor antagonist, and the double bond of the cyclohexenyl acetic acid group was essential for selectivity of A1 receptor binding. Furthermore, the solubility in water of the sodium salt of FR166124 was high.
IT 131185-37-0, FK838 171050-45-6, FR 166124
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
RN 131185-37-0 CAPIUS
CN 1-(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPIUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



IT 171050-53-6P 171050-59-2P 171050-80-9P
171050-81-0P
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
RN 171050-53-6 CAPIUS
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-59-2 CAPIUS
CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-80-9 CAPIUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-81-0 CAPIUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 171051-03-9P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
RN 171051-03-9 CAPIUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, sodium salt (9CI) (CA INDEX NAME)




● Na


IT 131185-06-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 171050-40-1P 171050-41-2P 171050-49-0P
 171050-73-0P 171050-74-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
 RN 171050-40-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-41-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocyclopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-49-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-oxocycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-73-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)
 Relative stereochemistry.



RN 171050-74-1 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-[(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)
 Relative stereochemistry.




IT 171051-72-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrazolo-[1,5-a]pyridine FR166124 as adenosine A1 receptor antagonist)
 RN 171051-72-2 CAPLUS
 CN Cyclohexanone, 2-[(6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl)oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 61 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:206896 CAPLUS
 DOCUMENT NUMBER: 130:282079
 TITLE: Preparation of pyridazinyloxypropylidines as adenosine A1 receptor antagonists and pharmaceuticals containing them
 INVENTOR(S): Akabane, Acsushi; Kuroda, Satoshi; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11080157	A	19990326	JP 1997-252751	19970901
PRIORITY APPL. INFO.:			JP 1997-252751	19970901
OTHER SOURCE(S):			MARPAT 130:282079	




AB The title compds. I [R1 = aryl; R2 = CH2CHMeOH, CH2CMe2OH, lower alkanoylaminoalkyl, N-alkanoyl-N-alkylaminoalkyl, lower alkenyloxycarbonylaminoalkyl, 2-N,N-dialkylamino-2-methylpropyl, lower alkylaminoalkyl, aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, perhydroazepinylalkyl, perhydroazocinylalkyl, lower alkylpiperidinylalkyl, 2-, or 3-pyridylalkyl, (un)substituted pyrazolylalkyl, (un)substituted imidazolylalkyl] (II) or their salts are prepared II or their salts are prepared, e.g. by treatment of I (R2 = H) or their salts with R2OH (R2 = amino-protected aralkylaminoalkyl, pyrazolylalkyl having protected amino, amino-protected imidazolylalkyl, amino-protected lower alkylaminoalkyl) or their salts. II are useful as recognition enhancers, antiedentia agents, psychostimulants, analgesics, cardioprotectants, antidepressants, cerebral circulation improvers, tranquilizers, antihypertensives, diuretics, bronchodilators, etc., 3-[2-(imidazol-4-yl)methyl]-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine hydrochloride (preparation given) at 10-7M showed >90% inhibition against ligand binding by

IT human A1 receptors.
 222722-75-0P 222722-77-2P 222722-79-4P
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyridazinyloxypropylidines as adenosine A1 receptor antagonists and pharmaceuticals containing them)
 RN 222722-75-0 CAPLUS
 CN Carbanic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-1(6H)-pyridazinyloxyethyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 222722-77-2 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 222722-79-4 CAPLUS
 CN Acetamide, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-1(6H)-pyridazinyloxyethyl]- (9CI) (CA INDEX NAME)




IT 222722-39-6P 222722-40-9P 222722-41-0P
 222722-42-1P 222722-46-5P 222722-50-1P
 222722-52-3P 222722-55-6P 222722-58-9P
 222722-60-3P 222722-61-4P 222722-62-5P

222722-63-6P 222722-64-7P 222722-65-8P
 222722-66-9P 222722-67-0P 222722-69-2P
 222722-71-6P 222722-81-8P 222722-83-0P
 222722-85-2P 222722-87-4P 222722-89-6P
 222722-92-1P 222722-94-3P 222722-96-5P
 222722-98-7P 222723-65-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyridazinylpyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)

RN 222722-39-6 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1H-imidazol-2-ylmethyl)-6-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])- , monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 222722-40-9 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1H-imidazol-4-ylmethyl)-6-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])- , monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 222722-41-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-(1H-imidazol-4-yl)ethyl)-6-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])- (9CI) (CA INDEX NAME)




RN 222722-42-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-(1H-imidazol-4-yl)ethyl)-6-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])- , monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 222722-46-5 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])-2-((1H-imidazol-2-yl)methyl)- (9CI) (CA INDEX NAME)




RN 222722-50-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(1H-imidazol-2-ylmethyl)-6-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])- (9CI) (CA INDEX NAME)




RN 222722-52-3 CAPLUS
 CN 1H-Imidazole-1-acetic acid, 2-((6-oxo-3-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])-1(6H)-pyridazinyl)methyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 222722-55-6 CAPLUS
 CN 1H-Imidazole-1-acetic acid, 2-((6-oxo-3-(2-phenylpyrazolo[1,5-
 alpyridin-3-yl])-1(6H)-pyridazinyl)methyl)- (9CI) (CA INDEX NAME)




RN 222722-58-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-((1-methyl-1H-imidazol-2-yl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-60-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-61-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-62-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-63-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-((1-methyl-1H-imidazol-5-yl)methyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-64-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-(5-amino-1H-pyrazol-1-yl)ethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-65-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




● HCl

RN 222722-87-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(methylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-89-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(phenylmethyl)amino]propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222722-92-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[methyl(phenylmethyl)amino]propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-94-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1H-azepin-1-yl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 222722-96-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(2R,6S)-2,6-dimethyl-1-piperidinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 222722-98-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hexahydro-1(2H)-azocinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 222723-65-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-pyrazol-4-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 131185-06-3 210879-61-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridazinylpyrazolopyridines as adenosine A1 receptor antagonists and pharmaceuticals containing them)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:120305 CAPLUS
DOCUMENT NUMBER: 130:320362
TITLE: Discovery of 6-Oxo-3- (2-phenylpyrazolo[1,5-a]pyridin-3-yl)- 1(6H)-pyridazinebutanoic Acid (FK 838): A Novel Non-Xanthine Adenosine A1 Receptor Antagonist with Potent Diuretic Activity

AUTHOR(S): Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi; Kato, Takeshi; Kinoshita, Takayoshi; Kita, Yasuhiro; Kusunoki, Takahiro; Terai, Takao; Yoshida, Keizo; Shiokawa, Youichi

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Company Ltd., Yodogawa-ku Osaka, 532-8514, Japan

SOURCE: Journal of Medicinal Chemistry (1999), 42(5), 779-783.
CODEN: JMCWAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Based on an X-ray crystal structure of FK 453, the authors designed and synthesized a new series of pyrazolo[1,5-a]pyridines, in which heterocyclic groups were introduced instead of the acryloylamide of FK 453. 6-Oxo-3- (2-phenylpyrazolo[1,5-a]pyridin-3-yl)- 1(6H)-pyridazinebutanoic Acid (FK 838) displayed the most potent diuretic activity and was a potent and selective adenosine A1 receptor antagonist with good oral availability and solubility in water. FK 838 can be classified as the first of a new generation of adenosine A1 receptor antagonists, which are useful for the treatment of diseases such as hypertension and renal failure.

IT 131185-37-0, FK 838


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)

RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-06-3P 131185-30-3P 131185-31-4P


131185-32-5P 131754-91-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)
 RN 131185-06-3 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) - (9CI) (CA INDEX NAME)




RN 131185-30-3 CAPLUS
 CN 3(2H)-Pyridazinone, 2-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) - (9CI) (CA INDEX NAME)




RN 131185-31-4 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) - (9CI) (CA INDEX NAME)




RN 131754-91-1 CAPLUS
 CN 3(2H)-Pyridazinone, 2-(3-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) - (9CI) (CA INDEX NAME)




IT 131185-04-1P 131185-05-2P 131185-08-5P
 131185-40-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (adenosine A1 receptor antagonist and diuretic activity of the pyrazolo-pyridine FK 838)
 RN 131185-04-1 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridazinyl) - (9CI) (CA INDEX NAME)




RN 131185-05-2 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridinyl) - (9CI) (CA INDEX NAME)




RN 131185-08-5 CAPLUS
 CN 1(6H)-Pyridazinecarboxylic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) - (9CI) (CA INDEX NAME)




RN 131185-40-5 CAPLUS
 CN 1(6H)-Pyridazinecarboxylic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl) - (9CI) (CA INDEX NAME)




IT 131185-02-9P 131185-07-4P 131185-28-9P
 131185-39-2P 223753-60-4P
 RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (adenosine A1 receptor antagonist and diuretic activity of the
 pyrazolo-pyridine FK 838)
 RN 131185-02-9 CAPLUS
 CN 1(4H)-Pyridazinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 131185-07-4 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-28-9 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 131185-39-2 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-
 yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223753-60-4 CAPLUS
 CN 1(4H)-Pyridinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-,
 ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

I5 ANSWER 63 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:45448 CAPLUS
 DOCUMENT NUMBER: 130:246861

TITLE: Pyrazolopyridine derivatives act as competitive
 antagonists of brain adenosine A1 receptors:

[35S]GTPyS binding studies
 Ito, Harunobu; Maemoto, Takuya; Akahane, Atsushi;
 Butcher, Steven P.; Oliverman, Henry J.; Finlayson,
 Keith

CORPORATE SOURCE:
 SOURCE: Fujisawa Institute of Neuroscience, Japan
 European Journal of Pharmacology (1999), 365(2/3),
 309-315

PUBLISHER: EJPHAZ; ISSN: 0014-2999
 DOCUMENT TYPE: Elsevier Science B.V.

LANGUAGE: English


AB The effects of adenosine receptor ligands and three novel pyrazolopyridine
 derivs. on guanosine-5'-O-(3-[35S]thiotriphosphate ([35S]GTPyS)
 binding to rat cerebral cortical membranes were examined [35S]GTPyS
 binding was stimulated in a concentration dependent manner by several adenosine
 receptor agonists. The adenosine A2a receptor selective agonist,
 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS
 21680), was ineffective confirming specificity for adenosine A1 receptor
 activation. 2-Chloro-N6-cyclopentyladenosine (CCPA; 10-7 M)-stimulated
 [35S]GTPyS binding was inhibited by xanthine and pyrazolopyridine
 based adenosine receptor antagonists. The concentration-response curve for
 CCPA-stimulated [35S]GTPyS binding was shifted to the right with
 increasing concns. of antagonist without significant changes in maximal
 response. Schild analyses determined pKB values of 8.97, 8.88, 8.21, 8.16,
 7.79 and 7.65 for 8-cyclopentyl-1,3-dipropylxanthine (DPCPX),
 (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine
 ethanol (FK453), 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-
 pyridazinebutyric acid (FK838), 9-chloro-2-(1,2,4)triazolo-
 [1,5-c]minazolin-5-amine (CGS 15943), 8-cyclopentyl-1,3-methylxanthine
 (CPT) and (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
 acryloyl]-piperidin-2-yl acetic acid (FK352), resp. Schild slopes were

close to unity, confirming that these novel pyrazolopyridine derivs. act as competitive antagonists at rat brain adenosine A1 receptors. Also, [3S]GTPyS binding provides a convenient pharmacol. assay for the functional activity of adenosine A1 receptors in rat cortical membranes.

IT

131185-37-0, FK838
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(pyrazolopyridine derivs. act as competitive antagonists of brain adenosine A1 receptors in [3S]GTPyS binding studies in relation to effect of other ligands in rat cerebral cortical membranes)

RN 131185-37-0 CAPLUS
CN 1-(6H)-Pyridazinonebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 64 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

1998-635675 CAPLUS

DOCUMENT NUMBER:

129-239894

TITLE: Preventives and remedies for hyperphosphatemia

INVENTOR(S): Nomura, Kazuhiko; Sasaki, Emiko; Nakazi, Kazumi; Kajiho, Tokunaki

Fujiwara Pharmaceutical Co., Ltd., Japan

PCT Int. Appl., 59 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841237	A1	19980924	WO 1998-JP933	19980305
W: CA, CN, JP, KR, US				
RN: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 972525	A1	20000119	EP 1998-905796	19980305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6303624	B1	20011016	US 1997-380617	19991104
PRIORITY APPLN. INFO.:			JP 1997-64034	A 19970318
			WO 1998-JP933	W 19980305

OTHER SOURCE(S): MARPAT 129:239894

AB The invention relates to efficacious preventives and/or remedies for hyperphosphatemia or secondary accessory thyroid hyperfunction and concomitant symptoms thereof which contain adenosine antagonists as the active ingredient.


IT 131185-37-0 171050-45-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preventives and remedies for hyperphosphatemia)


RN 131185-37-0 CAPLUS

CN 1-(6H)-Pyridazinonebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS

CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

1998-499463 CAPLUS

DOCUMENT NUMBER:

129:216575

TITLE: Pilot-Scale Synthesis of a Novel Non-Xanthine

Adenosine A1 Receptor Antagonist. 1,3-Dipolar

Cycloaddition of Pyridine N-Imine to an Acetylene

Zanka, Atsuhiko; Hashimoto, Norio; Uematsu, Ryoichi;

Okamoto, Takumi

Technological Development Laboratories, Fujisawa

Pharmaceutical Co. Ltd., Yodogawa-ku Osaka, 532, Japan

Organic Process Research & Development (1998), 2(5),

320-324

CODEN: OPRDFK; ISSN: 1083-6160

PUBLISHER: American Chemical Society

DOCUMENT TYPE: English

LANGUAGE: English

AB Adenosine A1 receptor antagonist, FK838, has been synthesized in 44% overall yield by a five-step sequence which is operationally

straightforward and readily carried out on a large scale. Investigations

into the 1,3-dipolar cycloaddn. process that afforded a

pyrazolo[1,5-a]pyridine derivative are also described. Process improvements

and optimization of each step permitted elimination of column chromatog.,

resulting in a practical and cost-effective synthesis of FK838. These

methods were successfully scaled up in a pharmaceutical pilot plant to

give bulk drug used in clin. trials.

IT 131185-06-3p


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)


(pilot-scale preparation of FK838)

RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 131185-37-0P, FK838
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (pilot-scale preparation of FK838)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 66 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998-430761 CAPLUS
 DOCUMENT NUMBER: 129:144876
 TITLE: Pyrazolopyridines as adenosine antagonists and pharmaceuticals containing them
 INVENTOR(S): Itani, Hiromichi
 AkaBne, Atsushi; Nishimura, Shintaro; Kurota, Satoshi;
 Fujisawa Pharmaceutical Co., Ltd., Japan
 Jpn. Kokai Tokkyo Koho, 33 pp.
 CODEN: JKXXAF
 PATENT ASSIGNEE(S): Patent
 SOURCE: Japanese
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10182643	A	19980707	JP 1996-357706	19961226
PRIORITY APPLN. INFO.:			JP 1996-357706	19961226
OTHER SOURCE(S):			MARPAT 129:144876	




AB Pharmaceuticals contain pyrazolopyridines I [R = (substituted) lower alkanoyl(lower)alkyl, N-[(substituted) lower alkyl]carbamoyl(lower)alkyl, etc.] or their salts as adenosine, especially A1, antagonists with cognition-enhancing, analgesic, and locomotor-stimulant effects, and other pharmacol. actions. 3-[2-(1-Methyl-2-oxopropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine (preparation given) (at 3.2 + 10-7M) showed >90% inhibition of [3H]-N6-cyclohexyladenosine binding to rat A1 receptors.
 IT 210879-77-9P 210879-80-4P 210879-85-9P
 210880-03-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)
 RN 210879-77-9 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, α , α -dimethyl- β , β -dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 210879-80-4 CAPLUS
 CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210879-85-9 CAPLUS
 CN Glycine, N-[(2,2-dimethyl-1,3-dioxo-4-{6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl}butyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210880-03-8 CAPLUS
CN 1(6H)-Pyridazinonebutanoic acid, α,α -dimethyl-, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 210879-61-1P 210879-62-2P 210879-63-3P
210879-64-4P 210879-65-5P 210879-66-6P
210879-67-7P 210879-68-8P 210879-69-9P
210879-70-2P 210879-71-3P 210879-72-4P
210879-73-5P 210879-74-6P 210879-75-7P
210879-76-8P 210879-78-0P 210879-79-1P
210879-81-3P 210879-82-6P 210879-83-7P
210879-84-8P 210879-87-1P 210879-88-2P
210879-91-7P 210879-94-0P 210879-96-2P
210879-99-5P 210880-04-9P 210880-05-0P
210880-07-2P 210880-09-4P 210880-11-8P
210880-13-0P 210880-14-1P 210880-15-2P
210880-16-3P 210880-18-5P 210880-20-9P
210880-21-0P 210880-23-2P 210880-25-4P
210880-27-6P 210880-28-7P 210880-29-8P
210880-30-1P 210880-31-2P 210880-32-3P
210880-33-4P 210880-34-5P 210880-35-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)
RN 210879-61-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-62-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-63-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3,3-dimethyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-64-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-65-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-acetyl-2-methylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-66-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-methyl-2-oxopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-67-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-cyclohexyl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-68-8 CAPLUS


CN 3(2H)-Pyridazinone, 2-(3-cyclopentyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-69-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-cyclohexyl-2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-70-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-71-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-methyl-2-oxobutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-72-4 CAPLUS
CN 1(6H)-Pyridazinepentanoic acid, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-73-5 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, ̢,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 210879-74-6 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, ̢,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-75-7 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, ̢,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 210879-76-8 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, ̢,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester, (̢z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 210879-78-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-phenylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-79-1 CAPLUS
CN Benzoic acid, 2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 210879-81-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-(3,4,5-trimethoxyphenyl)ethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-82-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-[1,1'-biphenyl]-4-yl-2-oxoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-83-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-(3-pyridinyl)ethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-84-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-2-tricyclo[3.3.1.1.3,7]dec-1-ylethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210879-87-1 CAPLUS
CN Benzeneacetic acid, 2-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]amino]-, methyl ester, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210879-88-2 CAPLUS
CN 2-Piperidineacetic acid, 1-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210879-91-7 CAPLUS
CN Glycine, N-[2,2-dimethyl-1,3-dioxo-4-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)butyl]- (9CI) (CA INDEX NAME)


RN 210880-04-9 CAPIUS

CN Benzoic acid, 4-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-05-0 CAPIUS

CN 1(6H)-Pyridazineacetamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)





RN 210880-07-2 CAPIUS

CN 1(6H)-Pyridazineacetamide, N-ethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-09-4 CAPIUS


CN 1(6H)-Pyridazineacetamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210879-94-0 CAPIUS

CN Benzeneacetic acid, α-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 210879-96-2 CAPIUS


CN 2-Piperidineacetic acid, 1-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 210879-99-5 CAPIUS

CN Benzoic acid, 2-[[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-11-8 CAPLUS
CN 3-Pyrrolidinol, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 210880-13-0 CAPLUS
CN 1(6H)-Pyridazinebutanamide, N,N,α,α-tetramethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-14-1 CAPLUS
CN 1(6H)-Pyridazinepentanamide, γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-15-2 CAPLUS
CN 1(6H)-Pyridazinepentanamide, N-methyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-16-3 CAPLUS
CN 1(6H)-Pyridazinepentanamide, N,N-dimethyl-γ,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-18-5 CAPLUS
CN Piperidine, 1-[[1,4-dioxo-5-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]pentyl]- (9CI) (CA INDEX NAME)




RN 210880-20-9 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1-methylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-21-0 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-(1,1-dimethylethyl)-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-23-2 CAPLUS
CN 1(6H)-Pyridazineacetamide, N-ethyl-N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-25-4 CAPLUS
CN 1(6H)-Pyridazineacetamide, N,N-diethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-27-6 CAPLUS
CN Pyridoline, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-28-7 CAPLUS
CN Piperidine, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-29-8 CAPLUS
CN Morpholine, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-30-1 CAPLUS
CN Piperazine, 1-methyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-31-2 CAPLUS
CN 3-Azetidinol, 1-[[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-32-3 CAPLUS
CN 3-Azetidinol, 1-[[1,4-dioxo-5-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 210880-33-4 CAPLUS
CN 1-(6H)-Pyridazinebutanamide, N,N-dimethyl-β,6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 210880-34-5 CAPLUS
CN Piperidine, 1-[[1,3-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]butyl]- (9CI) (CA INDEX NAME)




RN 210880-35-6 CAPLUS
CN 3-Pyrrolidinone, 1-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]acetyl]- (9CI) (CA INDEX NAME)




IT 131185-06-3 131185-08-5 210880-36-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyridines as adenosine antagonists for pharmaceuticals)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-08-5 CAPLUS
CN 1-(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 210880-36-7 CAPLUS
CN 1-(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 67 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 1998:219808 CAPLUS
 128:230381
 TITLE: Preparation of pyrazolopyridazine derivatives
 as phosphodiesterase inhibitors

INVENTOR(S): Kouno, Yasushi; Ogata, Takenobu; Awano, Katsuya;

PATENT ASSIGNEE(S): Matsuzawa, Kayoko; Tooru, Taro
 Kyorin Pharmaceutical Co., Ltd., Japan
 PCT Int. Appl., 39 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814448	A1	19980409	WO 1997-JP3434	19970926
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RN:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2267103	A1	19980409	CA 1997-2267103	19970926
CA 2267103	C	20060530		
AU 9743213	A	19980424	AU 1997-43213	19970926
AU 733316	B2	20010510		
CN 1232463	A	19991020	CN 1997-198468	19970926
CN 1083841	B	20020501		
HU 9903018	A2	20000328	HU 1999-3018	19970926
EP 989129	A1	20000329	EP 1997-941255	19970926
EP 989129	B1	20021211		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
AT 229527	T	20021215	AT 1997-941255	19970926
ES 2187814	T3	20030616	ES 1997-941255	19970926
TW 494100	B	20020711	TW 1997-8611443	19971003
KR 200004874	A	20000725	KR 1999-702894	19950402
US 6265577	B1	20010724	US 1999-269734	19950405
			JP 1996-283148	19961004
			WO 1997-JP3434	W 19970926

PRIORITY APPL. INFO.: MARPAT 128:230381

OTHER SOURCE(S): GI



I




II

AB Novel pyrazolopyridazine deriva. (I: R1 = Cl-4 alkyl or C3-6 cycloalkyl; R2-R5 = H, Cl-4 alkyl, Ph, or alternatively R3 and R5 may be united to form a double bond) are prepared I possess phosphodiesterase inhibiting activity and have a selective potent bronchodilating effect on the respiratory tract. Thus, compound (II; preparation given) was refluxed with NH2NH2.H2O in EtOH to give I (R1 = R2 = Me, R3-R5 = H). One of I was tested and showed bronchodilating effect on the respiratory tract.

IT 204504-56-3P
 RN: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolopyridazine derivs. as phosphodiesterase inhibitors)

RN 204504-56-3 CAPLUS
 CN 3(2H)-Pyridazine, 6-(2-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 68 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 1998:87731 CAPLUS
 128:154090

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE: Preparation of pyrazolopyridine compounds as adenosine

antagonists

INVENTOR(S): Akanane, Akiyoshi; Kuroda, Satoru; Itani, Hiromichi;

Shimizu, Yasuyo

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 92 pp.

CODEN: FIXXD2

Patent


English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9803507	A1	19980129	WO 1997-JP2493	19970717
W: AU, CA, CN, HU, IL, JP, KR, NO, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2260990	A1	19980129	CA 1997-2260990	19970717
AU 9734621	A	19980210	AU 1997-34621	19970717
AU 733034	B2	20010503		
EP 925299	A1	19980630	EP 1997-930832	19970717
EP 925299	B1	20020925		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1230186	A	19980929	CN 1997-197819	19970717
HU 9903527	A2	20000328	HU 1999-3527	19970717
JP 2000514821	T	20001107	JP 1998-506791	19970717
AT 224893	T	20021015	AT 1997-930832	19970717
ES 2179352	T3	20030116	ES 1997-930832	19970717
US 6124456	A	20000926	US 1999-147543	19980119
PRIORITY APPLN. INFO.:			AU 1996-1110	A 19960718
			WO 1997-JP2493	W 19970717
OTHER SOURCE(S):				
GI				


MARPAT 128:154090




AB The title compds. [I; R1 = aryl; R2 = lower alkyl (un)substituted with unsatd. 3 to 8-membered heteromonocyclic group, etc.] are prepared I are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular disease, Parkinson's disease, etc.), anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine (preparation given) was reacted with 4-chloro-1-methyl-piperidine.HCl in the presence of NaH to give I (R1 = Ph, R2 = Me), which was tested and showed adenosine antagonistic activity.

IT 202646-79-5P 202646-80-8P 202646-82-0P
202646-84-2P 202646-85-3P 202646-87-5P
202646-89-7P 202646-90-0P 202646-91-1P
202646-92-2P 202646-93-3P 202646-94-4P
202646-95-5P 202646-96-6P 202646-97-7P
202646-98-8P 202646-99-9P 202647-00-5P
202647-01-6P 202647-02-7P 202647-03-8P
202647-04-9P 202647-05-0P 202647-06-1P


202647-07-2P 202647-08-3P 202647-09-4P
202647-10-7P 202647-11-8P 202647-12-9P
202647-13-0P 202647-14-1P 202647-15-2P
202647-23-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[preparation of pyrazolopyridine compds. as adenosine antagonists]
RN 202646-79-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 202646-80-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-82-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride. (9CI) (CA INDEX NAME)




● HCl

RN 202646-84-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN	202646-85-3	CAPLUS
CN	3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyrrolidinyl)-, monohydrochloride, (S)-(9CI) (CA INDEX NAME)	

Absolute stereochemistry.



● HCl


URN	202646-87-5	CAPLUS
CN	3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)-, monohydrochloride (9CI)	(CA INDEX NAME)




● HCl

URN	202646-89-7	CAPLUS
CN	3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-pyrrolidinyl)-, (S)- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.




RN	202646-90-0	CAPLUS
CN	3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (9CI)	6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-piperidinyl)- (CA INDEX NAME)




RN	202646-91-1	CAPLUS
CN	3(2H)-Pyridazinone, 2-(1-ethyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5- alpyridin-3-yl])- (9CI)	(CA INDEX NAME)




BRN	202646-92-2	CAPLUS
CN	3(2H)-Pyridazinone, piperidinyl- (9CI)	6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1-propyl-4-
		(CA INDEX NAME)




URN	202646-93-3	CAPLUS
CN	3(2H)-Pyridazinone, 2-(1-butyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI)	(CA INDEX NAME)




ERN	202646-94-4	CAPLUS
ICN	312H)-pyridazinone, 2-(1-pentyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5- alpyridin-3-yl)- (9CI) (CA INDEX NAME)	




RN 202646-95-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-hexyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-96-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-[1-(1-methylethyl)-4-piperidinyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-97-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methyl-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202646-98-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-(phenylmethyl)-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 202646-99-9 CAPLUS
CN Piperidine, 1-acetyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 202647-00-5 CAPLUS
CN Piperidinium, 1,1-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, iodide (9CI) (CA INDEX NAME)




RN 202647-01-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202647-02-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-azabicyclo[2.2.2]oct-3-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-03-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-3-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-04-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-2-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-05-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(1-methyl-2-piperidinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-06-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(2-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 202647-07-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-4-piperidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-08-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-(1-methyl-4-piperidinyl)ethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 202647-09-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 202647-10-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 202647-11-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(2-pyrrolidinylmethyl)-, (S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202647-12-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-hydroxy-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 202647-13-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[[4-hydroxy-4-piperidinyl]methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-14-1 CAPLUS
CN 4-Piperidinol, 1-acetyl-4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 202647-15-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-methyl-4-thiazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 202647-23-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(1-methyl-2-pyrrolidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.



IT 141060-69-7
RL: RCT (Reactant); RACT (Reactant or reagent)
RL: [preparation of pyrazolopyridine compds. as adenosine antagonists]
RN 141060-69-7 CAPLUS
CN 1(6H)-Pyridazineacetonitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 202647-16-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
RL: [preparation of pyrazolopyridine compds. as adenosine antagonists]
RN 202647-16-3 CAPLUS
CN 1(6H)-Pyridazineethanethioamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 69 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:16460 CAPLUS
 DOCUMENT NUMBER: 128:24224
 TITLE: Efficient large-scale synthesis of 4-phenyl-3-butyn-2-one, a key intermediate for a novel potent adenosine antagonist
 AUTHOR(S): Zanka, Atsuhiko
 CORPORATE SOURCE: Technological Development Laboratories, Fujisawa Pharmaceutical Co. Ltd., Osaka, 532, Japan
 SOURCE: Organic Process Research & Development (1998), 2(1), 60-62
 CODEN: OPDPK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Phenylacetylenic bromide Grignard reagent reacts with acetic anhydride under mild conditions to give 4-phenyl-3-butyn-2-one in high yield. This method was applicable to a large-scale synthesis, and optimized reaction conditions have been investigated.
 IT 131185-37-0P, FK 838
 RL: IMF (Industrial manufacture); PREP (Preparation)
 (large-scale synthesis of phenylbutynone intermediate for)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 70 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:751670 CAPLUS
 DOCUMENT NUMBER: 128:97575
 TITLE: Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists
 AUTHOR(S): Maemoto, Takuya; Finlayson, Keith; Olverman, Henry J.; Akahane, Atsushi; Horton, Roger W.; Butcher, Steven P.; Fujisawa Institute of Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ, UK
 CORPORATE SOURCE: British Journal of Pharmacology (1997), 122(6), 1202-1208
 SOURCE: CODEN: BJPCBM; ISSN: 0007-1188
 PUBLISHER: Stockton Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The pharmacol. profile of adenosine A1 receptors in human, guinea-pig, rat and mouse brain membranes was characterized in a radioligand binding assay by use of the receptor selective antagonist, [3H]-8-cyclopentyl-1,3-dipropylxanthine ([3H]-DPCPX). The affinity of [3H]-DPCPX binding sites in rat cortical and hippocampal membranes was similar. Binding site affinity was higher in rat cortical membranes than in membranes prepared from guinea-pig cortex and hippocampus, mouse cortex and human cortex.

PKD values (M) were 9.55, 9.44, 8.85, 8.94, 8.67, 9.39 and 8.67, resp. The binding site d. (Bmax) was lower in rat cortical membranes than in guinea-pig or human cortical membranes. The rank order of potency of seven adenosine receptor agonists was identical in each species. With the exception of 5'-N-ethylcarboxamidoadenosine (NECA), agonist affinity was 3.5-26.2 fold higher in rat cortical membranes than in human and guinea-pig brain membranes; affinity in rat and mouse brain membranes was similar. While NECA exhibited 9.3 fold higher affinity in rat compared to human cortical membranes, affinity in other species was comparable. The stable GTP analog, Gpp(NH)p (100 μM) reduced 2-chloro-N6-cyclopentyladenosine (CPA) affinity 7-13.9 fold, whereas the affinity of DPCPX was unaffected. The affinity of six xanthine-based adenosine receptor antagonists was 2.2-15.9 fold higher in rat cortical membranes compared with human or guinea-pig membranes. The rank order of potency was species-independent. In contrast, three pyrazolopyridine derivs., (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-piperidine ethanol (FK453), (R)-1-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-piperidin-2-yl acetic acid (FK352) and 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinebutyric acid (FK838) exhibited similar affinity in human, guinea-pig, rat and mouse brain membranes. PKI values (M) for [3H]-DPCPX binding sites in human cortical membranes were 9.31, 7.52 and 7.92, resp. Drug affinity for adenosine A2A receptors was determined in a [3H]-2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine([3H]-CGS 21680) binding assay in rat striatal membranes. The pyrazolopyridine derivs., FK453, FK838 and FK352 exhibited pKi values (M) of 5.90, 5.92 and 4.31, resp., compared with pKi values of 9.31, 8.18 and 7.57 determined in the [3H]-DPCPX binding assay in rat cortical membranes. These novel pyrazolopyridine derivs. therefore represent high affinity, adenosine A1 receptor selective drugs that, in contrast to xanthine based antagonists, exhibit similar affinity for [3H]-DPCPX binding sites in human, rat, mouse and guinea-pig brain membranes.
 IT 131185-37-0, FK838
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (species differences in human and laboratory animal brain adenosine A1 receptor pharmacol. revealed by use of xanthine and pyrazolopyridine based antagonists)
 RN 131185-37-0 CAPLUS
 CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)





REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 71 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:717919 CAPLUS
 DOCUMENT NUMBER: 128:10318
 TITLE: Preventives and remedies for ischemic intestinal lesion and ileus
 INVENTOR(S): Kadowaki, Makoto; Tomoi, Masaaki
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Kadowaki, Makoto; Tomoi, Masaaki
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740047	A1	19971030	WO 1997-JP1417	19970424
W: AU, CA, CN, JP, KR, US				
RA: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9724056	A	19971112	AU 1997-24056	19970424
EP 900796	A1	19990310	EP 1997-919667	19970424
EP 900796	B1	20041215		
R: CH, DE, ES, FR, GB, IT, LI				
US 6214843	B1	20010410	US 1999-147169	19990127
PRIORITY APPLN. INFO.:			JP 1996-105020	A 19960425
			WO 1997-JP1417	W 19970424
OTHER SOURCE(S):		MARPAT 128:10318		




I

II


AB Preventives and/or remedies for ischemic intestinal lesions and/or ileus which contain as the active ingredient pyrazolo[1,5-a]pyridine compounds. Represented by general formula (I) or salts thereof wherein R1 represents lower alkyl, etc.; R2 represents a group represented by general formula (II), etc. (wherein R4 represents protected amino, etc.; and R5 represents hydrogen, etc.); and R3 represents hydrogen, etc. The effects of I on intestinal transport and contractility were tested in rat models.

IT 131185-37-0 171050-45-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




LS ANSWER 72 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:58055 CAPLUS
DOCUMENT NUMBER: 127:262667

TITLE: Preparation of pyrazolo[1,5-a]pyridine derivatives as adenosine antagonists and their pharmaceutical uses
INVENTOR(S): Kuroda, Satoshi; Itani, Hiromichi; Akabane, Atsushi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JXXXXF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09216883	A	19970819	JP 1996-24146	19960209
PRIORITY APPLN. INFO.:			JP 1996-24146	19960209
OTHER SOURCE(S):		MARPAT 127:262667		




AB The deriva. I [R1 = aryl; R2 = oxodihydropyridazinyl Q [R3 = H, lower alkyl, acyl-lower alkyl, acyl-lower alkanoyl-lower alkyl, (un)substituted heterocyclyl, (un)substituted lower alkyl; R4 = H, acyl, cyano, heterocyclyl, lower hydroxyalkyl, (unprotected) amino; R5 = H, lower alkyl; R4 and/or R5 = substituent], pyridazinyl Q1 [R6 = halo, lower alkoxy, (un)substituted arylamino; R7 = acyl, lower hydroxyalkyl] or their pharmaceutically acceptable salts are claimed. Also claimed are pharmaceuticals containing I or their salts and carriers. I show cognition-enhancing, analgesic, antidepressant, vasodilating, diuretic, cardiotonic, renal circulation-increasing, lipolysis-promoting, antiasthmatic, insulin secretion-promoting, platelet aggregation-inhibiting effects, etc., and are especially useful as cardiac infarction inhibitors, antihypertensives, renal failure inhibitors, and diuretics. 3-Propionyl-2-phenylpyrazolo[1,5-a]pyridine (0.50 g), prepared by acylation of 2-phenylpyrazolo[1,5-a]pyridine with (EtCO)2O, was successively treated with CO(CO2Et)2 at 100° for 65 h then with H2NNH2.H2O at 125° for 8 h to give 0.42 g 3-(4-(2-isopropylidenehydrazino)carbonyl-1-methyl-3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine.

IT 195826-94-9P 195826-95-0P 195826-96-1P
195826-97-2P 195826-98-3P 195826-99-4P


195827-00-0P 195827-01-1P 195827-02-2P
 195827-03-3P 195827-04-4P 195827-05-5P
 195827-07-7P 195827-08-8P 195827-09-9P
 195827-10-2P 195827-12-4P 195827-13-5P
 195827-14-6P 195827-15-7P 195827-16-8P
 195827-17-9P 195827-18-0P 195827-19-1P
 195827-20-4P 195827-21-5P 195827-22-6P
 195827-23-7P 195827-24-8P 195827-25-9P
 195827-26-0P 195827-27-1P 195827-28-2P
 195827-29-3P 195827-30-6P 195827-31-7P
 195827-32-8P 195827-33-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of pyrazolo[1,5-a]pyridine derivs. as adenosine antagonists and their pharmaceutical uses)


RN 195826-94-9 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-5-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)




RN 195826-95-0 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-5-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195826-96-1 CAPLUS
 CN 3(2H)-Pyridazinone, 5-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195826-97-2 CAPLUS
 CN 3(2H)-Pyridazinone, 5-methyl-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195826-98-3 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, hydrazide (9CI) (CA INDEX NAME)




RN 195826-99-4 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-00-0 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 195827-01-1 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195827-02-2 CAPLUS
CN Glycine, N-[(2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-03-3 CAPLUS
CN Glycine, N-[(2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl)- (9CI) (CA INDEX NAME)




RN 195827-04-4 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-05-5 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-07-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 195827-08-8 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-09-9 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-10-2 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-2-(2-oxopropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-12-4 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-13-5 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2-(3,3-dimethyl-2-oxobutyl)-2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-14-6 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-15-7 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-methyl-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-16-8 CAPLUS


CN 1(6H)-Pyridazinepentanoic acid, 5-(ethoxycarbonyl)-γ, 6-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-17-9 CAPLUS
CN 1(16H) 3'-Bipyridazine]-5-carboxylic acid, 1', 4', 5', 6'-tetrahydro-6, 6'-dioxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)




RN 195827-18-0 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-[(4-methoxyphenyl)methyl]-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-19-1 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-2-[(4-methoxyphenyl)methyl]-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-20-4 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-chloro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 195827-21-5 CAPLUS
CN 4-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-[(3,4,5-trimethoxyphenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-22-6 CAPLUS
CN 4-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 195827-23-7 CAPLUS


CN 4-Pyridazinecarboxylic acid, 3-ethoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 195827-24-8 CAPLUS
CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-25-9 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-chloro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-26-0 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 195827-27-1 CAPLUS
CN 4-Pyridazinecarboxylic acid, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-28-2 CAPLUS
CN 4-Pyridazinemethanol, 3-methoxy-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-29-3 CAPLUS
CN 3(2H)-Pyridazinone, 4-(hydroxymethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-30-6 CAPLUS
CN 3(2H)-Pyridazinone, 4-(hydroxymethyl)-2-[(3-methoxyphenyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

1997:262220 CAPLUS
126:272373


Pyrazolopyridine derivatives for prevention and treatment of constipation and allergic intestinal diseases

INVENTOR(S): Takeda, Masahiro; Ishe, Masayuki; Kadowaki, Makoto;
PATENT ASSIGNEE(S): Horiiai, Haruo; Tomoi, Masaaki
SOURCE: Fujisawa Pharmaceutical Co, Japan
Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JXXXXF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09059157	A	19970304	JP 1995-208815	19950816
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			JP 1995-208815	19950816
GI			MARKPAT 126:272373	



I

AB Pyrazolopyridine derivs. (I: R1 = allyl, heterocyclic; R2 = protected amino, amido-carboxyl, cyano, -C(R5) =NR4, -R-R6, unsatd. heterocyclic; R3 = H, halogen, low alkyl, low alkoxy; R4 = protected amino, OH; R5 = H, low alkyl; R6 = amino; A = low fatty carboxylate) are claimed for prevention and treatment of constipation and allergic intestinal diseases. I can be formulated into oral and parenteral dosage forms. I (3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine) given orally promoted defecation in normal and constipated mice.



IT

131185-37-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pyrazolopyridine derivs. for prevention and treatment of constipation and allergic intestinal diseases)

RN 131185-37-0 CAPLUS


CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-31-7 CAPLUS
CN 3(2H)-Pyridazinone, 4-(2-hydroxyethyl)-2-[(3-hydroxyphenyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 195827-32-8 CAPLUS
CN Carbanic acid, [2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 195827-33-9 CAPLUS
CN 3(2H)-Pyridazinone, 4-amino-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 73 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

L5 ANSWER 74 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

1996-521818 CAPLUS

Effects of selective adenosine A1 receptor antagonist on glomerular microcirculation and tubuloglomerular feedback

AUTHOR(S):
CORPORATE SOURCE:
SOURCE:

Han, Wen-Hua
Department of Internal Medicine (II), Kanazawa University, Kanazawa, 920, Japan
Kanazawa Daigaku Juzen Igakkai Zasshi (1996), 105(2), 239-248
CODEN: JUZIAG; ISSN: 0022-7226
Juzen Igakkai
Japanese

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:


AB Renal clearance and micropuncture studies were carried out in anesthetized Sprague-Dawley rats to examine the effects of a selective adenosine A1 receptor antagonist, FK 838 on the glomerular microcirculation and tubuloglomerular feedback (TGF) mechanism. A low dose (1 µg/min/kg) and a high dose (10 µg/min/kg) infusion of FK 838 increased urine volume by 2.2 and 3.8 times and fractional excretion of sodium by 25 and 59 times, resp. While the mean blood pressure and renal plasma flow remained unaltered. The glomerular filtration rate showed a transient minimal increase during the high dose infusion. TGF responsiveness was estimated by measuring changes in the early proximal flow rate (EPFR) when the loop of Henle was perfused orthogradely with Ringer's solution at 40 nL/min. Loop perfusion decreased EPFR by 46.8% from 31.5 to 17.1 nL/min/g kidney weight. The reduction of EPFR in response to loop perfusion was 31.9% at the low and 9.8% at the high dose of FK 838 infusion, showing a suppression of TGF response. To determine the proximal tubule transport of FK 838, probenecid (100 mg/kg + 30 mg/h/kg) was administered i.v. before infusing the high dose of FK 838. The plasma concentration of FK 838 was increased by 2.8-apprx.3.4-fold and natriuresis was enhanced by probenecid, although its urinary excretion was unaltered. EPFR reduction was 6.1% after probenecid and comparable with the high dose of FK 838 alone. The effect of FK 838 from the tubular lumen was also studied by perfusing FK 838 (10-7, 10-6, and 10-5 M) in Ringer's solution into the loop at 40 nL/min. TGF-mediated reduction of EPFR was decreased to 34.8, 21.8 and 6.8%, resp. in a dose dependent manner. In conclusion, FK 838 induces marked natriuresis and diuresis through the direct tubular effect. Intravascular and intratubular FK 838, after gaining access to the juxtaglomerular apparatus, blocks the sensing mechanism of macula densa cells and antagonizes afferent arteriolar vasoconstriction induced by endogenous adenosine, and thus inhibits TGF. This study demonstrates a crucial role of A1 receptor activation by endogenous adenosine in the control of glomerular microcirculation and tubular sodium handling.

IT 131185-37-0, FK 838

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(adenosine A1 receptor antagonist effect on glomerular microcirculation and tubuloglomerular feedback in rats)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 75 OF 88
ACCESSION NUMBER:
DOCUMENT NUMBER:
TITLE:

1996:440609 CAPLUS
125:88637

Preparation of novel pyrazolopyridine derivatives as adenosine antagonists

INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:

Shiokawa, Yoichi; Akaha, Atsushi; Katayama, Hirohito; Mitsuura, Takafumi
Fujisawa Pharmaceutical Co, Japan
Jpn Kokai Tokkyo Koho, 9 pp.
CODEN: JFXXAF
Patent

DOCUMENT TYPE:

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.:

KIND

DATE

APPLICATION NO.:

DATE

JP 0809976

A

19960416

JP 1994-237543

19940930

PRIORITY APPLN. INFO.:


JP 1994-237543

19940930

OTHER SOURCE(S):

WARPAT 125:86637

GI



AB Pyrazolopyridine compds. I [R1 = aryl; R2 = acylalkyl, N-monoalkylcarbamoylalkyl, substituted aralkyl] and their pharmaceutically acceptable salts as adenosine antagonists are prepared. Thus, 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine was treated with NaH, then reacted with Et 8-bromooctanoate to give 3-[2-(7-ethoxycarbonylheptyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine (III). II was then hydrolyzed to give 3-[2-(7-carboxiheptyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine, 10-8 M solution of which showed 96.7% adenosine antagonism in guinea pig.

IT 131185-08-5P 178878-89-2P 178878-90-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)


(intermediate for adenosine antagonistic dihydropyridazinylpyrazolopyridine derivs.)

RN 131185-08-5 CAPLUS


CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 178878-89-2 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 178878-90-5 CAPLUS
CN Benzonitrile, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 178878-91-6 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 131185-06-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of adenosine antagonistic dihydropyridazinylpyrazolopyridine derivs.)
RN 131185-06-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 178878-84-7P 178878-85-8P 178878-86-9P
178878-87-0P 178878-88-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyridine derivs. as adenosine antagonist)
RN 178878-84-7 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 178878-85-8 CAPLUS
CN Benzamide, 4-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 178878-86-9 CAPLUS
CN 1(6H)-Pyridazineoctanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 178878-87-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-phenylpropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of adenosine subtype-1 receptor antagonist (FK-838) on salt-induced hypertension in Dahl salt-sensitive rats in relation to diuretic activity and kidney protection and effect on renin-angiotensin system)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 77 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:54563 CAPLUS

DOCUMENT NUMBER: 124:164769

TITLE: A new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats

AUTHOR(S):

Uehara, Yoshio; Numabe, Atsushi; Hirawa, Nobuhito; Kawabata, Yukari; Nagoshi, Hiroshi; Kaneko, Hiroshi; Gomi, Tomoko; Goto, Atsuo; Toyooka, Teruhiko; Omata, Masao

CORPORATE SOURCE: Dep. Medicine, Univ. Tokyo, Tokyo, Japan

SOURCE: American Journal of Hypertension (1995), 8(12, Pt. 1), 1189-99

CODEN: AJHVE6; ISSN: 0895-7061

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors investigated the effects of the adenosine type-1 receptor antagonist FK-838 on salt-induced hypertension in Dahl-Sea salt-sensitive (Dahl S) rats. Dahl S rats fed a high-salt (4% NaCl) diet for 4 wk were treated with FK-838 or hydrochlorothiazide for 4 wk and alterations in kidney function and morphol. changes were assessed. FK-838 attenuated the development of hypertension in Dahl S rats, and caused a decrease in aortic weight in a dose-dependent fashion. The adenosine antagonist did not produce any detectable metabolic disturbance. The blood pressure reduction by FK-838 was associated with attenuation of glomerular and arterial injury in the kidney. The renal protective effect of FK-838 treatment was associated with a reduction of plasma renin activity and plasma aldosterone concentration

In

contrast, the thiazide diuretic, which produced almost the same blood pressure reduction as FK-838, did not attenuate renal damage. These data indicate that adenosine A1 receptor antagonist reduces salt-induced hypertension and the consequent renal injuries.

IT 131185-37-0, FK 838

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(a new adenosine subtype-1 receptor antagonist, FK-838, attenuates salt-induced hypertension in Dahl salt-sensitive rats)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

RN 178878-88-1 CAPLUS

CN 1(6H)-Pyridazinepropanamide, N-methyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 76 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:227703 CAPLUS

DOCUMENT NUMBER: 124:306972

TITLE: The effects of adenosine subtype-1 receptor antagonist (FK-838) on salt-induced hypertension in Dahl salt-sensitive rats

AUTHOR(S):

Kaneko, Hiroshi; Numabe, Atsushi; Doumoto, Maho; Uehara, Yoshio; Yagi, Shigeru

CORPORATE SOURCE: Sch. Med., Dokkyo Univ., Japan

SOURCE: Dokkyo Igakki Zasshi (1995), 10(2), 235-44

CODEN: DIZAE6; ISSN: 0911-5900

PUBLISHER: Dokkyo Igakki


DOCUMENT TYPE: Journal

LANGUAGE: Japanese

AB The authors investigated the effects of an adenosine type-1 (A1) receptor antagonist (FK-838) on salt-induced hypertension in Dahl-Sea salt-sensitive (Dahl S) rats. Alterations in kidney function and morphol. changes were assessed in Dahl S rats treated for 4-wk with FK-838 (1.0 mg/kg, 10.6 mg/kg) or hydrochlorothiazide (HCTZ, 9.7 mg/kg), a thiazide diuretic. All prolonged treatments decreased systolic blood pressure in Dahl S rats fed a high-salt (2% NaCl) diet. There was a trend toward increased urinary excretion and fractional excretion of sodium with FK-838 treatment. The blood pressure reduction by FK-838 was associated with the partial resolution of glomerular and arterial injury in the kidney. The renal protective effect of FK-838 treatment was associated with the reduction of plasma renin activity and plasma aldosterone concentration. In contrast, HCTZ which produced almost the same blood pressure reduction as FK-838, did not attenuate renal damage. These data indicate that A1 receptor antagonist ameliorates salt-induced hypertension and the consequent renal injury. The protective effects of FK-838 may be mediated in part by a decrease in the activity of the renin-angiotensin system.

of

IT 131185-37-0, FK-838




L5 ANSWER 78 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:960198 CAPLUS
 DOCUMENT NUMBER: 124:8834
 TITLE: Preparation of (oxopyridazinyl)pyrazolopyridines as

adenosine antagonists
 Inventor(s): Akahane, Atsushi; Nishimura, Shintaro; Itani,
 Hiromichi; Durkin, Kieran P. M.
 Patent Assignee(s): Fujisawa Pharmaceutical Co., Ltd., Japan
 Source: PCI Int. Appl., 167 pp.
 CODEN: PIXXD2

Document Type: Patent
 Language: English
 Family Acc. Num. Count: 1
 Patent Information:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518128	A1	19950706	WO 1994-JP2230	19941226
W: AU, CA, CN, FI, HU, JP, KR, NO, RU, US				
CA 2180253	A1	19950706	GB, IE, IT, LU, MC, NL, PT, SE	19941226
AU 9512817	A	19950717	CA 1994-2180253	19941226
AU 694157	B2	19980716	AU 1995-12817	19941226
EP 737193	A1	19961016	EP 1995-903969	19941226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1139928	A	19970108	CN 1994-194724	19941226
CN 1046724	B	19951124		
HU 76280	A2	19970728	HU 1996-1789	19941226
JP 09507485	T	19970729	JP 1995-517911	19941226
JP 3572617	B2	20041006		
ZA 9410409	A	19950926	ZA 1994-10409	19941229
IL 112193	A	20001031	IL 1994-112193	19941229
BR 9500905	A	19951024	BR 1995-905	19950306
IN 1995M00292	A	20050225	IN 1995-M0292	19950310
US 5773530	A	19980630	US 1996-663119	19960913
US 635640	B1	20020312	US 1998-72696	19980506
PRIORITY APPLN. INFO.:			GB 1993-26524	A 19940304
			GB 1994-4323	W 19941226
			WO 1994-JP2230	A1 19960913
OTHER SOURCE(S):			US 1996-663119	
GI			MAPPAT 124:8834	




AB Title compds. [I; R1 = aryl; R2 = (un)substituted cycloalkyl] were prepared
 Thus, I (R1 = Ph, R2 = H) was alkylated by 2-chlorocyclohexanone and the
 product condensed with (EtO)2P(O)CH2CO2Et to give, after saponification, title
 compound II and the exo-unsatd. Product. II gave reduction of serum creatinine
 from 3.60 (control) to 1.10mg/dL i.v. in rats experiencing
 cisplatin-induced renal failure.

IT 171050-39-8P 171050-40-1P 171050-41-2P
 171050-42-3P 171050-43-4P 171050-44-5P
 171050-45-6P 171050-46-7P 171050-47-8P
 171050-48-9P 171050-49-0P 171050-50-3P
 171050-51-4P 171050-52-5P 171050-53-6P
 171050-54-7P 171050-55-8P 171050-56-9P
 171050-57-0P 171050-58-1P 171050-59-2P
 171050-60-5P 171050-61-6P 171050-62-7P
 171050-63-8P 171050-64-9P 171050-65-0P
 171050-66-1P 171050-67-2P 171050-68-3P
 171050-69-4P 171050-70-7P 171050-71-8P
 171050-72-9P 171050-73-0P 171050-74-1P
 171050-75-2P 171050-76-3P 171050-77-4P
 171050-78-5P 171050-79-6P 171050-80-9P
 171050-81-0P 171050-82-1P 171050-83-2P
 171050-84-3P 171050-85-4P 171050-86-5P
 171050-87-6P 171050-88-7P 171050-89-8P
 171050-90-1P 171050-91-2P 171050-92-3P
 171050-93-4P 171050-94-5P 171050-95-6P
 171050-96-7P 171050-97-8P 171050-98-9P
 171050-99-0P 171051-00-6P 171051-01-7P
 171051-02-8P 171051-03-9P 171051-04-0P
 171051-05-1P 171051-06-2P 171051-07-3P
 171051-08-4P 171051-09-5P 171051-10-8P
 171051-11-9P 171051-12-0P 171051-13-1P
 171051-14-2P 171051-15-3P 171051-16-4P
 171051-17-5P 171051-18-6P 171051-19-7P
 171051-20-0P 171051-21-1P 171051-22-2P
 171051-23-3P 171051-24-4P 171051-25-5P
 171051-26-6P 171051-27-7P 171051-28-8P
 171051-29-9P 171051-30-2P 171051-31-3P
 171051-32-4P 171051-33-5P 171051-34-6P
 171051-35-7P 171051-36-8P 171051-37-9P
 171051-38-0P 171051-39-1P 171051-40-4P
 171051-41-5P 171051-42-6P 171051-43-7P
 171051-44-8P 171051-45-9P 171051-46-0P
 171051-47-1P 171051-48-2P 171051-49-3P
 171051-50-6P 171051-51-7P 171051-52-8P
 171051-53-9P 171051-54-0P 171051-55-1P
 171051-56-2P 171051-57-3P 171051-58-4P
 171051-59-5P 171051-60-8P 171051-61-9P
 171051-62-0P 171051-63-1P
 RU: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study): PREP (Preparation): USES (Uses)

(Preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)


RN 171050-39-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-cyclohexyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)



RN 171050-40-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-41-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocyclopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-42-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-43-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-((1R,2R)-2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171050-44-5 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171050-45-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-46-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-hydroxy-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, [1S-(1α,3β,4α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171050-47-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-48-9 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-49-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxocycloheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-50-3 CAPLUS
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-51-4 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclopentylidene]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-52-5 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 171050-53-6 CAPLUS
CN 1-Cyclopentene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-54-7 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclopentylidene]- (9CI) (CA INDEX NAME)




RN 171050-55-8 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-56-9 CAPLUS
CN 1-Cycloheptene-1-acetic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-57-0 CAPLUS
CN 1-Cycloheptene-1-acetic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-58-1 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cycloheptylidene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-59-2 CAPLUS
CN 1-Cycloheptene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 171050-60-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171050-61-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1,4-dioxaspiro[4.5]dec-8-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-62-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-63-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-3-pyrrolidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-64-9 CAPLUS
CN 1,3-Cyclohexanedione, 2-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 171050-65-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2-oxo-3-furanyl)- (9CI) (CA INDEX NAME)




RN 171050-66-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-oxo-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-67-2 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)




RN 171050-68-3 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 3,4-dihydro-2,4-dioxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 171050-69-4 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 3,6-dihydro-2,6-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 171050-70-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1,2,3,4-tetrahydro-2-hydroxy-6-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 171050-71-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171050-72-9 CAPLUS
CN Cyclopentaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-73-0 CAPLUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-74-1 CAPLUS
CN Cyclohexaneacetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-75-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171050-76-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-hydroxy-2-methylcyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (1R-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 171050-77-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(octahydro-2-oxo-7-benzofuran-1-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171050-78-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171050-79-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 171050-80-9 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-


1(6H)-pyridazinyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-81-0 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, (1R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-82-1 CAPLUS
CN Cyclopentanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-83-2 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 171050-84-3 CAPLUS


CN 1-Pyrrolidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-85-4 CAPLUS
CN Glycine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-86-5 CAPLUS
CN Glycine, N-[1-oxo-4-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]butyl]- (9CI) (CA INDEX NAME)




RN 171050-87-6 CAPLUS
CN β-Alanine, N-methyl-N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-88-7 CAPLUS
CN Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 171050-89-8 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)
Relative stereochemistry.



RN 171050-90-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)
Relative stereochemistry.




RN 171050-91-2 CAPLUS
CN 1(2H)-Pyrimidineacetic acid, 3,6-dihydro-2,6-dioxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 171050-92-3 CAPLUS

CN 1 (2H)-Pyrimidineacetic acid, 3,4-dihydro-2,4-dioxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 171050-93-4 CAPLUS
CN Cyclohexanecarboxylic acid, 1-hydroxy-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 171050-94-5 CAPLUS
CN Acetic acid, [4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)



RN 171050-95-6 CAPLUS
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-96-7 CAPLUS
CN 1-Cyclohexene-1-butanolic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171050-97-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171050-98-9 CAPLUS
CN Glycine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171050-99-0 CAPLUS
CN β-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171051-00-6 CAPLUS
CN Acetic acid, [[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]amino]oxy]- (9CI) (CA INDEX NAME)




RN 171051-01-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-02-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-cyclohexylidene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-03-9 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, sodium salt (9CI) (CA INDEX NAME)




● Na


RN 171051-04-0 CAPLUS
CN Glycine, N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-05-1 CAPLUS
CN 1-Cyclohexene-1-propanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 171051-06-2 CAPLUS
CN 1-Cyclohexene-1-butanoic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 171051-07-3 CAPLUS
CN Glycine, N-methyl-N-[(2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-08-4 CAPLUS
CN 1-Cyclohexene-1-acetamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




171051-09-5	CAPLUS
1-Cyclohexene-1-butamide, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-	(9CI) (CA INDEX NAME)




171051-10-8	CAPLUS
1-Cyclohexene-1-acetamide, N,N-dimethyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5- alpyridin-3-yl)-1(6H)-pyridazinyl]- (9Ci) (CA INDEX NAME)	




IRN	INDEX NAME
171051-11-9	CAPLUS
CN	β -Alanine, N-methyl-N'-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(5H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl-, ethyl ester (9CI)




INDEX NAME	pyridazinyl-1-cyclohexen-1-yl acetyl amino]-, methyl ester (9CI) (CA
171051-12-0	CAPLUS
Butanoic acid, 4-[[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-	




RN	171051-13-1	CAPLUS	(CA INDEX NAME)
CN	1-Cyclohexene-1-acetamide, N-(2-hydroxyethyl)-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-	(9CI)	




171051-14-2 CAPLUS
β-Alanine, N-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




171051-15-3 CAPLUS
1-Cyclohexene-1-acetamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-
a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




171051-16-4	CAPLUS
1-cyclohexene-1-butamide, N-methyl-2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI)	(CA INDEX NAME)




RN 171051-17-5 CAPLUS
CN 1-Cyclohexene-1-ylbutanamide, N,N-dimethyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl-1-(6H)-pyridazinyl- (9CI) (CA INDEX NAME)




RN 171051-18-6 CAPLUS
CN Glycine, N-[(1-oxo-4-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-19-7 CAPLUS
CN Thiomorpholine, 4-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-20-0 CAPLUS
CN Piperazine, 1-methyl-4-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-21-1 CAPLUS
CN Piperazine, 1-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 171051-22-2 CAPLUS
CN Morpholine, 4-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-23-3 CAPLUS
CN Pyrrolidine, 1-[[2-[[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1-(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-24-4 CAPLUS


CN Piperidine, 1-([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl)- (9CI) (CA INDEX NAME)




RN 171051-25-5 CAPLUS
CN 4-Piperidinamine, N-methyl-1-([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl)- (9CI) (CA INDEX NAME)




RN 171051-26-6 CAPLUS
CN Hydrazinecarboxamide, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171051-27-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydrazonocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-28-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(hydroxyimino)cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-29-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(methoxyimino)cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-30-2 CAPLUS
CN Acetic acid, ([2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]amino)oxy-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-31-3 CAPLUS
CN Hydroxylamine-O-sulfonic acid, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]- (9CI) (CA INDEX NAME)




RN 171051-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methylenecyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-33-5 CAPLUS
CN Acetic acid, [4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, ethyl ester (9CI) (CA INDEX NAME)



RN 171051-34-6 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-35-7 CAPLUS
CN 1-Cyclohexene-1-acetic acid, 6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 171051-36-8 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-37-9 CAPLUS
CN Acetonitrile, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-38-0 CAPLUS
CN Acetonitrile, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 171051-39-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[(5,6-dihydro-4,4,6-trimethyl-4H-1,3-oxazin-2-yl)methylene]cyclohexyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


3-yl)- (9CI) (CA INDEX NAME)




RN 171051-44-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-45-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-oxocyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171051-46-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-hydroxycyclohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-(2-hydroxyethyl)-1-cyclohexen-1-yl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-40-4 CAPLUS
CN Acetic acid, [2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]cyclohexylidene]-, 1,1-dimethylethyl ester, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 171051-41-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-phenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-42-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-methoxyphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 171051-43-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-methoxyphenyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN	171051-48-2	CAPLUS
CN	3(2H)-Pyridazinone, 2-[2-(2-oxopropyl)-1-cyclohexen-1-yl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)	




RN	CN	NAME
171051-49-3	CAPLUS	Cyclohexanecetic acid, 1-hydroxy-2-[6-oxo-3-(2-phenylpyrazolo[1,5- alpyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester, cis- (9CI) [CA INDEX


Relative stereochemistry.




URN	171051-50-6	CAPIUS
CN	Cyclohexanecarbonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)	




RN	171051-51-7	CAPLUS
CN	Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)	




RN	171051-52-8	CAPLUS
CN	1-Cyclohexene-1-acetonitrile, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl] - (9CI) (CA INDEX NAME)	




RN	171051-53-9	CAPLUS
CN	3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-ylmethylene)cyclohexyl]- (9CI) (CA INDEX NAME)	




RN	171051-54-0	CAPLUS
CN	Piperazine, 1-acetyl-4-[[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)	




171051-55-1 CAPLUS
Piperazine, 1-[[12-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-1(6H)-pyridazinyl]-1-cyclohexen-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 171051-56-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-oxo-3-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-oxo-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 171051-58-4 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 171051-59-5 CAPLUS
CN 1-Piperidineacetic acid, 2-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-60-8 CAPLUS
CN Acetic acid, [(5,6,7,8-tetrahydro-5-oxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 171051-61-9 CAPLUS
CN Acetic acid, [(5,6,7,8-tetrahydro-5-oxo-6-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)




RN 171051-62-0 CAPLUS
CN Cyclohexanecarboxylic acid, 3-oxo-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 171051-63-1 CAPLUS
CN Cyclohexanecarboxylic acid, 4-oxo-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)

CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylethynyl)-3-pyridazinyl]-
(9CI) (CA INDEX NAME)




RN 171051-73-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-hydroxy-3-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 171051-74-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-hydroxy-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 79 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:652344 CAPLUS

DOCUMENT NUMBER: 123:55871

TITLE: Preparation of pyrazolopyridine derivatives as allergy

INVENTOR(S): inhibitors

PATENT ASSIGNEE(S): Ogata, Takenobu; Amada, Junichiro; Ohashi, Mitsuo;

SOURCE: Matsuzawa, Kayoko

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

JP 07033769 A 19950203 JP 1993-203566 19930726

PRIORITY APPLN. INFO.: JP 1993-203566 19930726




IT 171051-72-2P

RL: BVP (Byproduct); PREP (Preparation)

(preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)

RN 171051-72-2 CAPLUS

CN Cyclonexanone, 2-[(6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridazinyl)oxy]- (9CI) (CA INDEX NAME)




IT 131185-06-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)

RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 131185-57-4P 171051-64-2P 171051-73-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists).

RN 131185-57-4 CAPLUS


CN Pyrazolo[1,5-a]pyridine, 3-(6-chloro-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 171051-64-2 CAPLUS

OTHER SOURCE(S):
GI


MARPAT 123:55871




AB The title compds. I (R = H, alkyl, etc.; m = 0 - 2; n = 0 or 1) are prepared against the title compound II (preparation given) showed min. ED of 3 mg/Kg p.o. against anaphylactic airway constriction in guinea pigs.

IT 164391-26-8P 164391-27-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolopyridine derivs. as allergy inhibitors)

RN 164391-26-8 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclopropyl-3-(3,6-dihydro-2H-thiopyran-4-yl)-(9CI) (CA INDEX NAME)



RN 164391-27-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-cyclopentyl-3-(3,6-dihydro-2H-thiopyran-4-yl)-(9CI) (CA INDEX NAME)




L5 ANSWER 80 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:117558 CAPLUS
DOCUMENT NUMBER: 122:123153

TITLE: Pyrazolopyridine derivatives for prevention and treatment of Meniere's disease
INVENTOR(S): Robaato, Gelburieru Feterora
PATENT ASSIGNEE(S): Air Products and Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent


LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
JP 06192092 A 19940712 JP 1993-247703 19931004
PRIORITY APPLN. INFO.: GB 1992-20894 A 19921005
OTHER SOURCE(S): MARPAT 122:123153
AB Pyrazolopyridine derivs. such as (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(2-hydroxyethyl)piperidine are therapeutics for prevention and treatment of Meniere's disease.
IT 131185-08-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrazolopyridine derivs. for prevention and treatment of Meniere's disease)
RN 131185-08-5 CAPLUS
CN 1(6H)-Pyridazepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-(9CI) (CA INDEX NAME)



L5 ANSWER 81 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:435602 CAPLUS
DOCUMENT NUMBER: 121:35602
TITLE: Preparation of pyrazolopyridines as intermediates for pharmaceutical dihydropyridazinopyrazolopyridines
INVENTOR(S): Nakamura, Hitoshi; Kawakami, Ryoichi; Yamazaki, Hiroshi; Hashimoto, Norio; Taki, Isao
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
JP 06009631 A 19940118 JP 1993-120928 19930423
PRIORITY APPLN. INFO.: JP 1992-107289 A1 19920427
OTHER SOURCE(S): CASREACT 121:35602; MARPAT 121:35602
GI



AB Pyrazolopyridines I (R₁ = lower alkyl; R₂, R₃ = H, substituting group; X =


= anion) are prepared by treatment of R2C6H4C.tpi bond.CCOR1 (R1, R2 = same as above) with aminopyridines II (R3, X- = same as above). Treatment of 5.00 g I (R1 = Me, R2 = H) with 11.55 g II (R3 = H, X- = iodide) and K2CO3 in DMF at 33-37° for 1 h gave 6.66 g I (R1 = Me, R2 = R3 = H).

IT 131185-06-3P 131185-07-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation and reaction of)


RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-07-4 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




IT 131185-08-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of, acetylphenylpyrazolopyridine as intermediate for)

RN 131185-08-5 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 82 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1994:153722 CAPLUS

DOCUMENT NUMBER:

120:153722

TITLE:

Pyrazolopyridine compounds for the treatment of anemia

INVENTOR(S):

Kohno, Yutaka; Nagatomi, Itsuo; Hanaoka, Kaori

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 61 pp.

CODEN: PIXXD2

PATENT

DOCUMENT TYPE:

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325205	A1	19931223	WO 1993-JP762	19930607
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 644762	A1	19950329	EP 1993-913487	19930607
EP 644762	B1	19971217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08500338	T	19960116	JP 1993-501330	19930607
AT 161178	T	19980115	AT 1993-913487	19930607
JP 5265084	B2	20020325	JP 1994-501330	19930607
US 5643938	A	19970701	US 1994-338539	19941208
			GB 1992-12264	A 19920610
			GB 1992-15794	A 19920724
			WO 1993-JP762	W 19930607

OTHER SOURCE(S):

GI

MARPAT 120:153722



AB Pyrazolopyridine compds. [I; R1=lower alkyl, R2= Q (R4= protected amino, R5=H), R3=H] or salt thereof are useful for the prevention and treatment of anemia. Monkeys were injected with 1.25% saline solution and treatment with phenylhydrazine.HCl on days 1 and 3 followed by oral administration of 3.2 mg 3-[(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine/kg twice a day for 5 days. The hematocrit value and erythropoietin level on day 5 was 24 and 272.2 resp., as compared to 19% and 250.8 mIU/mL for controls.


IT 131185-37-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(Preparation of, for treatment of anemia)

RN 131185-37-0 CAPLUS

CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 83 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1992:605214 CAPLUS

DOCUMENT NUMBER:

117:205214

TITLE:

Preparation and use of adenosine antagonists for the prevention and treatment of pancreatitis and ulcer

INVENTOR(S):

Shiokawa, Youichi; Akahane, Atsushi; Katayama, Hirohito; Mitsunaga, Takafumi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 45 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 497258	A2	19920805	EP 1992-101308	19920128
EP 497258	A3	19931013		
EP 497258	B1	20020102		
	R: AT, BE, CH, DE, DK, FR, IT, LI, LU, NL, SE			
US 5155114	A	19921013	US 1991-713460	19910614
CA 2060138	A1	19920730	CA 1992-2060138	19920128
AT 211384	T	20020115	AT 1992-101308	19920128
JP 05058913	A	19930309	JP 1992-13506	19920129
PRIORITY APPL. INFO.:			US 1991-648320	A 19910129
			US 1991-715460	A 19910614
			PH 1991-42760	A 19910709
			GB 1889-1423	A 19890123
			US 1890-466929	A2 19900118
			US 1990-626009	B2 19900118

OTHER SOURCE(S): MARPAT 117:205214

AB Adenosine antagonists are disclosed for preparation of medicaments for prevention and/or treatment of pancreatitis and/or ulcers. Preparation of a large number of pyrazolopyridine derivative adenosine antagonists is included. The trans isomer of (2R)-1-[3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2-(carboxymethyl)piperidine (I) (preparation given) inhibited gastric ulcer induced by N6-cyclohexyladenosine by 99.8%. I also inhibited (as reflected by serum amylase level reduction) N6-cyclohexyladenosine-induced pancreatitis.

IT 131185-06-3P 131185-32-5P 141060-80-2P

141060-81-3P 141060-82-4P 143881-06-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation and reaction of, for adenosine antagonist preparation for ulcer and

Pancreatitis treatment)


RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS

CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-80-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 141060-81-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-(4-(acetyloxy)butyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-82-4 CAPLUS

CN 3(2H)-Pyridazinone, 2-(4-hydroxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 143881-06-5 CAPLUS


CN 3(2H)-Pyridazinone, 2-(5-bromopentyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 141060-38-0P 141060-39-1P 141060-40-4P
 141060-41-5P 141060-42-6P 141060-43-7P
 141060-44-8P 141060-45-9P 141060-46-0P
 141060-48-2P 141060-49-3P 141060-50-6P
 141060-51-7P 141060-52-8P 141060-53-9P
 141060-54-0P 141060-55-1P 141060-56-2P
 141060-57-3P 141060-58-4P 141060-59-5P
 141060-60-8P 141060-61-9P 141072-32-4P
 143881-04-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as adenosine antagonist for ulcer and pancreatitis treatment)

RN 141060-38-0 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[2-(4-morpholinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-42-6 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)


● HCl

RN 141060-39-1 CAPLUS
 CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-40-4 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[2-(dimethylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-41-5 CAPLUS
 CN 3(2H)-Pyridazinone, 2-[3-(dimethylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-42-6 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)
















RN 141060-43-7 CAPLUS


CN 1(6H)-Pyridazinepropanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 141060-44-8 CAPLUS

CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)






● HCl


RN 141060-54-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[4-(dimethylamino)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)

(CH₂)₄-NMe₂




● HCl

RN 141060-55-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-hydroxyethyl)-1-piperazinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 141060-56-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-[4-(2-methoxyphenyl)-1-piperazinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 141060-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 141060-58-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[3-(1H-tetrazol-5-yl)propyl]- (9CI) (CA INDEX NAME)




RN 141060-59-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[4-(1H-tetrazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 141060-60-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-62-0 CAPLUS
CN 1(6H)-Pyridazinehexanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-63-1 CAPLUS
CN 1(6H)-Pyridazineheptanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 141060-64-2 CAPLUS
CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-65-3 CAPLUS
CN 1(6H)-Pyridazinononanitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-66-4 CAPLUS
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-61-9 CAPLUS
CN 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 141072-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)













RN 143881-04-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2,3-dihydro-2-oxo-5-oxazolyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 141060-62-0P 141060-63-1P 141060-64-2P
141060-65-3P 141060-66-4P 141060-67-5P
141060-68-6P 141060-69-7P 141060-70-0P
141060-71-1P 141060-72-2P 141060-73-3P
141060-74-4P 141060-75-5P 141060-76-6P
141060-77-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(Preparation of, for adenosine antagonist for ulcer and pancreatitis treatment)






RN 141060-76-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[10-(1H-tetrazol-5-yl)decyl]- (9CI) (CA INDEX NAME)




RN 141060-77-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[12-(1H-tetrazol-5-yl)dodecyl]- (9CI) (CA INDEX NAME)




IT 141060-83-5P 141060-84-6P 141060-85-7P
141060-86-8P 141060-87-9P 141060-88-OP
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for adenosine antagonist preparation for ulcer and pancreatitis treatment)


RN 141060-83-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(6-bromohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-84-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(7-bromoheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-85-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(8-bromooctyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-86-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(9-bromononyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-87-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(10-bromodecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-88-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(12-bromododecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-80-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-[6-(phenylsulfonyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 141060-81-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-[4-(acetyloxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)]




RN 141060-82-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(4-hydroxybutyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-83-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(6-bromohexyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


RN 141060-84-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(7-bromoheptyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-85-7 CAPLUS
CN 3(2H)-Pyridazinone, 2-(8-bromooctyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-86-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-(9-bromononyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 141060-87-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-(10-bromodecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-88-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(12-bromododecyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 141060-38-0P 141060-39-1P 141060-40-4P
141060-41-5P 141060-42-6P 141060-43-7P
141060-44-8P 141060-45-9P 141060-46-0P
141060-47-1P 141060-48-2P 141060-49-3P
141060-50-6P 141060-51-7P 141060-52-8P
141060-53-9P 141060-54-0P 141060-55-1P
141060-56-2P 141060-57-3P 141060-58-4P
141060-59-5P 141060-60-8P 141060-61-9P
141060-62-0P 141060-63-1P 141060-64-2P
141060-65-3P 141060-66-4P 141060-67-5P
141060-68-6P 141060-69-7P 141060-70-0P
141060-71-1P 141060-72-2P 141060-73-3P
141060-74-4P 141060-75-5P 141060-76-6P
141060-77-7P 141072-32-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as adenosine antagonist)

RN 141060-38-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(4-morpholinyl)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-39-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-40-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-(dimethylamino)ethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-41-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-[3-(dimethylamino)propyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-42-6 CAPLUS
CN 1H-isoindole-1,3(2H)-dione, 2-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 141060-43-7 CAPLUS


CN 1(6H)-Pyridazinepropanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-44-8 CAPLUS
CN 1(6H)-Pyridazinebutanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-45-9 CAPLUS
CN 1(6H)-Pyridazinepentanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-46-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-(phenylmethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-47-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-oxo-5-oxazolidinyl)methyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-48-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)




RN 141060-49-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-aminoethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-50-6 CAPLUS
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 141060-51-7 CAPLUS
CN Glycine, N-[2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 141060-52-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-hydroxy-3-(1-naphthalenyloxy)propyl)amino]ethyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-53-9 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-hydroxy-3-(1-naphthalenyloxy)propyl)amino]ethyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-54-0 CAPLUS
CN 3(2H)-Pyridazinone, 2-[4-(dimethylamino)butyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 141060-55-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-[(2-hydroxyethyl)-1-piperazinylethyl]-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 141060-56-2 CAPLUS
CN 3(2H)-Pyridazinone, 2-[2-{4-(2-methoxyphenyl)-1-piperazinylethyl}-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 141060-58-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 141060-59-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[4-(1H-tetrazol-5-yl)butyl]- (9CI) (CA INDEX NAME)




RN 141060-60-8 CAPLUS
CN 3(2H)-Pyridazinone, 2-ethenyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-61-9 CAPLUS
CN 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 141060-62-0 CAPLUS
CN 1(6H)-Pyridazinehexanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-63-1 CAPLUS
CN 1(6H)-Pyridazineheptanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-64-2 CAPLUS
CN 1(6H)-Pyridazineoctanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-65-3 CAPLUS
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-66-4 CAPLUS
CN 1(6H)-Pyridazinedecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-67-5 CAPLUS
CN 1(6H)-Pyridazineundecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-68-6 CAPLUS
CN 1(6H)-Pyridazinetridecanenitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-69-7 CAPLUS
CN 1(6H)-Pyridazineacetoneitrile, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 141060-70-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 141060-71-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[5-(1H-tetrazol-5-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 141060-72-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[6-(1H-tetrazol-5-yl)hexyl]- (9CI) (CA INDEX NAME)




RN 141060-73-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[7-(1H-tetrazol-5-yl)heptyl]- (9CI) (CA INDEX NAME)




RN 141060-74-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[8-(1H-tetrazol-5-yl)octyl]- (9CI) (CA INDEX NAME)




RN 141060-75-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[9-(1H-tetrazol-5-yl)nonyl]- (9CI) (CA INDEX NAME)




RN 141060-76-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[10-(1H-tetrazol-5-yl)decyl]- (9CI) (CA INDEX NAME)



RN 141072-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-[12-(1H-tetrazol-5-yl)dodecyl]- (9CI) (CA INDEX NAME)



RN 141072-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 85 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN .

ACCESSION NUMBER: 1991-62080 CAPLUS

DOCUMENT NUMBER: 114:62080

TITLE: Preparation of 3-heterocyclyl- α -phenylpyrazolo[1,5-a]pyridines as adenosine antagonists

INVENTOR(S): Shiohara, Youichi; Akahane, Atsushi; Katayama,

Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-(4-

pyridinylmethyl)- (9CI) (CA INDEX NAME)

PATENT ASSIGNEE(S): Hirohito; Mitsunaga, Takafumi

SOURCE: Fujisawa Pharmaceutical Co., Ltd., Japan

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 379979	A1	19900801	EP 1990-101042	19900119
EP 379979	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				

ZA 9000200	A	19901031	ZA 1990-200	19900111
IL 93050	A	19950526	IL 1990-93050	19900114
US 4985444	A	19910115	US 1990-466929	19900118
FI 96205	B	19960215	FI 1990-307	19900119
FI 96205	C	19960527		
AT 150462	T	19970415	AT 1990-101042	19900119
ES 2098229	T3	19970501	ES 1990-101042	19900119
CA 2008263	A1	19900723	CA 1990-2008263	19900122
CA 2008263	C	20000314		
NO 9000306	A	19900724	NO 1990-306	19900122
NO 176356	B	19941212		
NO 176356	C	19950322		
JP 02243689	A	19900927	JP 1990-12995	19900122
JP 07094454	B	19951011		
HU 53368	A2	19901028	HU 1990-228	19900122
RU 2007403	C1	19940215	RU 1990-4742944	19900122
KR 159502	B1	19981201	KR 1990-690	19900122
AU 9048696	A	19900726	AU 1990-48696	19900123
AU 628913	B2	19920924		
NO 1044656	A	19900815	CN 1990-100900	19900123
CN 1031570	B	19960417		
CN 1031570	A	19960326	JP 1995-64422	19950323
JP 08081465	A	19960326	GB 1989-1423	19890123
PRIORITY APPL. INFO.: CASREACT 114:62080; MARPAT 114:62080				
OTHER SOURCE(S): A				
GI				



II

AB The title compds. [I; R1 = aryl; R2 = (substituted) unsatd. heterocyclyl], were prepared. Thus, 3-acetyl-2-phenylpyrazolo[1,5-a]pyridine and glyoxylic acid hydrate were stirred 205 h at 100° to give a product which was refluxed with N2H4 in aqueous NH3 to give 3-(3-oxo-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine. The latter was stirred 2 days with Br(CH2)3CO2Et and triton B in CHCl3 and the product was saponified to give title compound II. II had an ED50 of ~.31 mg/kg orally in rats for diuretic activity.


IT 131185-02-9P	131185-03-0P	131185-04-1P
131185-05-2P	131185-06-3P	131185-07-4P
131185-08-5P	131185-09-6P	131185-10-9P
131185-11-0P	131185-12-1P	131185-13-2P
131185-14-3P	131185-15-4P	131185-16-5P
131185-17-6P	131185-18-7P	131185-19-8P
131185-20-1P	131185-21-2P	131185-22-3P
131185-23-4P	131185-24-5P	131185-25-6P
131185-26-7P	131185-27-8P	131185-28-9P
131185-29-0P	131185-30-3P	131185-31-4P
131185-32-5P	131185-33-6P	131185-34-7P
131185-35-8P	131185-36-9P	131185-37-0P
131185-38-1P	131185-39-2P	131185-40-5P
131185-41-6P	131185-42-7P	131185-43-8P
131185-44-9P	131185-45-0P	131185-46-1P

131185-47-2P 131185-48-3P 131185-49-4P
 131185-50-7P 131185-51-8P 131185-52-9P
 131185-53-0P 131185-54-1P 131185-55-2P
 131185-56-3P 131185-57-4P 131185-58-5P
 131185-59-6P 131185-60-9P 131185-61-0P
 131185-62-1P 131185-63-2P 131185-64-3P
 131185-65-4P 131185-66-5P 131185-67-6P
 131185-68-7P 131185-69-8P 131185-70-1P
 131185-71-2P 131185-72-3P 131185-73-4P
 131185-74-5P 131185-75-6P 131185-76-7P
 131185-77-8P 131754-91-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of as adenosine antagonists)


RN 131185-02-9 CAPLUS

CN 1(4H)-Pyridazinecarboxylic acid, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-03-0 CAPLUS

CN 1(6H)-Pyridazinecarboxylic acid, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-04-1 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 131185-05-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 131185-06-3 CAPLUS

CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-07-4 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-08-5 CAPLUS

CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-09-6 CAPLUS


CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




RN 131185-10-9 CAPLUS
CN 1(4H)-Pyridinecarboxylic acid, 3-chloro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-11-0 CAPLUS
CN 1(4H)-Pyridinecarboxylic acid, 3-acetyl-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-12-1 CAPLUS
CN 1(4H)-Pyridinecarboxylic acid, 3-cyano-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-13-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methyl-4-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-14-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(5-methyl-4-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-15-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 131185-16-5 CAPLUS
CN 2(1H)-Pyridinone, 5,6-dihydro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-17-6 CAPLUS
CN 2-Pyrimidinamine, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-18-7 CAPLUS
CN 2(1H)-Pyridinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


INDEX NAME)




RN 131185-19-8 CAPLUS
CN 3(2H)-Pyridazinone, 4,5-dihydro-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 131185-20-1 CAPLUS
CN 3H-Pyrazol-3-one, 1,2-dihydro-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-
(9CI) (CA INDEX NAME)




RN 131185-21-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methylimidazo[2,1-b]-1,3,4-thiadiazol-6-yl)-
2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-22-3 CAPLUS
CN 3-Pyridinecarbonitrile, 1,2-dihydro-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-23-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-24-5 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(1-methyl-1H-pyrazol-4-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-25-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 2-phenyl-3-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 131185-26-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methyl-5-pyrimidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-27-8 CAPLUS
CN 2-Pyrimidinamine, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-28-9 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 131185-29-0 CAPLUS
CN 1(6H)-Pyridazineacetic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-30-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-methyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-31-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2-propyl- (9CI) (CA INDEX NAME)




RN 131185-32-5 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-hydroxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-33-6 CAPLUS
CN 3(2H)-Pyridazinone, 2-(2-ethoxyethyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-34-7 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, 5-hydroxy-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-35-8 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-36-9 CAPLUS
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 131185-37-0 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (9CI) (CA INDEX NAME)




RN 131185-38-1 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




• Na


RN 131185-39-2 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 131185-40-5 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, (9CI) (CA INDEX NAME)




RN 131185-41-6 CAPLUS
CN 1(6H)-Pyridazinebutanoic acid, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




• Na


RN 131185-42-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,2-dihydro-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 131185-43-8 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 5,6-dihydro-2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-44-9 CAPLUS
CN 1(4H)-Pyridazinepropanoic acid, 5,6-dihydro-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, sodium salt (9CI) (CA INDEX NAME)




RN 131185-45-0 CAPLUS
CN 1H-Pyrazole-1-propanoic acid, 5-hydroxy-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)


● Na




RN 131185-46-1 CAPLUS
CN 2(1H)-Pyridinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-47-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-chloro-4-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-48-3 CAPLUS
CN Ethanone, 1-[4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 131185-49-4 CAPLUS
CN 3-Pyridinecarbonitrile, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-50-7 CAPLUS
CN 1(6H)-Pyridazinepropanamide, 6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-51-8 CAPLUS
CN 1(6H)-Pyridazinepropanamide, N,N-dimethyl-6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-52-9 CAPLUS
CN Piperidine, 1-[1-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinylpropyl]- (9CI) (CA INDEX NAME)




RN 131185-53-0 CAPLUS
CN 2(1H)-Pyrimidinone, 5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-54-1 CAPLUS
CN 2(1H)-Pyrimidinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-55-2 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyridinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-56-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-chloro-4-pyrimidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-57-4 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-chloro-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-58-5 CAPLUS
CN 3-Pyridazinamine, N,N-dimethyl-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-59-6 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methoxy-4-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-60-9 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methoxy-4-pyridinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-61-0 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(2-methoxy-4-pyrimidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 131185-62-1 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(6-methoxy-3-pyridazinyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 131185-63-2 CAPLUS
CN 3(2H)-Pyridazinone, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-64-3 CAPLUS
CN Pyrazolo[1,5-a]pyridine, 3-(3-methyl-4-pyridazinyl)-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 131185-65-4 CAPLUS
CN 3-Pyridazineethanol, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-α-(trichloromethyl)- (9CI) (CA INDEX NAME)




RN 131185-66-5 CAPLUS
CN 2-Propenoic acid, 3-(4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3-

pyridazinyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 131185-67-6 CAPLUS
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-68-7 CAPLUS
CN 1(2H)-Pyrimidinepropanoic acid, 2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-69-8 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-70-1 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-carboxy-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, α-methyl ester (9CI) (CA INDEX NAME)




RN 131185-71-2 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-cyano-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-72-3 CAPLUS
CN 1(6H)-Pyridazinepropanoic acid, 6-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-73-4 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 2-oxo-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-74-5 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-carboxy-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-75-6 CAPLUS
CN 1(2H)-Pyridinepropanoic acid, 3-cyano-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 131185-76-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 1,2-dihydro-1-methyl-2-oxo-5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 131185-77-8 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, dimethyl ester (9CI) (CA INDEX NAME)




RN 131754-91-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(3-hydroxypropyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




L5 ANSWER 86 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989-95084 CAPLUS
 DOCUMENT NUMBER: 110:95084
 TITLE: Preparation of new nitrogen-bridged heterocycles. 18. Facile formations of 3-arylpyrazolo[1,5-a]pyridines and 1-arylindolizines Kakehi, Akikazu; Ito, Suketaka; Kinoshita, Naosumi; Abaka, Yukio
 AUTHOR(S): Fac. Eng., Shinshu Univ., Nagano, 380, Japan
 CORPORATE SOURCE: Bulletin of the Chemical Society of Japan (1988), 61(6), 2055-61
 SOURCE: CODEN: BCSJAG; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 110:95084
 GI




AB The base treatment of [(benzylthio)methyleneamino]pyridinium I (X = N; R, R1 = H, Me; R2 = Ph, substituted Ph, R3 = SMe, Ph, OEt, NEt2) and [(benzylthio)vinyl]pyridinium bromides I (X = CR4; R, R1 = H, Me; R2 = Ph, substituted Ph, R3 = SMe, R4 = CO2Et, cyano, COPh), possessing an electron-withdrawing substituent such as a nitro or cyano group in the presence or absence of a dehydrogenating agent afforded 3-arylpyrazolo[1,5-a]pyridines II (X = N) and 1-arylindolizines II (X = CR4) resp. in moderate to good yields, while the reactions of the parent pyridinium salts and those having an electron-releasing group did not produce any significant products. The mode of the reaction, a ring contraction-desulfurization, is the same as that observed in related monocyclic species.
 IT 119093-32-2P 119093-39-9P 119093-44-6P
 119093-50-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (Preparation of)
 RN 119093-32-2 CAPLUS
 CN Benzonitrile, 2-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 119093-39-9 CAPLUS
 CN Benzonitrile, 4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 119093-44-6 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(2-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 119093-50-4 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, 3-(4-nitrophenyl)-2-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 87 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1973:71992 CAPLUS
 DOCUMENT NUMBER: 78:71992
 TITLE: Reactive intermediates. XXI. Thermal decarboxylation of 2,6-diazatricyclo[5.2.1.0.2,6]deca-4,8-diene-3,10-diones to pyrazolo[1,5-a]pyridines Rees, C. W.; Yelland, M.
 AUTHOR(S): Chem. Dep., Univ. Leicester, Leicester, UK
 CORPORATE SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1973), (3), 221-5
 CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 78:71992
 GI For diagram(s), see printed CA issue.
 AB Oxidation of pyrazolin-5-ones (I; R = H, Ph, or CH₂Ph) in the presence of tetracyclone gave the corresponding adducts (II), which on heating lost CO₂ and rearranged to the pyrazolo[1,5-a]pyridines (III).
 IT 22889-10-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 RN 22889-10-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, hexaphenyl- (8CI, 9CI) (CA INDEX NAME)



L5 ANSWER 88 OF 88 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1969:422062 CAPLUS
 DOCUMENT NUMBER: 71:22062
 TITLE: A novel heterocyclic rearrangement. Extrusion of carbon dioxide from non-adjacent carbonyl groups
 AUTHOR(S): Rees, Charles W.; Yelland, M.
 CORPORATE SOURCE: Univ. Leicester, Leicester, UK
 SOURCE: Journal of the Chemical Society [Section] D: Chemical Communications (1969), (8), 377-8
 CODEN: CCJDAO; ISSN: 0577-6171

DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA issue.
 AB Oxidation of 4-substituted-3-phenyl-2-pyrazolin-5-ones with Pb(OAc)₄ in CH₂Cl₂ containing tetraphenylcyclopentadienone (I) gave good yields of the Diels-Alder adducts (II). Thermolyses of I at 210°/1 mm. 16 hrs. caused extrusion of CO₂ and formation of 30-45% III. The proposed mechanism for this unusual rearrangement involved N-C bond fission (1st part of stepwise retro-Diels-Alder) to give a zwitterion, formation of a lactone produced by attack of the pyrazolone O at the cyclopentenone carbonyl group, and subsequent loss of CO₂ with formation of III. The thermolyses also produced 35-40% I, the stable product of the normal retro-Diels-Alder reaction.
 IT 22889-10-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 RN 22889-10-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine, hexaphenyl- (8CI, 9CI) (CA INDEX NAME)



=>
 =>
 =>
 => d his
 (FILE 'HOME' ENTERED AT 12:37 ON 21 JUN 2007)
 FILE 'REGISTRY' ENTERED AT 11:12:46 ON 21 JUN 2007
 STRUCTURE UPLOADED
 L1 2214 S L1 FULL
 L2 0 S L2 FULL
 L3 88 S L3 FULL
 L4
 L5
 FILE 'CAPIUS' ENTERED AT 11:14:28 ON 21 JUN 2007
 => log y
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE ENTRY 511.23
 SINCE FILE ENTRY -68.64
 TOTAL SESSION 856.09
 TOTAL SESSION -68.64
 STN INTERNATIONAL LOGOFF AT 12:14:58 ON 21 JUN 2007